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1014-127 Targeted Delivery of Immunoliposomes Containing 
Vascular Endothelial Growth Factor to Post Myocardial 
Infarction Tissue Improves Cardiac Function and 
Microvascular Perfusion
Jenna M. Rosano, Robert C. Scott, Zhanna Ivanov, Bin Wang, Parkson Lee-Gau Chong, 
Deborah L. Crabbe, Mohammad F. Kiani, Temple University, Philadelphia, PA
Background: Stem cell therapies have yielded inconsistent improvements in cardiac 
function. One potential reason is the lack of a supporting vascular microenvironment. 
Selective targeting of vascular endothelial growth factor (VEGF) to post-myocardial 
infarction (MI) tissue may improve microvascular perfusion and cardiac function.
Methods: Seventeen Sprague-Dawley rats underwent coronary ligation to create 
a large MI. Animals were randomly selected to receive either a dose of 0.1 ml anti-P-
selectin conjugated immunoliposomes containing VEGF (0.12 ug/kg, n=8) or blank 
immunoliposomes (n=5) injected via tail vein immediately post-MI. Untreated MIs were 
followed for comparison (n=4). Immunohistochemical staining with CD31 and DiOC7 was 
used to quantify the number of anatomical and perfused vessels in the border zone 
respectively. Animals were followed for 4 weeks with serial echocardiograms to measure 
LV internal dimensions and function.
Results: Data are expressed as mean ± SEM. ANOVA was used to determine differences 
between experimental groups. Values of p<0.05 were considered statistically signiﬁcant. 
After targeted VEGF, an increase in the number of anatomical and perfused vessels 
occurred at 4 weeks compared to untreated MI group. These improvements in vessel 
density were associated with increased fractional shortening by 4 weeks.
Conclusions: Targeted delivery of low doses of VEGF to post-MI tissue results in 
signiﬁcant improvements in microvascular structure and LV function. 
9:30 a.m.
1014-128 The Role of Uncoupling Protein (UCP3) in Myocardial 
Necrosis and Cardiomyocyte Energetics During 
Ischemia-Reperfusion Injury
Cevher Ozcan, Monica Palmeri, Raymond R. Russell, III, Section of Cardiovascular 
Medicine, Yale University School of Medicine, New Haven, CT
Background: Recently, we have demonstrated that hearts lacking endogenous uncoupling 
protein 3 (UCP3) are vulnerable to ischemia-reperfusion (IR) injury. However it is not clear 
whether this sensitivity is associated with myocardial necrosis during oxidative stress. 
We hypothesize that UCP3 may prevent myocardial necrosis during IR by maintaining 
cardiomyocyte energetics through preserving mitochondrial function and structure.
Methods: This study examined the role of UCP3 in myocardial necrosis. UCP3-deﬁcient 
and wild type mouse hearts (8-10 week-old male) were subjected to 20-min of in vivo 
ischemia by complete occlusion of the left coronary artery followed by 2 hours of 
reperfusion. Serum troponin I levels were measured as an indicator of myocardial 
necrosis by ELISA in both groups with IR injury and compared to sham operated mice. 
In addition, myocardial nucleotide proﬁle, as a marker of cellular energy status, was 
measured by HPLC.
Results: Following IR injury, the serum troponin I level was signiﬁcantly higher in UCP3-/- 
mice (347±57 ng/ml) compared to wild type mice (124.5±17 ng/ml), (p=0.009). However 
both groups had similar troponin I level in control state with no IR injury (0.63±0.45 ng/
ml versus 0.43±0.08 ng/ml, p>0.05). The AMP/ATP ratio, a marker of metabolic stress, 
increased with IR in wild type (from 0.45±0.1 to 0.90±0.03, p=0.03) and UCP3-/- mouse 
hearts (from 0.46±0.03 to 1.05±0.2, p=0.02). The amount of ATP in UCP3-/- mice hearts 
decreased signiﬁcantly with IR injury (from 3.59±0.2 to 1.48±0.14 nmoles/mg protein, 
p=0.0001) as well as in wild type mouse hearts (from 3.82±0.4 to 2.3±0.01 nmoles/mg, 
p=0.02). However, wild type mice had signiﬁcantly higher levels of ATP after IR injury 
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1014-125 Three-Dimensional RGD-Modiﬁed Alginate Scaffold 
Designed to Enhance Efﬁcacy of Cell Transplantation to 
Infarcted Myocardium
Hugo P. Sondermeijer, Fiona See, Tetsunori Seki, Silviu Itescu, Columbia University, 
New York, NY
Background: Cell transplantation strategies for cardiac repair are currently limited by poor 
survival of transplanted cells. Three-dimensional (3D) scaffolds improve cell transplant 
survival after delivery to infarcted myocardium. We aimed to design a biocompatible 
porous 3D scaffold using custom puriﬁed alginate that augments cell viability. Two-
dimensional surfaces coated with cyclic RGDfK peptides have been shown to improve cell 
viability. We hypothesized that a three dimensional alginate scaffold covalently modiﬁed 
with cyclic RGDfK peptides would improve cell viability and could be used to transplant 
cells to infarcted myocardium following myocardial infarction (MI).
Methods: Cyclic RGDfK peptide modiﬁed porous alginate scaffolds were seeded with 
3x10e6 neonatal rat cardiomyocytes (nrCM), 3x10e6 neonatal rat cardiac ﬁbroblasts 
(nrCF) or 3x10e5 human mesenchymal stem cells (hMSCs), followed by culture for 
one week. Cell viability was determined by trypan blue exclusion and WST-1. Circular 
scaffolds (16mm x 0.75mm) without hMSCs (n=4), 1x10e6 hMSCs (low dose, n=13) or 
3x10e6 hMSCs (high dose, n=6) were applied to the epicardial surface of nude rat hearts 
48 hours after MI. Intramyocardial saline injected animals served as controls. 1 week later, 
cardiac function was determined by echocardiography.
Results: At 1 week, nrCM viability inside scaffolds increased from 3.3±1.2% (0 mg/g 
cRGDfK) to 12.3±0.1% (10 mg/g cRGDfk) to 28.9±7.3% (10 mg/g cRGDfk + gelatin) 
(p<0.05). Clusters of beating myocytes could be detected. nrCF viability increased from 
48.8±21% (0 mg/g cRGDfK) to 77.2±3.2% (10 mg/g cRGDfK) (p<0.05). Human MSC 
viability increased from 15.3±0.7% (0 mg/g cRGDfK) to 59.5±2.2% (20 mg/g cRGDfK) 
(p<0.01). Fractional shortening (FS) decreased by 15.2±2.5% in saline controls. Following 
epicardial scaffold application, FS decreased by 2.4±15.4% (without hMSCs) and 
17.1±6.8% (3x10e6 hMSCs), whereas FS increased by 6.9±10.3% (1x10e6 hMSCs) 
(p<0.05).
Conclusion: 3D alginate scaffolds modiﬁed with cRGDfK peptide promote cell viability 
in vitro. Epicardial application of 3D modiﬁed alginate scaffolds seeded with low dose 
hMSCs improves cardiac function following MI.
9:30 a.m.
1014-126 Human Fetal Mesenchymal Stem Cells Exert More 
Powerful Cytoprotective Paracrine Effects Than Bone 
Marrow-Derived Mesenchymal Stem Cell.
Elisabetta Cervio, Patrizia Danieli, Chiara Ciuffreda, Andrea Di Marco, Roberto Bassani, 
Marianna Roccio, Gianluca Viarengo, Peter J. Schwartz, Massimiliano Gnecchi, 
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Università di Pavia, Pavia, Italy
Background:We and others have shown that adult mesenchymal stem cells (MSC) repair 
experimental infarcted hearts mainly through paracrine mechanisms. In particular, MSC 
produce and release anti-apoptotic factors (AAF) that lead to cytoprotection. However, the 
production of AAF may be negatively inﬂuenced by donor age. We hypothesized that MSC 
of fetal origin may exert more powerful cytoprotective effects compared with adult MSC.
Methods: MSC were isolated from amniotic membranes (A-MSC) of human term 
placenta or from the bone marrow (BM-MSC) of healthy donors. The immunophenotype 
was determined by FACS analysis. The ability of MSC to turn into terminally differentiated 
cell types was also tested. The production of several known AAF was measured by RT-
PCR. Rat neonatal cardiomyocytes (H9c2 cells) were used to test the anti-apoptotic 
effects exerted by the MSC. H9c2 cells were exposed for 24 h to hypoxia in presence of 
control medium (CTRL-M) or conditioned medium (CM) from either A-MSC or BM-MSC. 
The rate of apoptosis was quantiﬁed by TUNEL staining. Cleaved Caspase 3 in H9c2 cells 
was evaluated by ﬂuorimetric assay and Western blotting.
Results: MSC were successfully isolated from 15 amniotic membranes and 10 BM 
aspirates (donor age: 59.2 ± 3.8 years). At passage two, cells from both the amnios 
and the BM displayed the antigen proﬁle typical of MSC and efﬁciently differentiated into 
osteocytes, adipocytyes and chondrocytes. Compared with BM-MSC, A-MSC expressed 
signiﬁcantly higher levels of PDGF-b (+ 6.6 folds), EPO (+4.8), IGF-1 (+2.1), BMP2 (+1.7), 
FGF2 (+1.4) and VEGF (+1.3). A-MSC-CM reduced the number of TUNEL positive H9c2 
cells by 70% compared with CTRL-M (p<0.05) and by 60% compared with BM-MSC-
CM (p<0.05). Fluorimetric assay showed reduced levels of cleaved Caspase 3 in the 
presence of A-MSC-CM (- 33% vs CTRL-M, p<0.05; - 25% vs BM-MSC-CM, p<0.05). 
Western blotting conﬁrmed the reduction of Caspase 3 in the presence of A-MSC-CM 
(-27% vs BM-MSC-CM).
Conclusions: A-MSC produce high amount of AAF and exert remarkable cytoprotective 
effects on hypoxic cardiomyocytes. A-MSC may represent a novel and powerful approach 
to cardioprotective therapy for ischemic heart disease.
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compared to UCP3-/- mice (p=0.008). Thus, lack of UCP3 in the mouse heart caused 
more severe necrosis and worse energetic status in the setting of IR injury.
Conclusion: Endogenous UCP3 prevents further myocardial necrosis during ischemia-
reperfusion injury while maintaining nucleotide proﬁle and cellular energetics, particularly 
ATP production. UCP3 plays a critical role in myopreservation under oxidative stress.
9:30 a.m.
1014-129 Erythromycin Attenuates Myocardial Ischemia 
Reperfusion Injury in Rats via Inhibition of 
Microcirculatory Disturbance and Inﬂammatory 
Response
Yusuke Jo, Toshihisa Anzai, Koji Ueno, Takashi Kohno, Kotaro Naito, Yuji Nagatomo, 
Yuichiro Maekawa, Toshiyuki Takahashi, Tsutomu Yoshikawa, Satoshi Ogawa, Division of 
Cardiology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Background: Myocardial ischemia-reperfusion (I/R) injury is associated with systemic 
inﬂammatory response, in which neutrophils and inﬂammatory cytokines play critical 
roles. Macrolides have been widely used in patients with chronic obstructive pulmonary 
disease based on their inhibitory effects against inﬂammatory changes in the bronchial 
epithelium. However, the effect of macrolides on I/R injury has not been clariﬁed. The aim 
of this study is to determine the effect of erythromycin on I/R injury.
Methods: Eleven week-old rats were divided into 2 groups and given intravenous 
administration of erythromycin (25 mg/kg, EM/IR) or saline as control group (CON/
IR), 30-minute prior to myocardial ischemia. Rats underwent 30-minute occlusion of 
left coronary artery, followed by reperfusion. Myocardial contrast echocardiography 
was performed an hour after reperfusion to assess microcirculatory impairment of the 
myocardium. Hemodynamic study, echocardiography and myeloperoxidase (MPO) 
staining were performed 24 hours after reperfusion. Real time RT-PCR was performed to 
assess myocardial mRNA expression in the area at risk 24 hours after I/R.
Results: Contrast echocardiography revealed that EM/IR had greater contrast intensity 
in the area at the risk compared with CON/IR (P=0.03). Hemodynamic study 24 hours 
after I/R revealed that LV end-diastolic pressure in EM/IR was lower and LV +dP/dt in 
EM/IR was higher than those in CON/IR (3±1 vs.5±2 mmHg, P=0.01, 8489±1036 vs. 
5984±1258 mmHg/sec, P=0.01, respectively). LV ejection fraction by echocardiography 
was signiﬁcantly greater in EM/IR than that in CON/IR (79±3 vs. 67±9 %, P=0.0001). MPO 
staining revealed that neutrophil inﬁltration in EM/IR was signiﬁcantly lower than that in 
CON/IR (P<0.05). Myocardial mRNA expression of IL-6 in the area at risk was signiﬁcantly 
lower in EM/IR than that in CON/IR (P<0.05).
Conclusion: Intravenous administration of erythromycin attenuated ischemia-reperfusion 
injury through inhibition of microcirculatory disturbance, neutrophil inﬁltration and 
inﬂammatory response. Erythromycin may be effective as an adjunctive therapy to 
reperfusion for acute myocardial ischemia.
9:30 a.m.
1014-130 Extracellular Matrix Processing Is Activated During 
Early Postischemic Reperfusion with Differential 
Effects of Temperature on Matrix Degradation and 
Endothelial Barrier Function
Alexander Lauten, Ewa Majos, Thorsten Wahlers, Wilma Rademacher, Christian Jung, 
Juergen H. Fischer, Hans R. Figulla, Wilhelm Bloch, Friedrich-Schiller-University, Jena, 
Germany
Background: Acute ischemia is a well known inductor of extracellular matrix (ECM) 
remodelling, which leads to the development of congestive heart failure and is associated 
with left ventricular dilatation. Here we investigate the timecourse of ECM processing 
with release of endostatin (ES) and other low molecular weight fragments during early 
ischemia-reperfusion (I/R) of the heart.
Methods: In this blinded study, 30 pigs where randomized to 60min of global myocardial 
ischemia at either 4C or 37C or served as control. Five transmyocardial tissue samples 
and blood samples from the coronary sinus where collected at baseline and after ischemia 
within 150min of reperfusion. Collagen XVIII cleavage products of 10-75kDa including ES 
(25kDa) and Creatin Kinase (CK) as maker of myocardial injury where analyzed by the 
Western Blot and ELISA methods and by immunohistochemistry in tissue sections.
Results: We demonstrate that processing of the extracellular matrix protein collagen 
XVIII starts during early reperfusion, as a signiﬁcantly increased expression of cleavage 
products at 10kDa and 75kDa as well as ES was observed at 150min of normothermic 
I/R. We further demonstrate a differential processing of collagen XVIII depending on 
temperature conditions during myocardial ischemia, as an increase in cleavage products 
was observed after normothermic ischemia only, however release of ES and other 
fragments remained unchanged after hypothermic ischemia and in controls. Increased 
postischemic processing of matrix proteins after normothermic ischemia correlated to 
increased CK-levels in this group. ES-levels in the coronary sinus where signiﬁcantly 
lower at 30min and 150min after normothermic I/R as result of compromised endothelial 
barrier function.
Conclusion: This blinded study ﬁrst demonstrates extracellular matrix processing 
during early ischemia-reperfusion with differential effects of temperature conditions and 
endothelial damage after normothermic I/R. These ﬁndings may contribute to a broader 
understanding of postischemic ECM remodelling and endothelial function.
9:30 a.m.
1014-131 Islet-1 Promotes Cardiac Differentiation and Is 
Activated in Response to Myocardial Infarction in Adult 
Mouse Heart
Satoshi Matsushita, Anthony J. White, James S. Forrester, Tarun Chakravarty, Eduardo 
Marbán, Raj Makkar, Cedars-Sinai Medical Center, Los Angeles, CA
Background: In the mammalian embryo, tissue injury heals without scarring, a response 
lost with the appearance of the inﬂammatory response. We hypothesized that a muted 
form of this healing response may persist in the adult, offering an opportunity for 
myocardial regeneration.
Methods: Myocardial infarction was created by ligation of the LAD coronary artery 
in C57BL/6 mice. Following a literature review of the transcription factors known to 
regulate cardiogenesis, expression of 8 transcription factors was determined in normal 
and infarcted myocardium by RT-PCR [baseline, 2, 7 and 14 d. following infarction (n=5 
each)] and Western blotting. Immununohistochemistry was used to localize transcription 
factor(s) and c-kit to identify stem cells. Periostin and collagen expression were measured 
by RT-PCR and Masson’s trichrome stain used to identify collagenous scar.
Results: Infarction was conﬁrmed by upregulation of collagen (37.6±10.4-fold at 14 d), 
and by histology. Periostin expression increased 123.9±32.5 fold. Two transcription factors 
were consistently upregulated in infarct tissue compared to normal tissue: Isl1 (4.7±0.5-
fold at 14d) and HAND1 (3.4±0.4-fold at 7d) [mean±SE, ANOVA<0.01]. Isl1, the most 
upregulated gene at 14 d, was also accompanied by an 18.3±4.6 fold increase in Isl1 
protein. Immunohistochemistry revealed that Isl1 and the stem cell marker c-kit were 
expressed in the same small round cells.
Conclusion: Two embryonic transcription factors were upregulated in infarcted compared 
to normal myocardium, accompanied by markedly increased expression of Isl1 protein, 
which co-localized in the same cells with c-kit. Hand1 is known to co-operatively control 
development of the left ventricule in the embryonic heart. Isl1 is a marker of the embryonic 
second heart ﬁeld, and its expression disappears as the cells begin to express cardiac 
markers. Periostin promotes reentry of adult cells into the cell cycle. These data suggest 
that a response paralleling cardiogenesis is activated following myocardial infarction, but 
that the balance of local factors favors scar formation. A change in the local environment 
toward the embryonic state could favor myocardial regeneration.
9:30 a.m.
1014-132 Is the Cardioprotective Paracrine Action of Bone 
Marrow Cells Inﬂuenced by Clinical Conditions?
Vien Khach Lai, José Linares-Palomino, Manuel Galiñanes, University of Leicester, 
Leicester, United Kingdom
Background: We have demonstrated that bone marrow cells (BMCs) have a potent 
cardioprotective effect. Here we have investigated whether clinical conditions such 
as diabetes and poor LV function inﬂuence the cardioprotection elicited by BMCs and 
whether the cause for any loss in protection resides in the BMCs or in the myocardium.
Methods: BMCs and right atrial appendage were obtained from patients undergoing 
elective cardiac surgery with and without diabetes, and from poor (EF<30%) and 
preserved LV function. Muscles were subjected to 90min ischemia/120min reoxygenation 
at 37oC. Tissue injury was assessed by creatine kinase (CK) released into the media 
during the reoxygenation period (IU/mg wet wt), and cell necrosis and apoptosis was 
determined by propidium iodide and TUNEL (% of aerobic control).
Results: CK release and cell necrosis and apoptosis induced by ischemia in the diabetic 
myocardium were not signiﬁcantly affected by IP or the co-incubation with autologous or 
non-diabetic allogenic BMCs. However, when non-diabetic myocardium was co-incubated 
with autologous BMCs or with allogenic diabetic BMCs there was a signiﬁcant reduction in 
CK release (from 1.41±0.18 to 0.48±0.11 and 0.44±0.14; p<0.05) and cell necrosis (from 
9.54±0.98% to 3.29±1.32% and 0.60±0.50%; p<0.05) and apoptosis (from 11.59±3.13% 
to 0.92±0.46% and 1.01±0.63%; p<0.05, n=6/group). Muscles from patients with poor 
LV function were not protected by autologous BMCs but, importantly, CK release and 
cell necrosis were signiﬁcantly reduced by allogenic BMCs obtained from patients 
with normal LV function (CK release from 1.16±0.10 to 0.61±0.14 and necrosis from 
13.45±0.67% to 8.62±1.20%; p<0.05 in both instances, n=5/group) although apoptosis 
remained unaffected (from 8.09±1.53% to 6.08±1.02%; p=NS). By contrast, muscles 
from individuals with normal LV function could not be protected with BMCs obtained from 
patients with poor LV.
Conclusions: The cause for the loss of the cardioprotective paracrine action of BMCs in 
subjects with diabetes resides in the myocardium and not in the BMCs whereas in those 
with poor LV function the BMCs are responsible for the deﬁcit in cardioprotection.
9:30 a.m.
1014-133 Adjunctive Infusion of AZD6140, but Not Clopidogrel, 
With t-PA Enables Sustained Coronary Artery 
Recanalization With Recovery of Myocardium Perfusion 
in a Canine Model of Myocardial Infarction
Kai Wang, Xiaorong Zhou, Yanming Huang, Mazan Khalil, Dominik Wiktor, Yu Peng, 
Marc S. Penn, The Cleveland Clinic, Cleveland, OH
Background: We assessed the effect of AZD6140, the ﬁrst reversible oral P2Y12 receptor 
antagonist, vs clopidogrel (CLOP) on platelet aggregation, thrombus formation, and 
myocardium perfusion in a dog coronary thrombosis model. Methods. Five min before 
administration of t-PA (1 mg/kg, 20 min), 10 animals received CLOP 10 mg/kg IV bolus 
for 5 min, 10 received AZD6140 initiated with a 1-min bolus (75 μg/kg/min) followed by 
continuous infusion (10 μg/kg/min) for 2 h, and 10 received IV saline for 2 h. All received a 
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heparin 80 U/kg bolus followed by continuous infusion of 17 U/kg/h. Results. Reocclusion
rate, cyclic ﬂow variation, and infarct size were signiﬁcantly decreased with AZD6140 
(P<0.05). ADP-induced (20 μmol/L) platelet aggregation was decreased by AZD6140 (1.9 
mm ±2.67%) and CLOP (1.11 mm ±2.0%) vs control (26.3 mm ±23.5%, P<0.05) at the 
end of adjunctive therapy. Bleeding time increases were signiﬁcantly greater with CLOP 
vs AZD6140 (8.24±2.61 vs 5.16±2.17 min, P=0.01). Compared to their own baseline, 
contrast echocardiography showed complete recovery of myocardial perfusion in the 
AZD6140 group (73% recovery, P=0.221) compared to CLOP (50% recovery, P=0.051) 
and saline group (62% recovery, P=0.060). Conclusion. Administration of AZD6140 in 
combination with t-PA in a dog coronary thrombosis model blocks ADP-induced platelet 
activation, aggregation and recruitment, and prevents platelet-mediated thrombosis, 
suggesting that AZD6140 has a better antiplatelet effect than clopidogrel. 
RR (%) TR (min) RD (min) CFV (%) Reocclusion (%) Infarct size (cm2)
Control 90 24.4±7.7 87.4±44.9 30 50 13.63±4.19
CLOP 100 27.2±6.2 96.9±38.9 30 30 14.34±4.29
AZD6410 100 22.9±8.1 120±0.00* 0* 0* 6.31±2.86*
*P<0.05 vs CLOP and control groups. RR-reperfusion rate; TR-time to reperfusion; RD-
reﬂow duration; CFV-cyclic ﬂow variation. All data mean ± SD. Predetermined limit of 
observation after reperfusion was 120 min.
9:30 a.m.
1014-134 Dose-Dependent Contribution of Adult Human Stem 
Cells in Post-Infarct Myocardial Recovery
Winston Shim, Genevieve Tan, Yacui Gu, Shiqi Li, Ling Qian, Yingying Chung, Sze 
Yun Lim, Ting Huay Ooi, Eugene Sim, Terrance Chua, Seng Chye Chuah, Tian Hai 
Koh, Philip Wong, National Heart Center, Singapore, Singapore, National University of 
Singapore, Singapore, Singapore
Background: Functional deterioration post myocardial infarction can be relieved by 
stem cell therapy. We investigate systolic and diastolic contribution of cell therapy on 
myocardial function.
Methods: Mesenchymal stem cells (MSCs) were derived from sternum of 46 patients. 
MSCs were differentiated into cardiomyocyte-like cells (CLCs) using cardiomyogenic 
induction medium. One week after ligating left anterior descending artery of Wistar rats, 
Vibrant DiI-labeled low dose MSCs (1x 106, n=9) and high dose MSCs (5 x 106, n=18)
or CLCs (5 x 106, n=15) and serum-free medium (n=19) were injected into the peri-
infarcted regions of myocardium. Left ventricular (LV) function was analyzed 6 weeks post 
transplantation by Millar’s 2-F Mikro-tip pressure-volume (PV) catheter.
Results: High dose cell therapy signiﬁcantly improved post-infarct remodeling by 
preventing expansion of end-diastolic and end-systolic volume. Furthermore, high dose 
CLCs (76.3 ± 8.1%, p<0.001) and MSCs (70.2 ± 11.1%, p<0.001), but not low dose MSCs 
(54.6 ± 18.8%), enhanced LV ejection fraction as compared to medium-injected control 
(48.1 ± 16.1%). However, both high and low dose MSC transplant impaired myocardial 
tissue compliance that elevated end-diastolic (13.9 ± 8.3 mmHg, p<0.05) and end-systolic 
pressure (163.8 ± 53.6 mmHg, p<0.01) respectively when compared to medium-injected 
animals (8.5 ± 3.1 mmHg [EDP] and 129.6 ± 27.7 mmHg [ESP]). In contrast, CLCs, 
but not MSCs, enhanced cardiac output (43674.2 ± 11854.6 uL/min, p<0.05) and stroke 
work (12303.3 ± 3174.1 mmHg*uL, p<0.05) by improving contractile dynamics of dP/
dt
max
(14734 ± 3306 mmHg/s, p<0.01) and dV/dt
max
(5842 ± 2547 uL/s, p<0.05). The 
hemodynamic changes were correlated with engraftment of CLCs in collagen V-rich 
myoﬁbers in peri-infarct region and preferential localization of MSCs within collagen I 
matrix and vascular structures in the infarct.
Conclusions: CLCs augment functional recovery by maintaining contractile efﬁciency 
and myocardial compliance at infarct borders. Cardiac differentiated stem cells may 
be more effective than undifferentiated stem cells in sustaining post-infarct recovery of 
myocardial function.
9:30 a.m.
1014-135 The N-Terminal Cleavage Product of PAR1 (Parstatin) 
Is a Potent Cardioprotective Agent Against Myocardial 
Ischemia and Reperfusion Injury by Recruiting NOS, 
ERK1/2, p38 MAPK, and KATP Channels
Jennifer L. Strande, Nikos E. Tsopanoglou, Anna Hsu, Jidong Su, John E. Baker, 
Medical College of Wisconsin, Milwaukee, WI, University of Patras, Patras, Greece
Background: The Protease-Activated Receptor 1 is fundamental to mediating thrombin’s 
effects in cardiovascular injury. It has been implicated in atherosclerosis, acute coronary 
thrombosis, restenosis, and ischemia-reperfusion injury. Thrombin activates the receptor by 
proteolytic cleavage of the N-terminus to expose a tethered ligand, which then transactivates 
the receptor. Although much research has focused on the activated receptor, little is known 
about the 41 amino acid N-terminal cleavage product (Parstatin). We hypothesized that 
Parstatin would protect the heart against ischemia-reperfusion injury.
Methods/Results: Parstatin was synthesized at a peptide facility. We assessed the 
potential protective role Parstatin in an in vivo and in vitro rat model of myocardial 
ischemia-reperfusion injury. Parstatin (1-25 μg/kg) treatment before ischemia decreased 
infarct size by 26% in an in vivo model of I/R injury at an optimal dose of 10 μg/kg. Parstatin 
(0.1-10 μM) treatment immediately before ischemia decreased infarct size by 65% in the 
in vitro model and increased recovery in ventricular function by 23% following ischemia-
reperfusion at a optimal concentration of 1 μM. The survival pathways known to be up-
regulated by pharmacologic cardioprotectants were then explored. The cardioprotective 
effects of Parstatinwere abolished by inhibition of NOS (L-NMA), ERK1/2 (PD98059), p38 
MAPK (SB203508) and KATP channels (glibenclamide). L-NMA, PD98059, SB203508, 
and glibenclamide alone had no effect on cardioprotection in vitro.
Conclusion: A single treatment of Parstatin administered prior to ischemia confers 
immediate cardioprotection by recruiting NOS, ERK1/2, p38 MAPK, and KATP channels. 
This suggests a potential therapeutic role of Parstatin in the treatment of injury resulting 
from myocardial ischemia and reperfusion.
9:30 a.m.
1014-136 Ischemic Preconditioning Selectively Protects 
Subsarcolemmal Mitochondrial Respiration Against 
Ischemic Injury
Juan A. Crestanello, Daniel S. Lee, Gregory E. Steinbaugh, Douglas R. Pfeiffer, Jay L. 
Zweier, The Ohio State University, Columbus, OH
Ischemic preconditioning (IPC) protects mitochondrial (mito) respiration from ischemia-
reperfusion injury. It is unclear whether IPC induces mito protection from subsequent 
ischemic injury or from reperfusion injury and whether there is a selective protection of 
subsarcolemmal (SS) or interﬁbrillar (IF) mito. We studied pre and post ischemic SS and 
IF mito respiration to elucidate the timing of IPC protection and its effect on the different 
mito populations.
Isolated rat hearts were subjected to either A) CONTROL: 30 minutes (min) equilibration 
(EQ) and 30 min of ischemia or B) IPC: 10 min EQ, two 5 min episodes of IPC, and 30 
min of ischemia. SS and IF mito were isolated at end equilibration and at the end of the 
30 minute of ischemia. Mito respiration (state 2, 3, 4, respiratory control index (RCI: state 
3/state 4), and ADP:O ratio) was measured by polarography using glutamate and malate 
as substrates in SS and IF mitochondria. Data is expressed as Mean±SEM. 
End Equilibration
n = 7 State 2 State 3 State 4 RCI (3/4) ADP:O
SS IF SS IF SS IF SS IF SS IF
CONTROL 29±4 20±2 103±10 80±9 35±4 22±3 2.9±0.2 3.6±0.2 2.9±0.2 3.3±0.1
IPC 27±3 21±2 97±7 83±8 34±2 24±3 2.9±0.1 3.6±0.2 2.8±0.2 3.5±0.2
End Ischemia
n = 6 State 2 State 3 State 4 RCI (3/4) ADP:O
SS IF SS IF SS IF SS IF SS IF
CONTROL 34±2 19±1 70±7† 48±3† 42±2 29±2 1.7±0.1† 1.7±0.1† 2.2±0.1† 2.5±0.1†
IPC 33±2 22±4 94±3 * 53±5§ 37±2 25±2 2.6±0.1* 2.2±0.1§ 3.0±0.2* 3.0±0.2
(State 2, 3, and 4 are expressed as ng atoms O/min/mg protein) *p<0.05 vs End Ischemia 
CONTROL. † p<0.05 vs End EQ CONTROL. § p<0.05 vs End EQ IPC
Ischemia induces signiﬁcant damage to both SS and IF mito as evidenced by impaired 
respiration (state 3, RCI, and ADP:O ratio). IPC prevents ischemic damage to SS mito 
as evidenced by preserved state 3, RCI, and ADP:O ratio at end ischemia compared to 
CONTROL. IPC did not prevent damage to IF mito. We conclude that 1) the protective 
effects of IPC on mito function is present at end ischemia, 2) that this protection against 
ischemic injury is selective to SS mito, and 3) this selective protection suggests that there 
are subcellular differences in IPC induced protection.
9:30 a.m.
1014-137 Acute Systemic and Local Neutrophil and Monocyte 
Degranulation Prior to Primary Percutaneous Coronary 
Intervention in ST Elevation Myocardial Infarction
Catriona J. Marshall, Tessa Mocatta, Judy McKenzie, Anthony Kettle, James Blake, John 
Elliott, David Smyth, Mark Richards, Dougal R. McClean, Department of Cardiology, 
Christchurch Hospital, Christchurch, New Zealand, Free Radicals Research Group, 
University of Otago, Christchurch, New Zealand
Background: The role of the neutrophil in inﬂammatory events leading to coronary plaque rupture 
and occlusive thrombus is controversial. Neutrophils and monocytes contain myeloperoxidase 
(MPO) and leukocyte elastase (LE) within azurophilic granules. We hypothesized that increased 
neutrophil and monocyte degranulation is found systemically and locally in the culprit coronary 
artery in patients with ST elevation myocardial infarction (STEMI).
Methods: Twenty eight STEMI patients having primary PCI were compared to eleven 
chronic stable angina controls having elective PCI. Blood was sampled from the femoral 
artery, and culprit coronary artery pre PCI at the site of occlusive thrombus with a ﬁne 
sampling catheter. At 24 hours a peripheral venous sample was drawn. Flow cytometry 
measured neutrophil and monocyte MPO mean ﬂuorescence intensity (MFI). Lower MPO 
MFI reﬂects increased degranulation. An ELISA measured plasma LE.
Results: Acute degranulation of neutrophils and monocytes is shown below. 64% of 
STEMI patients had TIMI 0-1 ﬂow at time of coronary artery sampling. 24 hours post PCI, 
neutrophil and monocyte MPO stores were similar in both groups.
Conclusions: Acute neutrophil and monocyte degranulation in STEMI prior to restoration 
of epicardial ﬂow suggests a possible role for neutrophil activation in the pathophysiology 
of occlusive plaque rupture.
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Mean +/- SD STEMI Elective PCI p value
Neutrophil MPO MFI
Femoral Artery*
Coronary Artery pre PCI*
24 hours
14.6+/- 7.8
12.8+/- 6.5
19.4+/- 9.4
33.9+/-21.8
29.8+/- 18
21.1+/- 5.9
<0.001
<0.001
ns
Monocyte MPO MFI
Femoral Artery*
Coronary Artery pre PCI*
24 hours
4.9+/- 2.3
5.1+/- 2.4
7.9+/- 4.1
9.8+/-4.9
10+/- 4.8
8.1+/- 2.3
<0.001
<0.001
ns
Plasma LE ng/ml
Femoral Artery
Coronary Artery pre PCI
24 hours
21.8+/-10.6
28.8+/-28.3
17.3+/-10.3
11.6+/-6.3
17.5+/-9.0
17.5+/-3.7
<0.01
0.01
ns
*p<0.05 vs. 24 hrs in STEMI patients
9:30 a.m.
1014-138 An Insertion/Deletion Polyporphism in A2-Adrenergic 
Receptor Gene Is a Genetic Risk Factor for Sudden 
Cardiac Death
Jari A. Laukkanen, Timo Makikallio, Jussi Kauhanen, Sudhir Kurl, Lapland Central 
Hospital, Rovaniemi, Finland, Research Institute of Public Health, University of Kuopio, 
Kuopio, Finland
Background: A variant of the human A2B-adrenoceptor gene that encodes a D of three 
residues in an intracellular acidic motif has been shown to confer decreased receptor 
desensitization. This receptor variant could, therefore, be involved in cardiovascular 
diseases (CVDs) associated with enhanced vasoconstriction. Our aim was to study 
whether an insertion/deletion (I/D) polymorphism in the A2B-adrenoceptor gene is 
associated with the risk for sudden cardiac death
Methods: This study was part of a prospective population-based study investigating risk 
factors for CVDs in a cohort of middle-aged men from eastern Finland. The study sample 
is based on 1606 men 42 to 60 years of age followed for an average time of 17 years.
Results: In this study population, 338 men (21%) had the D/D genotype; 467 (29 %) had 
the I/I genotype, and 801 (50%) had a heterozygous genotype. There were 117 coronary 
heart disease deaths, of which 76 were due to sudden cardiac deaths within 24 hours 
from symptoms. In a Cox model adjusting for other coronary risk factors (age, systolic 
blood pressure, smoking, diabetes, serum LDL and HDL cholesterol, body mass index 
and exercise-induced myocardial ischemia), men with the D/D or I/D genotype had 1.95-
fold (95% conﬁdence interval, 1.07 to 3.55, P = 0.029) risk of sudden cardiac death and 
1.71-fold (95% conﬁdence interval, 1.08 to 2.73, P = 0.023) risk of coronary heart disease 
death as compared with men carrying the I/I genotype. The A2B-adrenoceptor genotype 
D/D or I/D were associated with the risk of sudden cardiac death (relative hazard 3.47, 
95 % conﬁdence interval, 1.36 to 8.87, p=0.009) among those with previously diagnosed 
cardiovascular disease CVD but not among those without previous CVD.
Conclusions: The D/D and I/D genotypes of the A2B -adrenoceptor are novel genetic risk 
predictors for unexpected sudden cardiac death and coronary heart disease mortality.
9:30 a.m.
1014-139 Ischemic Preconditioning Robustly Reduces In 
Vivo Myocardial Infarction in Both Male and Female 
Mice With Short or Long Ischemic Periods and This 
Protection Is Lost in the Absence of Endothelial Nitric 
Oxide Synthase
Fuchun Yang, M.A. Hassan Talukder, Jay L. Zweier, Davis Heart and Lung Institute, The 
Ohio State University, Columbus, OH
Ischemic preconditioning (IPC) is a powerful phenomenon that provides robust 
cardioprotection with reduced myocardial infarction. While it occurs in mammalian hearts 
with shorter periods of ischemia, little is known with prolonged periods of ischemia (I), 
and the relationship with aging and gender. Despite beneﬁcial effects of nitric oxide (NO) 
in IPC, the role of endothelial NO synthase (eNOS)-NO is controversial. Therefore, we 
performed an extensive characterization of IPC in wild-type (WT) and eNOS-knockout 
(eNOS-KO) mice to evaluate whether the infarct limiting effect of IPC depends on 
ischemic periods, eNOS, ages, and gender. Classical IPC was induced by 3-cycles of 
5-min regional coronary I (LAD occlusions) separated by 5-min reperfusion (R), and was 
followed by 30-min (30-IPC) or 60-min (60-IPC) index I and 24-hrs R. Control IR protocol 
had 30- or 60-min I followed by 24-hrs R, 30-IR or 60-IR, respectively. Protection was 
evaluated by measuring infarct size as a percentage of area at risk (Table). The major 
ﬁndings are that regardless of age and sex, WT mice exhibited robust IPC effects with 
signiﬁcantly smaller infarct size, whereas, eNOS-KO mice failed to exert this effect. Both 
aging and prolonged ischemia caused signiﬁcantly large infarction. Female WT mice 
had smaller acute IR injury compared to male WT. In conclusion, IPC protects WT mice 
against in vivo myocardial IR injury regardless of age, gender and/or ischemic duration, 
but, deletion of eNOS abolishes this potent cardioprotection.
Ischemic Preconditioning and Myocardial Infarction: Effects of Age, 
Sex, and Ischemic Periods
Gender / Age Parameter Protocols WT (n) eNOS-KO (n)
Male: 8-12 weeks % Infarct size 30-I/R 42±1.1 (10) 49±2.2 (8)
Male: 8-12 weeks % Infarct size 30-IPC 15.3±1.7*** (10) 47±2.5 (7)
Male: 8-12 weeks % Infarct size 60-I/R 55±3.2 (8) Lethal
Male: 8-12 weeks % Infarct size 60-IPC 20±2.1††† (8) Lethal
Male: 12-18 months % Infarct size 30-I/R 54.1±3 (7) ND
Male: 12-18 months % Infarct size 30-IPC 27.1±3*** (7) ND
Female: 8-12 weeks % Infarct size 30-I/R 32.1±3.1 (7) 44.8±4.1 (6)
Female: 8-12 weeks % Infarct size 30-IPC 20.4±2.8*** (7) 42.5±2.7 (5)
I/R, ischemia-
reperfusion;IPC, 
ischemic
preconditioning
***
P<0.001
vs. 
respective 
30-min I/R
††† P<0.001 
vs. respective 
60-min I/R
n = number of 
animals; ND = 
not determined
9:30 a.m.
1014-140 Stabilization of Cardiac Electrophysiology in Ischemic 
Myocardium by Granulocyte Colony Stimulating Factor
Natnicha Kanlop, Wasarut Rutjanaprom, Punate Weerateerangkul, Nipon Chattipakorn, 
Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Background: Granulocyte colony-stimulating factor (G-CSF) has been shown to have 
cardioprotective effects during ischemic/reperfusion (I/R) period in in vitro. However, its 
effects on cardiac electrophysiology in in vivo is unclear. We tested the hypothesis that 
G-CSF can stabilize cardiac electrophysiology during I/R injury by prolonging the effective 
refractory period (ERP), preventing the reduction of ventricular ﬁbrillation threshold (VFT) 
and preserving the deﬁbrillation threshold (DFT).
Methods: 17 pigs were divided into 3 groups. G-CSF (0.33ug/kg/min, n=6, Group1) and 
saline (n=4, Group2) were administered for 30 minutes prior to a 45-minute left anterior 
descending artery occlusion and at the time of reperfusion. The pacing threshold (DPT), 
ERP, VFT, DFT, QTc and QRS duration were determined in each pig before and during I/R 
period. In group3 (n=7), G-CSF was infused without artery occlusion.
Results: During ischemic period, G-CSF (group1) signiﬁcantly increased the DPT, ERP 
and VFT without altering the DFT (see table). The QT interval and QRS duration were 
not altered for the entire study periods. Vehicle (saline) did not change the ERP, VFT or 
DFT. In group 3, G-CSF increased only the DPT (0.7±0.2 vs. 0.3±0.1 mA, p<0.05) without 
altering other parameters.
Conclusions: G-CSF increases the ERP, DPT and VFT, thus stabilizing the cardiac 
electrophysiology and may prevent fatal arrhythmia in ischemic myocardium. However, 
G-CSF does not improve deﬁbrillation efﬁcacy during I/R injury.
G-CSF (Group 1) Control Ischemia Reperfusion
VFT
volts 34+11 64+20* 49+16
joules 0.10+0.05 0.30+0.20* 0.20+0.10
DFT
volts 480+115 539+13 490+145
joules 18+9 24+12 20+13
ERP ms 245+16 277+18* 243+36
DPT mA 0.2+0.1 0.5+0.2* 0.7+0.2*
9:30 a.m.
1014-141 Myocardial Regeneration With Autologous 
Mesenchymal Stem Cells in A Porcine Model Of 
Myocardial Infarction.
Montserrat Rigol, Núria Solanes, Jordi Farré, Mercè Roqué, Laura Novensà, Antonio 
Berruezo, Neus Bellera, Santiago Roura, David Tamborero, Cristina Prat, Montserrat 
Batlle, Marta Sitges, José Ramírez, Josep Brugada, Antoni Bayés-Genís, Magda Heras, 
Hospital Clínic. IDIBAPS, Barcelona, Spain, Hospital de la Santa Creu i Sant Pau, 
Barcelona, Spain
Background: Stem cell therapy offers a promising approach to reduce the short-term 
mortality rate associated with heart failure after a myocardial infarction (MI). We analyzed 
the regenerative capacity of mesenchymal stem cells (MSCs) and compared two types of 
administration pathways to deliver MSCs in a porcine model of MI.
Methods: Autologous MSCs were cultured from subcutaneous fat of 27 pigs, and 
labelled by transfection. MI was induced by balloon occlusion (90 min) of the mid-left 
anterior descending artery. Ten days later, animals that survived the MI induction (19) 
received: Group 1: intracoronary (ic) culture media (n= 4); Group 2: ic MSCs (n= 5); 
Group 3: transendocardial culture media (n= 4); and Group 4: transendocardial MSCs 
(n= 6). Cardiac function was tested before and 10 days after the MI using intracardiac 
echocardiography and again 3 weeks after MSCs administration. Then the percentage 
of left ventricle MI of the harvested hearts was measured by planimetry. Histological 
sections are being processed for the study of implantation and differentiation.
Results:See table. Macroscopic infarcts were observed in all hearts and there were no 
signiﬁcant differences in the percentage of left ventricle MI between different groups 
(group 1: 19,3±5,2%; group 2: 24±0,6%; group 3: 22,2±6%; group 4: 21,7±7,2%).
Conclusions: This study demonstrates that neither cardiac function nor infarct size were 
signiﬁcantly modiﬁed by the administration of ic or transendocardial MSCs in our porcine 
model of MI.
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Ejection fraction measured by intracardiac echocardiography
Intracoronary administration Transendocardial 
administration
culture media MSCs culture media MSCs
Before infarction 77±2% 79±1% 84±2% 80±1%
Ten days after infarction 55±10% 48±1%* 50±6% 54±4%*
3 weeks after treatment 58±8% 49±5% 50±5% 51±5%
* p< 0,05 vs before infarction
9:30 a.m.
1014-142 Increased Beta-Catenin Pathway Expression by a 
Remote Ischaemic Preconditioning Stimulus: First 
Evidence in Humans
Hussain Contractor*, Houman Ashraﬁan*, Ishtiaq Rahman, Andrew N. Redington, 
Michael P. Frenneaux, C. Jorge Mascaro, Robert S. Bonser, Rajesh K. Kharbanda, 
University of Oxford, Oxford, United Kingdom, University of Birmingham, Birmingham, 
United Kingdom
Background: Remote ischemic preconditioning (rIPC) induced by transient limb 
ischemia, protects central organs against ischemia- reperfusion (IR), and is effective in 
reducing myocardial injury in children and in adults during cardiac surgery. The PI3K/AKT/
GSK-3B/B-catenin cell survival pathway has been proposed as key in animal models. We 
tested the hypothesis that the same pathway is activated in human rIPC .
Methods: During a double blind, randomised, sham controlled trial of rIPC in patients 
undergoing on-pump coronary artery bypass grafting , left ventricular apical biopsy was 
taken 10 minutes after aortic cross-clamp release. Immunoblots were performed and 
quantiﬁed by densitometry (normalised to B-tubulin). Comparisons between control (n=6) 
and rIPC (n=7) was by unpaired t-testing.
Results: p-AKT and pan-AKT were increased in rIPC (p=0.05 and p=0.004 respectively). 
Total GSK-3B was increased by rIPC (p=0.0007) but there was no change in p-GSK-
3B(p=0.95). B-catenin was signiﬁcantly increased by rIPC (p=0.003)(see Figure 1).
Conclusions: We demonstrate for the ﬁrst time, that rIPC increases myocardial 
expression of the B-catenin pathway. As well as yielding insights into the cell biology of 
cardioprotection, this observation may contribute to the development of clinically viable 
therapeutic strategies for reducing IR injury.
Figure 1: Relative expression of B-catenin pathway constituents in control and rIPC 
subjects. A=p-AKT, B=pan-AKT, C=p-GSK-3B, D=GSK-3B, E=B-catenin
9:30 a.m.
1014-143 Ischemic Preconditioning Protects Mitochondrial 
Respiratory Function in Complex I and Complex II
Gregory E. Steinbaugh, Daniel S. Lee, Douglas R. Pfeiffer, Jay L. Zweier, Juan A. 
Crestanello, The Ohio State University, Columbus, OH
Mitochondrial respiratory complexes are damaged by ischemia reperfusion injury. While 
IPC preserves overall mitochondrial respiratory function after ischemia reperfusion, it is 
unclear which is the effect of IPC on individual mitochondria respiratory complexes.
The purpose of this study was to determine the effect of IPC on mitochondrial respiratory 
complexes.
Isolated rat hearts (n=6/group) were subjected to either A) 30 minutes (min) of equilibration 
(EQ), 30 min of ischemia (I), and 30 min of reperfusion (RP) (CONTROL) or B) 10 min of 
EQ, two 5 min episodes of IPC, 30 min I, and 30 min of RP (IPC group). Interﬁbrillar (IF) 
and subsarcolemmal (SS) mitochondria were isolated at end reperfusion. Complex I, II, 
and IV activities were assessed by polarography using speciﬁc substrates and inhibitors 
for each complex in the presence of ADP. Substrates for Complex I, II, and IV were 
glutamate and malate (4.7 mM) , succinate (7 mM) , tetramethyl-p-phenylenediamine 
(0.4 mM) respectively. Inhibitors for complex I, II, and III used were rotenone (188 nM), 
thenoyltriﬂuoroacetone (0.4 mM) , and antimycin A (18.8 nM) . Data is expressed as 
mean±SEM. 
Complex I Complex II Complex IV
SS IF SS IF SS IF
CONTROL 83±4 55±4 53±2 24±2 59±2 46±4
IPC 130±7 * 112±5 * 70±3* 38±3 * 62±4 73±4
Data expressed in ng atoms O/mg protein. * p<0.05 vs CONTROL
Ischemia reperfusion impairs mitochondrial complex I, II and IV activity. IPC preserves 
both complex I and II activity in subsarcolemmal and interﬁbrillar mitochondria at 
end reperfusion. Complex IV activity is not affected by IPC. Selective protection of 
mitochondrial complex I and II during reperfusion is the mechanism responsible for 
preservation of respiration by IPC.
9:30 a.m.
1014-144 Deterioration of Left Ventricular Function in Patients 
With Non-ST-Elevation Myocardial Infarction Awaiting 
Coronary Angiography
Bjornar Grenne, Christian Eek, Benthe Sjoli, Helge Skulstad, Svend Aakhus, Otto 
Smiseth, Thor Edvardsen, Harald Brunvand, Sorlandet Hospital, Arendal, Norway, 
Rikshospitalet University Hospital, Oslo, Norway
Background: Optimal timing of coronary angiography for patients with non-ST-
segment elevation acute coronary syndrome (NSTE-ACS) is debated. Current 
guidelines recommend an invasive strategy within 48-72 hours after admittance. We 
hypothesized that persistent ischemia cause progressive deterioration of LV function until 
revascularization.
Methods: Sixty-one patients with clinical evidence of NSTE-ACS were enrolled in the 
study. Global and territorial LV function were assessed as longitudinal peak systolic strain 
by speckle tracking echocardiography. Examinations were performed at admittance and 
immediately prior to coronary angiography.
Results: There was a progressive impairment of LV function measured by global strain 
from admittance to coronary angiography in patients with non-ST-elevation myocardial 
infarction (NSTEMI). This was due to a pronounced regional dysfunction in the culprit 
territory (strains, -14.3% vs. -13.0%, p=0.003), whereas average strain in segments in 
the remote area remained unchanged. The coronary angiography was done 31±16 hours 
after admittance. There were no changes in global or territorial strain among patients with 
unstable angina or non-coronary chest pain. 
Strain (%) at 
admittance
Strain (%) before 
coronary angiography
Mean difference 
(95% CI) p value
NSTEMI (n=32) -15.8 ±3.0 -14.9 ±2.8 -0.9 (-1.4, -0.5) <0.001
Unstable angina 
(n=14) -17.6 ±2.4 -18.1 ±2.2 0.5 (-0,1 1.1) 0.083
Non-coronary chest 
pain (n=15) -19.8 ±1.9 -19.8 ±2.1 0.05 (-0.9, 1) 0.92
Strain values are mean ± S.D.
Conclusion: LV function deteriorates in hospitalized patients with NSTEMI awaiting 
coronary angiography. Our results indicate ongoing impairment in the culprit territory most 
likely due to ischemia and necrosis.
9:30 a.m.
1014-145 The Loss of MKK7 Is Critical for Cardiac Physiology
Bernhard J. Haubner, Gregory Neely, Jakob Voelkl, Christian Kremser, Otmar Pachinger, 
Josef M. Penninger, Bernhard Metzler, Department of Cardiology, Innsbruck Medical 
University, Innsbruck, Austria
Background: The highly conserved mitogen-activated protein kinases have proven to 
be of great importance regarding myocardial development, hypertrophy, and survival. 
Mitogen-activated protein kinase kinase 7 (MKK7), an upstream activator of c-Jun 
N-terminal kinases, displayed a dramatic cardiac phenotype with premature death when 
constitutively activated. The in vivo role of MKK7, using a muscle speciﬁc knock-out 
strategy, in the cardiac pathology remained unclear.
Methods: We therefore generated muscle speciﬁc MKK7 knock-out (KO) mice and 
investigated their myocardial phenotype compared to MKK7 wild-type (WT) rodents. 
Cardiovascular magnetic resonance (CMR), echocardiography and histological methods 
were used to characterize the physiological appearance of KO hearts. In addition, the 
reversible left anterior descending artery (LAD)-ligation model facilitated the examination 
of MKK7 KO mice during myocardial stress.
Results: We found signiﬁcantly reduced fractional shortenings (WT: 56,2±2,1 vs. KO: 
43,6±1,9%, n=7, p<0,05; CMR data) combined with marked dilatation (transversal 
diameter WT: 3,004±0,084 vs. KO: 3,511±0,105 mm, n=7, p<0,05; CMR data) in MKK7 
KO rodents at the age of 12 weeks. In contrast, the extent of ischemia/reperfusion injury 
was signiﬁcantly reduced in MKK7 KO compared to WT mice. Following 30 minutes of 
ischemia and 3 hours of reperfusion, MKK7 mutagenic rodents presented signiﬁcantly 
reduced levels of troponin T (WT: 2,97± 0,39 vs. KO: 1,78± 0,26 ng/ml, n=13, p<0,05). 
This early decrement of troponin T in the transgenic cohort was followed by smaller areas 
of infarction after 1 week (WT: 3,58±0,50 vs. KO: 1,77±0,30mm², n=14, p<0,05, sum 
of 3 sections per heart). Concordantly, functional analysis after 1 week of reperfusion 
showed a greater reduction of fractional shortening in MKK7 WT mice compared to the 
transgenic strain.
Conclusions: Our data provide the ﬁrst in vivo knock-out evidence for the critical role of 
MKK7 in the heart: Whereas MKK7 KO hearts display reduced cardiac functions, they are 
partly protected from myocardial ischemia/reperfusion injury.
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1014-146 Remote Ischemic Preconditioning Modiﬁes Cardiac 
Micro RNA Expression In Vivo: First Observations in a 
Mouse Model
Jing Li, Wanli Xuan, Pingzhao Hu, Rajesh K. Kharbanda, Andrew N. Redington, The 
Hospital for Sick Children, Toronto, ON, Canada
Background: Remote ischemic preconditioning (rIPC) induced by transient limb ischemia 
has been shown to invoke potent myocardial protection in multiple animal models, and 
recently in adults and children undergoing cardiac surgery. We have previously described 
important effects of the rIPC stimulus on gene expression proﬁles in mouse myocardium 
and human neutrophils, but our understanding of the mechanisms by which rIPC exerts its 
effects on cell signaling remains incomplete. MicroRNAs (miRNAs) are a recently discovered 
classes of endogenous, small, noncoding RNAs that downregulate posttranscriptional gene 
expression. There are no data regarding their role in ischemic preconditioning, but they are 
increasingly recognized as modiﬁers of myocyte growth and stress responses. We therefore 
hypothesized that the rIPC induces changes in myocardial miRNA expression.
Methods and Results: Sham procedure (n=3) or rIPC (four cycles of 5 min of hind-limb 
ischemia and 5 min of reperfusion, n=5) was performed immediately prior to heart harvest 
in mature wild type mice. Extracted RNA was subjected to analysis using a mouse miRNA 
microarray containing 382 miRNA probes. The resulting data was standardized by a quantile 
normalization method, and SAM (signiﬁcance analysis of microarrays) analysis was used for 
statistical comparisons of control and rIPC proﬁles. Overall, 19 miRNA’s were signiﬁcantly 
down-regulated (n=17, fold change 0.83-0.67) or up-regulated (n=2, miRNA 206, fold change 
2.23; p=0.005, and miRNA 346, fold change 10.31; p<0.005). Most of the miRNA’s modiﬁed 
by rIPC have hitherto unknown roles in myocyte function and responses.
Conclusions: rIPC has potent effects on myocardial miRNA expression. This novel 
observation suggests a role for miRNA in regulating myocyte responses to ischemia-
reperfusion injury. Further studies of the role of individual miRNA’s will enhance our 
understanding of the mechanism of protection afforded by rIPC, and may establish new 
therapeutic targets.
9:30 a.m.
1014-147 Impact of Antioxidative and Antiapoptotic Effects of 
Mesenchymal Stem Cells on Salvaging Ischemic Heart 
Injury: Role of Transient Overexpression of Heme 
Oxygenaze-1
Toshinari Tsubokawa, Chiaki Nakanishi, Kunimasa Yagi, Atsushi Nohara, Noboru 
Fujino, Hidekazu Ino, Shotoku Tagawa, Masakazu Yamagishi, Hatsue Ueda, Kanazawa 
University Graduate School of Medicine, kanazawa, Japan, National Cardiovascular 
Center, Osaka, Japan
Background:Stem cell therapy has potential to reduce ventricular remodeling associated 
with ischemic myocardial injury. Under these conditions, Heme Oxygenase-1 (HO-1) plays a 
pivotal role as a graft survival protein and there exists a fundamental codependence between 
HO-1 and cytoprotection. However, few data exist regarding impact of expression of HO-1 
in mesenchymal stem cell (MSC) on cytoprotection. Therefore, we examined the effect of 
transient overexpression of HO-1 in anti-oxidative and anti-apoptotic activities of MSC.
Methods and Results:Transfer of human HO-1 gene into bone marrow-derived MSC 
was performed by lipofection method. To evaluate the effect of HO-1 overexpression, 
MSC or HO-1MSC were exposed to culture conditions with serum deprivation (SD) and 
hypoxia and characteristics of cell damage were analyzed by ﬂow cytometry. Cell viability 
was determined by MTS assay after exposing MSC or HO-1MSC to H2O2 as an oxidative 
stress. VEGF level in the supernatant of each cells culture after the load of H2O2 were 
measured by using ELISA. In rat infarction model, MSC (5×106 ± 0.4 ×106 cells/rat) or 
HO-1MSC was injected around the infracted border zone, and cardiac examination was 
performed on 28 days later. In vitro, the levels of HO-1 mRNA in MSC was maximum at 
day 2 and was decreased on and after the day 4. HO-1 overexpression prevented MSC 
from SD/hypoxia - induced apoptosis (MSC 30 ± 5% vs. HO-1MSC 17 ± 2 %, p<0.05) and 
were markedly resistant to cell death at 400μM H2O2 (2 ± 2% vs. 32 ± 3%, P<0.05). HO-
1MSC secreted a large amount, 2.5-fold more VEGF compared with MSC. When HO-1MSC
were delivery by intramyocardial injection, increased capillary density associated with 
decreased infarction size was observed in HO-1MSCs (1332 ± 75 /mm2 with 21.1 ± 2.4%) 
compared with MSCs and control groups (1224 ± 138 /mm2 with 27.8 ± 2.5% and 609 ± 
48 /mm2 with 36.9 ± 3.8%, p<0.05).
Conclusions:These results demonstrate that enhanced anti-apoptotic and anti-oxidative 
effects of MSCs can be obtained by transient overexpression of HO-1, and contribute to 
improving therapeutic efﬁcacy for acute myocardial ischemia, probably through paracrine 
action such as production of VEGF.
9:30 a.m.
1014-148 Pro-arrhythmic Risk of Embryonic Stem Cell-
Derived Cardiomyocyte Transplantation in Infarcted 
Myocardium
Song-Yan Liao, Chung-Wah Siu, Wing-Hon Lai, Ka-Wing Au, Yuan Liu, Ed Wu, Yin 
Wu, Pandora M. Yip, Ronald Li, Chu-Pak Lau, Hung-Fat Tse, Cardiology Division, 
Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong 
Kong, Hong Kong
Background: Embryonic stem cells (ESCs) and their cardiac derivatives have been 
explored as potential cell sources for treatment of post-myocardial infarction (MI) left 
ventricular (LV) dysfunction, however, their potential proarrhythmic risk remains unclear.
Methods: We compared the functional effects and proarrhythmic risk of direct 
intramyocardial transplantation of 3x105 undifferentiated mouse ESC (ESC group, 
n=20) and mouse ESC derived-cardiomyocytes (ESC-CM group, n=28) versus culture 
medium (Control group, n=24) at the infarct and border zone in mouse model of acute 
MI. Cardiac magnetic resonance imaging (MRI) was performed at 1 and 3 wks post-MI. 
Electrocardiogram telemetry was performed to monitor for proarrhythmias.
Results: At 4 wks, ESC-CM group had signiﬁcantly higher mortality rate compared with 
those in control group and ESC group (Figure 1, P<0.05). Telemetry monitoring conﬁrmed 
the presence of spontaneous ventricular tachyarrhythmias (VT/VF) as cause of death 
in majority of mice transplanted with ESC-CM (67%). Cardiac MRI showed a similar 
improvement in LV ejection fraction in those mice of ESC group and ESC-CM group 
compared with control group at 1and 3 wks post-MI (Figure 2, P<0.05).
Conclusions: Our results demonstrate that transplantation of undifferentiated ESCs and 
ESC-CMs provide similar improvement in cardiac function post-MI, however, ESC-CMs is 
associated with a signiﬁcant higher prevalence of spontaneous VT/VF and early mortality 
after transplantation. 
9:30 a.m.
1014-149 Increased Rho Kinase (ROCK) Activity in Hong Kong 
Subjects With Acute Coronary Syndrome (ACS)
Cheuk-man Yu, Ming Dong, Rui-jie Li, Mang Zhang, Qian-huan Zhang, James K Liao, 
The Chinese University of Hong Kong, Hong Kong SAR, Hong Kong
Background: Rho Kinase (ROCK) has been demonstrated to be involved in 
hypercontraction of vascular smooth muscle and implicated as playing a pathophysiological 
role in cardiovascular diseases such as coronary artery spasm. This study aimed to ﬁnd 
out if ROCK activity is increased in Hong Kong population with acute coronary syndrome 
(ACS).
Methods: 112 Hong Kong subjects admitted for ACS and 20 matched controls were 
studied. ACS patients included 3 groups: ST elevation myocardial infarction (STEMI) 
(n=50), Non-ST elevation myocardial infarction (NSTEMI) (n=50) and unstable angina 
(UA) (n=12).
Results: ROCK activity, as determined by phosphorylation of myosin binding subunit 
(MBS) in leukocytes, was greater in STEMI (4.70±1.64), NSTEMI (4.68±1.55), and UA 
subjects (3.37±1.10) when compared with controls (1.38±0.35, all p<0.01). It was even 
higher in STEMI and NSTEMI subjects than in UA subjects (both p<0.05). Furthermore, 
ACS patients with elevated peak WBC level (>10.1x109/l) showed a higher ROCK activity 
than those with low level (a10.1x109/l) (4.94±1.66 vs. 4.15±1.46, p<0.01). In addition, 
levels of troponin T (TnT), creatinine phosphokinase (CK), WBC, as well as total and 
LDL-cholesterol were associated with increased ROCK activity (Table).
Conclusion: This prospective study observed that ROCK activity was increased in 
patients with ACS, in particular those with myocardial infarction. The pathophysiological 
role of ROCK activity in ACS warrants further investigation. 
Correlations between ROCK activity and clinical / biochemical parameters in ACS
First TnT Peak TnT Peak CK Peak WBC TC LDL
Correlation coefﬁcient 0.304 0.374 0.275 0.226 0.221 0.226
P value 0.002 0.000 0.006 0.021 0.050 0.050
9:30 a.m.
1014-150 Neutralization of Interleukin (IL)-18 Ameliorates 
Ischemia/Reperfusion-Induced Myocardial Injury
William H. Boylston, Kaliyamurthi Venkatachalam, Sumanth D. Prabhu, Anthony J. 
Valente, Bysani Chandrasekar, Department of Veterans Affairs South Texas Veterans 
Health Care System, San Antonio, TX, University of Texas Health Science Center, San 
Antonio, TX
Background: Interleukin-18 is a proinﬂammatory, pro-apoptotic cytokine, whose 
expression increases during myocardial infarction and failure. We recently demonstrated 
that oxidative stress stimulates IL-18 expression in cardiomyocytes. Since ischemia/
reperfusion (I/R) causes oxidative stress and potently induces proinﬂammatory cytokines, 
we hypothesized that IL-18 is induced following I/R and contributes to inﬂammation and 
tissue injury. Neutralization of IL-18 should thus lessen I/R-mediated tissue injury. We also 
asked whether simulated I/R in vitro induces IL-18 expression in cultured cardiomyocytes, 
and identiﬁed the underlying molecular mechanisms.
Methods: I/R studies were performed in a chronically instrumented, closed-chest mouse 
model. Male C57BL/6 mice underwent 30 min LAD coronary artery ligation followed by 
various periods of reperfusion. Sham-operated or ischemia alone (30 min) mice served 
as controls. A subset of animals was treated with IL-18 neutralizing antibodies (500 μg/
mouse, i.v.) 1 h prior to LAD ligation. Ischemic LV tissue was used for analysis. Isolated 
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adult mouse cardiomyocytes underwent simulated I/R (30 min I/4 h R; sI/R) Downstream 
effectors were targeted by pharmacological inhibitors and adenoviral transduction of 
dominant negative expression vectors.
Results: Our results demonstrate low levels of NF-KB activity and IL-18 expression in 
naïve, sham-operated or ischemia alone animals. However, I/R signiﬁcantly increased 
ROI generation, upregulated NF-KB activity and IL-18 expression in the ischemic LV 
tissue. Further, I/R upregulated IL-18RB, but not IL-18RA expression. In contrast, IL-
18BP expression was induced in a delayed manner. Importantly, IL-18 neutralization 
signiﬁcantly attenuated I/R-induced tissue injury (31% reduction in infarct size vs. sham). 
Conﬁrming these in vivo results, sI/R enhanced ROI generation, IKK activity, NF-KB DNA 
binding activity, and IKK-NF-KB-dependent biologically active IL-18 expression in isolated 
adult mouse cardiomyocytes.
Conclusions: IL-18 signaling plays a critical role in I/R induced tissue injury and chronic 
inﬂammation, and thus represents a potential therapeutic target.
9:30 a.m.
1014-151 Long Acting Erectile Dysfunction Drug Tadalaﬁl 
Protects the Heart Against Ischemia/ Reperfusion 
Injury Through Hydrogen Sulﬁde Signaling
Fadi N. Salloum, Vinh Q. Chau, Jon-Erik Houser, Amit Varma, Nicholas N. Hoke, 
Antonio Abbate, Rakesh C. Kukreja, Virginia Commonwealth University Medical Center, 
Richmond, VA
Background: Emerging evidence suggests that the gaseous signaling molecule; 
hydrogen sulﬁde (H2S) plays an important role in cardioprotection against ischemia/
reperfusion injury (I/R). Also, plasma levels of H2S in patients with coronary artery 
disease (CAD) are signiﬁcantly lower than in angiographically normal control subjects. 
Since H2S-producing enzyme, cystathionine-G-lyase (CSE) is expressed in the heart, 
we hypothesized that novel phosphodiesterase-5 (PDE-5) inhibitor, tadalaﬁl (TAD) might 
utilize H2S signaling in cardioprotection.
Methods: After obtaining baseline left ventricular (LV) function using transthoracic 
echocardiography (TTE), adult ICR mice were injected i.p. with TAD (1 mg/kg), vehicle 
(10% DMSO), TAD+dl-propargylglycine (PAG, CSE blocker; 50 mg/kg), or vehicle+PAG 
1 h prior to 30 min ischemia and 24 h reperfusion. At the end of reperfusion, TTE was 
performed and hearts were collected for infarct size (IS) measurement using computer 
morphometry of TTC stained sections.
Results: Myocardial IS (mean ± SE) was signiﬁcantly reduced in mice pretreated with 
TAD (Fig. 1A; 68% decline). The risk area was not different between groups (Fig. 1B). 
Moreover, fractional shortening was preserved only with TAD (Fig. 1C).
Conclusion: PDE-5 inhibition with TAD may be a useful therapeutic tool to reduce IS and 
attenuate LV dysfunction secondary to I/R in patients with CAD. Moreover, these studies 
provide a novel mechanism involving H2S signaling in TAD-induced cardioprotection.
9:30 a.m.
1014-152 Down-Regulation of MicroRNA-29 Contributes to the 
Myocardial Protective Effect of Pioglitazone Against 
Ischemia-Reperfusion Injury- a PPAR-G Dependent 
Effect
Yumei Ye, Jose R. Perez-Polo, Douglas L. Mann, Yochai Birnbaum, University of Texas 
Medical Branch, Galveston, TX, Baylor College of Medicine, Houston, TX
Background: MicroRNAs (miRNAs) are involved in controlling diverse aspects of 
cardiac function, including proliferation, apoptosis and remodeling. Pioglitazone (PIO), 
a thiazolidinedione with PPAR-G agonist activity, protects against ischemia/reperfusion 
injury (I/R) and limits infarct size in experimental models. However, the underlying 
mechanisms involved in the protective effect of PIO are only partially understood. We 
assessed the role of miRNAs in protection against simulated I/R injury (SIR) by PIO. 
Methods: We used miRNA gene arrays to evaluate expression changes of miRNAs in 
the rat heart after 7-day PIO (5 mg/kg) administration, and then conﬁrmed the result by 
Northern Blot. We studied the effect of GW9662, a PPAR-G inhibitor, on the effect of PIO 
on miR-29 levels in H2C9 cardiomyocytes. We assessed the effects of miR-29 mimic 
and anti-sense inhibitor oligos, and their interactions with PIO on viability (MTT test), cell 
death (Trypan Blue) and apoptosis (Caspase-3 activity) of H2C9 cardiomyocytes exposed 
to 16h hypoxia and 2h reoxygenation (SIR). Finally, we assessed the effects of miR-29 
mimic and anti-sense inhibitor oligos on Mcl-1 (an anti-apoptotic Bcl-2 family member) 
cellular protein levels in H2C9 cells. Results: PIO signiﬁcantly decreased miR-29a and 
miR-29c levels. Down-regulation of miR-29a and miR-29c by antisense inhibitors or by 
PIO protected H9C2 cardiomyocytes against SIR (increased MTT activity, decreased 
cell death and decreased Caspase-3 activity). In contrast, transfection of cells with 
miR-29a and miR-29c mimic oligos promoted cell death. Co-transfection with miR-29a 
and miR-29c mimic oligos completely blocked the protective effect of PIO. The effect of 
PIO on miR-29s levels was blocked with GW9662. Overexpression of miR-29s reduced 
Mcl-1 cellular protein levels and transfection with inhibitor of miR-29 increased Mcl-1 
levels. Conclusions: PIO downregulated miR-29a and miR-29c levels. This effect was 
dependent on PPAR-G activation. Down-regulation of miR-29a and miR-29c contributed 
to the myocardial protection effect of PIO against SIR. These ﬁndings provide a rationale 
for the development of miRNA-based strategies for minimizing I/R damage.
9:30 a.m.
1014-153 Uncoupling Protein (UCP3) Plays an Important Role in 
Ischemic Preconditioning
Cevher Ozcan, Monica Palmeri, Raymond R. Russell, III, Section of Cardiovascular 
Medicine, Yale University School of Medicine, New Haven, CT
Background: Although mitochondria play a key role in ischemic preconditioning (IPC) 
of the heart, the exact mechanism of IPC remains unclear. Recently, endogenous 
mitochondrial uncoupling proteins (UCP) have been identiﬁed as mediators of a 
cardioprotective mechanism that prevent cardiac cell death under metabolic or oxidative 
stress. We hypothesize that mitochondrial uncoupling may have an important mechanistic 
role in IPC by preserving cellular energetics and metabolism.
Methods: Hearts from UCP3 null (UCP3-/-) and wild type mice were perfused in 
working mode and subjected to 30 min ischemia and 30 min of reperfusion either with 
or without prior preconditioning (4 cycles of 4 minutes of ischemia followed by 4 minutes 
of reperfusion). Left ventricular developed pressure (LVDP), heart rate and rate-pressure 
product were measured. In addition, the content of high-energy nucleotides was analyzed 
by HPLC.
Results: While myocardial contractile function was signiﬁcantly impaired by ischemia-
reperfusion injury, IPC improved left ventricular recovery in wild type hearts (No 
IPC: 19.7±3.5%, IPC: 37.0±7.2%, p=0.02). However, there was no improvement in 
postischemic recovery of function with IPC in UCP3-/- hearts (No IPC: 17.8±3.7%, IPC: 
16.2±2.4%, p=0.35). The recovery of function following IPC was greater in wild type 
hearts compared to UCP3-/- hearts (p=0.01). Also, myocardial ATP level, an indicator of 
myocardial energy status was signiﬁcantly greater with IPC in wild type hearts compared 
to non-IPC (0.82±0.1 vs 0.53±0.04 nmoles/mg protein, p=0.01). But the amount of ATP 
in UCP3-/- hearts after ischemia-reperfusion was not affected by IPC. Thus, protective 
efﬁcacy of ischemic preconditioning abolished in UCP3 knockout mouse.
Conclusion: Mitochondrial UCP3 plays an important mechanistic role in IPC and 
preserves myocardial function by maintaining cellular high-energy phosphate stores 
during ischemia-reperfusion injury, perhaps through the preservation of mitochondrial 
oxidative phosphorylation and structure during oxidative stress.
9:30 a.m.
1014-154 The Impact of Timing on the Safety of Transendocardial 
Delivery of Mesenchymal Precursor Stem Cells 
Following Acute Myocardial Infarction
Marlos R. Fernandes, Guilherme Silva, Cristiano Cardoso, Yi Zheng, Fred Baimbridge, 
Maria G. Cabreira, John Canales, Micheal Schuster, Silciu Itescu, Deborah Vela, 
Maximilian Buja, James T. Willerson, Emerson C. Perin, Texas Heart Institute, Houston, TX
Background:The ideal timing for stem cells delivery post acute MI is unknown and 
experience with transendocardial injections (TE) in this setting is very limited. There 
is concern regarding cell survival and procedural safety in the acute MI setting. We 
evaluated the safety and efﬁcacy of TE of mesenchymal precursor stem cells (MPC) at 
two different time points after MI.
Methods:Twenty two sheep underwent balloon occlusion of the LAD for 90 min. TE of 
225x106 MPC or placebo were performed at 5 days [4 control (C) and 5 treated (T)] and at 
10 days (5 C and 5 T) post MI. Sheep were followed for 8 weeks. Left ventricular ejection 
fraction (LVEF) was assessed by 2D echo. Arteriolar density, cell proliferation (Ki67), 
apoptosis (TUNNEL) and collagen density were evaluated in the infarct border.
Results:The incidence of VT was higher at 5 days post MI (4 vs 1 episode at 5 and 10 days, 
respectively - p=0.08).There was no peri procedural death or tamponade. Overall, T sheep 
had LVEF improvement at 8 weeks (ﬁg 1a). The maximum improvement was seen in T at 
10 days post MI (ﬁg1b). There was no inﬂammation or abnormal tissue growth. Increased 
arteriolar density (61.9±14 vs 40.3±12 vessels/mm2 - p=0.005) and a trend of higher cell 
proliferation (5.8±2.1 vs 3.9±1.7 positive nuclei/103 nuclei - p=0.06) were seen at the infarct 
border of T sheep. There were no differences in collagen content and apoptosis.
Conclusions:Postponing MPC delivery to 10 days after myocardial infarction might 
improve its overall safety and efﬁcacy. 
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9:30 a.m.
1014-155 Intravenous Infusion of Drag-Reducing Polymers:
A New Approach to Improve Left Ventricular Function
in a Rat Model of Myocardial Infarction
Xianghui Chen, Kai Cui, Jiancheng Xiu, Yi Lao, Hui Xue, Daogang Zha, Jianping Bin, Yili 
Liu, Nanfang Hospital, Guangzhou, People’s Republic of China
Background Blood soluble drag reducing polymers (DRPs) have been shown to reduce 
microvascular resistance and improve myocardial perfusion in a canine model of ﬂow-
limiting coronary artery stenosis. In animals with totally coronary artery occlusion, the 
effects of DRPs on cardiac function are unknown. In this study, we hypothesized the 
administration of DRPs can improve left ventricular (LV) function in rats post myocardial 
infarction (MI).
Methods 24 male SD rats were randomly allocated to either normal saline containing 
50 μg/ml of DRPs (n=12) or saline (n=12) at a constant rate of 3.5 ml/h. 15 mins later, 
the animals were subjected to coronary artery ligation. 24h after MI, noninvasive 
echocardiograpy was performed to assess the changes of impaired LV function. LV internal 
dimensions and the anterior wall thicknesses were measured, and wall motion score 
index and endocardial length of severe wall motion abnormality (SM) were calculated by a 
16 segment model on short axis view. Contrast agent was utilized to analyze the regional 
extent of myocardial perfusion defect (PD) by contrast score index and ratio of perfusion 
defect length to LV length.
Results At 24h post MI, DRP-treated animals had marked smaller LV end-systolic 
diameter (3.81±0.85 vs. 5.28±0.88mm, p < 0.01), better anterior diastolic and systolic 
wall thickness (1.63±0.28 vs 0.94±0.20mm, p< 0.001 and 1.91±0.35 vs 1.08±0.21mm, 
p < 0.001, respectively). Signiﬁcant improvement in fractional shortening (34.84±10.35% 
vs 21.07±5.05%, p< 0.05) was also detected in rats infused with DRPs, paralleled with a 
lower wall motion score index (1.79±0.54 vs 2.52±0.15, p< 0.01) and smaller ratio of SM 
length to LV length (0.27±0.24 vs 0.64±0.06, p< 0.01) . Compared with control group, both 
of contrast score index (1.73±0.42 vs 2.21±0.22, p < 0.05) and ratio of PD length to LV 
length were signiﬁcantly reduced in DRP-group (0.27±0.19 vs 0.54±0.08, p < 0.01).
Conclusions Intravenous infusion of nanomolar concentrations of DRPs improved LV 
function in a rat model of MI. This may be related to the reduction of akinetic myocardium 
and extent of myocardial PD. This ﬁnding has important therapeutic implications to the 
treatment of acute coronary syndrome.
9:30 a.m.
1014-156 Endothelial Cell Injury Induced by Intracoronary Sera in
Patients With ST Elevation Myocardial Infarction
Gopal Ghimire, Ann McCormack, Jonathan Spiro, Rajesh Kharbanda, Marlene Rose, 
Miles Dalby, Royal Brompton and Hareﬁeld NHS Trust, London, United Kingdom
Background:Integrity of endothelium is compromised in ST Elevation Myocardial Infarction 
(STEMI). We evaluated in-vitro the effect of sera derived from the atherothrombotic 
coronary artery aspirate (CA) and femoral arterial blood (FA) of patients with STEMI, 
on human umbilical vein endothelial cells (HUVECS). Since activated and apoptotic 
endothelial cells induce surface expression of vimentin and are an important source of 
autoantigens, we also evaluated the titres of antivimentin antibodies (AVA).
Methods:Paired sera obtained from the CA and FA of patients with STEMI during primary 
angioplasty(n=26) were incubated for 4 hours with HUVECS in presence of complement. 
The cell injury was assessed with ﬂow cytometry using Annexin V (AV) and Propidium 
Iodide (PI). ELISA was performed in both the sera for IgG and IgM AVA.
Results: A mean of 19.23 % (SD, 9.8) of the HUVECS incubated with the CA and 10.21 
% (7.93) with FA underwent apoptosis (AV+, PI-), p=6.7X1-5. The mean CA IgG and IgM 
AVA titres were 59.05 (35.9) and 66.08 (23.6)respectively. The FA IgG and IgM titres were 
respetively 78.78 (36.8), p= 1.71X10-5 and 77.92 (23.7) , p= 0.00023.
Conclusions: Soluble factors in the sera of coronary aspirate of patients with STEMI may 
induce endothelial injury and contribute to microvascular injury. Sequestration of the AVA 
on to the apoptotic endothelial cells may explain the observed reduction in AVA titres in 
CA: the AVA-antigen complex can ﬁx compliment and may contribute to mechanism of 
microvascular injuries. 
9:30 a.m.
1014-157 PI3k/akt Activation and Nuclear Accumulation of B
-Catenin Are Key Components in the Myocardial
Protection Afforded by Remote Ischemic
Preconditioning
Jing Li, Wanli Xuan, Ran Yan, Emilie Jean-St-Michel, Michael Tropak, Andrew 
Redington, Hospital for Sick Children, Toronto, ON, Canada
Background: Remote (r) ischemic preconditioning (IPC) induced by transient limb 
ischemia has been shown to invoke potent myocardial protection in multiple animal models, 
and recently in adults and children undergoing cardiac surgery. While the important role of 
PI-3 kinase/Akt activation in the cardioprotection afforded by local IPC is well described, 
our understanding of the intracellular signaling of rIPC remains incomplete. Furthermore, 
nuclear accumulation of B -catenin, a downstream target of GSK-3B, has recently been 
shown to have a key role in regulating cell survival and proliferation in cardiomyocytes. 
We therefore examined the hypothesis that rIPC activates intracellular kinases and leads 
to nuclear B -catenin accumulation in a mouse model of rIPC.
Methods and Results: A Krebs-perfused mouse Langendorff model (subjected to 30min 
global ischemia and 60 min reperfusion) was used. Sham procedure or rIPC (four cycles 
of 5 min of hind-limb ischemia and 5 min of reperfusion) was performed immediately 
prior to heart harvest. Compared to sham, recovery of left ventricular developed 
pressure (p=0.07), LVEDP (p<0.01)) and peak +ve and -ve dP/dt (both p<0.05) were all 
improved by rIPC. These changes were blocked by pretreatment (prior to limb ischemia) 
with Wortmannin (PI-3 kinase inhibitor) and 3,3’-diindolylmethane (DIM) (which blocks 
transcriptional activity of B -catenin). rIPC signiﬁcantly reduced infarct size (11.36±2.21% 
versus sham 39.31±7.02%, p<0.05) and this cardioprotection was reversed by 
pretreatment with Wortmannin or DIM (both p=ns compared with sham). Western blotting 
showed that rIPC signiﬁcantly increased phospho-Akt (1.66±0.11 fold vs. sham), inhibited 
GSK-3b by increasing phosphorylated GSK-3b (1.63 fold), and was associated with a 
1.92-fold increase in nuclear B -catenin. All of these changes were completely abrogated 
by pretreatment with Wortmannin.
Conclusions: The myocardial protection afforded by rIPC is mediated via the PI-3K/
Akt/GSK-3b signaling pathway, activation of which is associated with the novel ﬁnding of 
nuclear accumulation of B -catenin.
9:30 a.m.
1014-158 In Vivo Myocardial Ischemia Reperfusion (I/R)
Impairs Nitric Oxide Synthase (NOS) Activity:
Potent Cardioprotection With BH4 Treatment
Tiansheng Wang, Tse-Yao Wang, Jian Sun, Chun-An Chen, Fuchun Yang, M.A. Hassan 
Talukder, Jay L. Zweier, Davis Heart and Lung Institute, The Ohio State University, 
Columbus, OH
Tetrahydrobiopterin (BH4) is an essential cofactor of NOS that is highly redox-sensitive 
and causes NOS uncoupling during myocardial I/R. In an in vitro model of rat myocardial 
I/R, we have demonstrated that I time-dependently decreased cardiac BH4 content 
with concurrent decrease in eNOS activity and increase in NOS-derived superoxide. 
Supplementation of BH4 partially restored eNOS activity and suppressed eNOS-derived 
superoxide. It is well known that excessive superoxide formation and diminished nitric 
oxide generated by eNOS uncoupling have detrimental effects on myocardial I/R injury. 
Therefore, to address this issue in a clinically relevant model, in vivo regional myocardial 
I/R was performed in rats with measurement of myocardial NOS activity and infarction. 
Effect of BH4 treatment (100 μM in vitro or 10 mg/kg iv) was also investigated. Rats 
underwent 60-min regional myocardial I followed by R. Left ventricular samples from the 
area at risk (AAR) and non-ischemic area were harvested for NOS activity (L-arginine to 
L-citrulline assay). Myocardial NOS activity of AAR demonstrated a biphasic response 
where decreased NOS activity during I and early R (10-min) was followed by increased 
NOS activity. BH4 supplementation or treatment not only enhanced the NOS activity but 
also signiﬁcantly reduced myocardial infarct size. These ﬁndings provide direct evidence 
that in vivo myocardial I/R results in NOS dysfunction, and that BH4 treatment restores 
NOS activity and enhances myocardial salvage.
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9:30 a.m.
1014-159 Candesartan and Omapatrilat Modulate Matricellular 
Proteins and Matrix Proteases and Limit Remodeling 
During Healing After Reperfused Myocardial Infarction
Bodh I. Jugdutt, Arivazhagan Palaniyappan, Halliday Idikio, University of Alberta, 
Edmonton, AB, Canada
Background: We hypothesized that therapy with the angiotensin II type 1 receptor 
blocker candesartan (CN) or the vasopeptidase inhibitor omapatrilat (OMA), by reducing 
effects of angiotensin II, modulate healing-speciﬁc matricellular proteins such as 
secretory leucocyte protease inhibitor (SLPI), secreted protein acidic and rich in cysteine 
(SPARC) and osteopontin (OPN) as well as other matrix metalloproteases (MMPs) and 
cytokines during healing after reperfused myocardial infarction (RMI) and thereby limit left 
ventricular (LV) remodeling and dysfunction.
Methods: We randomized 60 Sprague-Dawley rats 24 h after RMI (1-h left anterior 
descending coronary occlusion; reperfusion) to 3 weeks of oral placebo, CN (30 mg/kg) 
and OMA (10 mg/kg). Sham rats had no RMI or drug. We measured serial LV function 
and remodeling (echocardiography/Doppler) and regional molecular expression of SLPI, 
SPARC, OPN, MMP, TIMP, and other proteins (Western blots), MMP activity (zymography), 
and infarct size at 3 weeks.
Results: Compared to sham, RMI-placebo induced ST-segment elevation, infarction 
(25% LV; 60% risk), LV dysfunction and remodeling. Compared to placebo, CN and 
OMA similarly limited LV dysfunction and remodeling. Compared to non-infarct zones, 
RMI induced robust increases (P<0.001) in SLPI, SPARC and OPN proteins, MMP-9 
and MMP-2 (activity and protein), and inducible-nitric-oxide-synthase (iNOS), interleukin 
(IL)-6, tumor necrosis factor (TNF)-A, transforming growth factor (TGF)-B1, Smad-2 and 
myelopeoxidase proteins in the ischemic zones. Both drugs normalized these changes 
and improved MMP-9/TIMP-3 balance.
Conclusions: Both CN and OMA modulate matricellular proteins, MMP-9/TIMP-3, 
angiotensin II and cytokines, thereby mitigating adverse LV remodeling and dysfunction 
during healing after RMI.
9:30 a.m.
1014-160 Leptin Modulates Metabolic Substrate Utilization 
in Ischemic Cardiac Tissue Through Inactivation of 
Andenosine Monophosphate Kinase
Kenneth R. McGafﬁn, Baobo Zou, Lia C. Romano, Charles F. McTiernan, Christopher P. 
O’Donnell, University of Pittsburgh, Pittsburgh, PA
Introduction: Under aerobic conditions, the normal heart uses mainly fatty acid (FA) for 
ATP production and responds to leptin by increasing FA oxidation. In ischemia, serum 
leptin increases, and the heart switches from aerobic to anaerobic metabolism. This 
metabolic switch is linked to the activity of a number of regulatory proteins, including 
AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC).
Aim: The present study was undertaken to test the hypothesis that leptin regulates 
the activity of AMPK and ACC in the heart, facilitating oxidative metabolism in normal 
myocardium and enhancing glycolysis in ischemia.
Methods/Results: Coronary artery ligation (CAL) (n=10) or sham (n=10) surgery was 
performed on 9 week old C57BL6 male mice. After 3 days, equal numbers were treated 
with leptin (0.3mg/kg ip) or vehicle for 30 minutes, followed by sacriﬁce. Data shown are 
mean±sem, with p values determined by t-test. Versus sham hearts, infarcted cardiac 
tissue showed a 22±1 fold increase in leptin, a 2.9±0.2 fold increase in glucose transporter 
1, a 37±6% decrease in FA binding protein, and a 46±3% decrease in FA translocase 
mRNAs by quantitative-PCR (all p<0.01). Leptin signaling, measured by phosphorylated/
total (p/t) cardiac STAT3 protein, was increased 3.7±0.1 fold in infarcted tissue, with a 
further 1.5±0.1 fold increase after exogenous leptin (both p<0.05). Consistent with a 
switch to anaerobic metabolism, CAL caused a 32±3% decrease in p/t AMPK and 46±4% 
decrease in p/t ACC, with an additional 58±6% and 42±5% reduction in p/t AMPK and 
ACC respectively, after exogenous leptin (all infarct tissue versus sham; all p<0.05). In 
contrast, and consistent with the activation of oxidative metabolism, exogenous leptin 
increased p/t AMPK and ACC in sham hearts by 50±8% and 75±8%, respectively (both 
p<0.05 versus vehicle treated shams).
Conclusions: Combined, these data suggest that leptin mediates differential metabolic 
responses in normal and ischemic myocardium by regulating factors involved in both 
substrate transport and utilization, stimulating elements of aerobic metabolism when oxygen 
supply is abundant (sham mice) and glycolysis when oxygen is scarce (CAL mice).
9:30 a.m.
1014-161 The Common Variant Rs9939609 in the FTO Gene Is 
Associated With Early-Onset Myocardial Infarction
Diego Ardissino, Carlo Berzuini, Piera Angelica Merlini, Daniela Lina, Maria Francesca 
Notarangelo, Marco Tubaro, Pier Mannuccio Mannucci, Luisa Foco, Luisa Bernardinelli, 
David Altshuler, Sekar Kathiresan, Azienda Ospedaliero-Universitaria, Parma, Italy
Background: Type 2 diabetes and body mass index (BMI) are major risk factors for 
myocardial infarction. Recently, in several genome-wide association studies, a common 
variant, rs9939609, in the fat mass and obesity-associated (FTO) gene was discovered 
to associate with type 2 diabetes and body mass index (BMI). In the present study 
we investigated whether FTO rs9939609 relates to the risk of early-onset myocardial 
infarction.
Methods: The Italian genetic study of early-onset myocardial infarction is a nationwide 
prospective case-control study involving 1842 patients hospitalised for a ﬁrst myocardial 
infarction before the age of 45 years, and 1842 healthy subjects matched for age, gender 
and geographical origin. The following baseline data were collected for each case and 
control: age, gender, family history, body mass index, smoking habits, hypertension, 
hypercholesterolemia, diabetes, cocaine use, physical activity and alcohol consumption. 
Genotyping was performed using the Sequenome MassARRAY platform.
Results: FTO rs9939609 was signiﬁcantly associated with early-onset myocardial 
infarction (odds ratio 1,25, 95% conﬁdence interval 1.08 to 1.45; p=0.000015) with a 
multiplicative model of the effect. The allele at FTO rs9939609 associated with higher 
BMI and risk for type 2 diabetes in earlier studies was associated with increased risk 
of myocardial infarction in the present study. After adjusting for type 2 diabetes, BMI, 
hypercholesterolemia and smoking FTO rs9939609 remained signiﬁcantly associated 
with early-onset myocardial infarction (odds ratio 1.20, 95% conﬁdence interval 1.05-1.38; 
p=0.006) suggesting that this variant may directly effect risk for myocardial infarction, 
independent of BMI. As previously reported FTO rs9939609 was also associated with 
BMI in this sample, more speciﬁcally the p-value of no association in the control group 
was equal to 0,01.
Conclusions: The allele at FTO rs9939609 corresponding to higher BMI and greater 
diabetes risk is associated with increased risk of early-onset myocardial infarction.
9:30 a.m.
1014-162 Intramyocardial Injection of Human Adipose Tissue-
Derived Stem Cells Improve Cardiac Function 
Following Acute Myocardial Infarction
Xiaowen Bai, Yasheng Yan, Yao-Hua Song, Lilly H Droll, Daynene Vykoukal, Eckhard Alt, 
University of Texas, MD Anderson Cancer Center, Houston, TX
Background: Various stem cells have shown a the beneﬁcial effect on cardiac 
regeneration after myocardial infarction (MI). Recently it has been shown that adipose 
tissue-derived stem cells (ASCs) from porcine improved cardiac function after MI. This 
study investigates for the ﬁrst time the effect of human ASCs (hASCs) on the cardiac 
function after MI in mice.
Methods: MI was induced in mice by occlusion of the left anterior descending coronary 
artery (LAD). The mice were divided into two groups: 1) PBS group (n=8); 2) hASCs group 
(n=7). Half million hASCs from passage 4 in 30 μl PBS or PBS alone were injected into 
the infarcted hearts following the ligation of LAD. Cardiac function was assessed at 2-3 
days before surgery (baseline), 1 week and 4 weeks after cell injection by MRI described 
below. The mice were imaged using a 7T small animal experimental MRI/MRS scanner. 
Ten series frames covering 2 cardiac cycles allowed for the accurate selection of images 
representing left ventricular end of systole (ES) and end of diastole (ED) volumes for 
calculating ejection fraction (EF) as the ratio of stroke volume (volume of ED - volume of 
ES) to end diastolic volume.
Results: MRI analysis showed that the left ventricular EF of PBS-injected hearts and 
hASCs-injected hearts was 63.74 ±3.32% (mean + SD) and 66.6 ±1.74% at baseline, 
respectively. EF in both groups declined by more than half (28.44± 9.92% for PBS vs 33.36 
± 9.83% for hASCs, p>0.05), which indicates that heart function in all mice was severely 
impaired 7 days following the LAD occlusion. Signiﬁcant functional loss continued over 
the following 28 days in PBS-injected hearts. Conversely, the hearts injected with hASCs 
demonstrated a trend to an increase in function. EF at 28 days post-infarction was 34.02 
± 9.42% with hASC treatment vs 18.7 ± 9.12% for PBS treatment (p<0.05).
Conclusions: In this study, we demonstrated for the ﬁrst time that hASCs signiﬁcantly 
improved cardiac function compared to PBS treatment group. This ﬁnding indicates the 
promising application of autologous hASCs for myocardial repair. 
9:30 a.m.
1014-163 Endothelial Progenitor Cell Derived Conditioned Media 
Reduces In Vivo Cardiomyocyte Apoptosis Acting 
Through TGFB1 and IGF1
Brian Hynes, Arun HS Kumar, Sharon Weiss, Jeffery Schmeckpeper, Grainne Murphy, 
Kenneth Martin, John O’Sullivan, Scott McCauley, Noel M. Caplice, Centre for Research 
in Vascular Biology, University College Cork, Cork, Ireland
Background: We recently reported the cardiotrophic effects of conditioned media 
(CM) derived from autologous EPCs in a porcine model of myocardial infarction (MI). 
Preliminary investigation indicated the important role of TGFB1 and IGF1 in the observed 
beneﬁcial effects, which we have further explored.
Methods: Landrace pigs (25-28 Kg) underwent MI generation via transluminal balloon 
occlusion of the proximal left circumﬂex artery for 80 minutes followed by 120 minutes 
of reperfusion. Intra-coronary conditioned media (CM) from autologous EPCs, or CM + 
anti-TGFB1, or CM + anti-IGF1, or X-vivo 15 (control) was administered in three 4 minute 
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cycles of balloon occlusion of the left circumﬂex artery. 24 hours post MI the animals were 
sacriﬁced and hearts sectioned from apex to base to quantify the infarcts. Cardiomyocyte 
apoptosis within the MI borderzone (50% MI and 50% normal myocardium/high power 
ﬁeld) was evaluated by TUNEL assay, Caspase 9 activity and protein expression.
Results:Infarct sizes were not statistically different between the four groups. However 
CM signiﬁcantly reduced the number of TUNEL positive cells/high power ﬁeld vs. control 
(TUNEL 149.82±15.45 vs. 409.94±23.88). Caspase 9 protein expression (0.36±0.06 vs 
1.00±0.10 Ab units) and activity (6.17±0.30 vs. 15.89±1.35/mg protein) was reduced in 
CM treated pigs. This response was signiﬁcantly (p<0.001) attenuated by the addition of 
anti-TGFB1 (308.98 ± 16.67 TUNEL positive cells/hpf; 0.71±0.08 Ab units; 11.16±0.63/
mg protein) and anti-IGF1 (307.02 ±19.67 TUNEL positive cells/hpf; 1.01±0.13 Ab units; 
15.83±1.13/mg protein) antibody to the CM.
Conclusion: EPC derived conditioned media reduces the apoptosis in the MI borderzone 24 
hours post MI generation. This effect is mediated substantially through TGFB1 and IGF1.
9:30 a.m.
1014-164 Collagen Matrix as a Delivery Vehicle Prevents Injected 
Stem Cells From Migrating out of Infarcted Myocardium 
to Remote Organs in a Rat Myocardial Infarction Model
Wangde Dai, Sharon L. Hale, Gregory L. Kay, Aarne J. Jyrala, Robert A. Kloner, Heart 
institute, Good Samaritan Hospital, Los Angeles, CA
Background: A limitation of cell therapy for heart disease is that stem cells injected 
directly into the myocardium are capable of entering the vasculature and migrating to 
remote organs. We determined whether collagen (COL) matrix as a delivery vehicle could 
prevent this migrating process. 
Methods: A myocardial infarction (MI) was induced by ligation of the left coronary 
artery in Fischer rats. Seven days after MI, saline (SAL group, n=12), saline plus 2 
million bone marrow derived rat mesenchymal stem cells (MSC) labeled with isotopic 
colloidal nanoparticles containing europium (NP) (SAL+MSC group, n=13), COL (COL 
group, n=13), or COL plus 2 million labeled MSC (COL + MSC group, n=13) were 
directly injected into the scar. Four weeks later, tissues from infarcted myocardium, non-
infarcted myocardium, and remote organs (including lung, liver, spleen and kidney) were 
sampled. Distribution of grafted MSCs was quantitatively analyzed by measuring the NP 
radioactivity in these tissues. 
Results: There was zero NP detected in the tissues that received saline or collagen alone. NP 
were detected in the heart and remote organs in SAL+MSC group. Labeled cells (expressed 
as cell number/g tissue weight) were present in 3/13 lungs (mean value equivalent to 
12,724±7,060 cells/ g), 4/13 livers (12,301±5,924 cells/g), 11/13 spleens (57,228±11,483 
cells/g), 0/13 kidneys, 13/13 MI (8,006,835±1,846,462 cells/g) and 9/13 non-infarcted 
myocardium (167,331±47,007 cells/g). However, compared with SAL+MSC group, NP 
were detected to a lesser extent in remote organs in COL + MSC group, and the relocated 
cell numbers were signiﬁcantly lower in these organs. NP were detected in 2/13 lungs 
(4,631±3,176 cells/g, p=NS), 0/13 livers (0 cells/g, p<0.05), 4/13 spleens (24,060±17,373 
cells/g, p<0.05), 0/13 kidneys (p=NS), 5/13 non-infarcted myocardium (51,522±21,548 
cells/g, p<0.05). In COL + MSC group, NP were detected in 12/13 MI (4,830,050±592,215 
cells/g), which did not signiﬁcantly differ from that in SAL+MSC group (p=NS). 
Conclusions: Collagen matrix as a delivery vehicle signiﬁcantly reduced the migration 
of transplanted MSCs from infarcted myocardium to remote organs and non-infarcted 
myocardium.
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3:30 p.m.
1023-125 Extracellular Matrix Scaffold Restores Ventricular 
Function by Attenuating Adverse Ventricular 
Remodeling After Myocardial Infarction
John R. Frederick, J. Raymond Fitzpatrick, III, Ryan C. McCormick, David A. Harris, Ah 
Young Kim, Max J. Smith, Carine M. Laporte, Jeffrey R. Muenzer, Alex J. Gambogi, Y. 
Joseph Woo, University of Pennsylvania School of Medicine, Philadelphia, PA
Background: Myocardial infarction (MI) causes cardiomyocyte death and subsequent 
scar formation, resulting in left ventricular (LV) dilation and progressive loss of cardiac 
function. Innate repair mechanisms are incapable of reversing this process. We 
hypothesized that the application of a scaffold of extracellular matrix (EMS) derived from 
decellularized porcine jejunal submucosa at the time of MI could mechanically reinforce 
the infarcted area of the LV. By adhering to surrounding normal myocardium, EMS could 
provide increased resistance to wall stress and reduce borderzone stretch, LV dilation, 
and subsequent adverse ventricular remodeling resulting in improved function.
Methods: Adult male Lewis rats (n=22) underwent LAD ligation to induce MI. At the 
time of ligation, EMS was afﬁxed to the entire LV free wall which included the region of 
ischemia in the experimental group. Control animals received a similar array of sutures 
with no scaffold. Eight weeks following infarction, ventricular function was assessed 
by echocardiography, pressure-volume conductance, and cardiac output monitoring. 
Ventricular geometry was assessed by digital planimetric analysis of sectioned hearts.
Results: Compared to controls, echocardiographic analysis of experimental animals 
showed increased fractional shortening (21 vs 37%, p=.017) and increased ejection 
fraction (50 vs 71%, p=.013). The slope of contractility as measured by pressure-volume 
conductance was also greater in the experimental group (.3 vs .46, p<.05), as was 
cardiac output (27 vs 33mL/min, p<.05) Digital planimetric analysis of sectioned hearts 
showed increased borderzone thickness (1.5 vs 1.9mm, p<.05) as well as decreased 
scar fraction expressed as a percentage of the total section area (20 vs 15%, p=.001) and 
circumferential scar length (7.9 vs 5.4mm, p<.05).
Conclusions: Application of EMS at the time of MI was shown to attenuate adverse 
ventricular remodeling as evidenced by reduced scar formation and increased borderzone 
thickness. Mechanical reinforcement preserved ventricular geometry and improved 
cardiac function after MI.
3:30 p.m.
1023-126 Very High Prognostic Value of Admission IL-6 Levels in 
Acute Myocardial Infarction. A Multiethnic Study
Nicole Cristell, Domenico Cianﬂone, Enrico Ammirati, Michela Banﬁ, Damiela Piraino, 
Alberto Monello, Alessandro Durante, Neal Uren, Hui Li, Dayi Hu, Attilio Maseri, 
Università Vita Salute San Raffaele, Milan, Italy
Background: Inﬂammation is implicated in many stages of Acute Myocardial Infarction 
(AMI) but its prognostic importance in a very early phase is not clear.
Methods: We enrolled 1099 patients with their ﬁrst AMI as their ﬁrst manifestation 
of coronary artery disease within 6 hours of symptom onset, in order to compare the 
prognostic value of C-Reactive Protein (CRP) and Interleukin-6 (IL-6) on in-hospital 
and 6-month adverse event rate in 3 ethnic groups: Italians, Scottish and Chinese from 
metropolitan areas. They had similar age, gender, risk factor and inﬂammatory marker 
elevation compared to controls.
Results: Patients presented with median levels of CRP and IL-6 more than double those 
of controls [Median (IQR): 2.5 (1.2-5.8) mg/L vs. 1.3 (0.6-2.9) mg/L; p < 0.001 and 5.1 
(2.8-9.2) pg/mL vs. 1.4 (0.7-2.7) pg/mL; p< 0.001) respectively].
The predictive value of IL-6 was much higher than that of CRP. For in-hospital events, 
high IL-6 levels were associated with a stepwise increase in rates of death, new onset 
or worsening heart failure (HF) and Major Adverse Cardiac Events (MACE). For 6-month 
follow-up, the predictive value remained signiﬁcant for death (p<0.0001). This association 
was similar in the three ethnic groups.
Conclusions: Of the inﬂammatory component assessed, admission IL-6 levels are the 
most important predictors of adverse events during hospital admission and follow-up in 
the very early phase of AMI, independent of ethnicity, suggesting environmental rather 
than a genetic mechanism. 
3:30 p.m.
1023-127 The Role of Heart-Type Fatty Acid Binding Protein in 
the Diagnosis of Acute Coronary Syndromes
Jonathan Rosman, Gita Kavala, Kotoro Obunai, Steven R. Bergmann, Beth Israel 
Medical Center, New York, NY
Background: Heart-type fatty acid binding protein (H-FABP) is a membrane bound 
protein which facilitates transport of fatty acid in the heart. It is being used outside 
the US for early diagnosis of myocardial infarction (MI). However, studies have shown 
inconsistent correlation with standard cardiac biomarkers.
Methods: Fifty patients admitted with ST-segment elevation MI (STEMI, n=25), non-
STEMI (NSTEMI, n=15) or unstable angina (n=10) were evaluated. The CaridoDetect® 
med cardiac infarction test (rennesens GmbH. Berlin, Germany) measured both qualitative 
and quantitative H-FABP. Results were compared with troponin.
Results: Of the 40 patients with acute MI, initial troponin was positive in 88% (35); the 
qualitative H-FABP was positive in 58% (23); and the quantitative H-FABP was positive in 
38% (15). No patient had a positive H-FABP with a negative initial troponin. The sensitivity 
and speciﬁcity of qualitative H-FABP assay for detecting MI were 0.57 (95%; CI= 0.41-
0.73) and 0.8 (95%; CI= 0.44-0.97). The sensitivity and speciﬁcity of quantitative H-FABP 
assay for detecting MI were 0.38 (95%; CI= 0.23-0.55) and 1.0 (95%; CI= 0.69-1.00). The 
diagnostic accuracy of patients presenting within 6 hours is shown in Table 1.
Conclusion: Neither qualitative nor quantitative H-FABP appeared temporally earlier or 
provided increased sensitivity or speciﬁcity compared with troponin in diagnosing acute MI or 
unstable angina. Accordingly, the use of this biomarker as a diagnostic tool for MI is limited.
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1023-130 Coronary Flow Velocity Reserve Gradually Decreases 
According to Glucometabolic State in Patients With 
Acute Myocardial Infarction
Brian B. Løgstrup, Dan E. Høfsten, Thomas B. Christophersen, Jacob E. Møller, Hans 
Erik Bøtker, Kenneth Egstrup, Department of Medical Research, OUH Svendborg 
Hospital, Svendborg, Denmark
Background: Coronary microvascular function is an emerging determinant of 
cardiovascular prognosis. However, the inﬂuence of glucometabolic dysfunction in 
patients with ﬁrst time acute myocardial infarction (AMI) is unknown.
Methods: 183 patients (72.1% male, mean age 62.5 ± 11.33 years) with ﬁrst time 
AMI without any signiﬁcant valvular disease or signiﬁcant stenosis in the left anterior 
descending coronary artery (LAD) were divided into four glucometabolic groups using a 
2-hour oral glucose tolerance test. Transthoracic echocardiographic Doppler recordings 
of coronary ﬂow in distal LAD were performed at rest and during Adenosine infusion (140 
μg/kg/min). Coronary ﬂow velocity reserve (CFVR) was calculated as the hyperaemic to 
resting coronary diastolic peak velocity ratio.
Results: Prior to admission 161 of 183 patients included had no history of diabetes. In 
this group, using multiple linear regression analysis, 2-hour blood glucose levels were 
independently associated with CFVR (P<0.007). After classiﬁcation of the183 patients in 
four groups according to WHO criteria, 64 patients had a normal glucometabolic response, 
58 as having impaired glucose tolerance (IGT), 39 as having a new diagnosis of diabetes, 
and 22 had a pre-study diagnosis of diabetes. There was a stepwise decrease in CFVR 
with increasing glucometabolic dysfunction (PTREND = 0.005) adjusting for confounders 
(including age, gender, Wall Motion Score Index, heart rate, location of infarction, and 
history of hypertension).
Conclusions: Microcirculation assessed by CFVR, in ﬁrst time AMI is, continuously 
decreased according to glucometabolic state. This ﬁnding may reﬂect microvascular 
dysfunction in prediabetic and diabetic patients with AMI.
3:30 p.m.
1023-131 Circulating Very Small Embryonic-Like Stem Cells 
and the Recovery of the LVEF in Patients With Acute 
Myocardial Infarction
Wojciech Wojakowski, Magda Kucia, Ewa Zuba-Surma, Maciej Kazmierski, Marcin 
Syzdol, Grzegorz Smolka, Wieslaw Cybulski, Edyta Paczkowska, Marek Krol, Andrzej 
Ochala, Boguslaw Machalinski, Mariusz Z. Ratajczak, Pawel Buszman, Michal Tendera, 
Medical University of Silesia, Katowice, Poland, Stem Cell Institute, Louisville, KY
Background: In patients with acute myocardial infarction (MI) a signiﬁcant mobilization of 
bone marrow-derived non-hematopoietic very small embryonic-like cells (VSELs) occurs. 
VSELs are small (7-8 um), negative for lineage and CD45 markers, enriched for markers 
of embryonic pluripotent stem cells (Oct4, Nanog) and express CD133 and CXCR4. VSEL 
mobilization is reduced in older, diabetic patients with signiﬁcantly reduced left ventricular 
ejection fraction (LVEF). Aim was to assess the correlation between the recovery of the 
(LVEF) and mobilization of VSELs in patients with acute myocardial infarction.
Methods: 40 patients with anterior MI and 30 healthy controls (CTRL) were enrolled. 
Number of VSELs was measured 24 hours after primary PCI and after 1 year. After lysis of 
erythrocytes population of lin-CD45-CD133+CXCR4+ VSELs was isolated using a live cell 
sorting system (FACSAria). VSELS were characterized using immunoﬂuorescence, FACS 
and ImageStream and RQ-PCR. MRI was used for measurement of LVEF and volumes.
Results: In acute MI there was a signiﬁcant mobilization of VSELs [4.9 (0.1-7.3); p<0.001] 
enriched in pluripotent (Oct-4, Nanog) and cardiac lineage markers (GATA-4, Nkx2.5, 
MEF2C). Number of VSELs after 1 year was comparable to CTRL [0.7 (0.1-3.3) vs 0.8 
(0-1.3) cells/μL; p<0.53]. VSELs mobilization in MI was signiﬁcantly lower in patients with 
reduced (<40%) LVEF in the acute MI as well as in patient with persistently reduced 
LVEF <40% after 1 year of follow-up [3.2 (0.1-4.9) vs. 4.8 (0.5-6.4) cells/μL]. Mobilization 
of VSELs was signiﬁcantly positively correlated with absolute increase of LVEF during 
1-year follow-up (R=0.51; p=0.01). Patients with better mobilization of VSELs (> median) 
were more likely to have signiﬁcant (>5%) absolute increase of LVEF after 1-year [OR 0,2 
(0,04-0,5), p=0.006].
Conclusion: Mobilization of small non-hematopoietic embryonic-like stem cells is 
positively correlated with the recovery of LVEF in patients with acute MI treated with 
primary PCI.
Conclusion: Acute MI induced mobilization of VSEL SCs expressing pluripotent markers, 
early cardiac and endothelial markers, and chemokine receptor CXCR4.
3:30 p.m.
1023-132 Relation of Coronary Thrombus Age With Plaque 
Rupture and Association of No-Reﬂow With Coronary 
Aspirated Material in Patients With Acute ST-Elevation 
Myocardial Infarction: A Clinico-Pathological Study
Giuseppe Ferrante, Francesco Burzotta, Giampaolo Niccoli, Giovanni Paolo Talarico, 
Carlo Trani, Antonio Maria Leone, Rocco Mongiardo, Antonio G. Rebuzzi, Guido Fadda, 
Annalisa Angelini, Filippo Crea, Felicita Andreotti, Catholic University of the Sacred 
Heart, Rome, Italy, University of Padua, Medical School, Padua, Italy, Padua, Italy
Background:Thrombi weeks old have been reported in coronary aspirates from patients
with acute ST-elevation myocardial infarction (STEMI), suggesting that plaque rupture 
may long precede the onset of symptoms. To test this hypothesis we assessed the relation 
between thrombus age and plaque debris. Further, we investigated the association of 
coronary aspirate with no-reﬂow.
Table 1: Accuracy of initial troponin and H-FABP obtained on 
presentation in ACS patients presenting
Sensitivity 95% CI Speciﬁcity 95% CI
Initial Trop 0.78 0.56-0.93 0.83 0.36-1.00
H-FABP qualitative 0.57 0.34-0.77 0.67 0.22-0.96
H-FABP quantitative 0.50 0.28-0.72 1.00 0.54-1.00
3:30 p.m.
1023-128 Ischemic Postconditioning Is a Powerful Antiarrhythmic 
Therapy With a Mechanism That Is Independent of 
Previous Standard Mechanisms Associated With the 
Cardioprotective Effects of Pre and Postconditioning
Joan Dow, Anil Bhandari, Robert A. Kloner, Heart Institute, Good Samaritan Hospital, 
Los Angeles, CA, Keck School of Medicine at University of Southern California, Los 
Angeles, CA
Background: There have been few truly successful antiarrhythmic therapies in the 
setting of ischemic heart disease. Ischemic postconditioning has shown promise but its 
mechanism of action is unknown. Methods: Anesthetized female rats were subjected 
to ﬁve minutes of proximal coronary artery occlusion and ﬁve minutes of reperfusion. 
They were either not postconditioned (NP) or subjected to four cycles of 20 seconds 
reperfusion, 20 seconds reocclusion (postconditioning [Po]) before ﬁnal reperfusion. ECG 
and blood pressure were monitored throughout. Proposed agonists and antagonists to Po, 
representing a number of mechanisms, were evaluated. Results: Po reduced the number 
of rats that exhibited any ventricular tachycardia (VT) from 9/10 in NP to 5/10 in Po and 
number with sustained VT (q 10 sec) from 7/10 in NP to 4/10 in Po. The median number 
of episodes of VT was 12 in NP and 0.5 in Po (p = 0.03), and the median duration of VT 
was 40 seconds in NP and 3.1 seconds in Po (p = 0.08). Cyclosporine A, a suppressor 
of the mitochondrial permeability transition pore (and a proposed agonist of Po) did not 
show a reduction in reperfusion  induced ventricular arrhythmias compared to control NP 
rats (VT occurred in 11/14 NP rats and 10/15 Cyclosporine A  treated NP rats); nor did 
Cyclosporine A reduce the episodes of sustained VT (5/14 in NP and 4/15 in Cyclosporine 
A NP rats). Thus Cyclosporine A did not mimic Po’s beneﬁcial effect on VT. The proposed 
antagonists of Po including Wortmannin (p13  kinase inhibitor; n = 7), 5 hydroxydecanoate 
(selective inhibitor of mitochondrial K-ATP channel; n =6), and 8  sulfophenyl  theophylline 
(a blocker of adenosine receptor; n =10) failed to block the reduction in VT induced by 
Po (n = 26). Conclusion: Ischemic postconditioning is a powerful maneuver to reduce 
ischemia/reperfusion induced arrhythmias. However, the mechanism by which Po reduces 
reperfusion induced VT is independent of known pathways that have been implicated 
in the infarct sparing effects of Po including mitochondrial permeability transition pore, 
p13  kinase pathways, mitochondrial KATP channel and adenosine. Alternative protective 
pathways must exist to explain the antiarrhythmic effect of postconditioning.
3:30 p.m.
1023-129 Intranasal Administration of Atrial Natriutetic 
Peptide Attenuates Left Ventricular Remodeling 
and Dysfunction Associated With Acute Myocardial 
Infarction in Rats
Akiko Soyama, Tatsuji Kono, Yasushi Kitaura, Osaka Medical College, Takatsuki, Osaka, 
Japan
Background:Neuronally produced atrial natriutetic peptide (ANP) is a neuromodulator 
that inhibits the release of noradrenaline and angiotensin II from neurons. In rats with 
myocardial infarction (MI), a substantial decrease of ANP was found in the paraventricular 
nucleus (PVN) and supraoptic nucleus (SON), which are involved in cardiovascular and 
ﬂuid regulation. We have demonstrated that alpha-hANP administered intranasally may 
access the brain directly. We hypothesized that alpha-hANP administered intranasally 
may attenuate progression of LV remodeling after MI. Methods:Forty rats were assigned 
to either alpha-hANP administered intranasally at a dosage 200μg in 10μL saline 
(ANP, n=20) or same amount of vehicle alone (MI, n=20), when the areas of ischemia 
(as a percentage of the free wall and septum) were determined by echocardiography 
at 30 minutes after left coronary artery ligation. Sham-operated rats (n=10) were used 
as controls. Hemodynamics and echocardiography were recorded at 3weeks later. 
Results:The areas of ischemia were similar, being 32±19 % and 29±9 % for the MI 
and ANP groups, respectively. Compared with the vehicle infusion, alpha-hANP 
signiﬁcantly improved survival (53 % versus 17 %; P=0.04), attenuated left ventricular 
(LV) chamber dilation, and improved LV function. (*=p<0.05 vs. Sham, †=p<0.05 vs. MI) 
Conclusions:Alpha-hANP administered intranasally may access the brain compartment 
directly and may attenuate progression of LV dysfunction.
Table 1
Sham (n=10) MI (n=20) ANP (n=20)
Heart rate (beats/min) 212±26 247±35* 222±35
LV systolic pressure (mmHg) 105±8 87±18* 91±6*
LV end-diastolic pressure (mmHg) 8±3 19±6* 12±4†
Peak dp/dt (mmHg/sec) 4070±610 2800±370* 3370±270*†
Negative dp/dt (mmHg/sec) 3750±380 1950±570* 2660±690*†
LV end-diastolic dimension (mm) 7.4±0.6 9.4±0.4* 8.6±0.7*†
LV ejection fraction (%) 52±2 19±3* 33±8*†
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patients presenting with MI, prior use of statins (OR 0.91), beta blockers (OR 0.92), ACE-
inhibitors (OR 0.88) and thienopyridines (OR 0.78) were all associated with lower odds 
of presenting with STEMI compared with NSTEMI, even after adjustment for potential 
confounders.
Conclusions: Patients with ACS were less likely to present with UA and STEMI over 
the past decade. This difference can be attributed, in part, to an increase in the use 
of cardiopreventive medications. Expanded use of preventive therapies appears to have 
favorably altered the pattern of presentation of ACS.
3:30 p.m.
1023-135 The Prevalence of Acute ST Elevation Myocardial 
Infarction (STEMI) Has Been Steadily Decreased Across 
the Gender and Ethnic Groups in the United States
Mohammad Reza Movahed, Mazen Jamal, Mehrtash Hashemzadeh, University of 
Arizona School of Medicine, Tucson, AZ
Background: Advances in the prevention and treatment of atherosclerosis risk factors 
have been dramatic in the last ten years. The goal of this study was to evaluate any 
decline in the age adjusted incidence of acute ST elevation myocardial infarction (STEMI) 
based on gender and race in the United State.
Method: The Nationwide Inpatient Sample (NIS) database was utilized to calculate the 
age-adjusted rate for STEMI from 1988 to 2004 retrospectively. Speciﬁc ICD-9-CM codes 
for myocardial infarctions that are consistent with STEMI were used to compile the data. 
Patient demographic data based on age, gender and race were analyzed and adjusted 
for age from the database.
Results: The NIS database contained a total of 1,352,574 patients who had a diagnosis of 
STEMI from 1988 to 2004. From 1988 the age-adjusted rate for all acute STEMI remained 
steady for 8 years in the entire population regardless of gender or race from 1988 until 
1996. However, from 1997, the age-adjusted incidence of STEMI steadily declined across 
all races and gender in a similar fashion to the half of the incidence in the year 2004 
(Figure 1 and Figure 2.,p<0.01).
Conclusion: The incidence of STEMI was stable from 1988 to 1996 with steady linear 
decline to half by the year 2004 in a similar degree across different gender and races. 
The cause of steady decline in STEMI is most likely reﬂecting the advancement in the 
prevention and treatment of atherosclerosis risk factors. 
3:30 p.m.
1023-136 Did Hurricane Katrina Affect the Incidence of Acute 
Coronary Syndromes in New Orleans?
Sandeep Gautam, Jonathan Menachem, Sudesh Srivastav, Patrice Delafontaine, Anand 
Irimpen, Tulane University School of Medicine, New Orleans, LA
Background: In August 2005, New Orleans was hit by Hurricane Katrina, the biggest 
natural disaster in the United States. Previous studies have shown an increase in acute 
myocardial infarction (AMI) in the immediate hours to weeks after natural disasters. The 
goals of our study were to detect any long-term increase in the incidence of AMI after 
Katrina and to investigate any pertinent contributing factors.
Methods: This was a single center retrospective cohort observational study. Patients 
admitted with AMI to Tulane University Hospital, in the two years before Katrina and in 
the two years after the hospital reopened (5 months after Katrina) were identiﬁed from 
hospital records. The two groups (pre- and post- Katrina) were compared for pre-speciﬁed 
demographic and clinical data.
Results: In the post-Katrina group, there were 246 admissions for AMI, out of a total 
census of 11,282 patients (2.18%), as compared to 150 AMI admissions out of a total 
21,229 patients (0.71%) in the pre-Katrina group (p<0.0001). The post-Katrina group had 
signiﬁcantly higher prevalence of unemployment (p=0.0003), lack of medical insurance 
(p<0.0001), medication noncompliance (p=0.0001), smoking (p=0.001), substance 
abuse (p=0.03), ﬁrst-time hospitalization (p<0.001), local residents rather than visitors 
(p<0.0001), and people living in temporary housing (p=0.003). There was no signiﬁcant 
difference in the racial distribution in the two groups.
Discussion: The role of chronic stress in pathogenesis of AMI is poorly understood, 
especially in the aftermath of natural disasters. Our data suggests that Katrina led to 
prolonged loss of employment and insurance, decreased access to preventive health 
services and an increased incidence of AMI. In addition, it appears that chronic stress 
Methods:Manual thrombus aspiration was performed, with the Diver CE system, 
in consecutive STEMI patients with native vessel occlusion, undergoing primary 
percutaneous coronary intervention. Aspirated material, after staining with hematoxylin 
eosin, was classiﬁed according to thrombus age at light microscopy analysis and 
atherosclerotic elements were reported. Myocardial perfusion after PCI was assessed 
by the angiographic Myocardial Blush Grade (MBG) score and ST resolution (STR) > 
70% on ECG.
Results: Forty ﬁve patients, 58±14 yrs old, 33 males entered the study. Detectable 
material, suitable for light microscopy analysis, was retrieved from 35 (78%) patients and 
was predicted by a baseline angiographic thrombus score q4 (odds ratio (OR) 24.1, 95% 
conﬁdence interval (CI) 2.5-233.5, p=0.006). Histological types were fresh thrombus in 
43%, old thrombus (>1 day) in 37%, and blood aggregates without evidence of ﬁbrin 
in 20%. Atherosclerotic elements were found in 23% of aspirates, exclusively with old 
thrombi (p<0.001) and more frequently with right coronary artery occlusions (35% vs 4%, 
p=0.015). The absence of detectable material was an independent negative predictor of 
no-reﬂow (deﬁned as the absence of combined endpoint of STR >70% and TIMI 3 ﬂow + 
MBG q2, OR 0.03, 95% CI 0.002-0.57, p=0.019), while there was no relationship between 
myocardial perfusion and histological types.
Conclusions: In STEMI patients with detectable aspirates after manual aspiration, the 
presence of atherosclerotic elements is associated uniquely with older thrombi, indicating 
that plaque rupture is not always simultaneous with “sudden” coronary occlusion. The 
absence of detectable aspirate is an independent negative predictor of no-reﬂow, 
suggesting an association between high thrombus burden and no-reﬂow.
3:30 p.m.
1023-133 Ventricular Arrhythmias in Patients With Non-ST 
Elevation Myocardial Infarction: Incidence, Predictors 
and Mortality
Shuchita Gupta, Vincent Figueredo, Shweta Gupta, Albert Einstein Medical Center, 
Philadelphia, PA
Background: While serious ventricular arrhythmias are well-documented in patients 
with ST elevation myocardial infarction (STEMI), their incidence and behavior in patients 
with non-STEMI (NSTEMI) have not been examined in detail. We aimed to study the 
incidence, predictors and mortality rates for ventricular arrhythmias in patients with 
NSTEMI undergoing early invasive treatment.
Methods: Patients admitted between January and December 2004 with NSTEMI 
who underwent cardiac catheterization within 48 hours of admission were identiﬁed 
retrospectively. The presence and type of ventricular arrhythmias and mortality rate were 
noted. Data on cardiac risk factors, laboratory tests, ﬁndings on electrocardiogram (EKG), 
echocardiogram, cardiac catheterization and revascularization procedures done were 
collected. The need for deﬁbrillation and/or anti-arrhythmic therapy was recorded.
Results: Out of 215 patients, sustained ventricular tachycardia (VT) or ventricular 
ﬁbrillation (VF) classiﬁed as malignant ventricular arrhythmias (VT/VF) occurred in 20 
patients (9.3%); 12 required deﬁbrillation. Non-sustained VT was seen in 12 (5.6%) 
patients (excluded from statistical analysis). Fourteen patients (6.5%) died, out of which 
7 had VT/VF. VT/VF occurred within the ﬁrst 12 hours in 40% of these patients. On 
univariate analysis, the presence of left bundle branch block (p=0.03), T wave inversions 
(p=0.005) on EKG, early coronary artery bypass grafting (p=0.012) and left ventricular 
ejection fraction (LVEF) (p=0.007) were signiﬁcantly associated with VT/VF. Potassium 
and magnesium levels were not signiﬁcantly associated (p=0.44 and 0.40 respectively). 
On multivariate analysis LVEF remained the only predictor of VT/VF. The risk of VT/VF 
increased by 33% for every 10% decrease in LVEF (odds ratio 0.97, 95% conﬁdence 
interval 0.94-0.99).
Conclusion: The incidence of malignant ventricular arrhythmias in patients with NSTEMI 
was higher than reported previously (2.1 to 2.6%). The only signiﬁcant predictor was LVEF. 
Among patients with NSTEMI who died, 50% had VT/VF. Further prospective studies are 
needed to better characterize ventricular arrhythmias in these patients.
3:30 p.m.
1023-134 Impact of Preventive Medications on Type of Clinical 
Presentation of Acute Coronary Syndromes
Robert W. Yeh, Malini Chandra, Alan S. Go, Kaiser Permanente of Northern California, 
Oakland, CA, University of California, San Francisco, San Francisco, CA
Background: Few studies have examined how preventive therapies may inﬂuence the 
nature of clinical presentation of acute coronary syndromes (ACS). We examined the 
association between receipt of preventive medications and the likelihood of presenting 
with unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI) or ST-
elevation myocardial infarction (STEMI) among ACS patients.
Methods: We identiﬁed all adults hospitalized for diagnosed UA, NSTEMI or STEMI [using 
ICD-9 codes] between 1998-2007 within Kaiser Permanente of Northern California, an 
integrated healthcare delivery system caring for >3 million patients. Medication use 
was obtained from health plan pharmacy databases. The proportions of ACS patients 
presenting with UA, STEMI and NSTEMI were compared across study year. Multivariable 
regression was performed to examine whether prior cardioprotective drug usage 
affected the likelihood of presenting with UA, NSTEMI or STEMI, after adjustment for 
sociodemographics, vascular risk factors, and comorbidities.
Results: Between 1998-2007, 42,890 Kaiser patients were hospitalized for UA, 40,076 
for NSTEMI and 20,895 for STEMI. The proportions of ACS patients presenting with 
UA and STEMI declined signiﬁcantly over time (51.4% and 23.5% in 1998 vs. 31.7% 
and 16.4% in 2007, respectively, P<0.0001 for trend by year) while use of preventive 
therapies has increased. In multivariable regression, prior use of statins (OR 0.65), beta 
blockers (OR 0.64), ACE-inhibitors (OR 0.94) and thienopyridines (OR 0.84) were each 
independently associated with lower odds of presenting with MI compared with UA. In 
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CrCl >90 33.6% 34.6% 38.3% <0.001 38.8% 38.9% 45.4% <0.001
Mean
SBP
(mmHg)
138 140 138 0.007 133 134 133 0.064
Mean HR 
(bpm) 75 77 76 <0.001 75 77 76 <0.001
Pain-
Lysis (hr) 3.1 2.9 3.3 <0.001 3.3 3.1 3.5 <0.001
30d Outcomes: Odds Ratios vs. Morning Pain onset Adjusted for TIMI Risk Score (P Values)
InTIME-II-TIMI 17 ExTRACT-TIMI 25
Morning Evening Overnight Morning Evening Overnight
All
Mortality 1.0 1.19(0.041) 0.97(0.72) 1.0 1.18(0.009) 1.01(0.90)
D/MI/Str/
Revsac 1.0 1.12(0.007) 1.12(0.011) 1.0 1.07(0.050) 1.17(<0.001)
D/C-
Shock/
CHF
1.0 1.16(0.007) 1.08(0.19) 1.0 1.15(0.015) 1.06(0.41)
3:30 p.m.
1023-139 A Comparison of Cardiovascular Death Rates in the 
Same City During a Losing Versus Winning Super Bowl 
Championship
Robert A. Kloner, Scott McDonald, Justin Leeka, W. Kenneth Poole, Heart Institute, 
Good Samaritan Hospital, Los Angeles, CA, Keck School of Medicine at University of 
Southern California, Los Angeles, CA
Background: A recent German Study suggested that viewing a stressful World Cup 
soccer match could increase cardiovascular events, but whether the Super Bowl could 
result in a similar phenomenon in the United States is unknown. The purpose of this study 
was to determine whether there were changes in local death rates and cardiovascular 
death rates, when a football team represented by that local population participated in 
the Super Bowl. To the best of our knowledge, this is the ﬁrst study to investigate total 
and cardiovascular deaths surrounding a winning and losing Super Bowl within the same 
city. Los Angeles (LA) played in the Super Bowl twice, and within a four year time frame 
once on January 20, 1980 (LA Rams versus Pittsburgh Steelers in which LA lost), and on 
January 22, 1984 (LA Raiders versus Washington Redskins in which LA won). Methods:
Data from Los Angeles County were analyzed for death rates from all causes; and deaths 
from circulatory, ischemic heart disease and acute myocardial infarction for three weeks 
surrounding the Super Bowl versus all other days (controls) from January 15 till end of 
February for 1980 to 1983 and 1983 to 1988. Results: The three weeks surrounding LA’s 
losing 1980 game was associated with higher daily death rates in LA County (per 100,000 
population) for circulatory deaths (1.2473 versus control 1.0660; p < 0.0001); death due 
to ischemic heart disease (0.8185 versus control 0.7144; p < 0.005); death from acute 
myocardial infarction (0.2664 vs. control 0.2316; p < 0.0193); and all deaths (2.3885 vs. 
control 2.0934; p < 0.0001). In contrast the three weeks surrounding the winning 1984 
game were associated with a trend toward lower circulatory deaths (1.0556 versus control 
1.1199; p = 0.0528), and a decrease in all deaths (2.1369 versus 2.3300; p = 0.0002). 
An analysis between 2000 to 2004, when LA did not have a professional team, did not 
show an increase in cardiovascular deaths surrounding the Super Bowl. Conclusions:
These results suggest that the emotional stress of loss by a local sports team in a highly 
publicized rivalry such as the Super Bowl can trigger total as well cardiovascular deaths; 
in contrast, the positive emotions surrounding a win may actually lower deaths.
3:30 p.m.
1023-140 Clinical Outcomes Of Bare Metal Stents Versus 
Drug-Eluting Stents Target Vessel Revascularization: 
Evidence for A High-Risk Bare Metal Stent Cohort
Kevin R. Hayes, Robert J. Applegate, Matthew T. Sacrinty, Michael A. Kutcher, Sanjay K. 
Gandhi, Renato M. Santos, William C. Little, Wake Forest University School of Medicine, 
Winston-Salem, NC
Background. Recent data suggest that mortality may be lower with drug-eluting 
stents (DES) than bare metal stents (BMS) in off-label patients. However, the potential 
mechanisms for this beneﬁt remain unclear.
Methods. We assessed clinical outcomes 2 years ± 30 days after treatment for target 
lesion revascularization (TLR) in 221 consecutive patients (137 of 1,451 (9.4%) BMS and 
84 of 1,883 (4.5%) DES) at WFUBMC between 2002 and 2005.
Results. Clinical presentations of TLR were similar including ACS (76% BMS and 75% 
DES, p=0.88), and stent thrombosis (11% BMS and 15% DES, p=0.33), although time to 
TLR was longer for DES, 385 (interquartile range 158-631) days, versus BMS 154 (97-
357) days, p<0.001. Treatment for TLR differed with brachytherapy in 37% BMS, versus 
4% DES, p<0.001 and DES placement in 25% BMS versus 65% DES, p<0.001. At one 
year post-revascularization for TLR, the DES versus BMS hazard ration (HR) for all cause 
death was 0.37 (0.13-1.11), and for non-fatal MI or death 0.65 (0.30-1.42) (see Figure), 
and was similar in those treated with or without brachytherapy.
after a natural disaster can foster tobacco abuse and medication and therapeutic 
noncompliance.
Conclusions: We found a three-fold increased incidence of AMI more than two years 
after Hurricane Katrina. Even allowing for the loss of some local hospitals after the 
disaster, this represents a signiﬁcant change in overall population health, and supports 
the need for further study into the health effects of chronic stress.
3:30 p.m.
1023-137 Impact of Gender on Treatment and Clinical Outcomes in 
Acute Coronary Syndrome Patients in the Middle East
Ayman A. El-Menyar, Mohammed Zubaid, Wael Almahmeed, Kadhim Souliman, Ahmed 
Al-Motarreb, Haitham Amin, Nidal Asaad, Khalid Al-Habib, Jassim Al Suwaidi, Hamad 
Medical Corporation, Doha, Qatar, Kuwait University, Kuwait, Kuwait
Background: Several western studies demonstrated signiﬁcant disparities in acute 
coronary syndrome (ACS) presentation and outcome between men and women. We 
aimed to evaluate the presentation of Middle-eastern women with ACS, management 
and their outcome. 
Methods: Gender differences in regards to baseline characteristics, therapy and outcome 
was performed Using data from the Gulf Registry of Acute Coronary Events (GulfRace) 
which is a prospective, multinational multicenter survey of 8187 (1986 women and 6201 
men) consecutive patients hospitalized with ACS from February to June 2007 in 6 middle 
eastern countries . Data were analyzed according to gender. RESULTS: When compared 
to men, middle-eastern women were 9 years older (62.1± versus 53.1 ±years; P<0.001) 
and more often had diabetes (54.6% versus 35.9%, p < 0.001), hypertension (70%versus 
43%, p < 0.001) and dyslipidemia (44% versus 28%, p<0.001) . Women were also more 
likely to have other co-morbidities including chronic lung disease, renal and peripheral 
vascular disease. On the other hand, men were more likely to be smokers (46%versus 
5.1%, p < .001). Atypical presentations (dyspnea and atypical chest pain) were more 
common in women than men (15.1% versus 8.1%; p=.001 and 8.0% versus 6.1% p=0.02). 
Women were less likely to be appropriately treated with thrombolytic therapy (79.9 %versus 
83.6%), primary PCI (4.9 %versus 8.4%)B-blockers (57% versus 64% ), clopidogrel (54% 
versus 60% ), and glycoprotein IIb/III inhibitor (2.2% versus 9.5% p=.001) than men. Door 
to needle time was more prolonged in women (median, IQR: 40, 50 versus 35, 41 min). 
Women had worse in-hospital outcomes compared to men [heart failure (27.6% versus 
14.4%), shock (19.5% versus 7%), and re- infarction (5% versus 2.7%)]. In-hospital death 
was higher in ST- and non-ST-elevation myocardial infarction in females (13.4% versus 
4.6% p=0.001 and 4.0% versus 1.9% p=0.01) .Conclusion: Similar to western studies, 
despite presentation with higher risk characteristics and having higher in-hospital risk, 
middle-eastern women with ACS are treated less aggressively than men. Female gender 
is independent predictor of poor outcome in all the spectrum of ACS.
3:30 p.m.
1023-138 Overnight Onset of STEMI Is Not Associated With 
Increased Mortality Despite Experiencing Greater 
Delays to Presentation and More Pre-Existing Coronary 
Artery Disease
Owen N. Mogabgab, Robert P. Giugliano, Marc S. Sabatine, Christopher P. Cannon, 
Stephen D. Wiviott, David A. Morrow, Satishkumar Mohanavelu, Elliott M. Antman, 
Eugene Braunwald, Brigham and Women’s Hospital, Boston, MA
Background: An AM peak of STEMI has been described. We explored the relationship 
between diurnal variation, pt characteristics, and outcomes in 2 worldwide lytic trials.
Methods: 35,492 STEMI pts were grouped into 8-hr intervals by symptom onset: 
morning (6AM-2PM), evening (2PM-10PM), overnight (10PM-6AM). We correlated pt 
characteristics with timing of symptom onset and calculated adjusted outcomes (using 
the baseline TIMI risk score) in InTIME-II-TIMI 17 (derivation set, N=15,031), with 
conﬁrmation in ExTRACT-TIMI 25 (validation set, N=20,461).
Results (table 1): As anticipated, symptom onset was more frequent in the morning - 
such pts were older, less likely smokers, and had k initial PTT post heparin. The evening 
group had more smokers, k initial HR and SBP. Pts with overnight MIs had better renal 
function; were more obese; had more prior MI, anterior MI, prior aspirin and b-blocker use; 
and longer delays to presentation. Mortality and composite outcomes were worse in pts 
with pain onset 2PM-10PM, but were similar between the other two groups.
Conclusions: Both time of symptom onset and pt characteristics demonstrate circadian 
variations in worldwide lytic trials. Worse outcomes seen with overnight primary PCI are 
not replicated in large lytic trials, potentially due to lytic resistance in AM pts and lesser in-
hospital delays with overnight lysis. Adjusted outcomes appear worst in pts with symptom 
onset from 2PM-10PM, in whom smoking is a major modiﬁable risk factor. 
Characteristics/Outcomes of Patients with MI Pain Onset Time in 8 hour Intervals
InTIME-II-TIMI 17 ExTRACT-TIMI 25
Morning Evening Overnight 3-way P Morning Evening Overnight P value
Pain 
Onset 48.5% 30.2% 21.3% <0.001 47.6% 31.3% 21.1% <0.001
Mean
Age(yr) 62.0 60.3 60.2 <0.001 60.5 59.4 58.9 <0.001
Obese
(BMIq30) 18.5% 20.4% 21.4% 0.002 20.3% 20.8% 23.4% <0.001
Smoking 40.8% 50.0% 47.4% <0.001 44.8% 49.8% 49.6% <0.001
Prior MI 15.1% 16.3% 18.5% <0.001 12.3% 13.1% 14.6% 0.001
Prior 
Revasc 5.8% 6.4% 7.1% 0.031 4.1% 4.0% 4.7% 0.165
Prior ASA 19.6% 18.8% 22.6% <0.001 18.0% 15.9% 18.8% <0.001
Prior BB 14.9% 14.9% 18.1% <0.001 14.3% 13.1% 15.9% <0.001
Anterior 
MI 42.3% 39.8% 44.7% <0.001 43.7% 43.1% 45.6% 0.038
PTT >70 59.1% 45.0% 55.6% <0.001 35.8% 34.6% 31.1% 0.001
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1023-143 Sudden Death Due to Coronary Disease in the Young: 
Examining Causes Other Than Atherosclerosis
David A. Appel, Jennifer A. McNear, Lena Avedissian, Laudino M. Castillo-Rojas, John 
E. Atwood, Lisa A. Pearse, Robert N. Potter, Allen P. Burke, Ladd Tremaine, Eric A. 
Shry, Philip J. Gentlesk, Stephen S. Reich, Robert E. Eckart, Department of Defense 
Cardiovascular Death Registry Group, Brooke Army Medical Center, San Antonio, TX, 
Armed Forces Institute of Pathology, Washington, DC
Background: Death due to coronary disease in the young is uncommon, and poorly 
described beyond case reports.
Methods: Clinical and pathologic records from the Ofﬁce of the Armed Forces Medical 
Examiner from 1998 to 2008 were reviewed.
Results: There were 760 deaths due to suspected cardiovascular disease that had an 
autopsy performed, with a mean age of 39±11 years (96.3% male). The etiology of death 
was structural heart disease in 589 (77.5%) and idiopathic in 150 (19.7%). Coronary 
disease represented the leading identiﬁable etiology (n=426, 56.1%). Of the cohort with 
disease of the coronary arteries, atherosclerosis was the leading abnormality; but less 
common in those <40 years (88.7%) compared to those q40 years (98.4%, p<0.001). 
Anomalous coronary artery (7.1% vs. 0.4%, p<0.001) and a signiﬁcant coronary bridge 
(3.6% vs. 0.4%, p=0.017) were more common in those <40 years compared to those 
q40 years, respectively. Deaths due to atherosclerosis were equally exertional and non-
exertional (49.7% vs. 50.3%); while deaths due to anomalous coronary artery or coronary 
bridge were signiﬁcantly more likely to be exertional (70.8%, p=0.041). Those with death 
due to atherosclerosis had a higher BMI than those with either anomalous coronary 
disease or myocardial bridge (29.3 vs. 25.3 kg/m2, p=0.022).
Conclusions: Coronary artery disease is the most common cause of cardiovascular 
death in the armed forces, especially in those over 40 years. Different types of coronary 
artery pathology have different clinical precipitants that must be recognized as part of 
risk reduction.
3:30 p.m.
1023-144 Comparison of Clinical Characteristics and Outcomes 
in Patients With Acute ST-Segment Elevation 
Myocardial Infarction Presenting During Working Hours 
Versus off Hours
Kang Yin Chen, Seung Woon Rha, Yong Jian Li, Kanhaiya L. Poddar, Jae Hyoung 
Park, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang 
Gyu Park, Hong Seog Seo, Dong Joo Oh, Young Keun Ahn, Myung Ho Jeong, Korea 
University Guro Hospital, Seoul, South Korea, Chonnam National University Hospital, 
Gwangju, South Korea
Background:Acute ST-segment elevation myocardial infarction (STEMI) requires urgent diagnosis 
and revascularization, which may vary due to the different time of presentation. We evaluated 
the impact of different time of presentation on the characteristics of STEMI management and 
subsequent outcomes in Korean Acute Myocardial Infarction Registry (KAMIR).
Methods:Using KAMIR data collected from November 2005 to September 2007, we 
analyzed the differences in clinical characteristics and outcomes among 4698 STEMI 
patients presented during working hours (weekdays 7 AM to 6 PM) versus off hours 
(weekends, holidays, and 6 PM to 7 AM weeknights).
Results:Overall, 2628 STEMI patients (55.9%) presented during off hours. Compared 
with patients presenting during working hours, off-hour patients were less likely to arrive 
within 6 hours after symptom onset (59.1% vs 71.5%, P<0.001), less likely to receive 
primary percutaneous coronary intervention (PCI) (66.9% vs 76.3%, P<0.001) with 
longer door-to-balloon time [median (h) 1.33 vs 1.00, P<0.001 in primary PCI] and 
fewer achievements of door-to-balloon time <2 hours (69.4% vs 78.8%, P<0.001 in 
primary PCI). In addition, patients arriving during off hours were more likely to receive 
thrombolysis treatment (13.6% vs 4.2%, P<0.001) with longer door-to-drug time [median 
(h) 0.83 vs 0.47, P<0.001] than those presenting during working hours. Clinical outcomes 
showed that patients presenting during off hours versus working hours had similar 
incidence of inhospital mortality (6.0% vs 5.6%, P=0.172) and 8-month mortality (7.5% 
vs 6.8%, P=0.334). Multivariate analysis showed that off-hour presentation was not an 
independent risk factor for inhospital death [odd ratio (OR) 1.03, 95% conﬁdence interval 
(CI) 0.78-1.37, P=0.838] or 8-month death (OR 1.11, 95% CI 0.85-1.43, P=0.434).
Conclusions:Despite fewer primary PCI and longer door-to-balloon time and door-to-
drug time, patients presenting with STEMI during off hours had similar in-hospital and 
8-month mortality to those presenting during working hours.
3:30 p.m.
1023-145 ECG Presentation of Left Main Disease in Acute 
Coronary Syndrome
Kjell C. Nikus, Markku Eskola, Heart Center, Cardiology Department, Tampere 
University Hospital, Tampere, Finland
Background: The ECG pattern with widespread ST-depression, maximally in leads V4-
V5 with inverted T waves and ST-elevation in lead aVR (“left main ECG”, =LM-ECG) is 
associated with severe left main or triple-vessel disease. 
Methods: The incidence at hospital admission and prognosis of the ECG pattern 
was studied in a population of consecutive patients with acute coronary syndrome in 
a university hospital setting. The patients (n=1188) were classiﬁed into seven different 
ECG categories: ST-elevation (29%), pathological Q waves without ST-elevation (23%), 
typical LBBB (6%), LVH without ST-elevation, except in leads aVR and /or V1 (7%), left 
main ECG (8%, n=97), other ST-depression and/or T-inversion (14%) and other ﬁndings, 
including normal ECG (13%).
Conclusions. Patients with TLR after BMS have similar clinical presentations as those 
with DES, but present more frequently and have signiﬁcantly worse one-year outcomes 
than those with DES. Further studies into this high-risk BMS subgroup are merited.
3:30 p.m.
1023-141 Rationale of Decreasing LDL-Cholesterol Level 
<70mg/dL in Patients With Coronary Artery Disease: 
Intravascular Ultrasound-Virtual Histology Study
Jang-Ho Bae, Taek-Geun Kwon, Ki-Young Kim, Charanjit S. Rihal, Amir Lerman, 
Konyang University Hospital, Daejeon, South Korea, Mayo Clinic, Rochester, MN
Background: It is recommended that low dense lipoprotein-cholesterol (LDL-C) levels 
are reduced to less than 70mg/dL in patient with coronary heart disease. We sought 
to evaluate the effect of reduction of LDL-C level at coronary plaque composition by 
intravascular ultrasound-virtual histology (IVUS-VH).
Methods: We analyzed the distal and proximal segment (96 segments in 62 patients 
(mean 59.9years old) to the stent using IVUS-VH, which had residual plaque, during 
percutaneous coronary intervention and at routine follow-up coronary angiography after 
7.7±1.5 months. Study subjects were taken lipid lowering agents (atorvastatin 10mg 
in 32 patients, rosuvastatin 10mg in 13 patients, pitavastatin 2mg in 17 patients) and 
divided into two groups according to LDL-C level measured at follow-up examination. 
Group1=LDL-Ca70mg/dL (19 segment), Group 2=LDL-C > 70mg/dL (74 segments).
Results: Total cholesterol, triglyceride and LDL-C were signiﬁcantly decreased, whereas 
HDL-cholesterol was insigniﬁcantly increased during follow-up period. However, percent 
change of total cholesterol and LDL-C showed no signiﬁcant difference among lipid 
lowering agents. In patient with LDL-C level less than 70mg/dL at follow-up examination, 
percent ﬁbrous volume (1.11% vs. -1.07%, p=NS) and percent dense calcium volume 
(-1.84% vs. 2.62%, p=NS) showed no signiﬁcant change. But percent ﬁbrofatty volume 
(7.00% vs. -0.55%, p=0.015) was increased and percent necrotic core volume (-6.26% vs. 
0.19%, p=0.007) was decreased in patients with LDL-C level less than 70mg/dL than those 
with LDL-C level over 70mg/dL. When we divided the study population into to groups based 
on the LDL-C level <100mg/dL, there was no signiﬁcant differences of plaque compositions 
between 2 groups. Percent change of segment plaque burden showed no signiﬁcant 
difference between two groups during follow-up period (-4.02% vs. 0.12%, p=NS).
Conclusions: This study showed that reduction of LDL-C level less than 70mg/dL, not 
100mg/dL, is important in terms of the necrotic core of coronary plaque, which is a main 
component of vulnerable plaque.
3:30 p.m.
1023-142 Clinical Characteristics and Mid-Term Outcomes of 
Acute Myocardial Infarction Patients With Previous 
Cerebrovascular Disease
Yong Jian Li, Seung Woon Rha, Kang Yin Chen, Kanhaiya L. Poddar, Jae Hyoung 
Park, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang 
Gyu Park, Hong Seog Seo, Dong Joo Oh, Young Keun Ahn, Young Keun Ahn, Myung 
Ho Jeong, Korea University Guro Hospital, Seoul, South Korea, Chonnam National 
University Hospital, Gwangju, South Korea
Background: Cerebrovascular disease (CVD) can be an important future cardiovascular 
event. The impact of previous cerebrovascular disease (CVD) on the clinical characteristics 
and midterm outcomes of patients (pts) with acute myocardial infarction (AMI) has not 
been well described in Asian population.
Methods: Data were analyzed from 8151 pts with AMI (either STEMI or NSTEMI) enrolled 
in Korea Acute Myocardial Infarction Registry (KAMIR) from 2005 to 2007.
Results: Of 8151 pts, 552 pts (6.8%) had previous CVD. The pts with CVD were older 
(68.95 ± 10.11 vs 62.83 ± 12.74, P<0.001), more incidence in women (70.4% vs 62.7%, 
P<0.001), showed higher incidence of hypertension and diabetes than the pts without 
CVD. The pts with previous CVD presented more often with NSTEMI and higher Killip 
class than the pts without CVD. Further, pts with CVD received less percutaneous 
coronary intervention (PCI) or thrombolysis compared with the pts without CVD. Intensive 
medical therapy was equally maintained in both groups.
Pts with CVD showed higher incidences of cardiac death [13.6% vs 5.1%, adjusted odd 
ratio (OR) 2.11, 95% conﬁdence interval (CI) 1.60-2.79, P<0.001], total death (15.9% vs 
5.9%, adjusted OR 2.15; 95% CI 1.65-2.80, P<0.001) and total major adverse cardiac 
events (MACE, 23.0% vs 11.6%, adjusted OR 1.45; 95% CI 1.14-1.85, P=0.003) at 8 
months. The incidences of recurrent MI and repeat revascularization at 8 months were 
similar between the two groups.
Conclusions: Pts with CVD showed more severe and worse clinical characteristics on 
admission and was associated with lower rates of PCI or thrombolysis. When we consider 
the poorer midterm clinical outcomes including higher mortality and MACE, in pts with 
prior CVD, more intensive and aggressive management for this particular subset of pts 
should be emphasized for better long-term clinical outcomes.
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of severe bleedings was lower in the fonda group. 
3:30 p.m.
1023-148 Troponin Positive, MB Negative Patients With Non-ST 
Elevation Myocardial Infarction: An Under-Ttreated but 
High-Risk Patient Group: Results From NCDR ACTION-
GWTG Registry
Michael C. Kontos, James A. de Lemos, Fang-Shu Ou, L Kristin Newby, Matthew T. Roe, 
Virginia Commonwealth University, Richmond, VA
Background: Despite the 2002 redeﬁnition of myocardial infarction (MI), patients (pts) 
who are troponin (Tn)+ but MB- may not be considered to have MI, particularly in the 
absence of known coronary disease (prior MI or revascularization; CAD), in which case Tn 
elevation may be ascribed to non-ACS causes. How this affects treatment and outcomes 
has not been well described. Methods: Pts with non-ST elevation MI (NSTEMI) enrolled 
in ACC NCDR ACTION-GWTG Registry from 1/07 to 6/08 were included. Pts missing 
marker data, who were Tn(-)(n=3198) and known CAD (n=15066) were excluded. Pts 
were categorized as Tn+MB+ (n=11563) or Tn+MB- (n=4501). Baseline characteristics, 
treatments and in-hospital outcomes were compared between the 2 groups using logistic 
regression. Results: Of the 16,064 NSTEMI pts, 28% were Tn+MB-. Tn+MB- pts were 
older (median age 68 vs 65) with more co-morbidities (HTN, 71 vs 66%, DM, 31 vs 27%, 
CHF, 22 vs 19%, all p<0.01). After adjusting for baseline characteristics, Tn+MB- pts were 
less likely to receive acute ACS treatment or angiography (Table). In-hospital mortality 
was higher in Tn+MB+ pts (4.9% vs 3.8% p<0.001), which remained signiﬁcant after 
adjusting for baseline variables (OR 1.4, 95% CI 1.2-1.8; p<0.001). Conclusions: In pts 
with NSTEMI without known CAD, Tn+MB- pts have a higher risk proﬁle but are less likely 
to receive guideline recommended acute ACS treatment. Given the high mortality in this 
group, increased emphasis on improving quality of care in Tn+MB- pts is warranted. 
Tn+MB+ Tn+MB- P value Adjusted OR (95% CI) P value
Acute ASA 97% 96% 0.056 1.19 (0.98-1.4) 0.08
Acute beta blocker 93% 92% 0.56 1.17 (1.01-1.35) 0.04
Acute clopidogrel 55% 50% <0.01 1.22 (1.13-1.31) <0.001
Acute GP 2b/3a 48% 32% <0.01 1.87 (1.71-2.06) <0.001
Acute Anti-thrombin 92% 89% 0.03 1.36 (1.20-1.54) <0.001
Cath within 48 hours 71% 62% <0.01 1.30 (1.19-1.42) <0.001
3:30 p.m.
1023-149 Is Pre-Existing Coronary Disease a Risk Factor for 
In-Hospital Mortality? An Analysis From the NCDR 
ACTION-GWTG Registry
Michael C. Kontos, Antonio Abbate, Fang-Shu Ou, Matthew T. Roe, Virginia 
Commonwealth University, Richmond, VA
Background: Many variables predict mortality in patients (pts) with non-ST elevation 
myocardial infarction (NSTEMI). Surprisingly, there is limited data comparing 
characteristics and outcomes of pts with and without known coronary disease (prior MI or 
revascularization; CAD) in pts with NSTEMI. Methods: Pts in the ACC NCDR ACTION-
GWTG Registry with NSTEMI from 1/07 to 6/08 were included. Pts without data on 
known CAD (n=485) were excluded. We compared outcomes among pts with and without 
known CAD using logistic regression and the effect of home treatment and baseline 
characteristics on outcomes. Results: There were 47,486 pts (42% known CAD). Known 
CAD pts were older and had more co-morbidities (Table). After adjusting for baseline 
variables, known CAD pts were less likely to receive early GP 2b/3a antagonists (OR 
0.81 [0.78-0.85]), anti-thrombins (OR 0.87 [0.82-0.94]) and early angiography (OR 0.85 
[0.82-0.89])(all p<0.01). In-hospital mortality was higher in known CAD pts, but after risk 
adjustment was no longer different (OR 0.91 95% CI 0.83-1.01). The most important 
independent predictors of in-hospital mortality (age, blood pressure, heart failure, dialysis, 
and peripheral vascular disease) were similar in the 2 groups. Conclusions: Pts with 
known CAD have a higher unadjusted in-hospital mortality compared to pts without known 
CAD that disappeared after risk adjustment. Known CAD appears to be a surrogate for 
other clinical variables for predicting in-hospital mortality in pts with NSTEMI. 
No Known CAD Known CAD P value
Age, yrs 65±15 (65) 69±13 (70) <0.001
Systolic BP, mmHg 146±32 (145) 143±33 (142) <0.001
Heart failure at presentation 18% 27% <0.001
Dialysis 1.9% 3.8% <0.001
Peripheral vascular disease 6.9% 19% <0.001
Mortality 4.1% 4.9% <0.001
Results: All patients with the left main ECG pattern, who had a coronary angiography, 
had signiﬁcant coronary artery disease, 8% had 1-vessel, 21% 2-vessel and 71% 3-vessel 
disease. In addition, 25% had signiﬁcant, 50% or more, left main disease. In patients with 
other ECG patterns, the proportion with at least 50% left main disease was: ST-elevation 
3%, Q-wave without ST-elevation 10%, LBBB 21%, LVH 15%, other ST/T pattern 3%, 
other ECG pattern 5% (p<0.001).
Of the ECG categories, left main ECG had the highest rate of major adverse cardiovascular 
events, including mortality both in-hospital (29%) and during median follow-up of 10 
months (49%). The revascularization rate in the left main ECG group was 41%.
In multivariable analysis, the left main ECG pattern predicted poor prognosis compared to 
other ECG patterns. The other variables that provided independent prognostic information 
in multivariable analysis were age, creatinine level at presentation and diabetes. 
Conclusions: The ECG pattern with widespread ST-depression, maximally in leads V4-
V5 with inverted T waves and ST-elevation in lead aVR was present in 8% of “all-comers” 
with acute coronary syndrome. In multivariable analysis, this “left main ECG pattern” 
predicted poor prognosis compared to other ECG patterns.
3:30 p.m.
1023-146 Chronic Kidney Disease and Dipstick Proteinuria Are 
Risk Factors for Stent Thrombosis in Patients With 
Myocardial Infarction
Nathan D. Lambert, Matthew T. Sacrinty, Terry R. Ketch, Samuel J. Turner, Renato M. 
Santos, Kurt R. Daniel, Robert J. Applegate, Michael A. Kutcher, David C. Sane, Wake 
Forest University Baptist Medical Center, Winston-Salem, NC
Background: Renal failure is an independent risk factor for stent thrombosis (ST). 
Moderate chronic kidney disease (CKD) and proteinuria are both associated with adverse 
cardiovascular events, including worse outcomes after myocardial infarction (MI). Whether 
moderate CKD and proteinuria increase the risk of ST after MI is not known.
Methods: We retrospectively analyzed clinical and laboratory data from 1,016 patients 
who were admitted with MI and received intracoronary stenting. Clinical follow up was 
collected at one year for deﬁnite or probable ST, as well as for all-cause mortality and 
non-fatal MI or death.
Results: After multivariate adjustment, patients with both estimated glomerular ﬁltration 
rate (eGFR) < 60 ml/min/1.73m² and q1+ dipstick proteinuria had increased cumulative 
incidence of ST [Hazard Ratio (HR) 4.22 (1.75-10.18)], all-cause mortality [HR 2.78 (1.40-
5.52)], and non-fatal MI or death [HR 3.43 (1.93-6.11)] at one year. There was a dose-
dependent increase in risk of ST as GFR declined (see ﬁgure). Dipstick proteinuria (q1+)
was associated with a trend towards increased risk for all outcomes.
Conclusions: In an acute MI population, stage CKD 3-4 (eGFR 15-59 ml/min/1.73m²) 
and proteinuria were identiﬁed as novel prognostic markers for ST. In addition, patients 
with both decreased GFR and proteinuria had higher incidences of all-cause mortality 
and non-fatal MI or death than patients with either condition alone. 
3:30 p.m.
1023-147 Two-Year Multicentre Experience of Routine Use of 
Fondaparinux in Acute Coronary Syndromes
Francois Schiele, Nicolas Meneveau, Marie-France Seronde, Vincent Descotes-Genon, 
Joanna Dutheil, Romain Chopard, Fiona Ecarnot, Jean-Pierre Bassand, University 
Hospital Jean Minjoz, Besancon, France
Background: Fondaparinux (fonda) is one of the anticoagulants recommended by 
guidelines in patients (pts) with acute coronary syndromes (ACS). Its use in routine 
practice is poorly documented.
Methods: From January 2006 to December 2007, we recorded the anticoagulant agent 
used in pts with ACS. Demographic, clinical and biological characteristics at admission, 
plus treatment, severe bleeds and 30 day outcome were recorded.
Results: Among 2776 pts included, fonda use increased from 4% to 48%, p<0.001; 
while use of unfractionated heparin (UFH) remained stable (18% in 2006; 16% in 2007, 
p=NS). The increased use of fonda resulted from a switch from enoxaparin. Fonda 
use varied depending on type of centre (ﬁgure). Pts treated with UFH were older, had 
more comorbidities, higher risk and bleeding scores and received fewer guidelines-
recommended therapies. At 30 days, severe bleeding and mortality were higher in UFH-
treated pts. There was no difference in 30 day mortality between enoxaparin and fonda 
groups. A higher rate of severe bleeding was observed in the enoxaparin group (2.3% 
versus 1.2%, p<0.01). Adjustment for a propensity score for being treated by enoxaparin 
did not alter these results.
Conclusions: The increasing use of fonda was the result of a switch from enoxaparin in 
low to medium risk pts, whereas higher risk pts were still treated with UFH. No difference 
in 30 day mortality was observed between pts treated by enoxaparin or fonda, but the rate 
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structure of plaque rupture. The ﬁnal image was examined from all angles as well as 
walk-through viewings.
Results:The cavity of plaque rupture has a mean longitudinal diameter of 4.0±2.4 mm, 
a mean short axis diameter of 1.4±0.7 mm, and its mean short / longitudinal ratio (S/L) 
of 0.43±0.24. A residual ﬁbrous cap could be seen in 53 patients (68%). A slit-like ﬁssure 
was observed in 36 cases (46%) at an edge of rupture cavity. Multiple ruptures in the 
same culprit coronary segment were seen in 19 cases (24%). A tunnel-like rupture with 
a ﬁbrous cap bridge could be detected in 21 patients (27%). Patients with an oval rupture 
cavity (S/L > 0.3) had a greater maximum-CPK than those with a spindly cavity (S/L < 
0.3)(p<0.02).
Conclusions:Coronary plaque rupture is not a simple phenomenon, but rather a complex 
one with a complicated variety of rupture process. This variability might determine the 
clinical outcome of patients with acute coronary syndrome. 
3:30 p.m.
1023-153 Differential treatments in Patients With Systemic Lupus 
Erythematosus or Rheumatoid Arthritis Hospitalized 
With Myocardial Infarction: A NRMI Data Analysis
Hosakote M. Nagaraj, Marc Mayhew, Paul Frederick, William Rogers, Vijay Misra, 
University of Alabama at Birmingham, Birmingham, AL
Background: Patients with rheumatoid arthritis (RA) and systemic lupus erythematosus 
(SLE) have an elevated risk of myocardial infarction (MI). We sought to determine the 
differences in cardiac risk factors, treatment of MI, and length of hospitalization between 
patients with and without SLE or RA
Methods: Data were obtained from the National Registry of Myocardial Infarction 
(NRMI)-5. This includes patients over age 18 years discharged from 456 participating 
U.S. hospitals between April 2004 and December 2006
Results: NRMI-5 contained the data of 161387 non-transfer-out patients of which 1143 
patients with SLE/RA were compared to a cohort of 1143 patients without SLE/RA. RA in 
969 and SLE in 157 patients was reported. 17 patients had both RA and SLE. Baseline 
characteristics and medications were matched for gender, presence of ST-segment 
elevation on ECG; hospital transfer status, history of hypertension, diabetes mellitus, 
dyslipidemia, peripheral vascular disease, prior MI; and family history of CAD. Figure 1 
illustrates an interesting trend towards lower use of initial reperfusion strategy (p<0.05), 
primary PCI (p<0.05), facilitated PCI, and immediate CABG in patients with SLE or RA 
when compared to the other cohorts. Though statistically insigniﬁcant, there is a trend 
towards longer length of in-hospital stay in patients with SLE or RA
Conclusions: During hospitalization for MI, patients with RA and SLE face a therapeutic 
disadvantage with lower use of all the modalities of reperfusion strategy 
3:30 p.m.
1023-150 Renal Dysfunction Adds Incremental Value to the TIMI 
Score
Jason Go, Ann Narmi, Aimin Chen, Dan Hilleman, Stephanie Maciejewski, John Sype, 
Aryan Mooss, Creighton University Medical Center, Omaha, NE
Background: The Thrombolysis in Myocardial Infarction (TIMI) risk score is a validated 
risk assessment tool to predict outcomes in patients with UA/NSTEMI. However, there 
are some concerns as to the broad applicability of the TIMI risk score in the real world 
setting because the score was derived from clinical trial cohorts and may not be as 
predictive in the general setting. Renal dysfunction is a well known independent predictor 
for adverse cardiovascular events in both clinical trials and community-based studies. It 
was not included in the original TIMI score criteria largely because the clinical trial cohorts 
excluded patients with renal dysfunction.
Objective: To evaluate if renal status adds incremental value to the prognostic utility 
of the TIMI risk score for UA/NSTEMI without sacriﬁcing its ease of use and bedside 
applicability.
Methods: We did a retrospective study of 798 consecutive patients diagnosed with 
UA/NSTEMI from 2000-2003. The 7 TIMI risk variables were obtained along with renal 
status determined from the admission Creatinine. The Creatinine Clearance (CrCl) was 
computed using the Cockroft-Gault Equation. Patients were categorized as having renal 
dysfunction if their creatinine clearance was less than 45ml/min. Adverse outcomes were 
deﬁned as an in-hospital composite of death, myocardial infarction, or severe ischemia 
requiring urgent revascularization. Logistic regression models were used to calculate 
Receiver Operator Characteristic (ROC) curves.
Results: Eighty seven patients (10.9%) had adverse outcomes. The ROC for the TIMI 
score yielded an area under the curve (AUC) of 0.56 (95% CI 0.50-0.62). Adding CrCl as 
an independent predictor to the TIMI score improved the AUC to 0.63 (95% CI 0.57-0.70). 
Comparison of the ROC curves suggested a signiﬁcant improvement in the AUC with the 
addition of CrCl to the TIMI score (p value = 0.014). CrCl < 45ml/min was associated with 
an odds ratio of 2.8 (95% CI 1.7-4.5) for adverse outcomes.
Conclusions: In a real world setting, addition of the renal status to the TIMI risk score 
added incremental value in prognostic accuracy without detracting from the ease of use 
and bedside applicability of the TIMI risk score.
3:30 p.m.
1023-151 Chronic Kidney Disease May Raise the Risk for 
Cardiovascular Disease by Increasing Number of Yellow 
Plaques in a Coronary Artery: Angioscopic Study
Tomoaki Higo, Shinichi Hirotani, Mitsuru Wada, Yuki Masumura, Kazunori Kashiwase, 
Mayu Nishio, Yasunori Ueda, Osaka Police Hospital, Osaka, Japan
Background: Chronic Kidney Disease (CKD) has emerged as an independent risk 
factor of cardiovascular disease. On the other hand, we have revealed in the previous 
angioscopic study that number of yellow plaques (NYP) in a coronary artery is an 
independent indicator of cardiovascular events, and that patients with multiple yellow 
plaques per vessel have a higher risk of suffering future cardiovascular events than those 
with NYP 0 or 1. We assumed that CKD might raise the risk for cardiovascular disease 
by increasing NYP.
Methods: Consecutive 136 patients with acute myocardial infarction who received 
primary PCI and successful angioscopic examination were enrolled in this study. The 
infarct-related artery was angioscoically examined. NYP, maximum yellow color intensity 
(max YP; grade1, light yellow; grade 2, yellow; or grade 3, intense yellow), and prevalence 
of disrupted yellow plaques with thrombus (DYP) in the non-culprit segments were 
compared between CKD group (eGFR< 60ml/min/kg/1.73m2) and No CKD group. 
Estimated GFR was calculated using MDRD equation and based on indirect calibration 
of serum creatinine.
Results: Mean age was 64 ±11 years, 81% were male and 31% had diabetes mellitus. 
The CKD group was older (69 ± 12 vs 62 ± 10, p=0.025), and had more females (30% 
vs 14%, p=0.001). NYP was signiﬁcantly larger in CKD group than in No CKD group (4.1 
± 2.2 vs 2.9 ± 1.9, p=0.001). Max YP and prevalence of DYP in the non-culprit segments 
were not statistically different between two groups (2.5 ± 0.5 vs 2.3 ± 0.6, p=0.064; 40% 
vs 27%, p=0.164, respectively). Multivariate logistic regression analysis revealed CKD as 
an independent risk factor of multiple yellow plaques per vessel (odds ratio 2.94, 95% CI 
1.05-8.32, p=0.041).
Conclusions: CKD was an independent risk factor of multiple coronary yellow plaques. 
Our data suggest that CKD raises the risk for cardiovascular events by increasing NYP 
in a coronary artery.
3:30 p.m.
1023-152 Three-Dimensional Morphologic Analysis of Coronary 
Plaque Rupture Using Intravascular Ultrasound and 
Novel Stereoscopic Image-Processing System
Tatsuhiro Fujimura, Takafumi Hiro, Jutaro Yamada, Takayuki Okamura, Manabu 
Nasu, Shintaro Akashi, Masayuki yoshimura, Hiroko Kanoh, Toshiro Miura, Masunori 
Matsuzaki, Yamaguchi University, Ube, Japan
Background:Coronary plaque rupture is likely to occur at the shoulder of eccentric 
plaque as well as at the proximal side-portion of plaque hill. However, three-dimensional 
structural features in plaque rupture are still unclear.
Methods:Intravascular ultrasound (IVUS) images from 78 patients (64±9 y.o.) with 
a coronary plaque rupture were analyzed by a 3D image-processing program (Avizo, 
Mercury Computer Systems). Coronary lumen was traced in all frame images of IVUS. 
The traced lumen was transferred and rendered to form a three-dimensional surface 
JACC March 10, 2009 ABSTRACTS - Myocardial Ischemia and Infarction  A321
M
yocardial Ischem
ia and Infarction
3:30 p.m.
1023-156 Mitogen-Activated Protein Kinases are Upregulated 
in T-Lymphocytes of Patients With Acute Coronary 
Syndromes
Ciro Indolﬁ, Annalisa Mongiardo, Carmen Spaccarotella, Daniela De Serio, Carla 
Vicinanza, Duino Boncompagni, Alessandro Ferraro, Angelo Leone, Valter Agosti, 
Daniele Torella, Antonio Curcio, Division of Cardiology, Magna Graecia University, 
Catanzaro, Italy
Background: Diagnosis of acute coronary syndromes (ACS) currently lacks of plaque 
instability markers. The aim was to estimate p-ERK1/2, p-JNK and p-p38 in T-cells of 
ACS patients.
Methods: Unstable angina (UA, N=22), acute myocardial infarction without ST elevation 
(NSTEMI, N=19) and MI with ST segment elevation (STEMI, N=19) patients underwent 
angiography and/or PCI. Healthy blood’s donors (CTRL, N=8) and stable coronary disease 
patients (CTRL CAD, N=21), were analyzed as controls. CD3 and CD19 positive T-cells 
fraction was separated and incubated with antibodies against p-ERK1/2, p-JNK, p-p38. 
Fluorescence was analysed by ﬂow cytometry and data conﬁrmed by western blotting.
Results: FACS analysis showed a signiﬁcantly increased p-ERK1/2 (mean of ﬂuorescence 
40±18) in UA patients, compared to CTRL (14±8; p<0.05, Figure). No change was found 
for p-JNK (UA, 12±7 vs. CTRL, 9±6). NSTEMI and STEMI groups showed a statistically 
signiﬁcant increased phosphorylation of ERK1/2 (NSTEMI, 26±15; STEMI, 34±23), and 
JNK (NSTEMI, 36±19; STEMI, 40±28; p<0,05), compared to CTRL CAD. Diagnostic 
performance as determined by ROC curve analysis showed that 22.5 p-ERK intensity of 
ﬂuorescence can signiﬁcantly discriminate, with 78% sensitivity and 90% speciﬁcity, UA 
patients from stable angina patients.
Conclusions: Isolated T-cells from ACS patients demonstrated signiﬁcant ERK, JNK 
and p38 activation. The identiﬁcation of these distinct molecular clues could be useful 
for diagnosis of UA. 
3:30 p.m.
1023-157 Necrotic Core Is a Major Component of Prolased Plaque 
and Is Associated With Post-Stenting Myonecrosis: 
Virtual Histology-Intravascular Ultrasound Analysis
Young Joon Hong1, Sang Wook Kim2, Myung Ho Jeong1, Yun Ha Choi1, Wang Soo 
Lee2, Kwang Je Lee2, Tae Ho Kim2, Doo Sun Sim1, Ju Han Kim1, Youngkeun Ahn1, 
Jeong Gwan Cho1, Jong Chun Park1, Chee Jung Kim2, Wang Seong Ryu2, Jung 
Chaee Kang1, 1The Heart Center of Chonnam National University Hospital, Gwangju, 
South Korea, 2Chung Ang University Hospital, Seoul, South Korea
Background: We used virtual histology-intravascular ultrasound (VH-IVUS) to evaluate 
the plaque components in prolapsed plaque.
Methods: The study group comprised 77 patients who underwent stent implantation and 
post-stenting VH-IVUS. Of these patients, 34 patients had plaque prolapse (PP) lesions 
(n=55) and 43 patients had no PP lesions (n=92). VH-IVUS classiﬁed the color-coded 
tissue into four major components: ﬁbrotic (FT); ﬁbro-fatty (FF); dense calcium (DC); and 
necrotic core (NC).
Results: Patients with PP had higher baseline creatine kinase-MB (6.4±7.7 U/l vs. 
4.5±1.6 U/l, p=0.021), troponin-I (3.7±7.3 ng/ml vs. 0.02±0.02 ng/ml, p=0.001), and high-
sensitivity C-reactive protein (1.8±2.7 mg/dl vs. 0.2±0.6 mg/dl, p<0.001). Cardiac enzyme 
was elevated more signiﬁcantly after stenting in patients with PP compared with patients 
without PP [$CK-MB; +9.5±38.1 U/l vs. -4.0±26.1 U/l, p=0.008, and $cTnI; +5.0±16.6 
ng/ml vs. -1.2±9.4 ng/ml, p=0.012, respectively]. Lesion site external membrane area 
(19.5±6.3 mm2 vs. 15.6±5.6 mm2, p<0.001), plaque area (15.1±5.6 mm2 vs. 9.2±3.5 mm2,
p<0.001), and remodeling index (1.04±0.17 vs. 0.91±0.13, p<0.001) were signiﬁcantly 
greater in PP lesions compared with non-PP lesions. In lesions with PP, PP area was 
2.9±1.2 mm2. In prolapsed plaque, FT component was greatest, however, NC component 
was also large (absolute plaque area: FT 0.44±0.43 mm2, FF 0.07±0.09 mm2, DC 
0.04±0.08 mm2, NC 0.10±0.22 mm2, and relative plaque area: FT 68±19%, FF 14±13%, 
DC 5±9%, NC 13±16%, respectively). In patients with PP, although there were no 
correlations between % FT, % FF, % DC areas vs. $creatine-kinase MB and $troponin-I,
% NC area in prolapsed plaque correlated with $creatine-kinase MB (r=0.311, p=0.026) 
and $troponin-I (r=0.388, p=0.005).
3:30 p.m.
1023-154 Increased Levels of Circulating Bone Marrow-Derived 
Erythroid Immature Cells in Patients in the Acute 
Phase of ST Elevation Myocardial Infarction and Better 
Ventricular Function
Elena Conti, Erika Pagannone, Maria Beatrice Musumeci, Andrea Marra, Marco De 
Giusti, Filippo Maria Cauti, Eleonora Dito, Sebastiano Sciarretta, Camillo Autore, 
Massimo Volpe, II Faculty of Medicine, University of Rome, Rome, Italy, IRCCS 
Neuromed, Pozzilli (IS), Italy
Background:“Large unstained cells”(LUC), present also in normal subjects, were 
recently described as progenitors cells (PC) with hematopoietic commitment (CD34+). 
Erythroid PC are in turn committed towards endothelial and myocardial PC with repair 
and substitution function, in response to endothelial damage and myocardial ischemia/
necrosis. The role of circulating LUC in acute myocardial infarction (AMI) has not yet been 
clariﬁed. We aimed to verify whether endogenous LUC output could exert a “beneﬁcial” 
role respect to infarct area and ventricular function (EF) in AMI (patients) pts, also in 
relation to treatment and revascularization efﬁcacy and strategies.
Methods: We enrolled 135 consecutive pts admitted at our CCU with ST elevation AMI 
(98M, 37F, mean age 63±13), with time from symptom onset of 701±342 minutes, 
undergoing different treatment strategies: medical (n=20), primary (p) angioplasty (PCI) 
(n=105), rescue PCI (n=5), post successful ﬁbrinolysis early PCI (n=5). For all pts, pre- 
and post-procedural TIMI ﬂow, total number of diseased vessels, culprit vessel proximality, 
as well as haemoglobin (Hb), WBC, and LUC at time 1 (admission, LUC1), 2 (3rd day of 
admission), and 3 (discharge), CKMB and troponin I peaks and AUCs, were recorded. 
As normally distributed, continous variables were compared with Student t test, and the 
relation between LUC1,2, and 3 and measures of infarct area and EF corrected for age, 
gender, time from symptom onset, recanalization performed/not performed, TIMI ﬂow and 
vessel proximality, was tested with multivariate analysis.
Results: Median LUC1 value separated two populations similar for Hb,Hct, WBC values 
at times 1,2 o 3. At the multivariate analysis detailed above, higher EF values were 
signiﬁcantly and independently related with higher LUC 1 (B= 0.22, p<0.05), and post-
procedural TIMI ﬂow (B= 0.29, p<0.05).
Conclusions: Our data show that higher admission LUC are independently associated 
with a better ventricular function (EF), thus suggesting that bone marrow-mediated LUC 
output exert a favourable role on EF in AMI, regardless of type and efﬁcacy of therapeutic 
strategy employed. Further investigation on topic is warranted.
3:30 p.m.
1023-155 Patient Characteristics in Myocardial Infarction (MI) 
and Non-MI Subsets Based Upon the New Universal MI 
Deﬁnition
Usman Javed, Waqas Aftab, John A. Ambrose, Deepak Thatai, Ralph Wessel, Mouatou 
Mouanoutoua, Fridolin Sy, Michael Weilert, Sundararajan Srikanth, Cyrus Buhari, UCSF 
Fresno, Fresno, CA
Introduction: Myocardial Infarction (MI) has recently been redeﬁned and classiﬁed according 
to elevated Troponin I (TnI) and associated clinical criteria of myocardial ischemia. (Circ 
2007;116;2634-2653). The incidence, demographic data, angiographic ﬁndings and hospital 
mortality of Type 1 (spontaneous plaque rupture/erosion), type 2 (altered supply demand) MI 
and non MI with increased TnI have not been previously reported.
Methodology: Over a 3 month period, all patients admitted to the hospital with TnI 
>0.04 ng/ml (MI cut off for TnI-Ultra, Siemens) were prospectively evaluated by the same 
physician. MI was deﬁned as TnI >0.04 ng/ml, with either associated clinical, EKG and/or 
imaging ﬁndings. In-hospital or recent coronary angiograms were reviewed by the same 
two physicians.
Results (Table 1: Mean ± SEM): Of 701 patients with elevated TnI, 216(30.8%) had MI-
143 (20.4%) had Type 1, 64 (9.1%) had Type 2 while 461 (65.8%) had no MI. 33(4.7%) 
could not be classiﬁed. Major risk factors were common in all groups.
Conclusions: Type 1 is the most common MI and is associated with higher TnI values 
(even without ST elevation MI) than the other groups and is more likely to undergo 
angiography. Type 2 MI is often associated with ﬁxed disease and illicit drug use. Non MI 
patients with increased TnI commonly have non signiﬁcant coronary disease in spite of 
a high in-hospital mortality.
Table 1. Patient Characteristics 
Type 1 MI Type 2 MI Non MI p*
n 143 (20.4%) 64 (9.1%) 461 (65.8%)
Peak TnI ng/ml 
Without STEMI
29.95 ± 5.29
12.26±2.46
1.68 ± 0.40
1.68 ± 0.40
1.26 ± 0.34
1.26 ± 0.34
<0.0001
<0.0001
Age (years) 65.9 ± 1.6 64.2 ± 2.5 64.3 ± 0.8 0.68
Male 84 (58.7%) 35 (54.7%) 260 (56.4%) 0.83
Diabetes 61 (42.7%) 24 (37.5%) 170 (36.9%) 0.46
Hypertension 126 (88.1%) 53 (82.8%) 371 (80.5%) 0.11
Smoking 66 (46.2%) 30 (46.9%) 208 (45.1%) 0.95
Hyperlipidemia 113 (79.0%) 34 (53.1%) 243 (52.7%) <0.0001
Obesity 54 (37.8%) 14 (21.9%) 122 (26.5%) 0.015
Illicit Drug Use 
(Cocaine/Methamphetamine) 2 (1.4%) 17 (26.6%) 21 (4.6%) <0.0001
In hospital Angiogram 111 (77.6%) 14 (21.8%) 47 (10.2%) 0.0002
Any Angiogram
Signiﬁcant obstruction
Non-obstructive/Normal 
124 (86.8%)
111
13
32 (50.0%)
25
7
150 (32.5%)
78
72
<0.0001
<0.0001
<0.0001
ICU admission 15 (10.5%) 8 (12.5%) 74 (16.1%) 0.21
In-hospital mortality 15 (10.5%) 9 (14.1%) 67 (14.5%) 0.47
*ANOVA or Chi-Square
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1023-160 Primary Percutaneous Coronary Interventions for Stent 
Thrombosis
Guido Parodi, Gentian Memisha, Benedetta Bellandi, Renato Valenti, Angela Migliorini, 
Ruben Vergara, Nazario Carrabba, Gian Franco Gensini, David Antoniucci, Department 
of Cardiology, Careggi Hospital, Florence, Italy
BACKGROUND: There are very few (and conﬂicting) data about the effectiveness of 
primary percutaneous coronary interventions (PCI) for stent thrombosis (ST) treatment. 
OBJECTIVE: We sought to evaluate the prevalence, efﬁcacy and outcomes of primary PCI 
in patients with ST-elevation acute myocardial infarction (STEMI) due to ST. METHODS
AND RESULTS: Among 2,464 consecutive patients with STEMI treated by primary PCI, 
ST was the cause of the STEMI in 67 (3%) patients. Patients with ST showed a lower 
rate of signiﬁcant collateral circulation (0% versus 6%, p=0.034) and a higher creatine 
kinase peak value (2,678±3,221 U/L versus 2,375±2,189 U/L, p=0.003) as compared to 
the other 2,397 STEMI patients. The PCI was successful (TIMI ﬂow grade 3, and residual 
stenosis < 20%) in 64 (96%) patients of the ST group and consisted in additional stenting 
(78%) or only balloon angioplasty (22%). Abciximab and rheolytic thrombectomy were 
used in 75% and 31% of patients, respectively. Procedure time (39±26 versus 32±19 
minutes, p=0.0001) and ﬂuoroscopy time (13±10 versus 10±8 minutes, p=0.0001) 
were longer, and contrast medium amount (221±89 mL versus 194±103 mL, p=0.034) 
higher in patients with ST as compared to the de novo STEMI patients. Six-month death 
(12% versus 8%; p=0.216) and nonfatal reinfarction (10% versus 1%; p=0.0001) rates 
were higher in patients with ST as compared to those without. At 6-month angiographic 
follow-up (n=1843/2269), restenosis/reocclusion rate was 54% versus 17% (p=0.0001) 
in patients with and without ST. CONCLUSION: The prevalence of primary PCI for ST 
is low. Additional stenting with or without thrombectomy is effective in restoring vessel 
patency in patients with ST, but restenosis and reocclusion are frequent. ST treated with 
successful PCI is associated with large infarct size and poor outcome. New strategies to 
prevent ST are needed.
3:30 p.m.
1023-161 Prior Coronary Artery Bypass Graft Portends High Risk 
in STEMI Patients Treated With Primary Percutaneous 
Coronary Intervention
Robert C. Welsh, Christopher B. Granger, Cynthia M. Westerhout, James C. 
Blankenship, David R. Holmes, William W. O’Neill, Christian W. Hamm, Frans J. Van de 
Werf, Paul W. Armstrong, University of Alberta, Edmonton, AB, Canada
Background: Limited information exists regarding outcomes of STEMI pts with prior 
CABG undergoing primary PCI.
Methods: 128 pts (2.2%) with prior CABG were enrolled in APEX-AMI (n=5745), a 
randomized, placebo-controlled trial of pexelizumab in STEMI pts with primary PCI. Their 
pt/procedural characteristics, whether the culprit coronary vessel (IRA) was a graft or native 
artery, and 90-day clinical outcomes were compared to those without prior CABG status.
Results: Pts with prior CABG were more frequently male, older, and had a higher 
incidence of comorbidities and multi-vessel CAD (Table). As compared to pts with prior 
CABG, primary PCI was not performed in 21% vs. 6.1% and TIMI-3 ﬂow was restored in 
80.2 % vs. 91.5% pts with prior CABG (both p<0.001). Amongst those with prior CABG, 
the IRA was a graft (n=63) vs. native vessel (n=55) and their post-PCI TIMI 3 was 60.3% 
vs. 88.0% respectively (p=.043). Prior CABG pts had a substantially increased hazard 
of 90-day death and the composite outcome of death/CHF/shock; however only death 
remained signiﬁcant after baseline adjustment. When prior CABG pts were stratiﬁed 
by graft (n=63) vs. native vessel (n=55) there was further discrimination of increased 
mortality (19.0% vs. 5.7%, p=0.05).
Conclusion: In high-risk STEMI pts: those with prior CABG were less likely to undergo 
acute reperfusion and had worse clinical outcomes. This appears mediated in part by 
worse angiographic outcomes, especially when the IRA was a bypass graft. 
Table. Selected patient characteristics and 90-day outcomes.
No Prior CABG Prior CABG p
n 5617 128
Age, yrs (median, IQR) 61(52-71) 69(58.3-76) <0.001
Female, % 23.3 14.1 0.014
Hypertension, % 49.0 70.3 <0.001
Prior MI, % 10.9 64.1 <0.001
Prior PCI, % 9.2 36.7 <0.001
Prior HF, % 3.3 16.4 <0.001
Diabetes mellitus, % 15.7 25.0 0.004
Multivessel disease, % 40.2 81.9 <0.001
90-day death, % 4.6 11.9 0.001
Adj HR: 1.9, 95%CI(1.1-3.3) p=0.025
90-day death, HF, shock, % 10.1 16.4 0.019
Adj HR: 1.1, 95%CI(0.7-1.7) p=0.816
Conclusions: Patients with PP have higher inﬂammatory condition and positive 
remodeling with large plaque burden, and more post-stenting cardiac enzyme elevation 
compared with patients without PP. NC component is a major component of prolapsed 
plaque, and only NC component in prolapsed plaque is associated with post-stenting 
myonecrosis.
3:30 p.m.
1023-158 Thin Cap Fibroatheroma Is an Important Predictor 
for Rapid Plaque Progression; An Intravascular 
Ultrasound-virtual Histology Study
Jang-Ho Bae, Taek-Geun Kwon, Ki-Young Kim, Charanjit S. Rihal, Amir Lerman, 
Konyang University Hospital, Daejeon, South Korea, Mayo Clinic, Rochester, MN
Background: Vulnerable plaque (VP) is deﬁned as a coronary plaque not only prone to 
thrombosis and/or rupture but also at risk for rapid progression. We sought to evaluate 
a lesion which shows rapid progression and to know clinical outcomes of intermediate 
lesion according to tissue type by intravascular ultrasound-virtual histology (IVUS-VH).
Methods: Study subjects consisted of 98 lesions in 94 patients (61.8±11.8 years old, 68 
males) with intermediate coronary artery lesion (stenosed 30%~70%), who underwent 
IVUS-VH examination. Clinical follow up was done in 64 patients out of 65 eligible 
patients (98.5%) and follow up IVUS-VH were performed in 48 lesions/66 eligible lesions 
(72.7%).
Results: Mean minimal luminal diameter was 1.79±0.53mm and % diameter stenosis 
was 43.4±9.05% in total study subjects. Gray scale IVUS data showed that mean minimal 
luminal area was 5.4±2.1mm2, number of lesion with minimal luminal area (MLA)<4.0mm2
was 31 lesions (31.6%), and lesion length was 13.9±7.2mm. Fibrous cap atheroma was 
the most common lesion type (n=42, 42.9%), followed by thin cap ﬁbroatheroma (TCFA, 
n=28, 28.6%), ﬁbrocalciﬁc atheroma (n=17, 17.3%), and pathological intimal thickening 
(n=7, 7.1%). The remaining 4 lesion could not be classiﬁed. There were 8 lesions in 7 
patients showing rapid lesion progression, which required intervention during mean 
8.7±2.9months follow up period. TCFA lesion type showed higher risk of rapid lesion 
progression (38.5% vs. 8.6%, p=0.014) than non-TCFA lesion and lesion MLA<4.0mm2
showed also higher risk (35.3% vs. 6.5%, p=0.010) than lesion MLA q4.0mm2. The risk 
of rapid lesion progression requiring PCI was highest (66.7%) in those presenting with 
MLA<4.0mm2 and TCFA, followed by MLA<4.0mm2 or TCFA (16.7%), and lowest (4.2%) 
in those without the above parameters.
Conclusions: This study suggests that TCFA is an important predictor for VP and IVUS-
VH derived TCFA can be considered as MLA<4.0mm2 by gray scale IVUS.
3:30 p.m.
1023-159 Prognostic Implications of the New Universal Deﬁnition 
of Myocardial Infarction
Rita Calé, Pedro Carmo, Nuno Santos, Jorge Ferreira, Carlos Aguiar, João Figueira, J. 
Aniceto Silva, Cardiology Department, Hospital Santa Cruz, CHLO, Lisbon, Portugal
Background: The clinical implications of the new ESC/ACCF/AHA/WHF universal 
deﬁnition of myocardial infarction (MI) are under debate.
Purpose: To evaluate the prognostic implications of the new diagnostic criteria -99th 
percentile of a normal reference population for cardiac troponin (cTn), as well as for the 
mass of CK-MB (MBm).
Methods: Prospective single centre registry of 444 consecutive patients (mean age 63±11 
years, 20% female) admitted to an ICCU with non-ST-segment elevation acute coronary 
syndrome. We measured cTn I, MBm and CK-MB activity at admission and serially at 6, 12 
and 24 hours. The peak value was used for analysis. We calculated the HR and 95% CI for 
death/MI at 1-year follow-up, adjusted for baseline demographic and clinical characteristics, 
between the presence or absence of MI using different criteria: 1) cTn I>99th percentile 
(0.04 ng/ml); 2) MBm>99th percentile (3.2 ng/ml); 3) MBm>2x ULN (12.2 ng/ml); 4) CK-MB 
activity>2x ULN (32U/L); 5) cTn I> best cut-off value (0.09 ng/ml).
Results:The new universal deﬁnition increased the incidence of MI in 86% for MBm 
>99th percentile but was not a predictor of death/MI at 1-year (see Table). Peak cTnI> 
0.09 ng/ml was the only independent predictor of death/MI at 1 year. 
Criteria of MI MI,
n (%)
Adjusted HR (95% CI) for death/MI at 
1-year p value
cTn I>99th percentile 294 (66.2) 1.52 (0.67-3.41) 0.32
MBm>99th percentile 221 (49.8) 1.77 (0.84-3.75) 0.14
MBm>2x ULN 119 (26.8) 1.30(0.82-2.06) 0.26
CK-MB activity>2x ULN 94 (21.2) 1.08 (0.46-2.56) 0.86
cTn I>0.09 234 (52.7) 1.62(1,05-2,51) 0.029
Conclusions:In a contemporary unselected population with non-ST-segment elevation 
acute coronary syndromes, the new universal deﬁnition of MI increased this diagnosis in 
86% but was not an independent predictor of prognosis at 1-year.
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1023-164 Patient Characteristics Associated With the Choice of 
Triple Antithrombotic Therapy in the Setting of Acute 
Coronary Syndromes
Jeremiah P. Depta, Christopher P. Cannon, Gregg C. Fonarow, Xin Zhao, Deepak L. 
Bhatt, Cleveland Clinic, Cleveland, OH, VA Boston Healthcare System and Brigham and 
Women’s Hospital, Boston, MA
Background: Evidence regarding the use of dual antiplatelet therapy and oral 
anticoagulation (i.e. triple therapy) in acute coronary syndromes (ACS) is lacking. We 
evaluated characteristics associated with the choice of triple therapy in ACS.
Methods: Using the Get With the GuidelinesSM national registry database, we studied 
patients presenting with ACS at 361 participating sites in the United States from 2000-
2007. Multivariable logistic regression was used to assess the factors associated with the 
choice of triple therapy upon discharge. The Generalized Estimating Equation method 
was used to account for within-hospital clustering.
Results: A total of 86,304 patients presented with ACS during the study period. At discharge, 
3,933 patients (4.6%) were prescribed triple therapy, whereas 60,716 patients (70.3%) received 
dual antiplatelet therapy, 2,348 patients (2.7%) received single antiplatelet plus oral anticoagulation, 
19,065 patients received antiplatelet monotherapy (22.1%), and 242 patients (0.3%) received 
oral anticoagulation alone. Patients with a history of atrial ﬁbrillation (odds ratio [OR] 6.56, 95% 
conﬁdence interval [CI] 5.67 to 7.59; p<0.001), documented new onset atrial ﬁbrillation (OR 3.57, 
95% CI 2.70 to 4.70; p<0.001), or history of atrial ﬂutter (OR 3.15, 95% CI 2.00 to 4.96; p<0.001) 
were more frequently discharged on triple therapy. Of patients with atrial ﬁbrillation or ﬂutter (n = 
6,064), 1,139 patients (18.8%) were discharged on triple therapy, 2,508 patients (41.4%) received 
dual antiplatelet therapy, 1,444 patients (23.8%) received antiplatelet monotherapy, 973 (16.0%) 
patients received a different antiplatelet and/or oral anticoagulation regimen.
Conclusions: Atrial ﬁbrillation or ﬂutter were most strongly associated with the choice 
of triple therapy in patients with ACS, yet used less often compared to dual or single 
antiplatelet therapy in patients with those factors. Further study is needed to evaluate the 
safety/efﬁcacy of triple therapy in ACS.
ACC.POSTER CONTRIBUTIONS
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1032-125 Fibrinolytic Therapy and Bleeding Complications: Risk 
Predictors From SWEDEHEART
Jonas Oldgren, Lisa Wernroth, Ulf Stenestrand, Uppsala Clinical Research Center, 
Uppsala, Sweden, Dept of Cardiology, University Hospital, Linköping, Sweden
Background: Fibrinolytic treatment for ST-elevation myocardial infarction (STEMI) is 
associated with increased bleeding risk but is still widely used world-wide, mainly because 
of limited access to primary PCI. The aim of this study was to analyse contemporary 
ﬁbrinolytic treatment patterns, in-hospital bleeding risk and prognosis during 2001 to 2005 
in unselected Swedish STEMI patients.
Methods: The SWEDEHEART registry covers almost all Swedish patients treated for 
myocardial infarction. Major in-hospital bleeding was deﬁned as lethal or intracranial 
bleedings or bleedings requiring surgery or blood transfusion. Survival status of the 14732 
patients was obtained from the National Cause of Death Register.
Results: The proportion of patients receiving ﬁbrinolysis decreased from 76 % in 2001 
to 23 % of STEMI patients in 2005. Major in-hospital bleedings (including lethal or 
intracranial) increased from 1.4 % (0.8%) in 2001 to 4.0 % (1.6 %) in 2005, p<0.001. 
History of serious bleeding, higher age, female gender, clopidogrel treatment prior to 
admission, pre-hospital administration of ﬁbrinolytics and ﬁbrin-speciﬁc ﬁbrinolytics were 
identiﬁed as predictors for bleeding. Major in-hospital bleeding was the strongest predictor 
of adverse prognosis with more than three-fold increase in one-year mortality. 
Conclusions: During 2001 to 2005 the use of ﬁbrinolytic treatment markedly decreased 
while the incidence of major bleedings was more than doubled, the latter might in part be 
explained by increasing use concomitant anti-platelet therapy, pre-hospital treatment and 
ﬁbrin-speciﬁc ﬁbrinolytics. Future close monitoring of bleeding complications is warranted, 
especially when considering the increased use of various combinations of antithrombotic 
drugs in conjunction with ﬁbrinolysis and the great impact of bleedings on long-term 
mortality.
3:30 p.m.
1023-162 Recombinant Human Interleukin-11 Has a Novel Role 
in the Mobilization of Endothelial Progenitor Cells and 
Reduction of Infarct Size in Mice
Julius Aitsebaomo, Siddharth Srivastava, Cam Patterson, University of North Carolina, 
Chapel Hill, NC
Background: Acute myocardial infarction (AMI) is the leading cause of death for both men 
and women in the western world, and studies in human subjects with coronary artery disease 
have shown that Endothelial Progenitor Cell (EPC) levels directly correlate with mortality after 
AMI. Currently, use of EPC for treatment of patients with ischemic heart disease involves 
delivery of ex vivo-processed EPC to patients during percutaneous coronary intervention or 
by direct injection of EPC to ischemic myocardium. A major limitation of EPC therapy in this 
patient population is lack of drug(s) to mobilize EPC in vivo.
Methods: In a preclinical study to evaluate the efﬁcacy of mobilized EPC, saline or 
recombinant human interleukin-11 (rHIL-11) was administered intravenously at a dose of 
200 microgram/kg/day to 8-week old C57BL/6 mice (n=8 in each group) 24 hours prior to 
30 minutes of coronary occlusion and reperfusion.. Area at risk was assessed by evans 
blue dye, infarct size by triphenyl-tetrazolium-chloride, and left ventricular volumes as well 
as ejection fraction by echocardiogram.
Results: There was a 5-fold increase in EPC mobilization within 24 hours of IL-11 
infusion. The area at risk was signiﬁcantly reduced, and the infarct size was reduced 
by 24% at 72 hours post infarction. The post-infarct reduction of ejection fraction was 
improved, and the left ventricular end-systolic and end-diastolic volumes were reduced 
by 7 days when compared to control.
Conclusions: Taken together, this data shows that rHIL-11 has a novel role in reduction 
of infarct size and has a favorable effect on post-infarct remodeling suggesting a novel 
role of rHIL-11 as an adjunctive therapy for patients with AMI.
3:30 p.m.
1023-163 Left Bundle Branch Block Without Concordant ST-
Elevation In Suspected ST-Elevation Myocardial 
Infarction Identiﬁes Patients With High False Positive 
Rates: Insights From the APEX-AMI Trial
Renato D. Lopes, Hany Siha, Yuling Fu, Paul W. Armstrong, Christopher B. Granger, 
Duke Clinical Research Institute, Durham, NC
Background: We sought to assess how left bundle branch block (LBBB) relates to the 
likelihood of ST-segment elevation myocardial infarction (STEMI) and need for primary 
percutaneous coronary intervention (PCI) in patients (pts) with suspected STEMI.
Methods: We evaluated cardiac biomarkers, coronary angiograms, outcomes according 
to LBBB in the 5473 pts included in the APEX-AMI trial. All electrocardiograms were 
interpreted in a core lab blinded to treatment and outcomes.
Results: LBBB occurred in 98 (1.7%) pts. Although pts with LBBB were intended to be 
eligible only if LBBB was “not known to be old” and with concordant q 1mm ST elevation, 
52 (53%) had concordant ST elevation and 46 (47%) did not. The associations of cardiac 
biomarkers, revascularization with primary PCI or coronary artery bypass graft (CABG) 
surgery, outcomes and LBBB are in the table. Patients with one deﬁnition of “false 
positive” STEMI (no biomarker elevation, or no initial TIMI 0 or 1 ﬂow, or no primary PCI/
in-hospital CABG) were less common in LBBB with concordant ST elevation (30.8%) vs 
without (71.7%, p< 0.001). Patients with LBBB and concordant ST elevation more often 
had primary PCI (84.6%) compared to no concordant ST elevation (71.7%).
Conclusion: In a clinical trial of pts requiring primary PCI, the incidence of “false positive” 
STEMI was high, especially if there was no concordant ST elevation. On the other hand, 
careful assessment of concordant ST elevation with LBBB can identify a population highly 
likely to require primary PCI.
Patient descriptors according to the presence of LBBB and 
concordance of ST-elevation
LBBB No LBBB P-value
LBBB with 
concordant
ST-elevation
LBBB without 
concordant
ST-elevation
P-value
CK-MB <=2x / 
troponin <=3x
13
(13.3%) 185 (3.3%) <0.001 4 (7.7%) 9 (19.6%) 0.002
Pre-PCI TIMI 
ﬂow 0-1
60
(61.3%) 4164(73.9%) 0.004 40 (76.9%) 20 (43.5%) 0.001
Pre-PCI TIMI 
ﬂow 2-3
38
(38.8%) 1466(26.1%) 0.004 12 (23.1%) 26 (56.5%) 0.001
Primary PCI 
or in-hospital 
CABG
79
(80.6%) 5401(95.7%) <0.001 46 (88.5%) 33 (71.7%) 0.037
“False 
Positive” 
STEMI
49(50.0%) 1639(29.0%) <0.001 16(30.8%) 33(71.7%) <0.001
90-Day 
mortality 5 (5.1%) 266(4.7%) 0.809 1 (1.9%) 4 (8.7%) 0.183
90-Day death/
heart failure/
shock
14
(14.3%) 572(10.1%) 0.179 7 (13.5%) 7 (15.2%) 0.804
“False Positive” STEMI = no biomarker elevation, OR no TIMI 0 or 1, OR no primary 
PCI/in-hospital CABG.
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1032-128 Trends in the Medical Management and Thirty-Day 
Mortality Among Patients With Renal Dysfunction 
Admitted With Acute Myocardial Infarction
Paul A. Santolucito, Dennis A. Tighe, Darlene Lessard, Robert J. Goldberg, University of 
Massachusetts Medical School, Worcester, MA
BACKGROUND: Patients with renal dysfunction are at increased risk for adverse 
outcomes after acute myocardial infarction (AMI). While comorbidities are often greater 
in these patients, lower usage of recommended therapies may also play a role. The 
purpose of this study was to examine recent trends in the hospital management and 30 
day mortality among patients with renal disease admitted with AMI.
METHODS: Data from 6,219 hospitalized AMI patients (mean age= 70.7; 43.7% women) 
during 6 biannual periods from 1995-2005 in the Worcester Heart Attack Study were 
examined. Trends in AMI management and 30 day mortality were stratiﬁed according to 
degree of renal function [preserved renal function (eGFR q60), mild to moderate renal 
disease (eGFR 30-60), or severe renal disease (eGFR a30)].
RESULTS: Aspirin and beta-blocker use increased over time to a greater extent among 
patients with renal insufﬁciency, especially those with eGFR a30 (ﬁgure). Statin use 
increased similarly in all groups (ﬁgure) irrespective of eGFR. While 30 day mortality 
was higher among those with renal dysfunction during all study years (ﬁgure), signiﬁcant 
declines in mortality over time were observed only among those with renal dysfunction.
CONCLUSIONS: Data from this large population based study demonstrate favorable 
trends in the medical management and short-term outcomes among patients with renal 
disease admitted with AMI. Despite these trends, patients with renal disease remain at 
increased risk for adverse outcome after AMI.
9:30 a.m.
1032-129 Utilization of Antithrombotic Agents Among Patients 
Admitted With Myocardial Infarction in the ACTION 
Registry-GWTG
Mitul B. Kadakia, Nihar R. Desai, Karen P. Alexander, Anita Y. Chen, JoAnne M. 
Foody, Christopher P. Cannon, Stephen D. Wiviott, Benjamin M. Scirica, TIMI Study 
Group, Cardiovascular Division, Brigham & Women’s Hospital and Harvard Medical 
School, Boston, MA, Duke Clinical Research Institute and Division of Cardiology, Duke 
University Medical Center, Durham, NC
Background: 
Current practice guidelines, as well as recent trial data, support the use of unfractionated 
heparin (UFH), low molecular weight heparin (LMWH), bivalirudin, or fondaparinux in 
NSTEMI and STEMI. Little is known about how these agents are selected in current 
clinical practice.
Methods: Between January 2007 to June 2008, data for 41,647 patients with NSTEMI 
and 27,355 patients with STEMI were captured at 289 U.S. hospitals for the ACTION 
Registry-GWTG. Patients were stratiﬁed based on the antithrombin strategy selected 
during hospitalization to evaluate patterns associated with their use.
Results: 37,716 pts (90.6%) with NSTEMI and 25,493 pts (93.2%) with STEMI received at 
least one antithrombin agent. While LMWH was used more often in NSTEMI, UFH was the 
most commonly used agent in both NSTEMI and STEMI. The newer antithrombin bivalirudin 
was given to 11% while fondaparinux was given to <1% (Graph). There were signiﬁcant 
differences in use of antithrombins by age (q75), risk factors, concomitant medications 
and invasive care (Table). There were also signiﬁcant differences in terms of unadjusted 
outcomes such as major bleeding, RBC transfusion, and in-hospital mortality.
Conclusions: While UFH remains the most often used antithrombin in patients with MI, 
key differences in antithrombin selection according to baseline characteristics and overall 
treatment strategies are evident. Further evaluation to clarify how antithrombin choice 
translates into clinical outcomes is warranted.
9:30 a.m.
1032-126 Predictors and Clinical Outcomes of Optimal Medical 
Therapy at Discharge in Patients With Acute Myocardial 
Infarction
Jang Hoon Lee, Shung Chull Chae, Hun Sik Park, Young-Jo Kim, Seung-Ho Hur, 
Chong-Jin Kim, Myeong-Chan Cho, Myung-Ho Jeong, Taek-Jong Hong, Doo-Il Kim, 
Kee-Sik Kim, Korean Acute Myocardial Infarction Registry Investigators, Kyungpook 
National University Hospital, Daegu, South Korea
Background: Only limited data are available for the recent trend of optimal evidence-
based medical therapies (OMT) at discharge after acute myocardial infarction (AMI). We 
evaluated the predictors associated with OMT at discharge, and the association between 
the use of OMT at discharge and 6-month outcome. Methods: Between November 
2005 and January 2008, we evaluated the discharge medications among 9474 post-MI 
survivors (6827 men and 2647 women; mean age=63.8±12.5 year-old) who did not have 
any contraindications to anti-platelet agents, beta-blockers (BB), angiotensin-converting 
enzyme inhibitors (ACE-I)/angiotensin II receptor blockers (ARB), or lipid-lowering drugs 
in the Korea Acute Myocardial Infarction Registry (KAMIR). OMT was deﬁned as the use 
of all indicated medications. Results: Of the 9474 patients, 4735 (50%) received OMT at 
the time of discharge. The discharge prescription rates of anti-platelet agents, BB, ACE-I/
ARB and lipid-lowering drugs were 98.8%, 72.2%, 81.2%, and 76.9%, respectively. In 
multivariate analysis, old age (age q65)(odds ratio [OR] 0.854, 95% conﬁdence interval 
[CI] 0.738 to 0.987, p=0.032), history of dyslipidemia (OR 1.382, 95%CI 1.107 to 1.726, 
p=0.004), percutaneous coronary intervention (PCI) (OR 1.970, 95%CI 1.629 to 2.382, 
p<0.001), and serum creatinine levels (OR 0.586, 95%CI 0.461 to 0.745, p<0.001) were 
independent predictors of OMT. Overall, 6-month mortality was 1.3%. The OMT group had 
signiﬁcantly lower 6-month mortality (0.9% vs. 1.7%, p=0.001). In multivariate analysis, 
OMT (OR 0.045, 95%CI 0.425 to 0.990, p=0.045), old age (OR 3.596, 95%CI 2.070 to 
6.245, p<0.001), Killip class q2 (OR 2.142, 95%CI 1.405 to 3.264, p<0.001), PCI (OR 
0.522, 95%CI 0.334 to 0.816, p=0.004), serum creatinine levels (OR 2.095, 95%CI 1.168 
to 3.759, p=0.013), and body mass index (OR 0.921, 95%CI 0.861 to 0.986, p=0.018) 
were independent predictors of 6-month mortality after adjustment for confounding 
variables. Conclusions: Only half of post-MI patients are receiving OMT at the time of 
discharge despite current guidelines for management of AMI. The OMT is an independent 
predictor of 6-month mortality.
9:30 a.m.
1032-127 Worsening of Renal Function After Primary PCI in 
Patients With Acute Myocardial Infarction Is Not 
Determined by Radio-Contrast Dose but by Left 
Ventricular Dysfunction
Norihisa Ito, Hiroshi Ito, Katsuomi Iwakura, Atsunori Okamura, Yasushi Koyama, 
Motoo Date, Yoshiharu Higuchi, Koichi Inoue, Ryusuke Kimura, Hiroyuki Nagai, Yuko 
Toyoshima, Michio Imai, Makito Ozawa, Yukinori Okazaki, Masahiko Shibuya, Hidetaka 
Suenaga, Asuka Kubota, Kenshi Fujii, Sakurabashi Watanabe Hospital, Osaka, Japan
Background: It is well known that heart failure or use of radio-contrast worsen renal 
function and result poor clinical outcomes. However it remains unknown whether 
worsening of renal function is caused by pump failure or contrast-induced nephropathy in 
patients with acute myocardial infarction (MI) undergoing primary PCI.
Methods: Consecutive 237 patients with acute MI underwent primary PCI on the day of 
MI. We performed echocardiography to measure left ventricular ejection fraction (LVEF) 
and early peak mitral annulus velocity (e’) at day-1 and day-14.
Results: Serum creatinine elevated by q0.3mg/dL after admission in 83 patients (35%), 
and we deﬁned them as worsening group. There were no differences in baseline serum 
creatinine, estimated glomerular ﬁltration rate or radio-contrast dose between two groups. 
LVEF (day-1 and day-14) and e’(day-14) were lower in worsening group. Incidence of 
proteinuria and peak CPK and CKMB were higher in the worsening group.
Conclusion. Worsening of renal function in acute MI patients is not determined by radio-
contrast dose or baseline renal function but by left ventricular dysfunction, proteinuria 
and MI size. 
Non-Worsening Worsening P value
Age, years 62±13 65±11 0.198
Male / Female 133/21 70/13 0.673
Hypertension, % 59 59 0.897
Dyslipidemia, % 61 41 <0.05
Diabetes mellitus, % 32 40 0.375
Proteinuria, % 32 46 <0.05
eGFR, ml/min/1.73m² 60.0±17.2 64.1±17.9 0.084
LVEF(day-1), % 54 ± 12 50 ± 10 <0.05
e’ velocity(day-1), cm/s 6.18 ± 2.00 5.96 ± 2.33 0.456
E/e’ ratio(day-1) 11.3 ± 4.16 11.5 ± 4.32 0.784
LVEF(day-14), % 59 ± 12 54 ± 14 <0.05
e’ velocity(day-14), cm/s 5.81 ± 1.73 5.23 ± 1.41 <0.05
E/e’ ratio(day-14) 10.2 ± 3.98 10.5 ± 4.15 0.637
Peak CPK, IU/L 2532 ± 2238 3844 ± 4030 <0.05
Peak CK-MB, IU/L 191 ± 164 273 ± 256 <0.05
Radio-contrast 208 ± 56 203 ± 50 0.466
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EP LP
FX06 0.32 (0; 7.1) 4.04 (0.1; 13.6)
Placebo 3.14 (0.7; 7.2) 2.60 (0; 6.4)
p=0.02 p=0.22 (two-sided)
IS at 4 months (LGE) in grams
EP LP
FX06 10.46 (4.7; 32.6) 23.29 (6.9; 44.2)
Placebo 22.93 (10.2; 38) 17.99 (6.5; 26.1)
p=0.02 p=0.14 (two-sided)
Values are mean (IQR)
Conclusion: In this pre-speciﬁed subgroup analysis, FX06, when given as an adjunct to 
primary PCI in STEMI, reduces IS signiﬁcantly at 5 days and at 4 months both in terms of 
LGE zone (not at 5 days) and NC zone in patients presenting early (pain-to-balloon < 3 
hrs). In contrast, in late presenters, FX06 seems to exhibit an effect in the short term, but 
there is no signiﬁcant effect compared to placebo in the long-term.
9:30 a.m.
1032-132 ST-Elevation Myocardial Infarction Care and Outcomes 
for the Oldest-Old
Daniel E. Forman, Anita Y. Chen, Stephen D. Wiviott, Tracy Y. Wang, David J. Magid, 
Karen P. Alexander, Brigham and Women’s Hospital, Boston, MA, Duke University 
Medical Center, Durham, NC
Background: Data regarding use of reperfusion therapy and outcomes in the oldest-old 
(q85 years [yrs]) STEMI patients (pts) are sparse.
Methods: We grouped STEMI pts from 286 sites enrolled in the NCDR ACTION Registry-
GWTG between 1/1/2007 and 6/30/2008 by age: <75, 75-84, and q85 yrs and describe 
baseline characteristics, use of reperfusion, and in-hospital outcomes.
Results: Compared to pts <85 yrs, the oldest-old STEMI pts (median age 88 yrs, IQR 
86-91) were more often female and had more comorbidity (Hypertension, Heart Failure, 
Peripheral Vascular Disease, and Prior MI; all p<0.0001). They were also more likely to 
have reperfusion contraindications, less likely to be reperfused even if eligible, and had 
longer wait times to EKG and balloon inﬂation (Table). Primary PCI was the most common 
reperfusion strategy across all age strata. Unadjusted rates of in-hospital death increased 
with age groups (4%, 12%, and 19%). Compared to pts not reperfused, adjusted mortality 
was signiﬁcantly lower for reperfused pts aged <75 yrs (OR 0.58, CI 0.40-0.84), but only 
trended to beneﬁt for reperfused pts aged 75-84 (OR 0.93 CI 0.57-1.54) and q85 (OR 
0.86, CI 0.44-1.69).
Conclusions: The oldest-old STEMI patients were more likely to have reperfusion 
contraindications, less likely be reperfused when eligible, and had longer reperfusion wait 
times. While reperfusion conferred beneﬁt among pts aged <75 yrs, pts aged 75-84 and q85 
only trended to beneﬁt, suggesting differences persist related to reperfusion across age 
STEMI Patients Age <75 (24,070)
Age 75-84 
(4,273)
Age q85
(1,845)
P for 
trend
Reperfusion Contraindicated 
(%) 13 25 42 <.0001
Reperfusion Eligible (20,121) (3,099) (1,038)
Reperfusion (%) 96 90 85 <.0001
Reperfused (19,686) (2,863) (900)
Primary PCI (%) 81 78 78 <.0001
Door to ECG (median minutes, 
IQR) 6 (3-13) 8 (4-16) 10 (4-21) <.0001
Door to Balloon (median 
minutes, IQR) 72 (55-91) 77 (59-98) 80 (63-103) <.0001
9:30 a.m.
1032-133 An Increased TIMI Risk Score Is Associated With a 
Decrease in TIMI Patency in Patients Treated With 
Thrombolytics for ST-Elevation Myocardial Infarction
Hans-Peter Hobbach, Uwe Zeymer, Peter Schuster, St. Marien-Krankenhaus Siegen, 
Siegen, Germany, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany
Background: While primary percutaneous coronary intervention (PCI) is the preferred 
reperfusion strategy in ST-elevation myocardial infarction (STEMI) the majority of patients 
(pts) is admitted to hospitals without PCI facilities. For the most part these pts will be 
treated with thrombolysis. Therefore clinical models to predict the success of thrombolysis 
are still needed.
Methods: 314 pts (age 62±12 years) with STEMI (<6 hours) were investigated; all pts 
received a thrombolytic therapy and underwent early (within 90 min of lytic) invasive 
management. A successful thrombolysis was identiﬁed by TIMI 3 ﬂow in the infarct related 
artery, risk of pts was stratiﬁed by TIMI Risk Score (TRS).
Results: There was a signiﬁcant linear relationship between STEMI pts and mortality (p 
for trend <0,0001) as well as TIMI 3 ﬂow (p for trend 6), we could identify STEMI pts where 
we have to assume a lower efﬁcacy of thrombolysis.
Conclusions: TRS for STEMI is a convenient clinical risk score for predicting mortality 
among pts with STEMI and may be also useful in assessing efﬁcacy of thrombolytic 
therapy, increasing risk was associated with decreasing patency. STEMI pts with TRS > 
4 treated with thrombolysis should be considered for an early invasive management and 
possible rescue PCI. Alternatively, they should be transferred urgently for primary PCI 
without administration of a thrombolytic agent. 
9:30 a.m.
1032-130 Percutaneous Intramyocardial Stem Cell Injection and 
Electromechanical Mapping in Patients With Acute 
Myocardial Infarction: First-in-Man Study
Korff T. Krause, Kai Jaquet, Carsten Schneider, Stefanie Haupt, Karl-Heinz Kuck, 
Asklepios Clinic St. georg, Hamburg, Germany
Background: First clinical studies on intracoronary stem cell infusion in patients with 
acute myocardial infarction (AMI) revealed promising results with regard on left ventricular 
ejection fraction (LVEF) improvement. Percutaneous intramyocardial cell injection (PICI) 
has shown to be superior to the intracoronary approach in preclinical studies, but PICI 
has only been reported in patients with chronic ischemic heart disease, so far.
Methods: On day 10.5±5 after AMI and PCI with stent implantation (culprit lesion: 
18 LCA, 2 RCA) 20 patients (mean 60.4±11.4 years) received bone marrow derived 
mononuclear cells (BMC) in the vital low voltage region of the infarction area using left 
ventricular electromechanical mapping (EMM)-guided PICI. We injected 2.0±0.3x10(8) 
cells including 1.0±0.3x10(6) CD45-/CD34+ stem cells in each patient. EMM (NOGA), 
coronary angiogram was performed in 15 patients including 6-month follow-up. 
Echocardiography, laboratory data and clinical assessment (6-month and 12-month 
follow-up) were performed in all 20 patients.
Results: None of the patients showed periprocedural complications or major adverse 
events during the 12-month follow-up. EMM showed an improvement from baseline UV 
45.5±14.3% to 59.3±19.2% of normal voltage (p=0.002) and reduction of the low voltage 
area from 28.7±12% to 20.3±13.5% (p=0.016) in 15 patients with EMM follow-up after 6 
months. Endocardial electrogram fragmentation showed no increase in the EMM. There 
was no ventricular tachycardia documented in the Holter-ECG’s. During the 12-month 
follow-up in all 20 patients, LVEF improved from 40.8±6.8% to 47,0±10,5%.
Conclusion: Left ventricular EMM and percutaneous intramyocardial cell injection in patients 
with AMI was shown to be a safe procedure and is associated with improved electromechanical 
parameters and increased left ventricular function during a 12-month-follow-up.
9:30 a.m.
1032-131 Impact of Time to Therapy on the Efﬁcacy of FX06 
as an Adjunct to Primary Percutaneous Coronary 
Intervention in Acute ST Elevation Myocardial Infarction
Jonas Hallen, Bernard Geudelin, Rainer Henning, Jurg Schwitter, Kurt Huber, Peter 
Petzelbauer, Peter Buser, Dan Atar, Fibrex Medical Research & Development GmbH, 
Vienna, Austria, Aker University Hospital, Div. of Cardiology, Oslo, Norway
Background: The “FX06 in Ischemia/REeperfusion Injury” (F.I.R.E)-trial found that FX06, 
a ﬁbrin peptide, reduced infarct size (IS) by mitigating reperfusion injury after 5 days in 
patients with STEMI undergoing primary PCI. The aim of this analysis was to determine 
whether the efﬁcacy of FX06 versus placebo was dependent on the timing of reperfusion 
therapy.
Methods: In this trial, 234 patients presenting with acute STEMI within 6 hours from 
onset of pain were randomized in 26 centres. IS was assessed at 5 days and 4 months 
by late gadolinium enhanced (LGE) cardiac MRI. IS was measured both as total LGE 
zone and necrotic core (NC) zone. Patients were divided into early presenters (EP) and 
late presenters (LP) based on their pain-to-balloon-time of 0-3 hrs versus 3-6 hrs. The 
P-values were calculated using the Wilcoxon rank-sum test.
Results: The median pain-to-balloon time was ~3.1 hrs for the overall study population. A 
total of 96 patients were EP (n=44, FX06, n=52, placebo) and 99 patients were LP (n=49, 
FX06, n=50, placebo). The results are summarised below. 
IS at 5-7 days (NC) in grams
EP LP
FX06 1.8 (0; 8.5) 1.42 (0; 9.1)
Placebo 4.9 (1.2; 10.9) 3.79 (0.1; 9.8)
p=0.02 p=0.12
IS at 5-7 days (LGE) in grams
EP LP
FX06 19.1 (5.7; 45.6) 22.69 (12; 53.3)
Placebo 26.97 (12.6; 53) 27.39 (9.6; 39.1)
p=0.12 p=0.94 (two-sided)
IS at 4 months (NC) in grams
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initial angiogram) was higher in treatment groups in which patients received pretreatment 
with clopidogrel (34.3%; 95% conﬁdence interval (CI), 32.9-35.8) compared with those in 
which patients did not receive clopidogrel before initial angiography (25.8%; 95%CI, 24.5-
27.1). For extensive analyses see table.
Conclusions: Initial patency and clinical outcome were improved in treatment groups 
that received pretreatment with clopidogrel. These results in patients undergoing pPCI 
are in line with the experience of pretreatment with clopidogrel in elective patients, non-
STEMI and thrombolytic studies.
Effect of pretreatment with clopidogrel on early reperfusion and 
adverse event rates.
Multivariate-
Adjusted
Treatment 
Effect*
Jackknife 
Estimation*
Propensity
Score-
Adjusted
Treatment 
Effect
Odds
Ratio
95%CI P
Odds
Ratio
95%CI P
Odds
Ratio
95%CI P
TIMI grade 
2/3 ﬂow
1.51 1.31-1.74 <0.0001 1.51 1.31-1.74 <0.0001 1.53 1.39-1.68 <0.0001
Mortality 0.57 0.38-0.85 0.0055 0.57 0.40-0.81 0.0019 0.52 0.41-0.67 <0.0001
Death/
reinfarction
0.54 0.38-0.75 0.0003 0.54 0.39-0.73 0.0001 0.50 0.40-0.62 <0.0001
*Adjusted for age, gender, history of diabetes mellitus, history of hypertension, heparin dose (high vs low 
dose), symptom duration, smoking, and year of publication.
9:30 a.m.
1032-136 Infarct Size in Off-Site Primary Angioplasty Versus 
Transferal to a Tertiary Center: A Single Photon 
Emission Computed Tomography Study
Victor A. Umans, Paul Knaapen, Jan H. Cornel, Friso van der Zand, MCA, Alkmaar, The 
Netherlands
Background. Primary percutaneous coronary intervention (PCI) performed in large 
community hospitals without cardiac surgery back-up facilities (off-site) reduces door-
to-balloon time compared with emergency transferal to tertiary interventional centers 
(on-site). The present study was performed to explore whether off-site PCI for acute 
myocardial infarction results in reduced infarct size.
Methods. 128 patients with acute ST-segment elevation myocardial infarction were 
randomly assigned to undergo primary PCI at the off-site center (n=68) or to transferal to 
an on-site center (n=60). Three days after PCI, 99mTc-sestamibi SPECT was performed 
to estimate infarct size.
Results. Off-site PCI signiﬁcantly reduced door-to-balloon time compared with on-site 
PCI (94±54 versus 125±59 min, respectively, p<0.01), although time-to-treatment was 
not signiﬁcantly reduced (257±211 versus 286±146 min, respectively, p=0.39). Infarct size 
was comparable between treatment centers (16±15 versus 14±12%, respectively p=0.35). 
Multivariate analysis revealed that TIMI 0/1 ﬂow grade at initial coronary angiography (OR 
3.125, 95% CI 1.17-8.33, p=0.23), anterior wall localization of the myocardial infarction 
(OR 3.44, 95% CI 1.38-8.55, p<0.01), and development of pathological Q-waves (OR 
5.07, 95% CI 2.10-12.25, p<0.01) were independent predictors of an infarct size > 12%.
Conclusions. Off-site PCI reduces door-to-balloon time compared with transferal to a 
remote on-site interventional center but does not reduce infarct size. Instead, pre-PCI 
TIMI 0/1 ﬂow, anterior wall infarct localization, and development of Q-waves are more 
important predictors of infarct size.
9:30 a.m.
1032-137 Left Ventricular Function After ST-Elevation Myocardial 
Infarction in Patients Treated With Primary Coronary 
Angioplasty and Abciximab or Tiroﬁban: Insights From 
the Facilitated Angioplasty with Tiroﬁban or Abciximab 
(FATA) Randomized Trial
Nevio Taglieri, Francesco Saia, Cinzia Marrozzini, Vincenzo Guiducci, Guido Rocchi, 
Elena Biagini, Giancarlo Piovaccari, Antonio Manari, Angelo Branzi, Antonio Marzocchi, 
Istituto di Cardiologia, Università di Bologna, Policlinico S. Orsola-Malpighi, Bologna, 
Italy, Unità Operativa di Cardiologia Interventistica, Ospedale S. Maria Nuova, Reggio 
Emilia, Italy
Background: Abciximab during primary percutaneous coronary intervention (PPCI) has 
shown to ameliorate left ventricular function recovery (LVFR). High-Dose Bolus (HDB) 
tiroﬁban has similar effect on platelet inhibition. Whether or not this is associated with 
comparable efﬁcacy on LVFR remains unclear. Then, we sought to compare the impact on 
left ventricular function of adjunctive therapy with HDB tiroﬁban or abciximab in ST elevated 
myocardial infarction (STEMI) patients treated with PPCI. Further we sought to deﬁne the 
predictors of favorable (q50%) left ventricular ejection fraction (LVEF) and LVFR.
Methods: This study comprised 314 patients (abciximab, n=154; tiroﬁban, n=160) 
undergoing PPCI in the randomized Facilitated Angioplasty with Tiroﬁban or Abciximab 
trial. LVEF and wall-motion-score-index (WMSI) were assessed within 48-h post-PPCI 
and at 30-day. Among patients with left ventricular systolic dysfunction at baseline, LVFR 
was deﬁned by one of the following: 1) increase of LVEF q10% as compared to baseline; 
2) LVEF q50%.
Results: Similar LVEF was observed in the two groups either post-procedure (abciximab 
49.7±10.1% vs. tiroﬁban 49.3±10.1%, p=0.9) and at 30-day (abciximab 53.1±9.8% vs. 
tiroﬁban 52.5±10.2%, p=0.6). Likewise, there was no difference in WMSI post-procedure 
9:30 a.m.
1032-134 Age and Outcomes After Myocardial Infarction With 
Persistent Total Occlusion of the Infarct Related Artery: 
An Analysis of the Occluded Artery Trial
Adam H. Skolnick, Vladimir Dzavik, Venu Menon, Lea Liu, Aldo P. Maggioni, Antonio C. 
Carvalho, Luis Gruberg, Rudyney Eduardo Uchoa Azevedo, Erwin Schroeder, Camille 
A. Pearte, Harvey D. White, Gervasio A. Lamas, Judith S. Hochman, New York University 
School of Medicine, New York, NY
Background: OAT demonstrated that opening an occluded infarct-related artery in stable 
patients did not reduce events over 5 years. There was a trend toward interaction between 
age and treatment.
Methods: Older patients (age>65 years, n=641) enrolled in OAT were compared with 
younger patients (<65 years, n=1560) with respect to baseline characteristics and 
outcomes by treatment with percutaneous coronary intervention (PCI) vs. optimal medical 
therapy (MED) alone.
Results: Older patients were more likely to be female, non-smokers, hypertensive and 
to have impaired renal function and multivessel disease. The 5-year primary outcome 
(death, MI or Class IV heart failure), and death and heart failure individually were more 
common in older pts (p<0.001) (Table). For the primary outcome, there was a trend toward 
a differential treatment effect based on age (p=0.03), and no difference between PCI and 
MED in either age group. Among younger patients MI rates tended to be higher in PCI vs. 
MED (HR 1.80 (CI:0.9-3.3), p=0.02), with no difference in older pts. During 5 year follow-
up, younger patients more often had angina vs. older pts (H.R. 1.28, p=0.003), but rates 
were reduced with PCI vs. MED for both age groups (H.R. 0.77, p<0.0003).
Conclusion: Older OAT patients had higher rates of most adverse outcomes, irrespective 
of treatment. PCI reduced angina to a similar degree in the young and old. There was a 
trend toward a differential effect of PCI in the young vs. the old for the primary outcome, 
which is likely a chance ﬁnding.
5-year Adjudicated Outcomes by Age Group and Treatment
Primary 
Outcome Death
Fatal and Non 
Fatal MI
Class IV Heart 
Failure
Younger MED (%) 12.8 8.6 4.5 3.1
Younger PCI (%) 18.1 10.3 8.0 4.2
Older MED (%) 23.4 18.5 6.5 7.2
Older PCI (%) 20.9 14.9 4.6 6.7
Younger: PCI vs MED H.R. 
(99% CI)
1.4 (1.0-2.0)
p=0.02
1.2 (0.7-
2.0)
p=0.40
1.8 (0.9-3.3)
p=0.02
1.1 (0.5-2.3)
p=0.73
Older: PCI vs MED H.R. 
(99% CI)
0.8 (0.5-1.4 )
p=0.37
0.8 (0.4-
1.5)
p=0.42
0.7 (0.3-1.9)
p=0.38
0.9 (0.4-2.1)
p=0.83
(The pre-speciﬁed signiﬁcance was deﬁned as p<0.01)
9:30 a.m.
1032-135 Impact of Pretreatment With Clopidogrel on Initial 
Patency and Outcome in Patients Treated With Primary 
Percutaneous Coronary Intervention for ST-Segment 
Elevation Myocardial Infarction: A Systematic Review
Pieter J. Vlaar, Tone Svilaas, Kevin Damman, Bart J. de Smet, Jan G. Tijssen, Hans 
L. Hillege, Felix Zijlstra, University Medical Center Groningen, Groningen, The 
Netherlands, Academic Medical Center, Amsterdam, The Netherlands
Background: The value of pretreatment with clopidogrel before primary percutaneous 
coronary intervention (pPCI) for ST elevation myocardial infarction (STEMI) is currently 
unclear.
Methods: Studies were retrieved through MEDLINE and Cochrane Register searches. 
Randomized trials were included when the research subjects were unselected patients 
with STEMI undergoing pPCI. Pilot trials, studies that enrolled patients undergoing rescue 
PCI, and studies with angiographic assessment not performed by core lab or 2 blinded 
investigators were excluded.
Treatment effect of clopidogrel was calculated using weighted logistic regression analyses. 
Jackknife estimation was used to establish the robustness of the multivariate model. A 
propensity score was calculated based on matching of alle baseline variables.
Results: 38 treatment groups (8429 pts) were included. Initial patency (TIMI 2/3 ﬂow on 
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compared to -0.8% and 2.6% in the 5X106 cells and controls, respectively.
Conclusions: Intracoronary infusion of autologous bone marrow CD34+ cells 
administered during the repair phase after STEMI, at higher doses than previously given, 
is safe, and may be associated with improved functional recovery as a result of enhanced 
perfusion to the peri-infarct zone.
9:30 a.m.
1032-140 Inﬂuence of Time-to-Reperfusion on the Presence 
and Extent of Myocardial Salvage, Infarct Size and 
Microvascular Damage in Patients With ST-Segment 
Elevation Myocardial Infarction: Evidence From 
Cardiovascular Magnetic Resonance
Chiara Bucciarelli-Ducci, Chiara Bucciarelli-Ducci, Marco Francone, Iacopo Carbone, 
Emanuele Canali, Raffaele Scardala, Francesca Calabrese, Gennaro Sardella, 
Emanuela Algeri, Francesco Fedele, Roberto Passariello, Luciano Agati, University “La 
Sapienza”, Rome, Italy
Background: Previous studies evaluating the inﬂuence of time-to-reperfusion on 
infarct size (IS) and myocardial salvage over time in patients with ST-segment elevation 
myocardial infarction (STEMI) yielded conﬂicting results. Cardiovascular magnetic 
resonance (CMR) can visualize areas of irreversible myocardial and microvascular injury 
(infarct size, IS and microvascular obstruction, MVO, respectively) with late gadolinium 
enhancement (LGE) imaging and areas of salvaged myocardium at risk with T2-weighted 
imaging.
Methods: Seventy patients with ﬁrst STEMI, successfully treated with primary PCI within 
12 hours from symptom onset, underwent CMR 5±2 days after hospital admission. 
Patients , patients were subcategorized into 4 quartiles on the basis of pain-to-balloon 
time distribution: <60 minutes (group A, n= 19), >60 to 150 minutes (group B, n= 17), 
>150 to 360 minutes (group C, n= 17), and >360 minutes (group D, n= 17). Breath-hold 
T2-weighted and LGE CMR imaging was used to characterize reversible and irreversible 
myocardial injury.
Results: Shorter time-to-reperfusion (group A) was associated with smaller IS and 
MVO and larger salvaged myocardium at risk. A progressive increase overtime in 
IS (8%, 11%, 12%, 18%, p=0.005, respectively), and MVO (0.5%, 1.5%, 3.7%, 6.6%, 
p=0.039, respectively) was observed, whereas salvaged myocardium at risk suddenly 
decreases after 60 minutes (8.5%, 3.2%, 2.4%, 2.1%, p =0.003, respectively). Lately 
reperfused patients (group D) had signiﬁcantly larger areas of IS and MVO with higher 
prevalence of intramyocardial hemorrhage compared to group A, with an almost complete 
disappearance of salvaged myocardium at risk
Conclusions: In patients with reperfused STEMI, time-to-reperfusion determines the 
extent of reversible and irreversible myocardial injury. CMR can identify and quantify 
areas of salvaged myocardium at risk representing an important tool to be used in large 
clinical trials assessing different reperfusion strategies.
9:30 a.m.
1032-141 Clopidogrel Therapy Following Acute Myocardial 
Infarction Hospitalization or Stent Insertion: What Are 
the Consequences of Stopping Therapy Before one 
Year?
Daniel Wiederkehr, Michelle Krukas, Lee Stern, Lois Lamerato, Dinara Makenbaeva, 
Essy Mozaffari, John Corbelli, Analytica International, Inc., New York, NY
Background: Clopidogrel has been shown to reduce the risk of recurrent acute coronary 
syndrome (ACS), as reﬂected by the ACC/AHA guidelines since 2002. Our goal was to 
evaluate the clinical impact of stopping clopidogrel therapy earlier than one year.
Methods: We conducted a retrospective observational cohort study of patients having 
an acute myocardial infarction (AMI: STEMI or non-STEMI) and/or coronary stent 
insertion from 2002-07. Patients were enrolled in an integrated commercial health plan 
which provides care across the continuum of inpatient and outpatient settings. Patients 
having pharmacy claims indicating less than 30-day supply of clopidogrel were excluded. 
The occurrence of AMI and/or ACS-related procedures (CABG, PCI with/without stent 
insertion) was tracked up to one year after initial hospitalization. Multivariate Cox 
regression using a time-dependent covariate for clopidogrel therapy was used to assess 
the association between stopping clopidogrel and risk of AMI rehospitalization, ACS-
related procedure, or all-cause mortality while adjusting for demographics, comorbidities, 
cardiovascular procedures at initial hospitalization, and at follow-up.
Results: A total of 1,152 patients had an AMI hospitalization or coronary stent procedure 
followed by at least 30 days of clopidogrel therapy. Average duration of therapy was 131 
days. Seventy-three percent (n=837) of the patients had not reﬁlled their medication 
routinely for a full year. Stopping clopidogrel was associated with nearly a three-fold 
increase in the risk of subsequent AMI rehospitalization or ACS procedure (HR 2.71, 
95% CI 1.63-4.50). When considering a composite endpoint of all-cause mortality, AMI 
rehospitalization or ACS procedure, stopping clopidogrel was associated with a two-fold 
increase in risk (HR: 1.84, 95% CI:1.28-2.65).
Conclusion: Stopping clopidogrel prior to a full year of therapy following an AMI 
hospitalization or coronary stent insertion is associated with a signiﬁcantly increased risk 
of death, AMI hospitalization, and/or ACS procedure. Healthcare decision makers should 
consider implementing evidence-based recommendations to minimize patients’ risk of 
recurrent events.
(abciximab 1.56±0.34 vs. tiroﬁban 1.56±0.37; p=0.9) and at 30-day (abciximab 1.42±0.39 
vs. tiroﬁban 1.42±49; p=0.9). Independent predictors of 30-day LVEF q50% were: pre-
procedure TIMI-ﬂow >0 (OR=2.4, 95% CI 1.32-4.34), anterior location (OR=0.25, 95% CI 
0.15-0.42), and age (OR=0.97, 95% CI 0.95-0.99). Pre-procedure TIMI >0 was the only 
predictor of LVFR (OR=6.73, 95% CI 2.69-16.88).
Conclusions: This study showed no differences in terms of left ventricular function in 
patients undergoing PPCI treated either with abciximab or HDB tiroﬁban. Pre-procedure
TIMI ﬂow grade > 0 seems the most important predictor of favourable LVEF and LVFR 
at 30 days.
9:30 a.m.
1032-138 Lack of Change in Occurrence Rate and Long-Term 
Outcome of Patients With Post-Infarction Ventricular 
Septal Rupture: A 21-year Study
Abel E. Moreyra, Alan C. Wilson, Yingzi Deng, Nora M. Cosgrove, John B. Kostis, for the 
MIDAS Study Group, UMDNJ-Robert wood Johnson Medical School, New Brunswick, NJ
Background: Ventricular septal rupture (VSR) is a dreaded complication of acute 
myocardial infarction (AMI). The impact of recent improvements in therapy on the 
frequency and outcomes of post-infarction VSR is not well known.
Methods: We used MIDAS data of patients (pts) admitted with ﬁrst AMI (n=399,491) for 
cases complicated with VSR (ICD9 429.71; n=367) in New Jersey between 1986 and 
2006. Clinical characteristics, revascularization procedures and 30-day, 1 and 5 year 
mortality were analyzed in three seven-year time periods.
Results: 98% of all VSR cases occurred in the ﬁrst AMI. Compared to pts without rupture, 
pts with VSR were older 71 vs 66 years (p=0.05), more likely to be female (53%, vs 43%, 
p<.0001), had more chronic renal disease (24 vs 9%), congestive heart failure (45 vs 
32%) and had less diabetes (18 vs 25% ) and hypertension (31 vs 44%); all p<.0001. By 
multivariate analysis, surgical repair signiﬁcantly decreased 30-day mortality (O.R. 0.51, 
0.31-0.84) but not 1-year mortality (O.R. 0.74, 0.46-1.19). 
TRENDS IN VENTRICULAR SEPTAL RUPTURE AND SURVIVAL
Time Period 1986-1992 1993-1999 2000-2006 P value
VSR cases, n (%) 67 (0.05) 186 (0.15) 114 (0.06) <.0001
Shock 31% 34% 39% 0.3
Anterior/Inferior MI 43% / 45% 43% / 44% 36% / 36%
0.008
Subendo. MI 1.5% 9.5% 16%
PCI 3.0% 7.9% 16% 0.002
Surgical Repair 34% 45% 50% 0.02
Mortality - 30 days 40% 51% 40% 0.1
Mortality - 1 year 54% 60% 54% 0.47
Mortality - 5 year 61% 64% 60% 0.77
Conclusions: In this large series of pts with AMI complicated by VSR, the occurrence 
rate of rupture ﬂuctuated but did not decrease over time. Signiﬁcantly we observed 
an increase in the proportion of VSR occurring in subendocardial infarctions. Despite 
signiﬁcant increases in the rate of PCI and surgery over time there were no improvements 
in associated mortality. Surgical repair was found to be associated with reduced short-
term mortality, but the beneﬁt was not maintained long-term.
9:30 a.m.
1032-139 CD34+ Cell Infusion after ST Elevation Myocardial 
Infarction is Associated with Improved Perfusion
Arshed A. Quyyumi, Jonathan R. Murrow, Fabio Esteves, James Galt, John Oshinski, 
Stamatios Lerakis, Salman Sher, Khan Pohlel, Edmund K. Waller, Douglas Vaughn, 
Emerson Perin, James Willerson, Dean Keriakis, Robert Preti, Andrew L. Pecora, Emory 
University School of Medicine, Atlanta, GA
Background: Cell therapy with intracoronary administration of unselected bone marrow 
cells has been shown to improve LV function in studies. The CD34+ bone marrow 
population is enriched for endothelial and other progenitors that may contribute to 
functional improvement by promoting neo-angiogensis and mitigating peri-infarct zone 
apoptosis. AMR-001 is an ongoing prospective, Phase I multicenter, escalating dose (5, 
10, and 15 million CD34+ cells), cohort controlled study, designed primarily to assess 
the feasibility and safety of isolating autologous bone marrow derived CD34+ cells 
from patients after STEMI and infusing them into the infarct related artery. Secondary 
endpoints include assessment of cardiac function using MRI and quantitative resting LV 
perfusion with SPECT imaging. We hypothesize that CD34+ cell harvest and infusion 
will be safe and that the improvement in myocardial perfusion and function will be cell 
dose-dependent.
Methods: To date 31 patients (16 treated and 15 controls) have been enrolled and 
6-month follow has been completed in the ﬁrst 2 cohorts. Cell harvest using mini-bone 
marrow harvest (mean volume 409 ml) under conscious sedation was safe. Adequate 
numbers of viable Isolex selected CD34+ cells were safely infused via the infarct related 
artery, 7 to 10 days post STEMI following successful stenting.
Results: Compared to baseline, the change in SPECT total severity score and exercise 
tolerance were both improved in those receiving 10X106 cells compared to patients 
receiving 5X106 cells and controls; change in SPECT total severity score of -360, +8, and 
-62, respectively, p=0.01,10X106 vs. others; and change in exercise duration of +3.3, 0.6 
and 1.9 minutes, respectively, p=0.05, 10X106 vs. others. There was also a non-signiﬁcant 
trend to a greater improvement in EF in the higher dose group; 5.8% in the 10X106
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1032-144 Enoxaparin in Patients Not Undergoing Reperfusion for 
ST-Elevation Myocardial Infarction
Gabriel Tatu-Chitoiu, Dragos Vinereanu, Maria Dorobantu, Mircea Cinteza, Maria 
Udeanu, Olivia Manfrini, Crina Sinescu, Elvira Craiu, Marius Vintila, Mariana Radoi, 
Raffaele Bugiardini, Spitalul Clinic de Urgenta “Floreasca”, Bucharest, Romania, 
University of Bologna, Bologna, Italy
Background: Enoxaparin therapy is beneﬁcial in ST-elevation myocardial infarction 
(STEMI) patients receiving ﬁbrinolytics and/or percutaneous coronary intervention. Its 
efﬁcacy in patients not undergoing reperfusion is still unproven.
Methods:We investigated the relative beneﬁts of enoxaparin compared with unfractioned 
heparin in the Romanian registry of ST-elevation acute myocardial infarction (RO-STEMI), 
which enrolled, 9288 consecutive patients from January 2000 to December 2007.
Results: There were 3812 (41.0%) patients who did not receive mechanical or 
pharmacological reperfusion, but admission therapy with enoxaparin (no=1462) or 
unfractionated heparin (no=2350). Logistic regression was used to adjust the outcome of 
in-hospital death for baseline characteristics. Patients who were given enoxaparin were 
more likely to have history of hypertension (60.1% vs. 51.7%, p<.0001), lipid disorders 
(42.3% vs. 29.5%, p<.0001), and prior myocardial infarction (13.4% vs. 9.0%, p<.0001), 
and to present heart failure (48.6% vs. 34.3%, p<.0001). They were more likely to receive 
concomitant medication with aspirin and/or clopidogrel (93.7% vs. 83.5%, p<.0001). The 
rate of death was reduced by enoxaparin compared with unfractionated heparin (14.5% 
versus 16.9 %; OR, reference unfractioned heparin: 0.83; 95% CI 0.69-0.99, p<0.05). 
After adjustment for age, any clinical confounder and antiplatelet therapy with aspirin and/
or clopidogrel, patients with enoxaparin had a 1.29-fold-lower risk of death (95% CI, 0.58 
to 0.88, p=0.001).
Conclusions: In the RO-STEMI registry, patients who did not undergo reperfusion had 
greater absolute and relative risk reductions when treated with enoxaparin compared with 
unfractionated heparin as admission therapy.
9:30 a.m.
1032-145 The Classic Electrocardiographic Algorithm for 
Identiﬁcation of the Right Coronary Artery as 
Infarct-Related Artery in Acute Inferior Myocardial 
Infarction Has Low Sensitivity in a Large Patient 
Cohort Undergoing Primary Percutaneous Coronary 
Intervention
Niels J. Verouden, Karel T. Koch, José P. Henriques, Jan Baan, René J. van der Schaaf, 
Marije M. Vis, Jan G. Tijssen, Jan J. Piek, Robbert J. de Winter, Academic Medical 
Center, Amsterdam, The Netherlands
Background: On the 12-lead electrocardiogram (ECG), ST-segment elevation (STE) in lead 
III exceeding that in lead II in combination with ST-segment depression (STD) in lead I or 
aVL is the generally accepted ECG algorithm for determination of the right coronary artery 
(RCA) as the infarct-related artery (IRA). However, this algorithm was derived from only few, 
small studies mainly from the thrombolytic era. We determined sensitivity and speciﬁcity of 
this ECG algorithm in a large cohort of patients undergoing primary percutaneous coronary 
intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).
Methods: Between 2000 and 2007, 1131 patients with inferior STEMI underwent 
primary PCI. All 12-lead ECGs were recorded immediately prior to PCI and the IRA was 
determined during emergency angiography. ST-segment deviation was measured at the 
nearest 0.05 mV in all standard leads.
Results: Coronary angiography conﬁrmed the RCA being the IRA in 895 patients (79%) 
with inferior STEMI. Application of the ECG algorithm resulted in 624 true positive cases of 
acute RCA obstruction (sensitivity 70%) and 170 cases with true negative result (speciﬁcity 
72%). Current results deviate substantially from previously published data (Table 1).
Conclusions: The ECG algorithm of exceeding STE in lead III compared to lead II 
combined with STD in lead I or aVL shows a substantially lower sensitivity for the non-
invasive diagnosis of acute RCA occlusion in a large cohort of inferior STEMI patients. 
9:30 a.m.
1032-146 Mitral Regurgitation Is an Independent Predictor 
of One-Year Mortality in ST-Elevation Myocardial 
infarction Patients Presenting in Cardiogenic Shock on 
Admission
Annemarie E. Engstrom, Krischan D. Sjauw, Marije M. Vis, Rene J. van der Schaaf, Jan 
Baan, Jr., Berto J. Bouma, Karel T. Koch, Robbert J. de Winter, Jan G. Tijssen, Jan J. 
Piek, José P. Henriques, Academic Medical Center, Amsterdam, The Netherlands
Background: Cardiogenic shock (CS) remains the most serious complication of acute 
ST-elevation myocardial infarction (STEMI). Mitral regurgitation (MR) is a frequent 
complication of STEMI and a well-known predictor of mortality in STEMI without CS. 
However, insight in the prognostic value of the presence and severity of MR is limited in 
9:30 a.m.
1032-142 Impact of Intracoronary Injection of Mononuclear Bone 
Marrow Cells in Acute Myocardial Infarction on Left 
Ventricular Perfusion and Function: Gated 99mTc-MIBI 
Single-Photon Emission Computed Tomography Study.
Piotr Lipiec, Maria Krzeminska - Pakula, Michal Plewka, Jacek Kusmierek, Anna 
Plachcinska, Remigiusz Szuminski, Tadeusz Robak, Anna Korycka, Jaroslaw D. 
Kasprzak, Medical University of Lodz, Lodz, Poland
Background: We sought to investigate the impact of intracoronary injection of autologous 
mononuclear bone marrow cells (BMC) in patients with acute ST-elevation myocardial 
infarction (STEMI) on left ventricular volumes, global and regional systolic function and 
myocardial perfusion.
Methods: 39 patients with ﬁrst anterior STEMI, treated with successful primary 
percutaneous coronary intervention were randomly assigned to the treatment group or 
the control group in a 2:1 ratio. 3-10 days after STEMI patients underwent baseline ECG-
gated 99mTc-methoxyisobutylisonitrile single-photon emission computed tomography 
(G-SPECT) with quantitative and qualitative analysis of left ventricular perfusion and 
systolic function. On the following day, patients from the BMC treatment group were 
subjected to bone marrow aspiration, mononuclear BMC isolation and intracoronary 
injection. No placebo procedure was performed in the control group. G-SPECT was 
repeated six months after STEMI.
Results: Baseline and follow-up G-SPECT studies were available for 36 patients. At 
6-months in the BMC group we observed a signiﬁcantly enhanced improvement in mean 
perfusion defect extent (p=0.02), left ventricular perfusion score index (p=0.03), infarct 
area perfusion score index (p=0.01) and infarct area wall motion score index (p=0.04) 
compared to the control group. However, the changes in left ventricular end-diastolic 
and end-systolic volumes, left ventricular ejection fraction and left ventricular wall motion 
score index did not differ signiﬁcantly between both groups.
Conclusions: Intracoronary injection of autologous mononuclear BMC in patients with 
STEMI improves myocardial perfusion and infarct area systolic function at 6 months with 
no apparent beneﬁt in global left ventricular systolic function.
9:30 a.m.
1032-143 Absence of an Interaction Between Drugs Metabolized 
by Cytochrome P450 Enzymes and the Beneﬁt of 
Treatment With Prasugrel Versus Clopidogrel in 
Patients With Acute Coronary Syndromes Undergoing 
Percutaneous Intervention: A TRITON-TIMI 38 Analysis
Michelle O’Donoghue, Stephen D. Wiviott, Sabina A. Murphy, Eric R. Bates, Marc S. 
Sabatine, Jessica L. Mega, Nihar R. Desai, Carolyn H. McCabe, Elliott M. Antman, 
Eugene Braunwald, Brigham and Women’s Hospital, Boston, MA
Background: Drugs that are metabolized by CYP P450 enzymes, including lipophilic 
statins and proton pump inhibitors (PPI), may alter the efﬁcacy of clopidogrel by inhibiting 
its conversion to the active metabolite. Prasugrel is a novel thienopyridine that is more 
efﬁciently converted to its active form by the liver and improves outcomes in patients 
with ACS. It is unknown whether prasugrel offers comparable beneﬁt over clopidogrel in 
patients who are or are not on P450-metabolized drugs.
Methods: TRITON-TIMI 38 randomized 13,608 subjects with ACS undergoing PCI to 
prasugrel or clopidogrel, in addition to standard therapy. The primary endpoint (EP) was 
CV death, MI or stroke. We performed a landmark post-hoc analysis from 3 days to 
capture medications at discharge.
Results: 9583 (70%) subjects were on a lipophilic statin and 3662 (27%)subjects 
were treated with a PPI. There was a consistent beneﬁt of prasugrel over clopidogrel 
in reducing the primary EP in subjects who were on a lipophilic statin (HR 0.82, 95% CI 
0.69-0.98) and those who were not (HR 0.76, 95% CI 0.60-0.96, P int=0.60). Similarly, 
prasugrel had a comparable beneﬁt over clopidogrel in subjects treated with a PPI (HR 
0.81, 0.62-1.04) and those who were not (HR 0.81, 0.68-0.95, P int=1.00). Signiﬁcant 
treatment interactions were not observed for other relevant exposures, including tobacco 
or amiodarone.
Conclusion: Prasugrel improves outcomes after PCI in ACS, irrespective of use of many 
drugs hypothesized to alter clopidogrel metabolism. 
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left anterior descending coronary artery. Mice were imaged using the Xengene Imaging 
System to track the grafted hASCs at day 2, 7, 14, 21, 28 after cell injection, respectively. 
The intensity of in vivo bioluminescence signals (BLSs) was quantiﬁed by drawing the 
region of interest using Living Image Software v.3.0. Twenty-four days after surgery, the 
hearts were collected and the heart sections were subjected to immunoﬂuorescence 
staining to detect injected hASCs using anti-lamin A/C antibody, which speciﬁcally binds 
to human cells.
Results: Our results show that the BLSs were detectable in the heart areas of 3 mice 
through 28 days of the experiment. During 2-14 days after cell injection, the intensity of 
BLSs was drastically reduced from (2.33±0.93)x106 (mean±SD) to (9.09±3.7)x105 in units 
of photons per second per centimeter squared per steradian. After that time, the BLSs 
gradually increased and arrived at (1.40±1.2) x106 at day 28 after cell injection. No BLSs 
were observed in other organs. The immunoﬂuorescence staining analysis showed the 
existence of hASCs in hearts, which conﬁrms that the BLSs detected in the heart area in 
vivo was from the hearts.
Conclusions: This study demonstrates for the ﬁrst time that bioluminescence imaging 
can feasibly be used to track transplanted hASCs in infarcted hearts of mice in vivo over 
the 28-day period. The injected cells were preferentially retained in injured myocardium 
rather than migrating to other organs or tissues. This ﬁnding provides further insight 
into the mechanisms underlying the effect of hASCs on cardiac function of infarcted 
myocardium.
9:30 a.m.
1032-149 The Effect of Failure Mode and Effect Analysis On 
Reducing Door-to-Balloon Time and Mortality in ST-
Segment Elevation Myocardial Infarction 
Feng-Yu Kuo, Wei-Chun Huang, Guang-Yuan Mar, Chin-Chang Cheng, Han-Lin Tsai, 
Kuan-Rau Chiou, Shue-Ren Wann, Shoa-Lin Lin, Chun-Peng Liu, Cardiovascular 
Medical Center and Department of Emergency, Kaohsiung Veteran General Hospital, 
Kaohsiung, Taiwan,ROC, School of medicine, National Yang-Ming Univeristy, Taipei, 
Taiwan,ROC
Background: The aim of this study was to evaluate the efﬁcacy of Failure Mode and 
Effect Analysis (FMEA) to reduce door-to-balloon (D2B) time, morbidity and mortality.
Methods: FEMA was used to evaluate our D2B process since 2007. We implemented 
changes into two systems: the emergency department (ED) system (reverse triage 
order) and the transfer system (a STEMI network with 14 cooperative transfer hospitals, 
two 24-hour special phone lines to active catheterization laboratory from ED in transfer 
hospitals).
Results: The retrospective (2005-2006), interphase (2007) and prospective (2008 Q1-
2) period had 83, 90 and 130 patients. The D2B median time decreased signiﬁcantly 
(p<0.001) (Figure 1). In the subgroup analysis, the transfer patients via STEMI network had 
signiﬁcantly shorter D2B median time (25.5 minutes) than on-site patients (47 minutes) 
(p<0.001) or transfer patients without previous contact (43.5 minutes) (p<0.001). The 
D2B less than 90 minutes ratio improved from 15% to 59%, and then to 95% (p<0.001). 
There was signiﬁcant reduction in the ED stay median time (126 minutes vs. 13 minutes, 
p<0.001), unplanned readmission percentage within 30 days (8.1% vs. 1.6%, p=0.02) and 
in-hospital mortality rate (10.8% vs. 3.8%, p=0.04).
Conclusions: FMEA is a powerful tool to systematically identify the D2B system weakness 
and decrease D2B median time, ED stay, readmission rate and mortality. STEMI transfer 
network showed more efﬁciency than transfer without contact or on-site patients. 
9:30 a.m.
1032-150 Comparison of Left Ventricular Wall Motion Recovery 
Between Primary Percutaneous Coronary Intervention 
With and Without Thrombosuction in Patients With 
Acute Myocardial Infarction. Results of Long-Term 
Echocardiographic Follow-Up Study
Hyunmin Choe, Sung Yun Lee, Seung Hwan Lee, Min-Soo Ahn, Kyung Hoon Lee, Jang 
Young Kim, Joon Hyung Doh, June Namgung, Won Ro Lee, Inje University, Ilsan Paik 
Hospital, Goyang-si, Gyeonggi-do, South Korea, Yonsei University, Won-ju College of 
Medicine, Won-ju-si, Kangwon-do, South Korea
Background: The thrombosuction by use of export aspiration catheter (EAC) during 
primary PCI has been proved to be safe and effective method for coronary reperfusion. 
However, the changes of left ventricular (LV) wall motion after thrombosuction have never 
been evaluated.
Methods: From April 2005 to January 2008, we analyzed 111 patients who were underwent 
primary PCI with and without thrombosuction and completed Echocardiographic 
examination on 1st to 5th days (baseline) and 6 to 12 months (follow-up). We divided 
them into the suction group (n=58) and non-suction group (n=53) and then compared 
two groups by use of the LV regional wall motion score (WMS) and ejection fraction 
STEMI complicated by CS. The purpose of this study was to determine the prognostic 
signiﬁcance of MR, in STEMI patients with CS on admission.
Methods: From January 1997 through March 2005, 292 consecutive STEMI patients 
presented with CS on admission and were treated by primary PCI. Early echocardiograms 
were performed in 147 patients, which constituted the ﬁnal study cohort. Color doppler 
of MR was graded with a 0 to 3 scale (none, n=26; 1=mild, n=62; 2=moderate, 
n=40;3=severe, n=19).
Results: Overall 1-year mortality was 27%. One-year mortality was 8%, 23%, 30% and 
58% for patients with no, mild,moderate and severe MR respectively (p<0.001). For each 
grade of MR increase, the odds for mortality increased with 80% (OR 1.8; 95% CI 1.1-3.0; 
p=0.025) when adjusted for age >60 years, gender, previous myocardial infarction, left 
ventricular ejection fraction (LVEF) <40%, multivessel disease and no-reﬂow.
Conclusions: The early presence of MR is an independent predictor of 1-year mortality 
in STEMI patients with CS on admission treated by primary PCI. Early identiﬁcation of 
MR allows risk stratiﬁcation and triage of high-risk patients towards new therapeutic 
approaches. 
9:30 a.m.
1032-147 Improvement of Reperfusion Rates With Thrombectomy 
Catheter in Acute Myocardial Infarction
Rogerio Moura, Fernando Barreto, Marcus Costa, Carlos Barreto, Luciano Brasileiro, 
Fernando Tavares, Hospital Balbino, Rio de Janeiro, Brazil
Background: Despite the great effectiveness of primary percutaneous coronary 
intervention (PCI) in AMI with ST elevation (AMIEST), the distal embolization of 
atherothrombotic material is related to reduction of
myocardial perfusion and worse outcome.
Objective: To demonstrate the importance of using thrombectomy
catheters in patients with AMIEST and the effectiveness of these devices in improving 
myocardial reperfusion.
Methods: prospective randomized trial, which were consecutively included 152 patients 
with AMIEST (<6h).From them, 76 patients were submited to conventional PCI with stent 
(CPCI) and 76 patients treated with thrombectomy aspiration catheter (TAC). Primary 
endpoints were evaluated as the >70% ST reduction and q2 Myocardial Blush grade. 
The secondary outcomes were occurrence of major adverse cardiac events (MACE), 
in-hospital, at 1 month and after 9 months (death, new AMI, stent thrombosis and target 
lesion revascularization).
Results: There was signiﬁcant improvement in the incidence of myocardial reperfusion in 
patients in the TAC group: >70% ST reduction (88.2%
vs. 43.4% p <0001) and Blush grade q2 (89.5% vs. 61 ,8% p = 0001). The need for IIb/IIIa 
inhibitors was lower in the TAC group (59% vs. 82% p <0005). The macroscopic effective 
extraction of thrombotic material
was achieved in 81.6% of cases. There was no signiﬁcant difference in relation to in 
hospital or late MACE occurrence up to 9 months. Conclusion: The use of thrombectomy 
aspiration catheter as an adjunct to primary PCI in AMIEST has proved to be safe and 
effective in improving the parameters of myocardial reperfusion in patients studied.
9:30 a.m.
1032-148 Noninvasive Tracking of the Survival, Proliferation, 
and Migration of Human Adipose Tissue-Derived 
Stem Cells Transplanted into the Infarcted Heart by 
Bioluminescence Imaging in Living Animals
Xiaowen Bai, Yasheng Yan, Yao-Hua Song, Brian Rabinovich, Roxana Metzele, Eckhard 
Alt, University of Texas, MD Anderson Cancer Center, Houston, TX
Background: Adipose tissue-derived stem cells (ASCs) show therapeutic value in the 
treatment of infarcted myocardium. However, there is little information about monitoring 
the fate of the injected ASCs in vivo. In this study, we used bioluminescence imaging for 
the ﬁrst time to noninvasively evaluate the survival, proliferation and migration of human 
ASCs (hASCs) injected into the infarcted hearts of living mice.
Methods: hASCs were transducted with the lentiviral vector carrying luciferase gene. Half 
million hASCs were injected into the hearts of Scid mice (n=3) following the ligation of the 
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image was obtained in 252 patients. Out of 252, 74 patients were diabetic. LDL-C and 
non-HDL-C at the end of the study were divided into quartiles and the association with % 
PV change was assessed in total and diabetic patients by ANOVA.
Results: Decreasing LDL-C and non-HDL-C quartiles were associated with a progressively 
smaller plaque burden in total and diabetic patients (table). When the patients were 
divided into 2 groups according to their LDL-C (cutoff; 75 mg/dl in diabetes, 100 mg/dl in 
total) or non-HDL-C levels (cutoff; 100 mg/dl in diabetes, 130 mg/dl in total), each group of 
patients with lower LDL-C or non-HDL-C had a signiﬁcantly greater reduction in PV.
Conclusions: Early intensive statin therapy in Japanese patients after ACS resulted in 
remarkable regression of coronary PV. Diabetic patients after ACS might have a beneﬁt 
with intensive therapy to achieve the lower target level of LDL or non-HDL cholesterol in 
Japanese. 
9:30 a.m.
1032-153 The Effect of Pre-hospital Initiation of High Dose Bolus 
Tiroﬁban in ST-Segment Elevation Myocardial Infarction 
on the Incidence of Complete ST-Segment Resolution 
Before Primary Percutaneous Coronary Intervention: A 
Sub-analysis of the On-TIME 2 Trial
A.A.C.M. Heestermans, J.W. van Werkum, J.M. ten Berg, A. Mosterd, M.J. de Boer, 
A.T. Gosselink, T. Dill, G. van Houwelingen, C. Hamm, A.W.J. van ‘t Hof, Department of 
Cardiology, Isala Klinieken, locatie Weezenlanden, Zwolle, The Netherlands
Background: In patients with ST-segment elevation myocardial infarction (STEMI), 
complete ST-segment resolution (STR) might occur during transportation, before 
primary percutaneous coronary intervention (PCI). In a sub-study of the On-TIME 2 
trial we looked for predictors of complete STR during transportation and evaluated 
whether pre-hospital initiation of High Dose Bolus Tiroﬁban (HDT) will increase the 
number of patients with complete STR before primary PCI.
Methods:Patients with STEMI were randomized to HDT or no HDT in the ambulance on 
top of 600 mg clopidogrel, 500 mg aspirin and 5000 IU unfractionated heparin and were 
referred for primary PCI. Complete STR before primary PCI was deﬁned as q70% STR on the 
electrocardiogram (ECG) obtained pre-angiography as compared to the inclusion ECG.
Results: In a total of 1121 out of 1398 patients (80.2%) an interpretable ECG was 
obtained at inclusion and at pre-angiography. The incidence of complete STR pre-
angiography was 16.8% (188/1121).
Patients with complete STR pre-angiography were younger (58.8 ± 11.0 yrs. vs. 62.2 
± 12.0 yrs, P< 0.001), were more often smokers (55.7% vs. 45.0%, P=0.008), had a 
shorter symptom-onset (SO) to diagnosis time-interval (91.9 ± 93.3 min. vs. 135.3 
± 170.3 min, P< 0.001) and more often were treated with HDT (55.9% vs. 48.0%, 
P=0.05). Patients who received HDT within 75 minutes after SO had the largest 
effect on resolution of ST segment deviation during transportation (24.6% vs. 
17.0%, p=0.03). Patients with complete STR during transportation, before primary 
PCI had a signiﬁcantly smaller enzymatic infarct size (650 ± 851 IU/L vs. 2139 ± 1816 
IU/L, p<0.0001) and a signiﬁcantly lower 30 day mortality (0.5% vs. 2.8%, p=0.045).
Conclusions: In patients with STEMI, pre-hospital initiation of high dose bolus 
tiroﬁban signiﬁcantly increased the number of patients with complete ST-segment 
resolution before primary PCI. This was particularly seen in patients who received 
high dose tiroﬁban shortly after the onset of symptoms. Complete ST-segment 
resolution before primary PCI was associated with a small infarct size and a low 
mortality.
9:30 a.m.
1032-154 Impact of Myocardial Perfusion After Primary 
Angioplasty on Ventricular Conduction Delay and Left 
Ventricular Remodeling in Patients With ST-Segment 
Elevation Myocardial Infarction
Shinichi Okino, Shigeru Fukuzawa, Juji Sugioka, Atsushi Ikeda, Jumpei Maekawa, 
Soichiro Ichikawa, Takashi Uchiyama, Masayuki Inagaki, Funabashi Municipal Medical 
Center, Funabashi, Japan
Background: The aim was to assess the impact of myocardial perfusion after primary 
angioplasty on ST-segment elevation myocardial infarction (STEMI) on ventricular 
conduction delay and remodeling. Methods: Myocardial blush grade (MBG) was 
assessed at the end of primary angioplasty in 159 STEMI patients. Signal-averaged 
electrocardiography to detect late potentials (LP) and echocardiography were examined 
during the acute phase and six months later. Results: Seventy-seven patients obtained 
MBG 3 and 57 had positive LP in the acute phase. LP was less found in MBG 3 (23.4% v.s. 
47.6%, p=0.001). Indexed left ventricular end-diastolic volume (LVEDVI) and end-systolic 
volume (LVESVI) were larger and left ventricular ejection fraction (LVEF) was lower in 
MBG 0-2 patients in the acute phase and at six months. LVEDVI and LVESVI were larger 
and LVEF was lower in positive-LP in the acute phase and at six months. Multivariable 
analysis revealed MBG 0-2 and positive LP were independent predictors of LVESVI>30 
mL/m2 (odds ratio (OR) 3.13 [95%CI 1.14-8.62], p=0.027, OR 4.36 [1.76-10.8], p=0.001, 
respectively) and LVEF <45% (OR 3.25 [1.11-9.50], p=0.031, OR 5.18 [1.86-14.5], 
p=0.002, respectively) at six months. Conclusions: MBG was associated with LP in the 
acute phase. Furthermore, both MBG and LP had an impact on LV remodeling. 
(EF) were assessed at the baseline and the follow-up period. The wall motion score was 
analyzed and calculated according to the 16-segment model of the American Society 
of Echocardiography. Wall motion was visually assessed using endocardial motion and 
wall thickening and was quantitated using a 5-grade scoring system (1 = normal, 2 = 
hypokinesia, 3 = akinesia, 4 = dyskinesia, and 5 = aneurismal changes). LV Ejection 
fraction (EF) was measured by modiﬁed Simpson’s method. To all patients, recovery of 
wall motion was deﬁned as an improvement in wall motion of q 2 contiguous segments in 
infarct-related segments between baseline and follow-up.
Results: Table
Conclusions: Our prospective randomized study shows that primary PCI with 
thrombosuction may be signiﬁcant beneﬁt to recovery of regional wall motion in patients 
with AMI.
Suction Group 
(n=58)
Non-Suction Group 
(n=53) P-value
Symptom to reperfusion time (min) 248.69 ± 154.73 233.17 ± 98.99 0.54
Peak CK-MB (ng/mL) 288.82 ± 206.08 278.21 ± 177.68 0.77
TIMI 3 ﬂow after PCI (%) 52 (89.7) 48 (92.3) 0.63
Blush score q2 after PCI (%) 29 (50.0) 18 (34.6) 0.10
WMS Baseline 21.86 ± 4.99 22.08 ± 4.14 0.81
WMS Follow-up 20.47 ± 5.11 22.14 ± 4.92 0.09
LVEF Baseline (%) 51.75 ± 10.10 49.68 ± 6.65 0.22
LVEF Follow-up (%) 53.70 ± 9.84 51.75 ± 9.58 0.31
Recovery of regional wall motion 
(%) 28 (48.3) 14 (28.6) 0.03
9:30 a.m.
1032-151 Immediate ST-Segment Resolution Is Associated With 
Left Ventricular Function and Infarct Size Measured by 
Cardiovascular Magnetic Resonance in ST-Segment 
Elevation Myocardial Infarction Patients Treated With 
Primary Percutaneous Coronary Intervention
Joost D. Haeck, Niels J. Verouden, Wichert J. Kuijt, René J. Van der Schaaf, José P. 
Henriques, Marije M. Vis, Jan Baan, Jr., Jan J. Piek, Jan G. Tijssen, Robbert J. De 
Winter, Mitchell W. Krucoff, Karel T. Koch, Academic Medical Center - University of 
Amsterdam, Amsterdam, The Netherlands, Duke Clinical Research Institute, Duke 
University Medical Center, Durham, NC
Background: Infarct size and preserved left ventricular function are major determinants of 
the prognosis of ST-segment elevation myocardial infarction (STEMI) patients. We sought 
to investigate whether ST-segment resolution (STR) immediately after percutaneous 
coronary intervention (PCI), determined by continuous 12-lead ECG monitoring, relates 
to infarct size and left ventricular function, as assessed by cardiovascular magnetic 
resonance (CMR).
Methods: 186 STEMI patients received both continuous ST-segment monitoring 
(evaluated at Duke Clinical Research Institute eECG Core Lab) during primary PCI and 
CMR at 4 months. Immediate complete STR was deﬁned as >70% STR at time of last 
contrast. CMR was used to determine left ventricular function and late enhancement to 
measure infarct size.
Results: 110 patients had complete STR and 76 patients had incomplete STR immediately 
after primary PCI. Patients with complete STR had a higher ejection fraction (EF), lower 
left ventricular end-diastolic volume (LVEDV), lower left ventricular end-systolic volume 
(LVESV), and smaller infarct size. The association between complete STR immediately 
after PCI and CMR parameters was highly statistical signiﬁcant (p<0.01).
Conclusions: Complete STR immediately after primary PCI for STEMI was associated 
with preserved left ventricular function, and smaller infarct size on CMR. These results 
suggest that STR immediately after primary PCI is moreover a clinical and simple tool 
for success of primary PCI.
9:30 a.m.
1032-152 Effect of Early Intensive Statin Therapy on Regression 
of Coronary Atherosclerosis in Patients With Acute 
Coronary Syndrome: Rationale for Lower Cholesterol 
Target in Diabetic Patients: Subanalysis of JAPAN-ACS 
Study
Hidenori Arai, Takeshi Kimura, Takeshi Morimoto, Takafumi Hiro, Katsumi Miyauchi, 
Hiroyuki Daida, Yoshihisa Nagkagawa, Yukio Ozaki, Tetsu Tamaguchi, Satoshi Saito, 
Kazuo Kimura, Masunori Matsuzaki, Japan-ACS investigators, Kyoto University 
Graduate School of Medicine, Kyoto, Japan, Yamaguchi University Graduate School of 
Medicine, Ube, Japan
Background: No study has been done to address the role of intensive lowering of LDL-
cholesterol (LDL-C) with statins after acute coronary syndrome (ACS) in Japan.
Methods: A prospective, randomized open-label study with blinded endpoint evaluation 
was performed at 33 centers in Japan. Patients with ACS undergoing IVUS-guided 
PCI were randomly assigned to receive either 4 mg/day of pitavastatin or 20 mg/day of 
atorvastatin within 72 hours after PCI. The primary endpoint was % change in non-culprit 
coronary plaque volume (PV) by IVUS from baseline to 8-12 months follow-up. IVUS 
JACC March 10, 2009 ABSTRACTS - Myocardial Ischemia and Infarction  A331
M
yocardial Ischem
ia and Infarction
9:30 a.m.
1032-157 ST-Segment Deviation Resolution After Primary 
Percutaneous Coronary Intervention Is Inversely 
Associated With Time to Reperfusion in Patients With 
Acute Myocardial Infarction
Niels J. Verouden, Wichert J. Kuijt, Joost D. Haeck, Karel T. Koch, José P. Henriques, Jan 
Baan, René J. van der Schaaf, Marije M. Vis, Jan G. Tijssen, Jan J. Piek, Robbert J. de 
Winter, Academic Medical Center, Amsterdam, The Netherlands
Background: Incomplete ST-segment deviation resolution (STR) after epicardial ﬂow 
restoration may represent microvascular obstruction and predicts an unfavorable outcome 
in patients with ST-segment elevation myocardial infarction (STEMI). We investigated 
whether time to reperfusion is associated with STR in a large cohort of STEMI patients 
undergoing primary percutaneous coronary intervention (PCI).
Methods: In this single-center study, 1900 STEMI patients with a complete dataset 
underwent primary PCI between 2000 and 2006. Time to reperfusion was deﬁned as time 
from symptom onset to ﬁrst balloon inﬂation. STR was deﬁned as the relative difference 
(in %) of the summed ST-segment deviation between the pre-PCI and the immediately 
post-PCI 12-lead electrocardiogram. STR of q 70% was considered complete.
Results: Median STR immediately after PCI was 51% (IQR 23% - 71%). Stratiﬁed by 
time to reperfusion, patients with a shorter time to reperfusion showed signiﬁcantly 
higher median STR compared to patients with a longer delay (P=0.017, Figure). Patients 
undergoing PCI within 3 hours of symptom onset showed complete STR signiﬁcantly 
more often compared to patients with a longer time to reperfusion (OR 1.2, 95% CI 1.0 
- 1.5; P = 0.04).
Conclusions: STEMI patients undergoing primary PCI earlier after symptom onset 
show more STR compared to patients with longer time to reperfusion. Therefore, 
treatment delays should be minimized to aim for microvascular rather than just epicardial 
reperfusion. 
9:30 a.m.
1032-158 Association Between Heart Rate Variability and Platelet 
Reactivity After Acute Myocardial Infarction
Giancarla Scalone, Ilaria Coviello, Pasquale Santangeli, Francesca Di Clemente, Lucy 
Barone, Roberto Mollo, Alfonso Sestito, Gaetano A. Lanza, Filippo Crea, Catholic 
University of Sacred Heart, Institute of Cardiology, Rome, Italy
Background. Patients with acute myocardial infarction (AMI) treated by primary 
percutaneous coronary intervention are treated with dual antiplatelet therapy (DAPT, 
aspirin+clopidogrel). However, a proportion of these patients shows suboptimal levels 
of platelet inhibition. AMI patients may present nervous autonomic imbalance with 
sympathetic predominance, and it is well known that catecholamines increase platelet 
reactivity. Thus, in this study we tested whether cardiac autonomic function shows any 
relation with platelet reactivity in AMI patients treated by DAPT.
Methods. We studied 14 AMI patients (55±12 years, 9 men) treated by primary PCI and 
discharged on DATP. At 1-month follow-up, we assessed platelet reactivity by measuring: 
1) the aggregation time on the PFA-100 method, and 2) monocyte-platelet aggregates 
(MPA) by ﬂow cytometry at baseline and after ADP-stimulated (10-7 M). Cardiac autonomic 
function was assessed by heart rate variability (HRV) on 24-hour ECG Holter recordings.
Results. An inverse correlation was found between HRV variables and both PFA-100 
aggregation time and basal and post-ADP MPA formation (Table).
Conclusions. The signiﬁcant inverse relation between HRV variables and platelet 
reactivity 1 month after AMI suggests that autonomic sympatho-vagal imbalance may 
contribute to a lower response to DAPT in these patients. The clinical implications of this 
ﬁnding merit to be investigated in a large population of AMI patients.
9:30 a.m.
1032-155 Treatments and Prognosis of Acute Myocardial 
Infarction Due to the Occlusion of the Left Main 
Coronary Artery in the Contemporary Coronary 
Reperfusion Era
Masaya Usami, Yasuhiko Sakata, Masahiko Shimizu, Shinichiro Suna, Sen Matsumoto, 
Hiroshi Sato, The OACIS Investigators, Osaka University Graduated School of Medicine, 
Suita-city, Japan
Background: Previous studies have shown that acute myocardial infarction due to the 
occlusion of the left main coronary artery (LMCAMI) is associated with poor prognosis. 
Due to the limited number of the sample size in these studies, however, the results 
including mortality varies with respect to each study. Accordingly, a study to investigate 
the prevalence, management and outcome of LMCAMI with a large cohort is required. 
Methods: Among consecutive 8,025 patients registered in the Osaka Acute Coronary 
Insufﬁciency Study (OACIS) between 1998 and 2007 (74.7% male, age 65.9±11.8 
y.o.), 178 patients (2.2%) had LMCAMI (75.3% male, age 67.6±11.8 y.o.).We sought to 
observationally assess treatments and prognosis of LMCAMI using the database of the 
OACIS. Results: Among them, 132 patients (age 67.5±12.2 y.o.) received primary PCI for 
LMCAMI lesion and remaining 40 patients (age 68.1±10.8 y.o.) received emergent CABG. 
Subjects received PCI had higher prevalence of cardiogenic shock, and PCPS use 
(53.8% vs 25.0%, p=0.004, 52.3% vs 17.5%, p<0.001). The 30-day mortality of LMCAMI 
was signiﬁcantly higher than that of non-LMCAMI (37.6 % vs 4.6 %, p<0.001), and it 
was particularly high when treated with PCI, compared with when treated with CABG 
(42.4% vs 17.5%, p=0.005). In addition, even after discharge, the long term mortality 
(mean follow-up, 803 days) after discharge in LMCAMI was higher than in non-LMCAMI 
(14.0%, 8.3%, 7.1%, 4.6% for LMCAMI, AMI with 3-vessel disease, 2-vessel disease, 
and 1-vessel disease, respectively, p<0.001). However, there was no difference in major 
adverse cardiac events between those who survived LMCAMI with PCI and CABG (21.1% 
vs 23.3%, p=0.66). Conclusions: The present investigation with a relatively large cohort 
showed that prognosis after LMCAMI is still poor even in the contemporary reperfusion 
era. In-hospital mortality of LMCAMI patients treated with PCI was worse than those with 
CABG, possibly reﬂecting the patients’ background, whereas mortality after discharge 
was similar between patients treated with PCI and CABG. Further efforts to improve 
survival after LMCAMI may be needed.
9:30 a.m.
1032-156 Comparison of the Pre-hospital or Cath-Lab 
Administration of High Dose Tiroﬁban in Patients 
Undergoing Primary Angioplasty: The AGIR2 Study
Carlos ElKhoury, Pierre Yves Dubien, Loic Belle, Guilaume Debatty, Olivier Capel, 
Thibaud Perret, Dominique Savary, Patrice Serre, Eric Bonnefoy, for the AGIR2 study 
investigators, Hospices Civils de Lyon, Lyon, France, Université Lyon I, Lyon, France
Background: Prehospital treatment with a high dose of tiroﬁban brings beneﬁts in 
patients with STEMI who undergo primary angioplasty. In these patients, prehospital high 
dose of tiroﬁban had not been directly compared to the administration of a high dose of 
tiroﬁban in the cath-lab.
Methods: The multicenter AGIR2 study, randomized 300 patients managed in a 
prehospital setting within 6 hours of a STEMI and who underwent primary angioplasty, to 
a pre-hospital high dose of tiroﬁban ((25 μg/kg bolus + 0.15mcg/kg/min) or to a high dose 
of tiroﬁban in the catheterisation laboratory. All patients received a prehospital loading 
dose of clopidogrel (600 mg) and heparin. The primary end-point was TIMI ﬂow grade 2-3 
of the infarct-related vessel at initial angiography. The effect of a pre-hospital high dose 
of tiroﬁban on each TIMI ﬂow grade, the ST segment resolution one hour after PCI, peak 
serum troponin I and management delays were secondary end-points.
Results: On september 25th, all 300 patients had been included in the AGIR2 study. The 
data are being processed for analysis.
Results will be available by the end of december 2008.
Conclusions: This randomized controlled trial will bring important evidence regarding the 
timing of initiation of a GPIIb/IIIa inhibition in patients managed in the prehospital setting 
for an acute myocardial infarction.
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1032-161 Percutaneous Coronary Intervention Related Infarction 
Is a Predictor of Late In-Stent Restenosis in Bare Metal 
Stents
Andrew G. Dickerson, Ian J. Neeland, Ayushi Ahuja, Riyaz Patel, Muhiddin Ozkor, 
Jonathan Murrow, Saurabh Dhawan, Habib Samady, S. Tanveer Rab, John Douglas, 
Douglas Morris, A. Maziar Zafari, Arshed A. Quyyumi, Emory University School of 
Medicine, Atlanta, GA
Background: Several clinical and angiographic variables are known to be predictors of 
in-stent restenosis (ISR). The impact of peri-procedural ischemia on ISR is unknown. We 
hypothesized that myocardial ischemia/infarction during PCI leads to elevated risk of late 
ISR requiring further intervention.
Methods: We conducted a retrospective analysis of 1150 subjects in the Emory 
Genebank Registry. Of these, we identiﬁed 104 patient episodes of a successful elective 
PCI with a bare metal stent (BMS), subsequent angiographic follow up, and cardiac 
biomarker data. Mean follow-up time was 23 months. Peri-procedural ischemia/infarction 
were deﬁned as next day Troponin I measures >0.05 and >0.15ng/mL, respectively, based 
on institutional assays.
Results: At 5 years of follow-up, there were 53 ISR events. Peri-procedural infarction 
at the time of ﬁrst BMS placement was associated with a signiﬁcantly higher risk of 
developing ISR requiring re-intervention (OR= 5.57, 95% CI [1.95, 15.87], p=0.001). The 
observed risk remained signiﬁcant after adjusting for age, gender, treated risk factors and 
smoking (OR= 6.3, 95% CI [1.99-19.9], p=0.002). Kaplan Meier analysis revealed median 
time to re-intervention was 27 vs. 52 months, log-rank p= 0.005, Figure. We did not ﬁnd a 
similar association with peri-procedural ischemia.
Conclusions: Peri-procedural infarction as assessed by Troponin I after BMS placement 
independently predicts a higher risk of developing late ISR requiring re-intervention at 5 years. 
9:30 a.m.
1032-162 Survival in Patients With Multivessel Coronary Artery 
Disease and Chronic Kidney Disease Presenting With 
Acute Coronary Syndromes
Shayibu Harruna, Brenda Brownell, P Diane Galbraith, Jean F. Legare, William A. Ghali, 
Merril L. Knudtson, Michael P. Love, Jaroslav Hubacek, Divisions of Cardiology/Cardiac 
Surgery Queen Elizabeth II Health Sciences Centre and Dalhousie Univ, Halifax, NS, 
Canada, Department of Medicine, University of Calgary, Calgary, AB, Canada
Background: Data regarding the optimal mode of revascularization for patients with chronic 
kidney disease (CKD) and multivessel coronary artery disease (MVCAD) who present with 
acute coronary syndromes (ACS) are conﬂicting. We examined the long-term survival of a 
large cohort of ACS patients with CKD and MVCAD according to treatment strategy.
Methods: We identiﬁed 235 consecutive ACS patients with CKD and MVCAD hospitalized 
between January 1998 and December 2000 using two registries in the Canadian provinces of 
Nova Scotia and Alberta. Our primary end-point was 7-year survival from index catheterization 
according to chosen therapeutic strategy: percutaneous coronary intervention (PCI), coronary 
artery bypass surgery (CABG), or medical management alone (MM).
Results: Baseline characteristics were similar in all three groups. The ﬁgure shows the 
crude 7-year survival according to treatment strategy. Risk-adjusted hazard ratio analysis 
suggests increased mortality risk with MM as compared to CABG (HR 2.44; 95% CI 1.58-
3.76) but not to PCI (HR 0.83; 95% CI 0.57-1.22). CABG compared to PCI was associated 
with reduced mortality risk (HR 0.48; 95% CI 0.31-0.74).
Conclusions: This registry-based observational study demonstrates a survival beneﬁt of 
CABG relative to MM and PCI in CKD patients with ACS and MVCAD. CABG appears to 
be the optimal revascularization option for these patients. 
Correlation between HRV parameters and platelet reactivity variables
SDNN HF
AT (PFA-100) R=0.6, P=0.025 R=0.4, P=0.19
MPA Baseline R=-0.7, P=0.008 R=-0.6, =0.015
MPA ADP R=-0.6, P=0.012 R=-0.6, P=0.017
9:30 a.m.
1032-159 Greater Adherence to the Mediterranean Diet Reduces 
the Risk for the Development of Left Ventricular 
Systolic Dysfunction in Patients Who Had Had an Acute 
Coronary Syndrome
Demosthenes B. Panagiotakos, Christina Chrysohoou, Panagiotis Aggelopoulos, Ioanna 
Kehagia, George Metallinos, Christos Pitsavos, Christodoulos Stefanadis, Athens 
Medical School, Athens, Greece
Background: We evaluated whether adherence to this traditional diet is associated 
with the development of left ventricular systolic dysfunction (LVSD) in patients who 
had had an acute coronary syndrome (ACS). Methods: During 2006-2007, 351 post 
ACS patients (66±13 years) who developed LVSD (ejection fraction<40%) immediately 
after the event and 386 patients (63±12 years) with preserved left ventricular systolic 
function (ejection fraction>50%), were included in the study. Detailed information 
regarding socio-demographic, clinical, lifestyle and anthro pometric characteristics, 
were retrieved from all patients. A semi-quantitative food frequency questionnaire was 
applied to assess the consumption of a variety of food groups, while the assessment 
of adoption of Mediterranean Diet conducted through the MedDietScore (range 0-55) 
that incorporates the inherent characteristics of this traditional dietary pattern. Results:
Patients with LVSD reported less adherence to the Mediterranean diet, compared 
to those with preserved left ventricular systolic function (p<0.01). The MedDietScore 
showed good accuracy in predicting LVSD (AUC: 0.552±0.02, p=0.05). Moreover, one 
unit increase in the diet score (i.e., greater adherence) was associated with 3.5% lower 
risk of developing LVSD (95%CI 0.93-1.00), after adjusting for age, gender, BMI, clinical 
status and presence of the common cardiovascular disease risk factors. A value of 
31/55 in the MedDietScore constitutes the optimal threshold for better diagnosing LVSD 
(sensitivity = 81%). Furthermore, the MedDietScore seems to be more accurate among 
people >65 years old (AUC:0.598±0.036, p=0.05), men (AUC:0.551±0.03, p=0.09) and 
diabetic patients (AUC:0.591±0.04, p=0.05). Conclusion: Greater adherence to the 
traditional Mediterranean diet seems to independently protect against development of 
LVSD after an ACS. The suggested MedDietScore is an accurate diet tool for screening 
ACS patients who are prone to develop LVSD. Our ﬁndings expand the beneﬁcial effects 
of this traditional diet on human health, and should be further promoted.
9:30 a.m.
1032-160 How Serum Levels of Glucose and Inﬂammatory 
Biomarkers Upon Presentation Affect 1-Year Mortality 
in Non-diabetics With Acute Coronary Syndromes
Stefanos G. Foussas, Michael N. Zairis, Stamatis Makrygiannis, Dimitrios Mytas, 
Georgios Z. Tsiaousis, Nikolaos Patsourakos, Joseph Papadopoulos, Andreas Melidonis, 
Anastasios Koutsovasilis, Stylianos Handanis, Tzanio State Hospital, Piraeus, Greece
Background: Serum levels of glucose and inﬂammatory biomarkers upon presentation 
seem to confer incremental predictive value for no-diabetics (and diabetics) with acute 
coronary syndromes (ACS). We sought to investigate the possible interrelation of 
serum levels of glucose and inﬂammatory biomarkers as well as the interaction of these 
biomarkers in the prediction of 1-year death in this setting.
Methods: 848 STEMI and 666 NSTE-ACS consecutive pts, without history of DM, who 
presented in the ﬁrst 12 and 24 h of index pain respectively, were studied. Serum glucose 
levels upon presentation and during hospitalization were a 11 mmol/L in all pts. Each 
cohort was divided into 3 groups according to glucose levels: Group A (<6.1 mmol/L), 
Group B (6.1-7 mmol/L) and Group C (7-11 mmol/L). Serum levels of inﬂammatory 
biomarkers including hs-CRP, interleukin-6 (IL-6) and ﬁbrinogen (FIB), were measured 
upon presentation.
Results: There was a signiﬁcant gradual increase of levels of all inﬂammatory biomarkers 
from Group A to Group C in pts with STEMI and NSTE-ACS. The incidence of 1-year 
mortality in A, B, and C Groups was 11.2%, 16.2% , 20.4% and 8%, 12.6%, 19.1% for 
STEMI (p=0.02) and NSTE-ACS (p=0.002) pts respectively. Inﬂammatory biomarkers 
were signiﬁcantly related to the incidence of 1-year mortality in pts with STEMI and NSTE-
ACS. Particularly, hs-CRP (p<0.001 and p<0.001), IL-6 (p=0.004 and p=0.008) and FIB 
(p=0.03 KA  p=0.02) were signiﬁcantly related to 1-year death in STEMI and NSTE-ACS 
pts respectively. By multivariate Cox analysis (inﬂammatory biomarkers not included), 
glucose levels independently predicted 1-year death. However, by multivariate Cox analysis 
(inﬂammatory biomarkers included), glucose levels did not predict 1-year death.
Conclusions: According to the present results serum glucose levels upon presentation 
are strongly associated with the degree of inﬂammatory response in non-diabetics with 
ACS. This may at least partially explain the association of serum glucose levels upon 
presentation and adverse outcome in non-diabetics with acute coronary syndromes.
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All diabetics were divided with respect to their renal status into: diabetics with CKD (DM-CKD; 
n=264) and without (DM-nCKD; n=735). Independent predictors of death and major adverse 
cardiovascular events (MACE) were selected with multivariate Cox-regression model.
Results: Mortality rates were signiﬁcantly higher in DM group compared to nDM in all 
observation periods. DM-CKD was associated with excessive total mortality (35.6%) 
when compared to DM-nCKD (11.6%, P<0.001) and to nDM (9.8%, P<0.001). Mortality 
and MACE rates did not differ signiﬁcantly between DM-nCKD and nDM group. Diabetes 
coexisting with CKD was one of the strongest independent risk factors for death (hazard 
ratio 1.93; conﬁdence interval 1.79-2.07; P<0.001).
Conclusions: The prognosis in diabetics with AMI is signiﬁcantly related to renal function. 
Diabetics without CKD had similar prognosis to non-diabetics. Multivariate models showed 
that unlike diabetes without renal dysfunction, DM-CKD was an independent risk factor for 
cardiovascular complications and total mortality.
ACC.ORAL CONTRIBUTIONS
906
Therapeutic Consideration In the Patient 
Undergoing CABG
Monday, March 30, 2009, 10:30 a.m.-Noon
Orange County Convention Center, Room W307A
0906-3 The Effect of Angiotensin-Converting Enzyme Therapy 
on Early Outcomes in Patients Undergoing Coronary 
Artery Bypass Grafting Surgery
Antonio Miceli, Faiza Zahir, Carlo Fino, Pradeep Narayan, Alan J. Bryan, Gianni D. 
Angelini, Massimo Caputo, Bristol Heart Institute, Bristol, United Kingdom
Background:Angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce 
mortality and prevent cardiovascular events in patients with coronary artery disease. 
However, their preoperative use in patients undergoing coronary artery bypass grafting 
(CABG) surgery is still controversial. This study evaluates the effect of preoperative ACE 
inhibitors therapy on early clinical outcomes after CABG surgery.
Methods:This was a retrospective, observational, cohort study of prospectively collected 
data on 10,023 consecutive patients undergoing isolated CABG surgery between April 
1996 to September 2007. Of these, 3,052 patients receiving preoperative Ace inhibitors 
were matched to a control group by propensity score analysis.
Results:Overall mortality was 1%. Preoperative ACE inhibitors therapy was associated 
with a doubling in the risk of death (1.3% vs 0.7%, odds ratio [OR] 2.01, 95% conﬁdence 
interval [CI] 1.17 - 3.45, p=0.014). There were a signiﬁcant difference between the ACE 
inhibitors and control group in the risk of postoperative renal dysfunction (PRD, 7.1% vs 
5.4%, OR 1.34, 95% CI 1.09 - 1.65, p=0.005), atrial ﬁbrillation (AF, 25% vs 20%, 1.33, 
95% CI 1.18 - 1.5, p<0.001) and use of inotropic support (45.9% vs 41.1%, OR 1.21, 
95%CI 1.1 - 1.35, p<0.001) respectively. Neither ACE inhibitors nor control group was 
associated with increased risk of postoperative myocardial infarction and cerebral events. 
In a multivariate analysis, preoperative Ace inhibitors treatment was an independent 
predictor of mortality (OR 2.02, 95% CI 1.2 - 3.38, p=0.007), PRD (OR 1.42, 95% CI 1.12 
- 1.75, p=0.001), use of inotropic support (OR 1.17, 95% CI 1.07 - 1.29, p=0.001) and AF 
(OR 1.41, 95% CI 1.26 - 1.57, p<0.001).
Conclusions:Preoperative therapy with ACE inhibitors is associated with an increased 
risk of mortality, post operative renal dysfunction and use of inotropic support. In addition, 
ACE inhibitors therapy was also a risk factor for new onset of postoperative atrial 
ﬁbrillation. Omitting ACE inhibitors before surgery and restarting postoperatively might 
be a reasonable approach to improve early outcomes and retain the beneﬁts of their 
cardioprotective effects after CABG surgery.
9:30 a.m.
1032-163 TIMI Risk Index Predicts Long-Term Mortality in 
Patients With ST-Elevation Myocardial Infarction in the 
TIMI-II Clinical Trial
Quynh A. Truong, Christopher P. Cannon, Neil A. Zakai, Ian S. Rogers, Robert 
P. Giugliano, Stephen D. Wiviott, Carolyn H. McCabe, David A. Morrow, Eugene 
Braunwald, TIMI Study Group, Brigham and Women’s Hospital, Boston, MA, 
Massachusetts General Hospital, Boston, MA
Background: TIMI Risk Index (TRI) is a simple bedside score, calculated as heart 
rate x [age/10]2 /systolic blood pressure, that predicts 30-day mortality in ST-elevation 
myocardial infarction patients. We sought to evaluate whether TRI was predictive of long-
term mortality and able to identify patients where an early invasive strategy would be 
beneﬁcial post-thrombolysis.
Methods: In the TIMI II trial, 3154 patients (age 57 ±10 years, 82% men) were randomized 
to invasive (n=1584) vs conservative (n=1570) strategy post-thrombolysis with median 
follow-up of 3 years. TRI was divided into 5 groups (Figure A).
Results: At 3 years, mortality was 25.4% (97/397) in Group 5 as compared to 5.1% 
(63/1368) in Group 1 and 2 (Figure A). When compared to Group 1, unadjusted 
hazard ratio (HR) was highest for Group 5 (HR 5.8, p<0.0001), then Group 4 (HR 2.8, 
p<0.0001), and Group 3 (HR 2.0, p=0.002) (c statistic 0.69). After controlling for multiple 
cardiovascular mortality risk factors, adjusted HR remained signiﬁcant: Group 5 (HR 4.2, 
p<0.0001), Group 4 (HR 2.2, p=0.0005), Group 3 (HR 1.7, p=0.02). No difference was 
seen between Group 2 and 1. When stratiﬁed by TRI groups, no difference in mortality 
between treatment strategies was found (Figure B).
Conclusions: TRI is predictive of long-term mortality in TIMI II with a 4-fold increased risk 
in the highest TRI group as compared to the lowest, but could not identify a subgroup of 
patients who may beneﬁt from an early invasive strategy after reperfusion therapy with 
thrombolysis. 
9:30 a.m.
1032-164 Prognosis in Diabetic Patients With Acute Myocardial 
Infarction Is Related to Renal Function
Jacek Kowalczyk, Radoslaw Lenarczyk, Krzysztof Strojek, Janusz Gumprecht, 
Agnieszka Sedkowska, Tomasz Kukulski, Oskar Kowalski, Beata Sredniawa, Lech 
Polonski, Zbigniew Kalarus, 1st Department of Cardiology, Medical University of Silesia, 
Silesian Center for Heart Diseases, Zabrze, Poland, bDepartment of Internal Diseases, 
Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland
Background: The prevalence of diabetes mellitus (DM) and chronic kidney disease 
(CKD) is rapidly increasing. The aim of the study was to evaluate the impact of DM with 
and without CKD on prognosis in pts with acute myocardial infarction (AMI) treated 
invasively.
Methods: Single-centre prospective study encompassed 3334 AMI-pts, who were divided 
into two groups: 999 pts with DM diagnosed prior to or during index hospitalization and 
2335 non-diabetics.
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0906-6 Identifying Patients at Risk for Reoperation for Bleeding 
After Coronary Artery Bypass Surgery
Rajendra H. Mehta, Shubin Sheng, Sean O.Brien, Frederick L. Grover, James S. Gammie, 
T Bruce Ferguson, Eric D. Peterson, Duke Clinical Research Institute, Durham, NC
Background: Patients (pts) undergoing CABG are at risk for reoperation for bleeding 
(RFB) that is associated with high morbidity and mortality. Rapid, accurate estimation of 
pts risk for RFB may help in clinical decision making.
Methods: We evaluated 528,279 pts from STS database undergoing CABG (2004-2007). 
Logistic regression was used to identify major predictors of RFB in 80% of the sample. 
The model coefﬁcients were converted to an additive risk score that was then validated 
in remaining 20% sample.
Results: Reoperation for bleeding was required in 12644 pts after CABG (2.4%). 
Independent preoperative risk factors associated with risk of RFB were age >/=60 yrs, 
male sex, lower body surface area, non-white race, surgery status (highest for emergent 
salvage), baseline creatinine or dialysis, clopidogrel <24 hrs, clopidogrel + GpIIbIIIa 
<24 hrs, IABP, prior cardiac surgery, nondiabetic pts and 3 vessel CAD (c-index 0.60). 
Individual pt risk scores ranged from 0 to 98. The risk score tool performed well in the 
validation set with good concordance between predicted values and the observed risk 
in this sample (Hosmer-Lemeshow p=0.11) and had good ability to identify pts at low, 
moderate and high-risk for RFB (Figure).
Conclusions: We have identiﬁed the major risk factors for RFB in pts undergoing CABG. 
These factors have been converted into a simple, accurate bedside risk tool. This tool 
should promote preventive measures when feasible in this at-risk group. 
0906-7 Timing of In-Hospital Coronary Artery Bypass Graft in 
Relationship to Mortality for Acute Coronary Syndrome 
Patients: Results From the NCDR ACTION Registry
Shailja V. Parikh, James A. de Lemos, Michael Jessen, Emmanouil Brilakis, Anita Y. 
Chen, Tracy Wang, Matthew Roe, Elizabeth Holper, University of Texas - Southwestern, 
Dallas, TX, Duke University, Durham, NC
Background: Because prior studies identiﬁed increased risk with early CABG after 
acute coronary syndrome, guidelines recommend delaying CABG in stable patients. It is 
unknown whether delay remains appropriate in the modern era of accelerated treatment 
and discharge pathways.
Methods: Patients enrolled in NCDR ACTION Registry - GWTG (1/2007 - 6/2008) 
who underwent in-hospital CABG after NSTEMI and STEMI without transfer were 
included. Logistic generalized estimating equations adjusting for differences in clinical 
characteristics were used to compare outcomes (death and composite of death, 
myocardial infarction, congestive heart failure and shock) associated with early (< 48 h) 
vs. delayed (> 48 h) CABG.
Results: In-hospital CABG rates for NSTEMI and STEMI were 12.9% and 6.7% 
respectively. Clinical characteristics by CABG timing are shown below. After multivariable 
adjustment, early CABG was associated with higher death (OR 2.53, 95% CI 1.33 - 4.82) 
and composite events (OR 3.11, 95% CI 1.61 - 6.00) compared with delayed CABG in 
STEMI patients. In contrast, outcomes did not signiﬁcantly differ for early vs. delayed 
CABG in NSTEMI patients (death: OR 1.39, 95% CI 0.88 - 2.19; composite: OR 1.10, 
95% CI 0.76 - 1.58).
Conclusions: While delayed CABG was associated with lower risk of adverse outcomes 
after STEMI, no difference was seen for NSTEMI. Further studies are needed to support 
this recommendation in NSTEMI patients as delaying surgery may increase resource 
utilization without improving outcomes.
0906-4 Aspirin-Insensitive Platelet Hyper-reactivity and 
Thromboxane Generation Are Independent Risk 
Factors for Early Vein Graft Occlusion After Coronary 
Artery Bypass Surgery
Jeffrey J. Rade, Tyler J. Gluckman, Rhondalyn C. McLean, Jason B. Thompson, David R. 
Thiemann, Katherine Laws, Jodi B. Segal, John V. Conte, Kathleen W. McNicholas, Todd 
C. Villines, Edward P. Shapiro, Steven P. Schulman, Thomas S. Kickler, Johns Hopkins 
School of Medicine, Baltimore, MD
Background: Aspirin (ASA) is routinely given to patients after coronary artery bypass 
(CABG) surgery to prevent early vein graft (VG) thrombosis. Little is known about the 
effect of ASA resistance or residual platelet reactivity on VG patency.
Methods: We prospectively studied 368 patients undergoing ﬁrst-time CABG maintained 
on chronic ASA therapy. VG patency was assessed 6 months after surgery in 297 patients 
by multidetector CT coronary angiography. At the time of angiography, tests of aspirin 
responsiveness and global platelet function were performed as indicated.
Results: Complete inhibition of AA-induced platelet aggregation was present in 256/258 
(99.2%) patients on ASA monotherapy. VG occlusion was associated with low PFA-100 
C/ADP CT and elevated levels of UTXB2. By multivariate analysis, a PFA-100 C/ADP CT 
<88 sec and UTXB2 level >321 pg/mg creatinine were associated with odds ratios for VG 
occlusion of 3.1 (p =0.002) and 1.9 (p =0.047), respectively. VGs in 74 (28.8%) patients 
at highest risk, deﬁned by low PFA-100 C/ADP CT and high UTXB2 level, had 6.5 times 
the odds of occlusion (p =0.003) compared to VGs in 67 (26.1%) patients at lowest risk, 
deﬁned by a high PFA-100 C/ADP CT and low UTXB2 level.
Conclusion: Despite suppression of platelet COX-1 activity by ASA, global platelet hyper-
reactivity (deﬁned by low PFA-100 C/ADP CT) and persistent thromboxane generation 
(deﬁned by an elevated UTXB2 level) are common 6 months after CABG surgery and are 
independent risk factors for early VG occlusion. 
0906-5 New Onset Postcoronary Artery Bypass Graft Atrial 
Fibrillation and Long-Term Survival
Giovanni Filardo, Cody Hamilton, Robert F. Hebeler, Jr., Baron Hamman, Paul Grayburn, 
Institute for Health Care Research and Improvement, Baylor Research Institute, Dallas, 
TX, Department of Statistical Science, Southern Methodist University, Dallas, TX
Background: The advancing age and generally increasing risk proﬁle of patients 
receiving isolated coronary artery bypass graft surgery (CABG) is expected to raise 
incidence of new-onset post-operative atrial ﬁbrillation (AFIB) resulting in potentially 
higher risk of adverse outcomes. In the early postoperative course, new-onset post-CABG 
AFIB is considered relatively easy to treat and is believed to have little impact on patients’ 
long-term outcome. However, little has been done to determine the effect of new-onset 
post-CABG AFIB on long-term survival, and this relationship is unclear.
Methods and Results: Survival was assessed in a cohort of 6,899 consecutive patients 
without preoperative AFIB who underwent isolated CABG at Baylor University Medical 
Center, Dallas, TX between 1/1/1997-12/31/2006 -patients who died during CABG were 
excluded. Ten-year unadjusted survival was 52.3% [48.4%, 56.0%] for patients with new-
onset post-operative AFIB and 69.4% [67.3%, 71.4%] for patients without it. A propensity-
adjusted model controlling for risk factors identiﬁed by the Society of Thoracic Surgeons 
and other clinical/non-clinical details was used to investigate the association between 
new-onset AFIB post-CABG and long-term survival. After adjustment, new-onset AFIB 
post-CABG was strongly associated (Hazard Ratio: 1.31; 95%CI: 1.17, 1.45) with 
increased risk of death.
Conclusions: This study provides strong evidence that new-onset post-CABG AFIB is 
strongly associated with increased long-term risk of mortality independent of patient pre-
operative severity. After controlling for a comprehensive array of risk factors associated 
with post-CABG adverse outcomes, risk of long-term mortality in patients that developed 
new-onset post-CABG AFIB was 31% higher than in patients without it.
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(n=117) treated with ASA (81 mg/daily) and clopidogrel for a median of 6 months.
Results: Demographic characteristic differed substantially depending on the underlying 
vascular disease, however IPA and bleeding risks were similar between CAD and IS. All 
three bleeding scales adequately captured serious hemorrhagic events, where the TIMI 
scale was the most exclusive, while BleedScore™ was the most inclusive. Over half of 
all patients experienced superﬁcial event(s), most commonly occurring during 2-3 distinct 
bleeding episodes. There was no correlation between IPA and duration of antiplatelet 
therapy. IPA above 50% strongly predicts minor (r2 =0.583), but not severe (r2 =0.109 ) 
bleeding events.
Conclusions: Chronic treatment with dual antiplatelet therapy is associated with a very 
high (56.5-60.7%) incidence of bleeding. We postulate that in trials and registries, these 
hemorrhages are grossly underestimated due to the bleeding deﬁnitions that are used. 
IPA is well suited for deﬁning the risk of minor complications, but more serious bleeding 
events cannot be predicted, suggesting that factors other than IPA may play a role.
3:30 p.m.
1041-127 Inﬂuence of Gender on Long-Term Mortality in Patients 
Presenting With Non-ST Elevation Acute Coronary 
Syndromes
Dharam J. Kumbhani, Mehdi H. Shishehbor, Anthony A. Bavry, Stephen G. Ellis, Venu 
Menon, Cleveland Clinic, Cleveland, OH, University of Florida, Gainesville, FL
Background: While an invasive strategy has been shown to beneﬁt patients with non- ST 
elevation acute coronary syndromes (NSTE-ACS), its role in low-risk women is unclear. 
We examined gender differences in a real world registry of patients with NSTE-ACS, who 
underwent an invasive approach.
Methods: Consecutive patients with NSTE-ACS undergoing PCI from 2003-2007 at 
our center were included. Mortality was assessed from the Social Security Death Index. 
Multivariate Cox proportional hazards models were constructed to study the inﬂuence of 
gender on mortality (follow-up: 4.5 years). The interaction between age (<60, 60-75, >75 
years) and gender was examined.
Results: The overall mortality rate in men (n=2,055) was similar to women (n=1,111): 
11.5% vs. 13.6%, p=0.09. Women were older (67.1 vs. 64.5 years, p<0.0001), and 
had higher prevalence of obesity, diabetes, and anemia (all p<0.05). Gender was not 
signiﬁcantly associated with mortality in the multivariate model, but the interaction term 
between age & gender was signiﬁcant (p=0.009). On age-stratiﬁed analysis, mortality 
was higher in women <60 years than men (p=0.004) (Figure). On subgroup analysis, 
the differential impact of age was true for troponin (Tn) negative (p=0.005), but not Tn + 
(p=0.26) women <60 years.
Conclusions: Low-risk women (Tn negative, age < 60 years) with NSTE-ACS have a 
higher mortality with an invasive strategy than men. An adequately powered clinical trial 
exploring the role of an invasive strategy in women appears warranted. 
3:30 p.m.
1041-128 The Signiﬁcance of Clopidogrel Low-Responsiveness 
Assessed by a Point-of-Care Assay in Acute Coronary 
Syndrome Patients Undergoing Coronary Stenting
kyounghoon Lee, Seung-Hwan Lee, Jun-won Lee, Young-Jin Youn, Seong-Yoon Kim, 
Jang-Young Kim, Byung-Su Yoo, Junghan Yoon, Kyung-Hoon Choe, Wonju Christian 
Hospital, Wonju, South Korea
Background: To prevent atherothrombotic events, clopidogrel and aspirin is currently 
routinely used in treatment of patients undergoing percutaneous coronary intervention 
(PCI). Despite clopidogrel therapy, patients undergoing PCI are at risk of recurrent 
coronary events. Therefore, we sought to prospectively evaluate the death and 
myocardial infarction (MI) of acute coronary syndrome patients and their responsiveness 
to clopidogrel.
Methods: We enrolled consecutive 610 patients (pts, 160 males, 65.2±10.3 years) 
who received percutaneous coronary intervention (PCI) with acute coronary syndrome 
(Unstable angina, non-ST elevation MI and ST elevation MI) from Jan. 2006 to Jun. 2008. 
Endpoint was deﬁned by cardiac death and stent thrombosis (ST) by deﬁnitions of the 
Academic Research Consortium (ARC). Aspirin and clopidogrel responsiveness were 
evaluated by VerifyNow™ tests (Accumetrics Inc, CA). Clopidogrel low-responsiveness 
was deﬁned as the less than 20% inhibition of P2Y12 receptor.
Results: Baseline demographic characteristics were similar between normal group (370 
Clinical Characteristics for NSTEMI and STEMI pts treated with early 
vs delayed CABG
NSTEMI
(n=2784)
STEMI
(n=974)
Early 
(n=870)
31.3%
Delayed 
(n=1914)
68.8%
p-value
Early 
(n=511)
52.5%
Delayed 
(n=463)
47.5%
p-value
Age (yrs)* 62.0(55.0,72.0)
65.0
(57.0,75.0) 0.04
63.0
(54.0,71.0)
62.0
(54.0,73.0) 0.63
Diabetes (%) 30.8 39.1 <0.0001 25.8 28.3 0.35
Prior MI (%) 17.1 21.8 0.01 16.6 19.7 0.48
Prior 
Revascularization 
(%)
17.6 21.2 0.01 17.8 22.0 0.30
Prior CHF (%) 3.9 9.8 <0.0001 1.8 4.8 0.03
Prior Stroke (%) 5.6 8.7 0.04 4.1 6.9 0.26
Arrival to 
catheterization (hrs)*
8.4
(2.9,17.5)
26.5
(15.5,49.0) <0.0001
1.0
(0.7,1.4)
1.2
(0.8,3.0) <.0001
Clopidogrel within 24 
hours of arrival (%) 27.9 38.1 0.002 39.5 61.2 0.001
* Median (25th, 75th percentiles)
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3:30 p.m.
1041-125 Oral Proton Pump Inhibitors and Their Impact on the 
Effectiveness of Dual Anti-platelet Therapy During the 
First Year After Elective Coronary Stenting
Georgios Z. Tsiaousis, Michael N. Zairis, Nikolaos Patsourakos, Stamatis Makrygiannis, 
Konstantinos Vogiatzidis, Evridiki Gougourela, Stylianos Karvounaris, Konstantinos 
Ritsatos, Konstantinos Fakiolas, Stefanos G. Foussas, Tzanio State Hospital, Piraeus, 
Greece
Background:Pts receiving dual anti-platelet therapy (clopidogrel and aspirin) after coronary 
stenting are commonly treated with oral proton pump inhibitors (PPIs) to protect against 
gastrointestinal bleeding. Due to the fact that clopidogrel is converted to its active metabolite 
by P-450 isoenzymes, which are also involved in the metabolism of PPIs, there is a concern 
about whether the action of clopidogrel would be reduced in pts also taking PPIs. The 3C 
(Combined Clopidogrel and aspirin resistance in Coronary stenting) study afforded us the 
opportunity to examine the effect of the treatment with PPIs on the long-term prognosis in 
pts also treated with clopidogrel and aspirin following coronary stenting.
Methods:The 3C (Combined Clopidogrel and aspirin resistance in Coronary stenting) 
study was a prospective study which evaluated the impact of the resistance to the 
combined therapy with clopidogrel and aspirin on the 1 year incidence of death and 
myocardial infarction in a total of 612 consecutive pts who underwent elective coronary 
stenting for stable or unstable coronary artery disease. Information concerning to the drug 
therapy, including treatment with PPIs, during the ﬁrst year of follow-up was prospectively 
collected. For the purpose of the present analysis the pts were divided into those with 
(365/612; 59.6%) or without PPIs (247/612; 40.4%) drug therapy during the follow-up.
Results:By the 1-year 21 (3.4%) pts died and 39 (6.4%) pts had a new myocardial 
infarction. There were not signiﬁcant differences in baseline clinical, angiographic and 
coronary stenting related data among the 2 groups. There was any difference in the 
other drug therapy between the 2 groups during the follow-up, and pts who received 
PPIs during the follow-up have similar incidence of death (3.6% vs 3.2; RR; 95%CI=1.1; 
0.7-1.4; p=0.8) and myocardial infarction (6.3% vs 6.5; RR; 95%CI=1; 0.8-1.3; p=0.9) than 
those who did not receive such therapy during the ﬁrst year.
Conclusions:The present results have shown that PPIs drug therapy does not have any 
impact on the effectiveness of anti-platelet drug therapy during the ﬁrst year following 
coronary stenting.
3:30 p.m.
1041-126 Correlation of Inhibition of Platelet Aggregation After 
Clopidogrel With Post Discharge Bleeding Events: 
Assessment by Different Bleeding Classiﬁcations
Victor Serebruany, Sunil Rao, Matthew Silva, Jennifer Donovan, Abir Kannan, Leonid 
Makarov, Dan Atar, Johns Hopkins University, Baltimore, MD
Background: Bleeding is a risk of dual antiplatelet therapy. There is an association 
between bleeding and cardiovascular mortality. However, the potential link of bleeding 
risk and inhibition of platelet aggregation (IPA) is not established.
Methods: We conducted secondary post-hoc analyses of 5μM ADP-induced IPA and 
bleeding complications assessed by TIMI, GUSTO, and BleedScore™ scales in a dataset 
consisting of patients with documented CAD (n=246) and previous ischemic stroke (IS) 
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underlies the importance of early assessment of renal function and metabolic 
abnormalities, in order to provide optimal management and risk stratiﬁcation to ACS 
patients.
3:30 p.m.
1041-131 Impact of Microvascular Dysfunction on Long-Term 
Cardiovascular Outcomes After Primary Coronary 
Intervention for Acute Myocardial Infarction
Koichi Tamita, Atsushi Yamamuro, Shuichiro Kaji, Minako Katayama, Takeshi Kitai, 
Takafumi Yamane, Makoto Kinoshita, Natsuhiko Ehara, Yutaka Furukawa, Takashi 
Akasaka, Kobe General Hospital, Kobe, Japan, Wakayama Medical College, Wakayama, 
Japan
Background: It has been reported that even if TIMI 3 ﬂow is achieved after primary 
percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI), 
microvascular dysfunction (MVD) results in insufﬁcient reperfusion. Recent studies have 
shown that MVD can be assessed from coronary ﬂow velocity (CFV) pattern. The aim of 
this prospective study was to examine whether the CFV pattern predicts the long-term 
cardiovascular outcomes after primary PCI in patients with AMI.
Methods: The study population consisted of 194 consecutive patients with a ﬁrst anterior 
AMI successfully treated with primary PCI. We examined the CFV pattern immediately 
after PCI using a Doppler guidewire. According to our previous reports, we deﬁned MVD 
as a diastolic deceleration time <600 ms and the presence of systolic ﬂow reversal. 
Patients were divided into 3 groups: those who achieved TIMI 3 ﬂow reperfusion without 
MVD (n=126; group 1), those who achieved TIMI 3 with MVD (n=35; group 2), and those 
with TIMI 2 ﬂow (n=33; group 3). We evaluated the association between the MVD and 
long-term major adverse cardiovascular event (MACE) rates.
Results: The age-adjusted data by multivariate analysis showed that the MVD was the 
strongest predictor for long-term MACE (hazard ratio: 4.02; 95% CI, 2.16-7.48; p<0.001).
Conclusion: The CFV pattern immediately after PCI is an accurate predictor of the long-
term cardiovascular outcomes after primary PCI in patients with anterior AMI. 
3:30 p.m.
1041-132 Impact of Two-Vessel Disease, Two-Vessel Disease 
and a Chronic Total Occlusion in a Non-infarct Related 
Artery on Long-Term Mortality After STEMI
Bimmer E. Claessen, Rene J. van der Schaaf, Karel T. Koch, Marije M. Vis, Jan G. 
Tijssen, Robbert J. de Winter, Jan J. Piek, Jose P. Henriques, Academic Medical Center, 
Amsterdam, The Netherlands
Background: Patients with multivessel disease (MVD) constitute a patient group with a 
high risk of mortality after STEMI. Recently, it was reported that the higher mortality in 
patients with MVD is determined by the presence of a chronic total occlusion (CTO) in a 
noninfarct-related artery. However, previous studies did not distinguish between 2-vessel 
and 3-vessel disease. Therefore we study the effect of 2-vessel disease without CTO, 
3-vessel disease without CTO, and a CTO in a noninfarct-related artery on long-term 
mortality after STEMI.
Methods: Between 1997 and 2005, we admitted 3277 patients with STEMI treated with 
primary PCI. We categorized patients as having single vessel disease (SVD), 2-vessel 
disease without CTO, 3-vessel disease without CTO and CTO based on the angiogram 
before PCI. Information on vital status was obtained from the Dutch national population 
registry per January 2007. Cox regression was used for multivariate analysis.
Results: SVD was present in 2115 patients (65%), 2-vessel disease without CTO in 534
patients (16%), 3-vessel disease without CTO in 208 patients (6.3%) and a concurrent 
CTO in 420 patients (13%). Median duration of follow-up was 2.7 years (IQR 1.3-4.6 
years). A total of 493 patients (15%) died; 227 (11%) in the SVD group, 70 (13%) in the 
2-vessel disease group, 54 (26%) in the 3-vessel disease group and 142 (34%) in the 
CTO group (p<0.01). After correction for differences in baseline variables (age>60 years, 
residual LVEF a40%, diabetes, hypercholesterolemia, smoking, previous MI and shock) 
the presence of 2-vessel disease is not an independent predictor for mortality (HR 1.1, 
95% CI 0.9-1.5, p=0.34), the presence of 3-vessel disease is an independent predictor 
for mortality with a HR of 2.2 (95% CI 1.6-3.0), and the presence of a CTO was an 
independent predictor with a HR of 3.2 (95%CI 2.5-4.0)
Conclusion: In STEMI patients without CTO, only patients with 3-vessel disease and 
not patients with 2-vessel disease have a signiﬁcantly higher risk for mortality. Even 
after correction for the number of diseased vessels, a CTO in a noninfarct-related artery 
represents the patient category with the worst prognosis after STEMI.
pts) and low responsiveness group (240 pts) of clopidogrel. Cardiac death occurred in 7 
pts (1.9 %) of normal group and 14 pts (5.8%) in low group (p=0.009). Stent thrombosis 
occurred in 5 pts of normal group (0.7%, 4 deﬁnit and 1 probable) and 10 pts of low 
group (4.2 %, 7 deﬁnite, 2 probable and 1 possible)(p=0.028). The associations between 
cardiac death and clopidogrel low-responsiveness were evaluated with multivariable 
logistic regression models adjusted for age and sex. The adjusted Odds ratio for cardiac 
death was 3.242 (p=0.013, 95%CI ; 1.281-8.205)
Conclusions: The low-responsiveness of clopidogrel measured with a point-of-care 
assay is an independent predictor of cardiac death and stent thrombosis in acute coronary 
syndrome patients undergoing PCI.
3:30 p.m.
1041-129 Outcomes After Acute Coronary Syndromes in Patients 
With Rheumatoid Arthritis
Anbazhagan Prabhakaran, Anitha Rajamanickam, Henri Roukoz, Anil Jain, Deepak L. 
Bhatt, Cleveland Clinic, Cleveland, OH
Background: Patients with Rheumatoid Arthritis (RA) have higher prevalence of 
cardiovascular disease compared to the general population. We assessed survival and 
cardiovascular outcomes in patients with RA after a Myocardial Infarction (MI).
Methods: Data was collected retrospectively in patients with RA who were admitted with 
MI between 11/99-5/06. Age and sex matched controls (CO) without RA, admitted with 
MI was randomly selected in a 2:1 ratio. Event free survival was analyzed using Kaplan-
Meier method and proportional hazards model.
Results: 86 patients with RA (36.5% males, 70.4±12.4yrs, 74% were on anti-rheumatic 
drugs), and 172 control subjects (38.4% male, age 72.1±12.5 yrs) were included. Patients 
with RA were less likely to be revascularized, compared with controls (38pts, 44.7% vs 
103pts, 59.9%, p=0.02). All cause mortality was signiﬁcantly higher in the RA group 
(ﬁgure, p<0.001). RA was an independent risk factor for all cause mortality (RR=1.66, CI: 
1.13-2.45, p=0.01) and peripheral arterial disease related re-hospitalizations (RR=2.23, 
CI: 1.02-6.08, p=0.038). RA was not associated with signiﬁcant cardiac related re-
hospitalizations.
Conclusions: After MI, all-cause mortality is increased in patients with RA compared to 
patients without RA. Further studies are needed to evaluate the effect of anti-rheumatic 
drugs in patients with RA sustaining a MI and whether aggressive revascularization would 
improve survival. 
3:30 p.m.
1041-130 Combining Renal Function and Glucose Metabolism 
Data: A More Efﬁcient Way to Assess Outcomes in 
Acute Coronary Syndromes Patients
Silvia Monteiro, Natalia Antonio, Carolina Lourenco, Rogerio Teixeira, Elisabete Jorge, 
Rui Baptista, Fatima Saraiva, Francisco Goncalves, Pedro Monteiro, Mario Freitas, 
Luis A. Providencia, Cardiology Department, Coimbra University Hospital and Medical 
School, Coimbra, Portugal
Background: Renal impairment and hyperglycaemia in acute coronary syndromes 
(ACS) are recognized predictors of in-hospital and post-discharge morbidity and mortality. 
However, the combined value of both parameters has not been assessed.
Aim: To evaluate, in an ACS population, the predictive combined value of creatinine 
clearance (CC) and admission glycaemia (GLY).
Population and methods: Retrospective analysis of 1023 consecutive patients admitted 
for ACS and followed for one year. Patients were divided in 4 groups according to their 
CC and GLY: A - CC>=60 mL/min and GLY<180 mg/dL (n=471); B - CC>=60 mL/min 
and GLY>=180 mg/dL (n=112); C - CC<60 mL/min and GLY<180 mg/dL (n=316) and 
D - CC<60 mL/min and GLY>=180 mg/dL (n=124).
Results: After univariate analysis, in-hospital morbidity (1.7% vs 5.4% vs 4.2% vs 17.5%; 
p<0.001) and mortality (1.3% vs 2.7% vs 4.1% vs 16.9%; p<0.001) were incremental and 
signiﬁcantly different in the 4 groups, as was death at one year follow-up (3.4% vs 13.0% 
vs 14.0% vs 12.9%; p<0.001).
We then identiﬁed, by multivariate analysis, independent predictors of mortality and 
morbidity: regarding in-hospital events, the combination of low CC and high GLY was a 
strong independent predictor, as were age, elevated Troponin I and low body mass index, 
while events in the follow-up were best predicted by the combination of CC and GLY, high 
troponin I and killip class, previous hypertension and low ejection fraction.
Conclusion: In this ACS population, the combination of admission GLY and CC is a 
powerful tool to predict in-hospital and post-discharge outcomes, with incremental 
predictive power regarding each isolated component. This fact, never before described, 
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1041-135 A Novel Risk Score System for the Assessment of 
Clinical Outcomes in Patients With Acute Non-ST-
Segment Elevation Acute Coronary Syndrome
Hyun Kuk Kim, Myung Ho Jeong, Young Keun Ahn, Shung Chull Chae, Jong Hyun Kim, 
Seung Ho Hur, Jeong Gwan Cho, Korea Acute Myocardial Infarction Registry (KAMIR) 
Study Group of Korean Circulation Society, Gwangju, South Korea
Background : Prognostic variables of Thrombolysis In Myocardial Infarction (TIMI) risk 
score have some limitations predicting short- and long- term clinical outcomes in patients 
with non-ST elevation acute coronary syndrome (NSTE-ACS). Utilizing a multivariable 
Cox regression analysis, multiple risk factors and angina symptom were associated with 
low predictability of death and myocardial infarction during one-year clinical follow-up in 
our database. The aim of this study was to develop a novel and simple assessment tool for 
the better risk stratiﬁcation using objective parameters such as heart rate, systolic blood 
pressure and Killip class.
Methods: Between Nov 2005 and Aug 2007, 5,409 patients with NSTE-ACS (64.6± 12.4 
years, 64.9% males) were enrolled in a nationwide prospective Korea Acute Myocardial 
Infarction Registry (KAMIR).
New risk score was calculated by the removal of variables with low predictability such as 
multiple risk factors, angina and not-adjusted age and the substitution of TIMI risk index 
[heart rate x (age/10)²/systolic blood pressure, < 30 : 0 point, 30 - 60 : 1 point, <60: 2 
points] and Killip class(>1 : 1 point) for these variables.
Our new risk score system was compared with the Global Registry of Acute Coronary 
Events (GRACE) and TIMI risk score for mortality during 6-month clinical follow-up.
Results: The accuracy for in-hospital mortality by TIMI, GRACE and new risk score 
system was 0.636 area under the curve (AUC) (CI : 0.599 - 0.674), 0.744 (CI : 0.717-
0.770) and 0.767 (CI : 0.735 - 0.800) respectively. A signiﬁcant difference is existed 
between TIMI and new risk score system (0.636 vs. 0.767, p < 0.0001).
For 6-month post discharge mortality rates, new risk score (AUC : 0.768;CI : 0.742 - 
0.794) demonstrated a signiﬁcant differences in predictive accuracy when compared with 
GRACE (0.768 vs 0.658, p<0.0001) and TIMI risk score(0.768 vs 0.651, p<0.0001).
Conclusion: The new risk score system for NSTE-ACS patients is a simple, objective, 
better risk scoring system than GRACE and TIMI risk score systems in the prediction of 
in-hospital and six-month mortality.
3:30 p.m.
1041-136 How Low Is Low Enough? Relationship of Blood 
Pressure and Cardiovascular Events in Patients With 
Acute Coronary Syndromes: An Analysis From the 
PROVE-IT TIMI 22 Trial
Sripal Bangalore, Jie Qin, Sabina A. Murphy, Christopher P. Cannon, PROVE-IT TIMI 22 
Trial Investigators, Brigham and Women’s Hospital, Boston, MA
Background: Aggressive blood pressure control has been advocated as an important 
measure to reduce recurrent cardiovascular events in patients with acute coronary 
syndromes (ACS). However, how low is low enough?
Methods: We evaluated 4162 patients enrolled in the PROVE-IT TIMI 22 trial [ACS 
patients randomized to Pravastatin 40 mg vs. Atorvastatin 80 mg]. The mean post 
baseline blood pressure (systolic and diastolic) was recorded and categorized into 10-mm 
Hg increments. Primary endpoint was a composite of death from any cause, myocardial 
infarction, unstable angina requiring rehospitalization, revascularization and stroke 
through an average of 2 years follow-up.
Results: The relationship between blood pressure (systolic or diastolic) followed a 
J-curve association with primary endpoint with increased events rates at both low and 
high blood pressure values, both unadjusted and after adjusting for baseline variables 
(Figure). Non-linear Cox proportional hazard model showed a nadir of 135.8 mm Hg for 
systolic and 84.2 mm Hg for diastolic pressure where the event rate was lowest. Similar 
J-curve association was found between blood pressure and the risk of all-cause mortality 
and myocardial infarction.
3:30 p.m.
1041-133 A Clinical Risk Stratiﬁcation Model Provides Accurate 
Long-Term Risk Stratiﬁcation For ACS Patients: The 
Olmsted County Acute Chest Pain Study
Louai Razzouk, Verghese Mathew, Guy S. Reeder, Peter A. Smars, Sameer Bansilal, 
Ryan J. Lennon, Heather J. Wiste, David R. Holmes, Jr., Michael E. Farkouh, Mount Sinai 
School of Medicine, New York, NY, Mayo Clinic College of Medicine, Rochester, MN
Background: The long-term outcomes of patients presenting with an index episode of 
acute chest pain (ACP) and classiﬁed by clinical risk stratiﬁcation remains unknown.
Methods: We identiﬁed all residents of Olmsted County (OC), Minnesota presenting to the 
county’s 3 emergency departments (ED) with non-ST elevation acute coronary syndrome 
(NSTE-ACS) over an 8-year period. The medical records of the study population were 
abstracted using the Rochester Epidemiology Project. Patients were classiﬁed into high 
(HR), intermediate (IR), and low-risk (LR) groups using the AHCPR criteria, a clinical, 
non-biomarker based risk model. Patients with an elevated CK-MB biomarker were 
classiﬁed as evolving myocardial infarction (MI). Cox models were used to estimate the 
adjusted association between AHCPR risk and mortality.
Results: Of the 2271 patients (mean age 63 yrs, 57.5% males), 436 patients (19.2%) 
were classiﬁed as HR, 1,557 (68.6%) as IR and 278 (12.2%) as LR. At median follow-
up of 16.6 years, HR patients had a 1.68 fold (p = 0.011) and IR 1.38 fold (p =0.09) 
increased mortality compared to LR patients. Survival was similar, whether or not the 
patient presented initially with an evolving MI (see ﬁgure).
Conclusions: A non-biomarker based clinical tool can reliably stratify long-term mortality 
in a community-based cohort with NSTE-ACS. More emphasis should be placed on the 
initial clinical risk stratiﬁcation which can be accomplished almost immediately upon 
presentation to an ED.
3:30 p.m.
1041-134 Relation Between Red Blood Cell Distribution Width 
and Mortality in Patients With Acute Myocardial 
Infarction
Salim Dabbah, Haim Hammerman, Michael Kapeliovich, Rafael Beyar, Walter 
Markiewicz, Doron Aronson, Rambam Medical Center, Haifa, Israel
Background: Increased red blood cell distribution width (RDW), a measure of the 
variability in size of the circulating erythrocytes, has been shown to be associated with 
adverse outcomes in patients (pts) with heart failure and with coronary disease. However, 
there is no information regarding the prognostic signiﬁcance of RDW in the acute phase 
of acute myocardial infarction (AMI).
Methods: We performed a post hoc analysis of data from a prospective study. Baseline 
RDW was measured in 2095 pts admitted with AMI and followed for a median of 19 
months. We used Cox proportional hazards models to examine the association between 
quintiles of RDW and all-cause mortality, adjusting for the Global Registry of Acute 
Coronary Events (GRACE) risk score and baseline hemoglobin.
Results: During the follow period 362 pts died. There was a graded positive association 
between increased RDW and mortality across quintiles of RDW (Figure). In a Cox model, 
the adjusted HRs of pts with RDW in the 2nd, 3rd, 4th, and 5th RDW quintile compared 
with pts in the 1st quintile were 1.0 [95% CI, 0.6 to 1.7], 1.5 [95% CI, 1.0-2.3], 1.9 [95% CI, 
1.2 to 2.9] and 2.7 [95% CI, 1.8 to 4.0], respectively (P for trend < 0.0001). The association 
between increased RDW and mortality remained highly signiﬁcant in sensitivity analyses 
that excluded pts with anemia (Hb < 12 g/dl) and pts with abnormally low (<82 μm3) or 
high (>98 μm3) mean corpuscular volume.
Conclusions: There is a graded independent relation between increased RDW and the 
risk of death in pts with AMI. 
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reduction and LDL-C reduction were similar between women and men (TC; -48±44 vs. 
-45±33, p=ns, LDL-C; -56±39 vs. 48±29, p=ns). However, %PV changes derived from 
statin treatment were signiﬁcantly greater in women than in men (-21±14% vs. -16±13%, 
p<0.05).
Conclusions: Despite unfavorable baseline lipid proﬁle in women as compared to men, 
statin conveyed greater plaque reduction in women than in men. Early intensive statin 
therapy would be more beneﬁcial in women rather than in men with ACS.
3:30 p.m.
1041-139 The Impact of In-Hospital Metabolic Changes on Long 
Term Mortality in Patients with Acute Myocardial 
Infarction
Robert Dragu, Michael Kapeliovich, Haim Hammerman, Rambam Health Care Campus, 
Haifa, Israel
Background: To assess the prevalence and long term prognostic signiﬁcance of changes in 
serum albumin levels during hospitalization in patients with acute myocardial infarction (AMI).
Methods: We prospectively studied 1418 consecutive patients admitted with AMI and 
normal synthetic liver function. Serum albumin concentration was tested daily during 
hospitalization. The mean follow-up period was 24 months. Multivariate Cox models were 
used to assess the relationship between nadir albumin level and long term survival.
Results: During hospitalization 54.5% of study population developed hypoalbuminemia 
(<3.5 g/dl). The mean nadir albumin was 3.38±0.58 g/dl (median 3.5, IQR 3.1-3.8 g/dl), 
0.31 g/dl lower then admission levels (p<0.0001). The long term mortality according to nadir 
albumin quartiles (from lowest to highest) was: 30.2%, 10.1%, 5.5%, 3.9% respectively 
(p<0.0001). After adjusting for age, gender, diabetes mellitus, hypertension, ST-elevation 
AMI, anterior wall involvement, left ventricular systolic function and creatinine clearance, 
the nadir albumin in lowest quartile (<3.1 g/dl) remained a strong predictor for mortality 
(HR 3.23, 95% CI [1.24-8.40], p<0.016). Figure 1 depicts the Kaplan-Meier cumulative 
probability for mortality curves for each group.
Conclusions: The development of hypoalbuminemia is frequent during hospitalization of 
patients with AMI and is strongly related to high long term mortality. 
3:30 p.m.
1041-140 Impact of Newly Diagnosed Diabetes Mellitus as an 
Important Predictor of Long-Term Cardiac Events After 
Myocardial Infarction
Shuichi Kitada, Yoritaka Otsuka, Nobuaki Kokubu, Yoichiro Kasahara, Yu Kataoka, 
Mitsuru Abe, Yoichi Goto, Genjirou Kimura, Hiroshi Nonogi, National Cardiovascular 
Center, Osaka, Japan
Background: It has been reported that patients with acute myocardial infarction (AMI) 
but without previous known diabetes mellitus (DM) have a high prevalence of glucose 
abnormalities. The purpose of this study was to investigate whether newly diagnosed DM 
and impaired glucose tolerance (IGT) after AMI, is related to long-term cardiac events.
Methods: A total of 515 patients with ﬁrst AMI were divided into 4 groups according to 
an oral glucose tolerance test (OGTT): 116 (23%) patients with normal glucose tolerance 
(NGT), 169 (33%) with IGT, 69 (13%) with newly diagnosed DM (NDM), and 161 (31%) 
with previous known DM (KDM). They were followed for major adverse cardiac events 
(MACE) deﬁned as cardiac death, non-fatal acute coronary syndrome, heart failure, 
and revascularization (mean follow-up period: 2.21±1.32 years). Results: There was no 
signiﬁcant difference in clinical backgrounds excluding body mass index and the state of 
glucose tolerance. The level of HbA1c of NDM was normal range but signiﬁcantly lower 
than those of KDM. (HbA1c: 5.69mg/dl for NDM vs 7.81mg/dl for KDM, p<0.001). For 
long-term periods, patients with NDM and KDM after AMI had similarly increased risk 
of MACE and had a signiﬁcant higher incidence of MACE compared to IGT and NGT 
(p<0.05). Conclusions: These date demonstrated that patients with newly diagnosed 
DM are at high risk of MACE after AMI as well as those with previous known DM. Early 
detection of newly diagnosed DM using OGTT may be important in the risk assessment 
of patients with AMI. 
Conclusions: In patients presenting with ACS, a J-curve association exists between 
blood pressure (especially diastolic) and the risk of future cardiovascular events, 
suggesting that excessive lowering of blood pressure in this cohort may be dangerous 
and a target of 80-90 mmHg is optimal.
3:30 p.m.
1041-137 High Clopidogrel Maintenance Dose Does Not Increase 
Platelet Aggregation Time in Patients With Acute 
Coronary Syndromes
Eleftheria Tsagalou, Charris Matsouka, Evangelos Repasos, Eleni Tseliou, Panagiotis 
Zotos, John Kanakakis, Anastasia Leonti, Vasiliki Kontopidi, John Nanas, 3rd 
Department of Cardiology, University of Athens School of Medicine, Athens, Greece
Background_After treatment with clopidogrel, a signiﬁcant portion of patients present 
reduced platelet inhibition. This could be of particular importance in the setting of acute 
coronary syndromes (ACS) since those patients present increased rates of reccurent 
ischemic events .
Purpose: The aim of this pilot study was to assess the functional impact of a high 
maintenance dose of clopidogrel in patients with ACS and suboptimal clopidogrel-
induced antiplatelet effects.
Methods: Consecutive patients with recent (<1month) ACS, on dual antiplatelet therapy, 
were screened to identify suboptimal clopidogrel responders. The latter were treated with 
a standard (75 mg x 1, n=12 ,Group A) or high (75x2, n=16, Group B ) daily maintenance 
dose. Platelet function was assessed at 2 time points baseline and at 30 days using 
PFA-100.
Results: A total of 67 patients were screened to identify 28 suboptimal responders. 
Baseline aggregation identiﬁed by PFA-100 was similar in the two treatment groups 
(72±12 vs 71±10 for Group A and B respectively, p=0.938). Thirty days after treatment, 
platelet aggregation time was similarly increased in both treatment groups (126±79 for 
Group A , p=0.029 vs baseline and 155±100 for Group B, p=0.006 vs baseline, p=0.411 
for Group A vs Group B) ). Suboptimal clopidogrel response was still present in 4 (31%) 
patients of the 75mg regimen and 7(44%) patients on the 150 mg regimen (p=0.702).
Conclusions: Ex vivo platelet reactivity decreases with time in a signiﬁcant percentage of 
patients with ACS and clopidogrel resistanse. A 150-mg maintenance dose of clopidogrel 
was not associated with enhanced antiplatelet effects compared with 75 mg in this high 
risk patient population
3:30 p.m.
1041-138 Impact of Statin on the Regression of Coronary 
Atherosclerotic Plaque in Women; An Intracoronary 
Ultrasound (IVUS) Subanalysis of Japanese Acute 
Coronary Syndrome (JAPAN-ACS) Study
Yukio Ozaki, Shino C. Kan, Hirouki Naruse, Masanori Okumura, Kousuke Hattori, 
Makoto Ishikawa, Tomoko Kawai, Hiroto Harigaya, Shigeru Matsui, Sadako Motoyama, 
Masayoshi Sarai, Junichi Ishii, Hitoshi Hishida, Masunori Matsuzaki, JAPAN-ACS 
Study Group, Fujita Health University Hospital, Toyoake, Japan, Yamaguchi University 
Graduate School of Medicine, Ube, Japan
Background: Although cardiovascular disease is a major cause of death in women, it has 
not yet been well established whether the degree of atherosclerotic plaque regression 
derived from statin is similar between women and men.
Methods: We performed a prospective multicenter randomized study to assess plaque 
regression by serial IVUS examinations in 307 patients with ACS in 33 centers in 
Japan (JAPAN-ACS). All patients received either a new statin (pitavastatin; 4mg/day) or 
atorvastatin (20mg/day) for 8 to 12 months starting within 72 hours following IVUS guided 
stenting for a culprit lesion in ACS. Non-culprit lesions located at >5mm distal or proximal 
to the stent were assessed by serial IVUS examinations in 252 patients from 8 to 12 
months apart. While percent plaque volume (%PV) changes (i.e. PV follow-up minus PV 
post divided by PV post) were compared between atorvastatin and pitavastatin groups, no 
signiﬁcant difference was observed between atorvastatin (-18.1±14.2%) and pitavastatin 
(16.9±13.9%, p=ns). Therefore, we compared the degree of %PV changes between 206 
men and 46 women together with atorvastatin and pitavastatin groups.
Results: Coronary risk factors such as diabetes and hypertension were similar between 
the two. While baseline total cholesterol (TC, mg/dl) level was signiﬁcantly higher in women 
than in men (211±35 vs. 194±35, p<0.01) and baseline low-density lipoprotein cholesterol 
(LDL-C) level was greater in women than in men (144±33 vs. 129±31, p<0.01), smoking 
habits were more common in men than in women (52% vs. 23%, p<0.01). While statin 
signiﬁcantly reduced TC and LDL-C in both groups during follow-up, the degree of TC 
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c)mean intima-media thickness (IMT) in common carotids and carotid bulbs using 
ultrasound imaging.
Results: ADR1 and 2 expression was lower in patients with coronary stenosis 
>50% in at least one vessel (n=40) than in those with no signiﬁcant stenosis (63±25 
vs. 84±27 and 82±37 vs.111±46 MFI-AU respectively, p<0.05). Both groups had 
similar atherosclerotic risk factors. Within patients with signiﬁcant CAD, increased 
expression of ADR2 was related to increased PWV (rs=0.67, p=0.01), carotid bulb 
IMT (rs=0.43, p=0.03) and presence of carotid plaques (IMT>1.5mm) (rs=0.39, p=0.04). 
Increased expression of ADR1 was also related to increased PWV (rs=0.46, p=0.03). 
These associations were not observed in patients without signiﬁcant CAD.
Conclusions: Expression of adiponectin receptors is reduced in patients with 
signiﬁcant CAD. Increased expression of ADR2 receptors on monocytes is related 
to peripheral vascular atherosclerosis in vivo. This increased expression of ADR 
in patients with more extensive atherosclerosis may reﬂect a compensatory 
mechanism for the low circulating adiponectin levels and may offer a potential 
therapeutic target for the use of PPAR-receptor agonists to activate the anti-
inﬂammatory and anti-atherogenic action of these receptors.
3:30 p.m.
1041-143 Interrelationships of Impaired Erectile Function, 
Increased Arterial Stiffness and Coronary Artery 
Disease
Charalambos Vlachopoulos, Nikolaos Ioakeimidis, Konstantinos Rokkas, Dimitrios 
Terentes-Printzios, Konstantinos Aznaouridis, Konstandina Aggeli, Katerina Baou, 
Thanos Askitis, Christodoulos Stefanadis, 1st Cardiology Department, Athens Medical 
School, Athens, Greece
Background : Accumulating evidence suggests that erectile dysfunction (ED) may be an 
early manifestation of generalized vascular disease. Arterial stiffness is an independent 
marker and prognosticator of cardiovascular risk. Aim of this study was to determine 
arterial stiffness and its predictive value for the presence of underlying cardiovascular 
pathology in men with ED.
Methods: Carotid-femoral Pulse Wave Velocity (PWV) as an index of aortic stiffness and 
radial Augmentation Index (AIx) as a measure of wave reﬂections were measured in 344 
consecutive men with ED of vascular origin. ED was diagnosed according to history and 
score of the 5-item Sexual Health Inventory for Men (SHIM, cut-off value <21). Lower 
scores indicate poorer erectile function and vice versa.
Results: Subjects were categorized according to tertiles of SHIM score [Group 1: ﬁrst 
tertile (SHIM score: 15-20, n=117), Group 2: second tertile (SHIM score: 10-14, n=115), 
Group 3: third tertile (SHIM score: <9, n=112)]. The patients with lower SHIM score were 
older (p <0.01) and have higher central pulse pressure (p <0.05) and greater proportion 
of diabetes (p<0.01). PWV and AIx were signiﬁcantly different between Groups 2 and 3 (p
<0.001 and p = 0.02) and between Groups 1 and 3 (p <0.001 and p < 0.01), respectively. 
The proportion of ED patients with angiographically documented coronary artery disease 
(CAD) and presence of multi-vessel CAD was signiﬁcantly higher in Group 3 (p <0.01
and p<0.001, respectively). In multivariable logistic regression analysis adjusting for age, 
mean blood pressure, metabolic proﬁle, C-reactive protein, arterial function parameters, 
use of statins and ACE inhibitors and SHIM score, only PWV [odds ratio (OR) 1.25 per 1 
m/s increase, 95% conﬁdence interval (CI) 1.03-1.52, p<0.01] and SHIM score [odds ratio 
(OR) 0.74 per 1 increase of SHIM score, 95% conﬁdence interval (CI) 0.55-0.98, p = 0.03] 
remained independent predictors for presence of CAD.
Conclusions: ED severity is associated with increased arterial stiffness and the latter is a 
predictor of CAD presence. Determination of arterial stiffness and severity of ED may help 
to identify underlying cardiovascular disease in men with ED.
3:30 p.m.
1041-144 Different Contributors to Thrombus Formation Between 
Sirolimus-Eluting Stents and Paclitaxel-Eluting Stents: 
Serial Angioscopic Observations
Tomoaki Higo, Shinichi Hirotani, Nobuyuki Ogasawara, Kazunori Kashiwase, Yasunori 
Ueda, Osaka Police Hospital, Osaka, Japan
Background: Late stent thrombosis after sirolimus-eluting stents (SES) and paclitaxel-
eluting stents (PES) implantation has emerged as a major concern. Previous angioscopic 
and pathological studies have revealed prevalence of yellow plaques and incomplete 
neointimal coverage over drug-eluting stents greatly increase thrombotic risk. However, 
the mechanism of thrombus formation of SES and PES has not been clariﬁed.
Methods: We examined 63 SES-implanted and 12 PES-implanted lesions. Angiographic 
and angioscopic examinations of stent-implanted lesions were serially performed immediate 
(baseline) and 10.7 ± 3.8 months (follow-up) after implantation. Maximum yellow color grade 
(Max color grade; 0, white; 1, light yellow; 2, yellow or 3, intense yellow), neointimal coverage 
of stent and prevalence of thrombus were angioscopically evaluated.
Results: Baseline clinical and angiographic characteristics were similar between two groups. 
Max color grade in SES-implanted lesions was signiﬁcantly increased from baseline to follow-
up (1.4 ± 1.1 vs 1.9 ± 0.6, p<0.001), although that in PES-implanted lesions did not change 
(1.8 ± 0.4 vs 1.4 ± 0.6, p=0.76). Especially in the area yellow plaques were not detected at 
baseline, newly formed yellow neiontima was observed at follow-up in 85% of SES-implanted 
lesions, but not in PES-implanted lesions. On the other hand, prevalence of thrombus in the 
area stent was not covered by neointima was signiﬁcantly higher in PES-implanted lesions 
than in SES-implanted lesions (64% vs 26%, p=0.029). Stent struts were not covered by 
neointima, at least in part, in approximately all lesions, and prevalence of yellow plaques in 
the area was not different between two groups.
Conclusions: SES promoted atherosclerotic change in the stent-implanted lesions. 
Thrombogenic potential of stented lesions with incomplete neointimal coverage was 
higher in PES than in SES. Our data suggest that contributors to thrombus formation are 
3:30 p.m.
1041-141 Persistent Elevated Levels of Plasma Myeloperoxidase 
as an Independent Predictorof Recurrent 
Cardiovascular Events in Patients With Unstable 
Angina Pectoris
Atsuko Furukawa, Takahiko Naruko, Yukio Abe, Ryushi Komatsu, Akira Itoh, Kazuo 
Haze, Masashi Nakagawa, Chizuko Kitabayashi, Nobuyuki Shirai, Shoichi Ehara, 
Yoshihiro Ikura, Makiko Ueda, Osaka City General Hospital, Osaka, Japan, Osaka City 
University Graduate School of Medicine, Osaka, Japan
.
Background: There is increasing evidence that myeloperoxidase (MPO) contributes 
to cardiovascular disease. The present study was designed to investigate time-course 
changes in plasma MPO levels in patients with unstable angina pectoris (UAP). 
Furthermore, we investigated whether plasma MPO levels predict recurrent cardiovascular 
events. Methods: Plasma MPO levels and serum high sensitivity C-reactive protein 
(hs-CRP) were measured in 144 UAP patients. Measurements were taken at the acute 
phase (on admission) and the chronic phase (14 days after admission), and the ﬁndings 
were related to recurrent cardiovascular events. Cardiac events were deﬁned as sudden 
cardiac death, fatal or non-fatal myocardial infarction, and other non-fatal events including 
UAP, or angioplasty, stenting, or coronary bypass grafting. Results: Serum hs-CRP 
levels at the chronic phase had increased signiﬁcantly compared with the acute phase 
(acute phase, 0.49±1.52; chronic phase, 0.70±1.27 mg/dl, P<0.005). In contrast, plasma 
MPO levels at the chronic phase had decreased signiﬁcantly compared with the acute 
phase (acute phase, 40.9±38.3; chronic phase, 18.3±10.5 ng/ml, P<0.0001). Over a 
mean follow-up period of 30.9 months, 33 patients (23%) had cardiac events. Patients 
were classiﬁed into 2 groups according to the median MPO value at the chronic phase 
(low-MPO group a 16.0 and high-MPO group > 16.0ng/ml). Kaplan-Meier survival curves 
showed that the high-MPO group had signiﬁcantly (P=0.016 by log-rank test) worse 
outcomes than the low-MPO group. However, there were no signiﬁcant differences in 
cardiovascular events among 2 groups according to the median hs-CRP value at the 
chronic phase (low-hs-CRP group a 0.2 mg/dl and high-hs-CRP group > 0.20 mg/dl). 
Multivariate analysis showed that elevated plasma MPO levels at the chronic phase was 
the only independent factor associated with the cardiovascular events (OR, 2.58; 95%CI, 
1.19 to 5.59; P=0.017). Conclusions: These ﬁndings suggest that persistence of an
increased level of plasma MPO at the chronic phase is associated with the progression 
and destabilization of human coronary atherosclerotic lesions.
3:30 p.m.
1041-142 Enhanced Monocyte Expression of Adiponectin 
Receptors Is Related to Increased Carotid Intima-
Media Thickness and Arterial Stiffness in Patients With 
Chronic Coronary Artery Disease
Ignatios Ikonomidis, A. Kollias, John Lekakis, Ioannis Palios, P. Tsiotra, E. Maratou, 
Katerina Fountoulaki, G. Dimitriadis, Sotirios A. Raptis, Dimitrios Th Kremastinos, 2nd 
Cardiology Department, ‘Attikon’ Hospital, University of Athens, Athens, Greece, 2nd 
Department of Internal Medicine, Research Institute and Diabetes Center, Attikon’ 
Hospital, Univ, Athens, Greece
Background:Adiponectin is reduced in patients with CAD. Adiponectin receptors 
1 (ADR1) and 2 (ADR2) are expressed on cells within atheromatic lesions and 
on monocytes transformed to macrophages and are activated by PPAR-receptor 
agonists. Carotid intima-media thickness and arterial stiffness are markers of 
subclinical atherosclerosis with prognostic signiﬁcance. We investigated whether 
ADR1 and 2 are associated with carotid intima-media thickness and arterial 
stiffness in patients with angiographically documented chronicCAD.
Methods: We studied 60 patients with suspected CAD who underwent coronary 
angiography (mean age: 59±7 years 39 male and 5 females). We measured a) 
expression of ADR1 and 2 on blood monocytes [mean ﬂuorescence intensity 
arbitary units -MFI-AU] by ﬂow-cytometry b) carotid to femoral artery pulse wave 
velocity (PWV), as an estimate of arterial stiffness using the Complior apparatus 
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3:30 p.m.
1041-147 Prevalence of Extra Coronary Arterial Disease in 
Patients With Coronary Artery Disease Undergoing 
Coronary Intervention
Yoshimitsu Soga, Hiroaki Kobayashi, Tatsuki Doijiri, Tomoko Urakawa, Kenji Ando, 
Hiroyoshi Yokoi, Masashi Iwabuch, Hideyuki Nosaka, Masakiyo Nobuyoshi, kokura 
memorial hospital, Kitakyushu, Japan
Background:The prevalence of carotid stenosis (CS), renal artery stenosis (RAS), 
peripheral artery disease (PAD) of lower extremities and abdominal aortic aneurysm 
(AAA) in patients with coronary artery disease (CAD) remains unclear.
Methods:Patients who underwent percutaneous coronary intervention (PCI) at our 
institution between November 2007 and July 2008 were prospectively studied. All patients 
gave informed consent for this investigation. The coexistence of CS, RAS, PAD and AAA 
were evaluated in all patients by carotid and aortorenal duplex ultrasound and an ankle-
brachial index (ABI).
Results:In total, consecutive 802 patients underwent elective PCI, with a mean age of 69 
± 10 years (range, 39-92), 76% of male gender, 41% with diabetes mellitus (DM), 71% 
with hypertension, 5% with renal failure, 22% with smoking, and 11% with stroke. Of them, 
190 patients (23.7%) suffered from coexsistence of arterial disease. Frequency of CS, 
RAS, PAD and AAA was 3.6%, 5.4%, 17.2%, and 3.4%, respectively. Frequency of triple 
and double vascular disease was 6 (0.7 %) and 35 (4.4%), respectively. On multivariate 
analysis, age, history of coronary artery bypass surgery (CABG), hemodyalysis, 
HDL<40mg/dl, prior stroke and acute coronary syndrome was independent predictors for 
extra-coronary artery disease.
Conclusions:Prevalence of extra-coronary arterial disease (CS, RAS, PAD and AAA) is 
high in patients with CAD undergoing PCI. Initial screening for them by duplex ultrasound 
and ABI is useful.
3:30 p.m.
1041-148 Endogenous Plasma Levels of VEGF Are Associated 
With Late Lumen Loss in Drug Eluting Stents
Walter S. Speidl, Katharina M. Katsaros, Stefan P. Kastl, Gerlinde Zorn, Kurt Huber, 
Gerald Maurer, Dietmar Glogar, Johann Wojta, Günter Christ, Medical University of 
Vienna, Vienna, Austria, Wilhelminenhospital, Vienna, Austria
Background: Drug eluting stents (DES) reduce the rate of instent restenosis (ISR) 
compared to bare metal stents (BMS) through inhibition of migration and proliferation 
of coronary smooth muscle cells. However, recent studies suggest that DES also inhibit 
endothelial cell proliferation leading to delayed healing of the endothelium. VEGF may 
reduce neointima formation through accelerated reendothelialization. The aim of this 
study was to evaluate whether endogenous plasma levels of VEGF are associated with 
development of ISR after implantation of DES.
Methods: We studied 85 patients that were treated with 159 DES. Blood samples for 
measurement of VEGF antigen were taken directly before and 24 hours after implantation 
of DES. Late lumen loss (LL) was evaluated at 6 to 8 months by coronary angiography.
Results: During the follow up period, 2 patients died of cardiovascular causes and 12 
patients developed ISR. High baseline VEGF levels were protective for ISR and restenosis 
rates declined according increasing tertiles of VEGF (25.9%, 14.3% and 3.6%; p<0.05). 
In contrast, the increase of VEGF after PCI correlated with LL (R=0.33, p<0.0001) 
independently from clinical and angiographic risk factors.
Conclusion: High endogenous plasma levels of VEGF before PCI are protective for ISR, 
however, the increase of VEGF after PCI was associated with LL. This dual role of VEGF 
in neointima formation after implantation of DES needs further studies.
3:30 p.m.
1041-149 Heterogeneity of Neointimal Coverage Can Explain 
Larger Late Loss and Higher Risk of Late Stent 
Thrombosis of Paclitaxel-Eluting Stents Than 
Sirolimus-Eluting Stents: Angioscopic Observations
Tomoaki Higo, Shinichi Hirotani, Nobuyuki Ogasawara, Kazunori Kashiwase, Yasunori 
Ueda, Osaka Police Hospital, Osaka, Japan
Background: Several studies have shown that paclitaxel-eluting stents(PES) have 
larger late loss and higher risk of late stent thrombosis (LST) than sirolimus-eluting 
stents (SES). However, the reason for these clinical results has not been elucidated. 
Previous pathological studies have revealed that lack of neointimal strut coverage and 
different between SES and PES. In SES, newly formed atherosclerosis may contribute to 
thrombus formation, whereas in PES, high thrombogenic potential of stented lesions with 
incomplete neointimal coverage may contribute to it.
3:30 p.m.
1041-145 Intramyocardial Autologous Bone Marrow Cell Injection 
In No-option Patients With Refractory Angina Pectoris 
and Documented Ischemia: A Randomized, Double 
Blinded, Placebo-Controlled Trial
Jan van Ramshorst, Jeroen J. Bax, Saskia L. Beeres, Stijntje D. Roes, Petra Dibbets, 
Albert de Roos, Marcel PM Stokkel, Ernst E. van der Wall, Martin J. Schalij, Douwe E. 
Atsma, Leiden University Medical Center, Leiden, The Netherlands
Background: Several non-randomized clinical studies have demonstrated that 
intramyocardial bone marrow-derived mononuclear cell (BMC) injection is safe and 
feasible in no-option patients with angina pectoris. In this randomized, double blinded and 
placebo-controlled trial, we investigated the efﬁcacy of intramyocardial BMC injection in 
no-option patients with angina pectoris and documented ischemia.
Methods: In 50 patients, bone marrow was aspirated from the iliac crest. After cell 
isolation, patients were randomly assigned to injection of autologous BMC or placebo 
solution. Using the NOGA system (Biosense-Webster, Belgium), injection of 98±7x106
BMC or placebo solution was performed.
Anginal symptoms and quality of life were evaluated at baseline and at 3 and 6 months. 
Gated single-photon emission computed tomography and magnetic resonance imaging 
were performed at baseline and at 3 months follow-up to assess myocardial perfusion 
and left ventricular function.
Results: Intramyocardial injection was performed without complications in all patients. 
Canadian Cardiovascular Society score improved from 3.0±0.6 at baseline to 2.3±0.7 at 3 
months and to 2.2±0.6 at 6 months (P<0.01) in the BMC group, whereas no improvement 
was observed in the placebo group (2.9±0.7 vs. 2.6±0.8 vs. 2.5±0.9, P=NS). Moreover, 
quality of life improved from 56±9% to 64±12% at 3 months and to 69±12% at 6 months 
(p<0.01) in the BMC group, compared to a smaller improvement in the placebo group 
(57±11% vs. 61±14% vs. 64±17%, P<0.01 compared to the BMC group).
The number of segments with stress-inducible ischemia per patient decreased from 
3.9±1.8 to 1.5±1.5 (p<0.01) in the BMC group, compared to a modest decrease from 
3.1±1.5 to 2.4±1.8 (P<0.01) in the placebo group. The absolute decrease was signiﬁcantly 
larger in the BMC group (-2.4±1.3 vs. -0.8±1.1, P<0.01).
LV ejection fraction increased from 56±12% to 59±11% at 3 months in the BMC group 
(P=0.01), whereas no improvement was observed in the placebo group (from 54±10% 
to 53±10%, P=NS).
Conclusion: In no-option patients with angina pectoris, intramyocardial BMC injection 
has a beneﬁcial effect on anginal symptoms, myocardial perfusion and left ventricular 
function.
3:30 p.m.
1041-146 Patient Perceptions Regarding Beneﬁts of Elective 
Coronary Revascularization for Stable Coronary Artery 
Disease in the Current Era
Apurva Motivala, Jeanine Mckeever, Anna Kezerashvili, Paolo Gabriel, Jackie Harold, 
Mark Menegus, Mark Greenberg, Robert Ostfeld, Monteﬁore Medical Center, Bronx, NY
BACKGROUND: Recent evidence from the COURAGE trial has shown that elective PCI, 
while relieving angina, does not improve survival or reduce the incidence of a future 
myocardial infarction (MI) over optimal medical management in stable coronary artery 
disease. We sought to survey patients presenting to our catherization laboratory for 
elective PCI, to examine if they were adequately informed about its risks and beneﬁts in 
addition to those of optimal medications, prior to their referral.
METHODS: Patients referred for a diagnostic catheterization to our laboratory since 
03/10/08 were screened for eligibility. Patients with prior bypass surgery, PCI or acute 
coronary syndrome were excluded. Qualifying patients were asked to ﬁll out a voluntary 
survey that included their demographics, medications and 12 questions, either in person 
or by telephone.
RESULTS: 60 eligible patients responded. The majority were males (55%) with a mean 
age of 61 years. 90% had an education level of high school or higher. Most felt under-
informed about the possible risks of angioplasty (52%) or their medications (50 %) by their 
referring physicians. A majority felt that an angioplasty would improve their symptoms 
(90%), would make them live longer (85%) and would prevent a future heart attack (88%). 
A majority also felt that their prescribed medications would improve their symptoms 
(87%), make them live longer (87%), and prevent a future heart attack (87%). Also, most 
realized that consuming a healthy diet and regular exercise would help them live longer 
(97%) and prevent a future heart attack (90%).
CONCLUSIONS: Patients with stable coronary artery disease referred to our 
catheterization laboratory for possible PCI remain erroneously over-optimistic about the 
additional beneﬁts of this procedure in the current era. They feel under-informed about 
the risks of PCI and their medications by their referring physicians. These ﬁndings are 
similar to those published a decade ago, and highlight the importance of improved 
communication of risks, beneﬁts, alternatives and ﬁndings of current literature to patients 
prior to referring them for an elective PCI.
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Conclusions: SDB has a high prevalence in pts with CAD. OSA was found more often 
(50.6 % vs. 23.3 %). AHI was higher in pts with CSA and in pts with higher BMI. Pts with 
SDB had a higher BMI than pts with noSDB.
3:30 p.m.
1041-152 The Prognostic Utility of Lipoprotein-Associated 
Phospholipase A2 Activity Versus Mass in Patients With 
Stable Coronary Artery Disease
Michelle O’Donoghue, David A. Morrow, Sarah Sloan, Marc S. Sabatine, Brigham and 
Women’s Hospital, Boston, MA
Background: Lipoprotein-associated phospholipase A2 (LpPLA2) is believed to contribute 
to atherogenesis. The relative prognostic utility of LpPLA2 measured as enzyme activity 
versus mass remains undeﬁned.
Methods: LpPLA2 activity and mass (diaDexus) were measured at baseline in 3743 
subjects in PEACE, a randomized trial of trandolapril vs placebo in stable CAD. The 
primary endpoint (EP) was CV death, MI or coronary revascularization (median 4.8 year 
follow up). Multivariable Cox regression was used to adjust for demographics, risk factors, 
and medications.
Results: Modeled separately, the adjusted risk for the primary endpoint per 1-SD increase 
was 1.23 (95% CI 1.16-1.31, P<0.001) for LpPLA2 activity versus 1.12 (95% CI 1.04-
1.19, P=0.002) for LpPLA2 mass. Analyses by quartile are shown in Figure (left). In ROC 
analyses, LpPLA2 activity (P=0.035), but not mass (P=0.16), signiﬁcantly improved the 
C-statistic over traditional predictors. LpPLA2 activity and mass were moderately strongly 
correlated (r=0.59, P<0.001). In a model that included both markers, activity (P<0.001) but 
not mass (P=0.70) remained signiﬁcantly associated with outcomes. In quartile analysis, 
elevated LpPLA2 activity was predictive of risk regardless of mass (Fig, right).
Conclusion: LpPLA2 activity and mass each independently predict outcomes in patients 
with stable CAD. The two markers are moderately correlated, and LpPLA2 activity appears 
to be the stronger independent predictor of outcomes.
3:30 p.m.
1041-153 Diastolic Dysfunction by Cardiac Magnetic Resonance 
Imaging in Women With Open Coronary Arteries and 
Microvascular Dysfunction
Janet Wei, Louise Thomson, Chrisandra Shufelt, YuChing Yang, Edward Gill, Margo 
Minissian, Saibal Kar, Daniel Berman, C. Noel Bairey Merz, Cedars-Sinai Medical 
Center, Los Angeles, CA
Background: Coronary microvascular dysfunction is an etiological mechanism of 
ischemia in women with persistent angina, open coronary arteries and clinical evidence 
of ischemia. The relationship between microvascular dysfunction and left ventricular 
diastolic dysfunction is unexplored.
Methods: Coronary reactivity testing and resting cardiac magnetic resonance (CMR) 
of 41 women with suspected microvascular dysfunction were analyzed. Left ventricular 
end-diastolic pressure at rest, coronary ﬂow reserve (CFR) and coronary blood ﬂow 
(CBF) were measured during cardiac catheterization. Cine CMR images of the entire 
left ventricle were obtained in consecutive short-axis planes and used to measure septal 
wall thickness, left ventricular ejection fraction, peak ﬁlling rate (PFR) and time to peak 
ﬁlling rate from end-systole (tPFR). Univariate correlations and logistic regression were 
examined.
Results: All women had evidence of ischemia, nonobstructed epicardial coronary 
arteries, mean age 55 ± 8.3 years, and mean left ventricular ejection fraction 65 ± 
13%. Mean left ventricular end-diastolic pressure was 15 ± 4.5 mmHg. Microvascular 
dysfunction (CFR<2.5 or CBF<50%) was present in 35/41 (85%) women. Mean tPFR was 
178 ± 110 msec; mean PFR was 3.2 ± 0.64 end-diastolic volume/sec. CMR evidence of 
diastolic dysfunction (tPFR>127 or PFR<3.2) was present in 36/41 (88%) women and in 
33/35 (94%) women with microvascular dysfunction. tPFR increased with age (r= 0.37, 
p= 0.017) and septal wall thickness (r= 0.47, p= 0.002), while PFR decreased with age 
(r= -0.45, p= 0.003). There was an inverse relationship between CFR and tPFR (r= -0.3, 
p= 0.058) and between CBF and PFR (r= -0.28, p= 0.08). Univariate logistic regression 
analysis was nonsigniﬁcant, but a trend toward signiﬁcance was found between PFR and 
age (B= 0.07, p= 0.072).
Conclusion: CMR indices of diastolic ﬁlling correlate inversely with CFR and CBF, 
both trending toward statistical signiﬁcance. The majority of women with microvascular 
dysfunction had resting diastolic dysfunction by CMR. This observation suggests a 
relationship between microvascular dysfunction and diastolic dysfunction, and may have 
therapeutic implications.
heterogeneous neointimal coverage over drug-eluting stents greatly increase thrombotic 
risk. The aim of this study is to compare by using angioscopy heterogeneity of neointimal 
coverage and thrombus formation between PES and SES.
Methods: We examined 30 PES-implanted lesions (29 patients) and 78 SES-implanted 
lesions (77 patients). Angiographic and angioscopic examinations at stent-implanted 
lesions were performed 1 year (11.1±3.5 months) after implantation. Maximum and 
Minimum neointimal coverage grade of the stent (Max coverage, Min coverage; 0, not 
covered; 1, covered by thin layer or 2, buried under neointima) and prevalence of thrombus 
were angioscopically evaluated. We also evaluated whether the neointimal coverage of 
stent was heterogeneous or not. Neointimal coverage was deﬁned as ‘heterogeneous’ 
when the stented lesion had multiple coverage grades.
Results: Baseline clinical and angiographic characteristics were similar between two 
groups. Max coverage was signiﬁcantly higher in PES-implanted lesions than in SES-
implanted lesions (1.8 ± 0.4 vs 1.4 ± 0.6, p<0.001). Min coverage was lower in PES-
implanted lesions, though it was not statistically different (0.5 ± 0.6 vs 0.7 ± 0.5, p=0.14). 
Neointimal coverage was heterogeneous in 93% of PES-implanted lesions and 68% 
of SES-implanted lesions (p=0.006). Prevalence of thrombus was signiﬁcantly higher 
in PES-implanted lesions than that in SES-implanted lesions (53% vs 36%, p=0.01), 
especially at the site struts were not covered (27% vs 3%, p<0.001).
Conclusions: Max coverage was greater, neointimal coverage was more heterogeneous 
and prevalence of thrombus was higher in PES-implanted lesions than in SES-implanted 
lesions. These angioscopic ﬁndings may explain larger late loss and higher risk of LST in 
patients with PES than those with SES.
3:30 p.m.
1041-150 The Strategy of High Pressure Balloon Predilatation 
May Lead Better Long-Term (Two-Year) Outcomes in 
Patients of Bare-Metal Stents Restenosis Treated With 
Silorimus-Eluting Stent
Katsuo Noda, Shuichi Oshima, Shinichi Nakamura, Kumamoto Chuo hospital, 
Kumamoto, Japan
Background: Silorimus-eluting stent (SES) has been shown to reduce restenosis, 
even in bare-metal stents restenosis (ISR). However, some reports have been shown 
the late catch-up beyond one-year. In de-novo cases, it has been reported that SES 
under-expansion became one of the predictors associated with long-term outcomes, 
but few reports existed in the association between SES under-expansion and long-term 
outcomes in ISR treated with SES. We performed a high-pressure pre-dilatation for ISR 
prior to SES implantation, and to evaluate the efﬁcacy of that strategy for the long-term 
outcomes. Methods:Between August 2004 and August 2006, a consecutive 138 ISR 
patients were treated. We divided into 2 groups, one was H (high-pressure pre-dilatation; 
n=80) and the other was N (no high-pressure pre-dilatation; n=58). High-pressure pre-
dilatation was performed >= 12-atmosphere pressure with non-compliant balloon before 
SES implantation. Pre-dilatation balloon size was decided at least the same size of prior 
implanted BMS. We investigated the 2-year outcomes in each group, and the predictors 
of MACEs were evaluated with multivariate analysis. Results: There were no signiﬁcant 
differences of clinical and angiographic characteristics in both groups. The 30-day MACEs 
were 2.5% in H, and 1.7% in N (p=NS). 1-year and 2-year MACEs were lower rate in H than 
N, signiﬁcantly (7.5% vs. 27.6%, p=0.002; 12.5% vs. 43.1%, p<0.0001). Stent thrombosis 
occurred one in each group. 2-year late loss was smaller in H, signiﬁcantly (0.6+/-0.7 mm 
vs. 0.9+/-1.0 mm, p=0.02). Multivariate analysis showed that ejection fraction (p=0.025, 
HR=1.03) and SES minimum stent area (MSA) with IVUS <5.0 mm2 (p=0.003, HR=3.47) 
were positive predictors, and high-pressure balloon pre-dilatation (p=0.008, HR=0.33) 
was a negative independent predictors of 2-year MACEs. A subgroup of SES-MSA>=5.0 
mm2 and high-pressure balloon pre-dilatation showed especially lower MACEs rate 
than the other group (3.7% vs. 38.6%, p<0.0001). Conclusions:These results lead that 
the high-pressure balloon pre-dilatation may change the 2-year long-term outcomes in 
patients with SES implantation for BMS-ISR.
3:30 p.m.
1041-151 Sleep Disordered Breathing in Patients With Coronary 
Artery Disease: A Prevalence Study
Christian Prinz, Thomas Bitter, Cornelia Piper, Dieter Horstkotte, Olaf Oldenburg, 
Department of Cardiology, Heart Center North Rhine- Westphalia, Ruhr University 
Bochum, Bad Oeynhausen, Germany
Background: Sleep disordered breathing (SDB) has a high prevalence and prognostic 
impact in patients (pts) with various cardiac diseases. Aim of this study was to investigate 
the prevalence of SDB in pts with coronary artery disease (CAD).
Methods: We consecutively included 257 pts (212 men; age 67.5 ± 1.0 years; CCS 
1.4 ± 0.2; body mass index (BMI) 28.4 ± 0.5 kg/m²) with relevant CAD (at least one 
stenosis q 70 %) and left ventricular ejection fraction (LVEF) q 50%. All pts underwent 
echocardiography, cardiac catheterisation and in-hospital unattended cardiorespiratory 
polygraphy (Embletta, Embla, NL). In case the apnea-hypopnea-index (AHI) was > 5/h 
pts were considered to have SDB. If thoracic and abdominal inspiration efforts were 
documented, SDB was considered to be obstructive (OSA), otherwise central sleep 
apnea (CSA) was diagnosed.
Results: SDB was documented in 188 pts (74 %) with an AHI of 16.4 ± 1.9 /h. 58 pts 
(23.3 %) had CSA (AHI 29.7 ± 4.5 /h) and 130 pts (50.6 %) OSA (AHI 16.9 ± 2.2 /h). Only 
69 pts (26.8 %) demonstrated no relevant SDB. Severity of SDB measured by AHI was 
higher in pts with CSA than in pts with OSA ( AHI 29.7 vs. 16.9 /h; p < 0.01). As expected 
severity of SDB was signiﬁcant lower in pts with BMI a 25 kg/m² (AHI 9.9 ± 3.4 /h) than in 
pts with BMI > 25 kg/m² (AHI 17.8 ± 2.2 /h; p = 0.002). Pts with OSA (BMI 29.0 ± 0.8 kg/
m²) had a signiﬁcant higher BMI than pts with noSDB (BMI 26.7 ± 0.8 kg/m²; p = 0.0002). 
Interestingly pts with CSA (BMI 28.9 ± 1.0 kg/m²) had also a higher BMI (p = 0.0006).
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of subdepressor dose of short-acting beta-blocker Landiolol before coronary artery 
occulusion may reduce the incidence of post-PCI MI.
Methods: Patients with stable angina undergoing PCI (n=26) were randomized in a 
prospective double-blind fashion to Landiolol at a dose of 3μg/kg/min (n=13) or placebo 
(n=13). Drug administration was started one hour before PCI and was continued for 24 
hours. Evidence of post-PCI MI was deﬁned as an increase in Troponin T to >2 times the 
upper limit of normal within 24 hours of PCI.
Results: Intravenous administration of subdepressor dose of Landiolol decreased 
incidence of post-PCI MI compared with placebo (7.7% vs. 46.1%, p=0.037) without 
affecting the hemodynamic determinants of myocardial work including heart rate and 
systemic blood pressure.
Conclusions: Intravenous administration of subdepressor dose of short-acting beta-
blocker Landiolol before coronary artery occulusion may reduce the incidence of post-
PCI MI in stable angina.
3:30 p.m.
1041-158 High Loading Dose of Clopidogrel Is Unable to 
Satisfactorily Inhibit Platelet Reactivity in Patients 
With Glycoprotein IIIA Gene Polymorphism : A Genetic 
Substudy of PRAGUE-8 Trial
Zuzana Motovska, Petr Widimsky, Jan Kvasnicka, Robert Petr, Dana Bilkova, Jaroslava 
Hajkova, Iuri Marinov, Stanislav Simek, Petr Kala, on behalf of the PRAGUE 8 study 
investigators, Third Medical Faculty Charles University and University Hospital Kralovske 
Vinohrady, Prague, Czech Republic
Background:The study aimed to assess the impact of 9 platelet receptors, enzymes, 
and haemostatic factor polymorphisms on clopidogrel efﬁcacy in patients with stable CAD 
undergoing elective coronary angiography ±ad hoc PCI.
Methods:The study was performed as a genetic substudy of the PRAGUE-8 trial. 95 
patients pretreated with 600mg clopidogrel >6h prior to coronary angiography were tested. 
Baseline platelet reactivity to ADP was assessed before the drug use. Clopidogrel efﬁcacy 
was tested again at 12 and 28h after administration. Polymorphisms of 6 platelet receptors 
(Figure), gene variations of COX-1, Leiden and factor II mutations were studied. Flow 
cytometric tests of VASP phosphorylation states were used as a measure of drug efﬁcacy.
Results:None of gene polymorphisms inﬂuenced baseline ADP-induced platelet reactivity 
signiﬁcantly. 28h after drug administration, differences in suppression of ADP-induced 
platelet reactivity were observed between polymorphism positive and polymorphism 
negative patients. Inhibition of platelet reactivity, after 600mg of clopidogrel, was 
signiﬁcantly less in carriers of PlA2 (p=0.009 for mean decrease in platelet reactivity index 
(PRI)). The proportion of clopidogrel non-responders (PRI>50%) was apparently higher in 
PlA2 carriers in comparison to PlA1/PlA1 patients (54% vs. 24%, p = 0.082).
Conclusions:A 600mg loading dose of clopidogrel failed to acceptably inhibit platelet 
reactivity in patients who were positive for the PlA2 polymorphism. 
3:30 p.m.
1041-154 Withdrawn.
3:30 p.m.
1041-155 Defective Recovery of QT Dispersion Predicts Late 
Cardiac Mortality After Percutaneous Coronary 
Interventions
Marco Zimarino, Alessandro Corazzini, Alfonso Tatasciore, Marcello Caputo, Nicola 
Maddestra, Cesare Di Iorio, Raffaele De Caterina, Institute of Cardiology and Center of 
Excellence on Aging - University G. d’Annunzio, Chieti, Italy
Background: The inter-lead difference in QT interval, known as QT dispersion (QTD), has 
been suggested to provide a measure of repolarization inhomogeneity. The relationship 
between QTD and cardiac outcomes is controversial. We aimed at testing the association 
between rapidly occurring changes in corrected QTD (cQTD) following percutaneous 
coronary interventions (PCI) and long-term survival.
Methods: The 12-lead ECG was analyzed before, as well as 6 h and 18 h after PCI 
in 612 patients (median age 63 years, range 29-87). The variation in corrected QT 
dispersion ($cQTD) was calculated as the difference between baseline and 6 h after 
PCI measurements.
Results: PCI reduced cQTD in 343 patients (56%). QTD and cQTD were signiﬁcantly 
reduced from baseline to 6 h after PCI (P<0.001 for all), while no signiﬁcant change 
occurred between the 6- and the 18-h assessments.
Over 49±10 months, a total of 46 deaths (7.5%) occurred, 21 for non-cardiac and 25 for 
cardiac causes; all cardiac deaths were classiﬁed as arrhythmic. Patients in the lowest 
tertile of $cQTD - i.e., those who increased cQTD after PCI - had a similar overall and 
event-free survival, but a higher cardiac mortality compared with other tertiles (log-rank 
P=0.001). In Cox regression analysis, a reduced $cQTD was an independent predictor of 
long-term cardiac mortality (HR=1.497; 95% Conﬁdence Interval=1.081-2.075; P=0.015 
for each 20 ms decrease), together with the number of treated lesions (P=0.008), 
diabetes (P=0.028), peak CK-MB (P=0.029), age (P=0.034) and the presence of 3-vessel 
disease (P=0.037). The area under the ROC curve for cardiac mortality was 0.712 for 
$cQTD and 0.645 for peak CK-MB. The 82 patients (13%) who were in the ﬁrst tertile of 
$cQTD and experienced a post-procedural increase of CK-MB above normal limit had a 
4-year cardiac mortality rate of 14.6%, signiﬁcantly higher than the remaining population 
(2.5%, P<0.001).
Conclusions: cQTD decreases after PCI. A defective recovery of cQTD suggests the 
persistence of myocardial areas with repolarization inhomogeneities and is related to 
long-term cardiac mortality, likely due to a relationship with sudden death.
3:30 p.m.
1041-156 Neopterin Predicts Left Ventricular Function in Patients 
With Chronic Stable Angina Pectoris
Rodrigo Estevez-Loureiro, Alejandro Recio-Mayoral, Juan A. Sieira-Rodriguez-Moret, 
Ernesto Trallero-Araguas, Juan Carlos Kaski, St. George’s Hospital, London, United 
Kingdom
Background: Left ventricular ejection fraction (LVEF) is the strongest predictor of survival 
in patients with CSA. Inﬂammation plays a pathogenic role in atherosclerosis, and an 
enhanced inﬂammatory status is known to impair patient outcome. A link exists between 
inﬂammation and LV dysfunction. Neopterin, a marker of inﬂammation and macrophage 
activation, is a predictor of risk in patients with CSA. We investigated whether increased 
neopterin levels correlate with the presence of left ventricular dysfunction in patients with 
chronic stable angina pectoris (CSA).
Methods: We prospectively assessed 181 CSA patients (symptoms stable for > 3 months) 
(age 69±9 years; 78% male) undergoing diagnostic coronary angiography. High sensitivity 
CRP and neopterin serum concentrations were measured immediately before angiography. 
LVEF was assessed angiographically and LV dysfunction deﬁned as LVEF <45%.
Results: A signiﬁcant negative correlation was found between neopterin levels - but 
not CRP- and LVEF (r= -0.222; p=0.003 and r= -0.097; p=0.194, respectively). After 
adjustment for relevant confounders, including extent and severity of coronary disease, 
neopterin was independently associated with LVEF (Beta -2.36, CI 95% -4.56 to -0.17, 
p=0.034). Moreover, high neopterin levels were an independent predictor of LV dysfunction 
(OR 8.52, CI 95% 1.10-65.64; p=0.040). Receiver operating characteristic analysis for 
neopterin showed an area under the curve of 0.73 (CI 95 % 0.59 - 0.87, p <0.009) for 
prediction of LV dysfunction.
Conclusions: Serum neopterin concentrations correlate with LVEF and high neopterin 
levels are a predictor of LV dysfunction in patients with CSA, irrespective of the extent 
and severity of coronary artery disease. Neopterin may thus be clinically useful for patient 
risk stratiﬁcation.
3:30 p.m.
1041-157 Intravenous Administration of Subdepressor Dose 
of Short-Acting Beta-Blocker Landiolol Before 
Percutaneous Coronary Intervention May Reduce the 
Incidence of Myocardial Infarction in Stable Angina
Hideaki Morita, Tatsuji Kono, Shuji Suzuki, Shogo Murakami, Tatsuya Umeda, Akiko 
Soyama, Yasushi Kitaura, Osaka Medical College, takatsuki, Japan
Background: Myocardial infarction (MI) after percutaneous coronary intervention 
(PCI) deﬁned as an increase in cardiac biomarkers is associated with higher incidence 
of late adverse clinical outcomes. We hypothesized that intravenous administration 
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1041-161 Diabetes Mellitus and Adiponectin Synthesis at 
Different Types of Adipose Tissue in Patients With 
Coronary Atherosclerosis
Constantinos Bakogiannis, Charalambos Antoniades, Dimitris Tousoulis, Alexios S. 
Antonopoulos, Antigoni Miliou, Costas Triantafyllou, Constantinos Psarros, Robin 
Choudhury, Janet Digby, Ilias Kylintireas, George Ekonomopoulos, Christodoulos 
Stefanadis, 1st Cardiology Department, Hippokration Hospital, Athens Medical School, 
Athens, Greece, Department of Cardiac Surgery, Hippokration Hospital, Athens, Greece
Background: Adiponectin is an adipokine with antiatherogenic properties, but it is 
still unclear which sites of adipose tissue (AT) are mainly responsible for its synthesis 
in patients with atherosclerosis. We examined the association between circulating 
adiponectin and its synthesis in human subcutaneous, pericardial and femoral AT in 
patients with advanced atherosclerosis, and we examined the effect of diabetes mellitus 
(DM) on its synthesis.
Methods: The study population consisted of 75 patients with advanced atherosclerosis 
undergoing elective CABG, 22 with type 2 DM and 53 without DM. Serum adiponectin 
was measured preoperatively by ELISA, while the following types of AT were collected 
intraoperatively: (a) Subcutaneous from the site of insertion (b) pericardial (surrounding the 
pericardium) (c) femoral, around saphenous vein (perivascular). Adipose tissue was cultured 
ex-vivo for 4 hours, and adiponectin was measured in the AT culture supernatants by ELISA.
Results: Adiponectin synthesis was lower in subcutaneous AT (152.9±10.8 pg/mg) 
compared to femoral (185.5±15.2pg/mg p<0.05) or pericardial (214.8±18.4pg/mg, 
p<0.05) AT. Circulating adiponectin was signiﬁcantly correlated with subcutaneous 
(r=0.416, p=0.005) and pericardial (r=0.828, p=0.002) but not with femoral (r=-0.251, 
p=ns) AT. Importantly, patients with DM had signiﬁcantly lower serum adiponectin (9.6±2.1 
vs 31.2±4.9 ug/mL p<0.001) as well as lower adiponectin synthesis in subcutaneous 
(126.6±16.8 vs 194.5±17.7pg/mg) and pericardial AT (152.7±25.5pg/mg vs 231.1±25.0pg/
mg p<0.05) but not in femoral AT (209.2±52.1 vs 183.7±22.6pg/mg p=NS).
Conclusions: Circulating adiponectin levels are mainly driven by its release from 
subcutaneous and pericardial AT, while adiponectin synthesis in femoral AT is regulated 
by different mechanisms. Type 2 DM decreases adiponectin synthesis in subcutaneous 
and pericardial AT, leading to a respective effect on its circulating levels, while it has no 
impact on adiponectin synthesis in femoral AT. These ﬁndings provide new insights into 
the mechanisms regulating adiponectin synthesis in human atherosclerosis.
3:30 p.m.
1041-162 Effects of Ezetimibe Plus Moderate-Dose Simvastatin 
Versus Higher-Dose Simvastatin Alone on C-Reactive 
Protein and Platelet Function in Patients With Stable 
Coronary Artery Disease
Antonio E.P. Pesaro, Carlos V. Serrano, Jr., Herlon Saraiva Martins, James De Lemos, 
Paulo R. Parra, Juliano L. Fernandes, Renata T. Ladeira, Roberto Rocha C.V. Giraldez, 
José Carlos Nicolau, Heart Institute (InCor), University of Sao Paulo, Medical School, 
Brazil, Sao Paulo, Brazil
Background: It is not clear if intensive cholesterol reduction, obtained either by ezetimibe 
plus moderate-dose simvastatin (E/S) or by higher-dose simvastatin alone (S), have 
similar anti-inﬂammatory and anti-platelet effects. The aim of this study was to compare 
the effects of E 10 mg / S 20 mg vs S 80 mg on C-reactive protein (CRP) and platelet 
aggregation (platelet function analyzer - PFA) of patients with stable CAD.
Methods: Patients (n=47, 63.5±9.03 years, 24 men), previously on S 20 mg, were 
randomly allocated to receive either E 10 mg / S 20 mg or S 80 mg for 6 weeks. Lipid 
proﬁle, levels of CRP and PFA were measured before and after lipid-lowering.
Results: See table. Baseline characteristics (age, sex, diabetes, hypertension and 
smoking) were similar in both groups. Liver and muscle parameters were unaffected. CRP 
was reduced by S 80 (p=0.01), but not by E10/S20 (p=0.85), despite a similar reduction of 
LDL-C (28.2% vs 28.1%, respectively; p=0.68). In a comparison of CRP reduction between 
groups, we identiﬁed a trend towards S 80 efﬁcacy (25.8% vs 3.5%, respectively; p=0,09). 
PFA increased similarly for both strategies (6.7% vs 11.0%, respectively; p=0.20).
Conclusions: S 80 and E10/S20, are effective to reduce cholesterol and platelet aggregation 
in patients with stable CAD. However, only S 80 was able to reduce CRP effectively. Higher 
simvastatin doses may be necessary to provide a larger pleiotropic effect.
Changes of lipid parameters, CRP and PFA
S 80 (n=25) E 10 / S 20 (n=22)
Baseline After 6 weeks p Baseline After 6 weeks p
LDL-C
(mg/dl)
93 (84.5-
133.5)
75 (58.0-
91.5) <0.001*
96 (89.0-
115.0)
71 (62.0-
79.0) <0.001*
HDL-C
(mg/dl)
43 (38.5-
48.5)
42 (38.0-
48.0) 0.5** 41 (37.0-47.0)
41 (38.0-
46.0) 0.90**
TG (mg/
dl)
128 (90.0-
172.5)
102 (85.0-
141.0) 0.06**
142 (113.0-
216.0)
121 (82.0-
164.0) 0.02**
CRP (μg/
ml) 2.1 (0.6-3.8) 0.9 (0.3-3.0) 0.01** 1.9 (0.3-3.0) 1.2 (0.7-3.3) 0.85**
PFA 
(seconds) 151.0+79.6 157.1+78.9 0.02* 168.7+70.1 203.4+67.5 0.02*
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; 
TG, triglycerides; PFA, platelet function aggregation; *ANOVA test; **Wilcoxon test; 
Data expressed in median (25th and 75th percentil); PFA expressed in average+SD.
3:30 p.m.
1041-159 Long-Term Prognosis of Patients With Cardiac 
Syndrome X: Data From the Italian Registry of 
Syndrome X (RISX)
Isabella Tritto, Gaetano A. Lanza, Fausto Rigo, Stefano Favale, Oberdan Parodi, M. 
Lorenza Muiesan, Salvatore Novo, Irma Porchetta, M. Giovanna Conti, Giuseppe 
Ambrosio, Cardiology, University of Perugia, Perugia, Italy
Background: Concomitant presence of effort angina, positive exercise stress test, and 
normal coronary arteries deﬁnes cardiac syndrome X. Its pathogenesis, although mostly 
attributed to dysfunction of coronary microcirculation, is still unclear. In addition, it is not 
known which clinical data might help identiﬁng patients at higher risk of cardiovascular 
events. As this condition is rare, most information comes from single center studies, 
recruiting a small number of patients. The Italian Registry of Syndrome X (RISX) is a 
multicenter prospective registry collecting clinical and prognostic data of patients with 
syndrome X.
Methods: Inclusion criteria were (all): effort angina, positive exercise stress test, 
angiographically normal (<20% stenosis) coronary arteries. Follow up was performed by 
ambulatory visits.
Results: 259 patients [61±11 years/old; 184 (71%) female], from 7 centers are currently 
in the registry. Incidence of risk factors for atherosclerosis was: hypertension 65.6%, 
hypercholesterolemia 58.7%, family history of coronary heart disease 25.9% smoking 
22.4%, diabetes 10%. At a median follow up of 40 months (Interquartile range 30.0-108.3), 
cardiovascular events were rare: 1 patient suffered acute coronary syndrome (0.4%) and 
2 developed heart failure (0.8%). However, 83% of women and 46% of men (p<0.05) still 
complained of angina: among them, 60% have >1 anginal episode/week, in 30% of cases 
severe enough to require at least one hospitalization. At multivariate logistic regression 
analysis, the only clinical ﬁndings predictive of persistence of angina were female gender 
(adjusted Odds Ratio of 5.43; 95% C.I. 2.33-12.65; p<0.0005), and family history of coronary 
heart disease (adjusted Odds Ratio 3.7; 95% C.I. 1.36-10.01; p<0.01).
Conclusion: Cardiac syndrome X is characterized by a good prognosis in terms of 
cardiovascular events. However, despite regular follow up visits at specialized centers, 
half of these patients still complain of frequent anginal episodes. Thus, while seemingly 
a benign condition, syndrome X is plagued by persistence of symptoms, which seriously 
limits quality of life of patients, and represents a major clinical and social issue.
3:30 p.m.
1041-160 Bivalirudin Versus Heparin Alone in Low-Risk 
Percutaneous Coronary Intervention: Indirect Versus 
Direct Comparison
Sanjay Kaul, Babak Azarbal, Prediman K. Shah, George A. Diamond, Cedars-Sinai 
Heart Institute, Los Angeles, CA, UCLA Medical Center, Los Angeles, CA
BACKGROUND: Indirect comparisons (IC) have been previously validated as effective 
tools for estimating relative effects of competing interventions when evidence from direct 
comparison (DC) is not available.
OBJECTIVE: To compare results of IC and DC of bivalirudin (Bv) vs heparin (Hep) alone 
on ischemic and bleeding complications in low-risk PCI.
METHODS: Relevant studies chosen for IC included a common comparator (abciximab + 
Hep): REPLACE-2 (Bv vs abciximab + Hep) and ISAR REACT (abciximab + Hep vs Hep). 
The IC was performed according to the formula:
RRBv vs Hep = (RRBv vs abciximab + Hep) x (RRabciximab + Hep vs Hep); RR = relative risk. The results of 
IC were compared with a DC of Bv vs Hep based on ISAR REACT-3. The studies were 
comparable in terms of patient population, outcomes, and concomitant therapies (>85% 
thienopyridine pretreatment). An interaction test was conducted to assess whether 
treatment outcomes differed between IC and DC.
RESULTS (Table): Compared with Hep alone, IC yielded a nonsigniﬁcant 27% increase 
in ischemic composite endpoint (death/MI/TVR) compared with a nonsigniﬁcant 16% 
increase with Bv in the DC (between-comparison P = 0.75). While the point estimates 
for bleeding were in opposite directions, the IC and DC results did not differ signiﬁcantly 
(interaction P value >0.05).
CONCLUSION: The results of IC accurately predicted the ﬁndings observed in a direct 
head-to-head comparison that Bv does not provide superior efﬁcacy or safety compared 
with Hep alone during low-risk PCI. . 
Bivalirudin vs Heparin Alone in Low-risk PCI
30-day 
Outcome
Bivalirudin 
vs
Abcix + 
heparin
(REPLACE-2)
Abcix+heparin
vs heparin 
(ISAR REACT)
Bivalirudin 
vs
heparin
(Indirect
Comparison)
Bivalirudin 
vs
heparin
(ISAR
REACT-3)
Interaction
P value
Death/MI/
urgent TVR
1.21
(0.93-1.58)
1.05
(0.69-1.59)
1.27
(0.77-2.08)
1.16
(0.91-1.49) 0.75
TIMI major 
bleeding
0.73
(0.41-1.32)
1.50
(0.62-3.66)
1.10
(0.38-3.17)
0.48
(0.23-0.98) 0.21
Transfusion 
rate
0.66
(0.46-0.94)
2.60
(1.25-5.37)
1.72
(0.76-3.85)
0.73
(0.46-1.16) 0.07
Data are shown as RR and 95% CI. Abcix: abciximab; TVR = target vessel 
revascularization; MI = myocardial infarction
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0912-5 Serial Inﬂammatory Biomarkers to Predict 
Angiographic and Clinical Outcomes in Patients With 
STEMI Undergoing Fibrinolysis: A CLARITY-TIMI 28 
Substudy
Michelle O’Donoghue, David A. Morrow, Songtao Jiang, Nader Rifai, Christoph Bode, C. 
Michael Gibson, Robert E. Gerszten, Christopher P. Cannon, Marc S. Sabatine, Brigham 
and Women’s Hospital, Boston, MA, Massachusetts General Hospital, Boston, MA
Background: Inﬂammation contributes to atherothrombosis. The utility of serial 
inﬂammatory biomarkers for predicting angiographic and clinical outcomes in ST-elevation 
myocardial infarction (STEMI) remains unknown.
Methods: C-reactive protein (CRP) and myeloperoxidase (MPO) were measured at 
baseline and prior to angiography (CRP cohort n=1250; MPO case-cohort n=701) in 
CLARITY-TIMI 28, a randomized trial of clopidogrel vs placebo in STEMI and ﬁbrinolysis. 
Angiography was performed at 2-8 d; events followed to 30 d. Analyses were adjusted for 
cardiac risk factors, timing and type of lytic therapy, Killip class, and peak CK-MB.
Results: Patients with a baseline CRP >2.8 mg/L (median) compared with those below 
had a higher risk of CV death or heart failure (CVD/HF) (adj HR 2.1, 1.2-3.8, P=0.02). Pre-
angiographic CRP in the top quartile was associated with a higher odds of intracoronary 
thrombus at angiography (adj Q4:Q1 OR 1.6, 1.03-2.6, P=0.04). MPO levels >232 pM were 
associated with a higher risk of CVD/HF (adj HR 3.0, 1.1-8.2, P=0.03). Pre-angiographic 
MPO in the top quartile was associated with higher odds of intracoronary thrombus 
(adj OR 2.3, 1.1-5.1, P=0.03). The combination of CRP and MPO provided incremental 
information for predicting CVD/HF and the presence of intracoronary thrombus (Figure).
Conclusions: In STEMI, serial measurement of CRP and MPO provide signiﬁcant and 
complementary predictive ability for clinical and angiographic outcomes independent of 
traditional risk factors.
5:15 p.m.
0912-6 Cytochrome P450 2C19 Polymorphism in Young Post-
Myocardial Infarction Patients Treated With Clopidogrel
Jean-Philippe Collet, Jean-Sebastien Hulot, Ana Pena, Eric Villard, Jean-Baptiste 
Esteve, Johanne Silvain, Laurent Payot, Guillaume Cayla, Farzin Beygui, Delphine 
Brugier, Christian Funck-Brentano, Gilles Montalescot, Hopital Pitie-Salpetriere Institut de 
Cardiologie, Paris, France, Hopital Pitié-Salpetriere Unite de Pharmacologie, Paris, France
Background: The frequent genetic functional variant 681 G>A (also called *2) of 
cytochrome P450 2C19 is an important contributor to the wide interindividual variability of 
the antiplatelet effect of clopidogrel. We evaluated whether the CYP2C19*2 polymorphism 
has an impact on the long-term clinical prognosis of young patients (< 45years) who 
survived a ﬁrst myocardial infarction and were chronically treated with clopidogrel.
Methods: 259 patients underwent CYP2C19*2 determination and had a median [25th-
75th] clopidogrel exposure time of 1.07 [0.28-3.0] years. The primary endpoint was a 
composite of death, myocardial infarction and urgent coronary revascularization occurring 
during exposure to clopidogrel. The key secondary endpoint was angiographically proven 
stent thrombosis.
Results: Baseline characteristics were balanced between carriers (heterozygous *1/*2, 
n=64; homozygous *2/*2, n=9) and non carriers (n=189) of the CYP2C19*2 genetic 
variant. The primary end point occurred more frequently in carriers than in non carriers 
of the CYP2C19*2 genetic variant (HR, 3.69; 95% CI, 1.69 to 8.05; p=0.0005). Stent 
thrombosis was also signiﬁcantly more frequent in carriers than in non carriers (HR 6.02; 
95%CI 1.81 to 20.04, p=0.0009). The detrimental effect of the CYP2C19*2 genetic variant 
persisted from 6 month after clopidogrel initiation up to the end of follow-up (HR 3.0; 
95%CI, 1.27 to 7.10; p=0.009). Following multivariable analysis, the CYP2C19*2 genetic 
variant was the unique independent predictor of cardiovascular events (HR 4.04; 95% CI 
1.81-9.02, p=0.0006).
Conclusion: The CYP2C19*2 genetic variant is a major determinant of prognosis in 
young post-MI patients on clopidogrel treatment. 
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0912-3 Differential Protein Biomarker Expression and Their 
Time-Course in Patients With a Spectrum of Stable 
and Unstable Coronary Syndromes in the Integrated 
Biomarker and Imaging Study-1 (IBIS-1)
Joanna J. Wykrzykowska, Hector Garcia-Garcia, Andrew Zalewski, Patrick W. 
Serruys, Thoraxcenter Erasmus MC, Rotterdam, The Netherlands, GlaxoSmithKline, 
Philadelphia, PA
Background: Inﬂammation is an established component of coronary disease 
pathogenesis and inﬂammatory biomarkers have been correlated with increased risk 
of events. IBIS-1 was a single center pilot study to assess invasive and non-invasive 
methods of identifying plaques with high risk/vulnerable features and to correlate this with 
circulating biomarker expression. We assessed the expression of standard biomarkers 
at index catheterization, three and six months post-procedure. We screened for novel 
markers using MSI ampliﬁed protein microarray (170 analytes).
Methods and Results: CRP and IL6 as well as L(p)PLA2 levels were observed to 
decrease in patients with acute coronary syndromes over time. With the exception of 
CRP and IL-6, the expression of classical biomarkers did not correlate with the presence 
of echogenic plaque on IVUS gray scale imaging or palpography. Proteomic microarray 
testing was performed in duplicate in 66 of the 89 patients with stable angina or acute 
coronary syndromes (including non-ST elevation MI and ST elevation MI). 78 analytes 
showed expression differences between baseline and a time point post-procedure 
in a subgroup of patients. This complex data set was further compressed using 
hierarchical clustering and principal component analysis and yielded two subsets of 
proteins demonstrating differences in abundance between two groups. The ﬁrst subset 
displayed initial up-regulation and decreased over time in one patient subgroup (D-dimer, 
Hepatocyte Growth factor, CXC L9/ MIG, platelet factor 4/ CXC L4, CTACK, C-6 Kine, 
follistatin, FGF-7). The second subset increased over time (PAI-1- anti-apoptotic protein 
and I-309 - chemokine induced on the human endothelium by Lp(a)). Only two analytes 
MIP-1d, TGF-b RIII showed change in expression at steady-state from 3 to 6 months.
Conclusions: Biomarkers identiﬁed by this exploratory analysis all appear to denote 
increased pro-coagulability, endothelial activation/injury or monocyte trafﬁcking into 
the plaque. All these mechanisms are at the root of pathogenesis of vulnerable plaque. 
Further large vulnerable plaque natural history studies are needed to better deﬁne 
patients at risk.
4:45 p.m.
0912-4 Growth-Differentiation Factor-15 for Risk Assessment 
in Patients With an Ongoing Non-ST-Elevation Acute 
Coronary Syndrome and After Clinical Stabilization
Kai M. Eggers, Kai C. Wollert, Bo Lagerqvist, Bertil Lindahl, Lars Wallentin, Tibor Kempf, 
University Hospital Uppsala, Uppsala, Sweden, Hannover Medical School, Hannover, 
Germany
Background: Growth-differentiation factor-15 (GDF-15) is a stress-responsive TGF-B
cytokine family member that has emerged as a prognostic biomarker in patients with a 
non-ST-elevation acute coronary syndrome (NSTE-ACS). The aim of the present study 
was to assess the time course and the prognostic relevance of GDF-15 levels in patients 
with an ongoing NSTE-ACS, and during a 6-month period after clinical stabilization.
Methods: GDF-15 was measured at randomization, after 6 weeks, 3 and 6 months in 950 
NSTE-ACS patients included in the FRISC II (FRagmin and Fast Revascularization during 
InStability in Coronary artery disease)-study. Patients were followed for the composite 
endpoint of death or recurrent myocardial infarction for 5 years.
Results: Median GDF-15 levels decreased from 1357 ng/L at randomization to 1302 
ng/L at 6 months. Patients randomized to an invasive strategy had a more pronounced 
decrease of GDF-15 (1316 to 1236 ng/L; p<0.001) as compared to patients randomized 
to a conservative strategy (1305 to 1268 ng/L; p=0.11). GDF-15 was consistently related 
during the 6-month observation period to cardiovascular high-risk features such as 
traditional risk factors, biomarkers of renal dysfunction (eGFR), inﬂammation (CRP) 
and hemodynamic stress (NT-proBNP). GDF-15 was an independent predictor for the 
composite endpoint both at randomization (adjusted HR 1.8 [1.1-2.8]; p=0.02) and 6 
months (adjusted HR 2.1 [1.1-3.9]; p=0.02). Patients with persistently elevated GDF-15 
levels > 1800 ng/L had a very high risk of the composite endpoint (n=47/141 [33.3%]) 
whereas patients with GDF-15 < 1200 ng/L at randomization had a low risk regardless of 
6-month GDF-15 levels (n=39/469 [8.3%]).
Conclusions: GDF-15 is a strong and independent risk predictor in both ongoing NSTE-
ACS and at later follow-up. The changes of GDF-15 levels between both randomization 
arms might reﬂect the prognostic beneﬁts related to an invasive strategy with early 
coronary revascularization. The relative stability of GDF-15 levels over time together with 
the results from the prognostic evaluation indicate a clinical utility of cut-offs of 1200 ng/L 
and 1800 ng/L both in ongoing NSTE-ACS and during later follow-up.
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1050-126 Promotion of Coronary Collateral Growth by External 
Counterpulsation in Patients With Coronary Artery 
Disease
Steffen Gloekler, Stefano F. de Marchi, Tobias Rutz, Pascal Meier, Kerstin Wustmann, 
Stefano F. Rimoldi, Mario Togni, Christian Seiler, University Hospital, Bern, Switzerland
Background:Arteriogenesis is a promising therapeutic option for patients with extensive 
coronary artery disease (CAD). External Counterpulsation (ECP) augments diastolic 
arterial pressure by sequential leg cuff compressions with increase in coronary perfusion. 
Augmented coronary perfusion with elevated laminar shear stress at the endothelial cell 
layer has been shown to induce arterial remodelling and collateral growth (arteriogenesis). 
It is unclear yet whether the clinical beneﬁt of ECP is related to its hypothesized effect of 
collateral growth. The purpose of the present study is to evaluate the effects of ECP on 
coronary collateral function.
Methods:Fifteen patients with stable CAD were included in this single-blind, sham-
controlled study. They were randomly assigned to 30 hours of ECP treatment (n=9: cuff 
inﬂation pressure 300mmHg in 8 patients and 120mmHg in 1 patient.) or 30 hours of 
sham-ECP treatment (n=6: cuff inﬂation pressure 80mmHg) over three weeks, i.e., 2 
hours per session. Invasive coronary collateral assessment was performed at baseline 
and after ECP. Collateral Flow Index (CFI) was determined invasively during balloon 
occlusion by means of a pressure guide wire distal to the balloon-occluded artery and 
was calculated as: (Poccl-CVP)/(Pao-CVP); Poccl=mean coronary occlusive pressure; 
Pao=mean aortic pressure; CVP=central venous pressure.
Results:In the ECP group, CFI changed from 0.122 +- 0.06 to 0.210 +-0.07 (p= 0.0002) 
and in the sham-ECP group from 0.165 +-0.08 to 0.130 +-0.06 (p=0.04). The treatment-
induced difference in CFI was +0.088 +-0.07 in the ECP group and -0.044 +- 0.07 in the 
sham-ECP group (p=0.00005).
Conclusions: This ﬁrst clinical study investigating the effect of ECP on coronary collateral 
function in patients with CAD clearly documents efﬁcacy. The clinical beneﬁt of ECP for 
CAD patients may be at least partly explained by its arteriogenetic effect.
9:30 a.m.
1050-127 Signiﬁcant Association of Left Mammary Arterial Wall 
Thickness With Arterial Stiffness in Hypertensive 
Patients With Coronary Artery Disease
Maria Marketou, Anastassios Koutsopoulos, Theoxaris Xenikakis, George Kochiadakis, 
Konstantina Dambaki, Polichronis Malliotakis, John Hassoulas, Efstathios Stathopoulos, 
Panos Vardas, Heraklion University Hospital, Heraklion, Greece
Background: Pulse wave velocity (PWV) measurements are useful for evaluating arterial 
stiffness, which reﬂects the overall opposition of large arteries to the pulsatile effects of 
ventricular ejection, and has independent predictive value for cardiovascular events. 
However, there is lack of data regarding the structural changes of the arterial wall in humans 
with increased PWV. We investigated the relation of PWV with the left mammary arterial 
wall thickness and ﬁbrosis in hypertensive patients with coronary artery disease (CAD).
Methods: Segments of the left mammary artery were obtained from 11 hypertensive 
patients (7 men, aged 67 ± 10 years) who underwent coronary artery bypass surgery 
because of 3-vessel stable CAD. A day before, PWV was measured noninvasively by 
Complior in all patients. Five μm tissue sections were cut and stained with hematoxylin 
and eosin for the evaluation of artery wall thickness and with Picrosirius Red for the 
evaluation of ﬁbrosis. In each artery, we determined the percentage of total and media 
ﬁbrosis, the wall thickness/lumen ratio, the media thickness and the media/lumen ratio.
Results: The carotid-femoral PWV showed a strong correlation with the left mammary 
arterial wall thickness/lumen ratio and the media thickness in patients with CAD (r=0.72, 
p <0.01, and r=0.62, p=0.02, respectively). No signiﬁcant association was found between 
the percentage of total and media ﬁbrosis with PWV.
Conclusions: Left mammary arterial wall and media thickness were signiﬁcantly 
associated with pulse wave velocity in hypertensive patients with CAD. Our data 
contribute to the understanding of the structural changes of the arterial wall that underlie 
the increased arterial stiffness in those patients.
9:30 a.m.
1050-128 Noninvasive Pressure Waveform Analysis in Women 
With Chest Pain and Nonobstructive Coronary Artery 
Disease
Wilmer W. Nichols, Scott J. Denardo, B. Delia Johnson, Barry L. Sharaf, Carl J. Pepine, 
University of Florida, Gainesville, FL
Background: Early return of reﬂected blood pressure (BP) waves from the lower 
body augments aortic systolic BP and increases systolic pressure-time index (SPTI) 
and wasted LV energy which increase left ventricular (LV) afterload and myocardial O2
demand. Such changes are due to increased arterial stiffness and pulse wave velocity 
(PWV) and can contribute to myocardial ischemia and angina pectoris, especially when 
coronary artery (CA) perfusion pressure is jeopardized. We sought to determine wave 
reﬂection characteristics and diastolic BP timing in a subgroup of Women’s Ischemia 
Syndrome Evatuation (WISE) participants referred for coronary angiography for suspected 
myocardial ischemia but without obstructive CAD.
Methods: Radial artery BP waveforms were recorded by applanation tonometry and 
central aortic BP waveforms derived. Data were collected from 63 WISE participants and 
compared to an asymptomatic reference group of 65 women matched for age, height, 
BMI, mean arterial BP and heart rate.
Results: Compared to the reference group, WISE participants had higher aortic systolic 
5:30 p.m.
0912-7 CRP1444, CD14 and MMP3 Polymorphisms Correlate 
With Coronary Plaque Volume in Patients With 
Coronary Artery Disease: IVUS Data From the ENCORE 
Trials
Matthias Hermann, Dieter Fischer, Michael M. Hoffmann, Theo Gasser, Kurt Quitzau, 
Thomas Meinertz, Thomas Munzel, Thomas F. Luscher, University Hospital Zurich, 
Zurich, Switzerland
Background: Several single-nucleotide polymorphisms (SNPs) have been linked to 
progression of atherosclerosis, coronary plaque size and incidence of acute coronary 
events. However, only few data from intravascular ultrasound (IVUS) studies on plaque 
size and correlation with SNPs are available.
Methods: In 173 out of 734 patients with established coronary artery disease from the 
ENCORE trials coronary plaque volume was assessed by IVUS and vessel size by 
quantitative coronary angiography. All 173 patients were genotyped for polymorphisms of 
CD14 C(-260)T, CRP C(+1444)T, and MMP3 promotor 5A/6A, using the single-nucleotide 
polymorphism polymerase chain reaction (SNP PCR) approach.
Results: Higher ratios of plaque volume/vessel size were observed in patients with the 
CRP 1444TT (n=84), MMP3 A5A5 (n=48) and CD14 260TT (n=62) genotypes (p= 0.002, 
p=0.016 and p=0.026, respectively). Baseline characteristics were comparable for all 
groups except for use of beta-blockers in the MMP group (p=0.033).
Conclusion: In patients with established and stable coronary artery disease the CRP 
1444TT, MMP3 A5A5 and CD14 260TT variants are associated with larger coronary 
plaque volume independently of concomitant cardiovascular risk factors. 
Plaque volume / vessel size p-value
CD14 (n=33)  CC 0.285 ± 0.103
CD14 (n=78)  CT 0.294 ± 0.113
CD14 (n=62)  TT 0.335 ± 0.128 0.026
CRP1444 (n=11) CC 0.286 ± 0.123
CRP1444 (n=78) CT 0.284 ± 0.110
CRP1444 (n=84) TT 0.331 ± 0.122 0.002
MMP3 (n=50) 6A/6A 0.268 ± 0.126
MMP3 (n=75) 5A/6A 0.310 ± 0.108
MMP3 (n=48) 5A/5A 0.344 ± 0.114 0.016
ACC.POSTER CONTRIBUTIONS
1050
Stable Ischemic Syndrome; 
Cardiopulmonary Resuscitation/
Emergency Cardiac Care/Shock; 
Coronary Artery Bypass Surgery/
Innovative Techniques
Tuesday, March 31, 2009, 9:30 a.m.-12:30 p.m.
Orange County Convention Center, West Hall D
9:30 a.m.
1050-125 Albuminuria, the Glomerular Filtration Rate, and 
Angiographically Determined Coronary Atherosclerosis
Philipp Rein, Christoph H. Saely, Lorenz Risch, Stefan Beer, Alexander Vonbank, 
Christian Boehnel, Vlado Jankovic, Ulrich Neyer, Heinz Drexel, Vorarlberg Institute for 
Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria, Private University in the 
Principality of Liechtenstein, Triesen, Liechtenstein
Background: We aimed at investigating the association of albuminuria and of 
the glomerular ﬁltration rate (eGFR) with angiographically determined coronary 
atherosclerosis.
Methods: Urinary albumin and creatinine concentrations were measured in 856 
consecutive patients undergoing coronary angiography for the evaluation of suspected or 
established stable coronary artery disease (CAD); the eGFR was calculated by the Mayo 
clinic quadratic equation.
Results: From our patients, 278 had an eGFR <90ml/min/1.73m², and 204 had albuminuria 
(ACR q30 mg/g). When compared to subjects with both normal eGFR and normal urinary 
albumin excretion (n = 467), the prevalence of signiﬁcant coronary stenoses (i.e. stenoses 
with lumen narrowing q50%) was signiﬁcantly higher in patients with normal eGFR and 
albuminuria (n = 111) and in those with decreased eGFR and albuminuria (n = 93), but 
similar in those (n = 185) who had decreased eGFR but not albuminuria (51.8 vs. 64.0%, 
p = 0.021; 51.8 vs. 65.8%, p = 0.015; and 51.8 vs. 49.2%.; p = 0.545, respectively). 
Concordantly, in logistic regression analysis the ACR but not the eGFR proved predictive 
of signiﬁcant coronary stenoses after adjustment for age, gender, diabetes, body mass 
index, LDL cholesterol, HDL cholesterol, blood pressure and smoking, with odds ratios 
(OR) of 1.26 [95% CI 1.02 - 1.56]; p = 0.032 and 1.05 [0.86 - 1.28]; p = 0.63, respectively. 
Further, in line with our results from univariate analyses, the association between the 
ACR and signiﬁcant coronary stenoses remained signiﬁcant after further adjustment for 
eGFR (OR = 1.28 [1.03 - 1.60]; p = 0.025).
Conclusion: Albuminuria is strongly associated with angiographically determined 
coronary atherosclerosis, independent of conventional cardiovascular risk factors and of 
the eGFR.
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Conclusions - Despite widely used non-invasive testing, only a minority of new, 
symptomatic pts referred for CATH have clinically signiﬁcant CAD. The rate is particularly 
low in women.
9:30 a.m.
1050-131 Association Between Genetic Variants on the 
Chromosomal Loci 9p21.3, 6q25.1, and 2q36.3 and 
Angiographically Determined Coronary Artery Disease
Christoph H. Saely, Axel Muendlein, Simone Geller-Rhomberg, Gudrun Sonderegger, 
Philipp Rein, Stefan Beer, Alexander Vonbank, Heinz Drexel, Vorarlberg Institute for 
Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria, Private University in the 
Principality of Liechtenstein, Triesen, Liechtenstein
Background: Recently, the chromosomal loci 9p21.3, 6q25.1, and 2q36.3, represented by 
their respective leading single nucleotide polymorphisms (SNPs) rs1333049, rs6922269 
and rs2943634 have been linked with a history of coronary artery disease (CAD) by 
genome-wide association studies. Whereas the association of variant rs1333049 with 
CAD was analysed in several subsequent studies, replication studies of SNPs rs6922269 
and rs2943634 are still missing.
Methods: Therefore, to further elucidate the role of variants rs1333049, rs6922269, and 
rs2943634 on the molecular genetics of CAD, we performed genotyping of these SNPs in 
two large cohorts of consecutive Caucasian patients undergoing coronary angiography for 
the evaluation of suspected or established stable CAD, comprising 671 and 940 subjects, 
respectively; coronary stenoses with lumen narrowing q50% were considered signiﬁcant.
Results: In models of dominant inheritance SNP rs1333049 was signiﬁcantly associated 
with an increased risk of signiﬁcant coronary stenoses in both study cohorts, with 
adjusted odds ratios (OR) of 1.71 [1.15-2.52]; p = 0.007 and 1.55 [1.10-2.18]; p=0.012, 
respectively. A signiﬁcant association of variant rs6922269 with an increased susceptibility 
for CAD could be observed in neither cohort. Carriers of the A allele of variant rs2943634 
showed a signiﬁcant association with an increased risk of signiﬁcant coronary stenoses 
in the second cohort (OR=1.41 [1.06-1.86]; p=0.018), but not in the ﬁrst cohort (OR=0.85 
[0.57-1.26]; p=0.420).
Conclusion: We conclude that variant rs1333049 is signiﬁcantly associated with 
angiographically determined CAD. By contrast, SNP rs6922269 did not show any impact 
on the presence of signiﬁcant stenoses. The association between variant rs2943634 and 
CAD warrants further investigation.
9:30 a.m.
1050-132 Use of Pulsed Electromagnetic Fields For Ischemic 
Cardiomyopathy Therapy (EFFECT Trial): A 
Randomized, Double-Blind, Parallel, Placebo-
Controlled, Prospective Trial 
Michael Y. H. Shen, Craig R. Asher, Mary Chandy, Tudor Scridon, Eric Dandes, Eduardo 
Vargas, Adrian Hernandez, Howard S. Bush, Kenneth R. Fromkin, Louis Ignarro, Arthur 
Pilla, Gian M. Novaro, Cleveland Clinic Florida, Weston, FL, Columbia University, New 
York, NY
Many studies have shown that pulsed electromagnetic ﬁelds (PEMF) are effective in 
treating chronic wounds, avascular necrosis & chronic pain by improving blood ﬂow/
angiogenesis via NO/cGMP pathway. This is the 1st pilot trial to evaluate PEMF safety 
& efﬁcacy in pts with chronic angina and ischemic heart disease (IHD). Methods:
Pts (n=33) with severe IHD (>70% stenosis) & angina, on max medical therapy & not 
amenable to revascularization, were randomized into sham (S, n=17) or treatment (T, 
n=16) groups. A PEMF device was put over the left chest (4msec, 27.12MHz, 50mG at 
2Hz, Ivivi Technologies) 30 min BID for 3 mon. Vital signs (VS), labs (C24), Seattle Angina 
Questionnaire, Echo & SPECT (17 segment summed stress score, SSS) were performed 
at baseline, 1, 3 & 5 mon. Continuous home telemetry performed 1 wk pre & post PEMF. 
Results: Two pts in S and 1 pt in T group were withdrawn due to adverse events. No 
signiﬁcant differences in VS, labs, tele or LVEF were found between the groups. Anginal 
score & physical capacity were signiﬁcantly improved with PEMF. Conclusions: This is 
the ﬁrst study using PEMF in pts with IHD. The trial shows that PEMF is safe to use 
and effective improving symptoms in pts with IHD and failed medical & revascularization 
options. This unique device is non-invasive, non-pharmacological & self-operable at 
home. Future studies are needed to investigate mechanistic effects, perfusion changes 
and clinical outcomes in large trials. 
(121±16 vs 115±14 mmHg, P<0.03) and pulse (40±12 vs 36±7.9 mmHg, P<0.04) BP. 
These differences were associated with an increase in augmented BP (12±5.1 vs 9.5±4.3 
mmHg, P<0.003), augmentation index (30±7.6 vs 25±8.9%, P<0.001) and reﬂected wave 
duration (194±21 vs 173±24 msec, P<0.001). These modiﬁcations in WISE participants 
were associated with an increase in ejection duration (330±23 vs 309±23 msec, P<0.001), 
SPTI (2562±398 vs 2344±408 units, P<0.003) and wasted LV energy (4806±2330 vs 
3534±1818 dyne-sec-cm−2, P<0.001) and a decrease in pulse BP ampliﬁcation (1.2±0.12 
vs 1.3±0.13, P<0.04), the myocardial viability ratio (1.3±0.25 vs 1.5±0.20, P<0.01) and 
the diastolic BP time fraction (DPTF) (0.61±0.04 vs 0.64±0.04, P<0.01).
Conclusions: WISE participants have changes in wave reﬂection characteristics and 
diastolic timing that increase LV afterload, myocardial O2 demand and wasted LV energy 
and reduce coronary perfusion. These alterations in cardiovascular function contribute to 
an undesirable mismatch in the myocardial O2 supply/demand ratio that favors ischemia 
and angina pectoris.
9:30 a.m.
1050-129 Incident Diabetes Mellitus in Patients With Stable 
Coronary Artery Disease
Apurva Badheka, Neha Garg, Mohammad A. Kizilbash, Samrat Bhat, Ankit Rathod, 
Sony Jacob, Luis Afonso, Wayne State University, Detroit, MI
Background: Predictors and signiﬁcance of new onset diabetes (NOD) in patients with 
stable coronary arterial disease (CAD) are poorly understood. Whether disparities in 
incidence of NOD exist among substrata of CAD patients is unclear.
Methods: The NHLBI Limited access dataset of the multicenter ‘Prevention of Events 
with Angiotensin Converting Enzyme Inhibition Trial’ (n=8290) comparing trandolapril 
versus placebo in patients with CAD and preserved ejection fraction was used. Patients 
with documented myocardial infarction (MI) formed Group I (n=3856). Groups II (n=1408) 
and III (n=994) comprised patients post revascularization (CABG and PTCA respectively) 
without history of MI. Group IV (n=651) included patients with non obstructive (a50%)
vessel stenosis (NOCAD) without prior MI or revascularization.
Results: Incident NOD occurred in 733 patients over mean follow-up of 4.6 yrs. 
Statistically signiﬁcant covariates (HR, 95% CI) associated with NOD were use of beta 
blocker (0.66, 0.55-0.80), trandolapril (0.74, 0.62-0.87) and BMI (1.11, 1.09-1.12). Groups 
III and IV were at signiﬁcantly higher risk of NOD (1.62, 1.30-2.02 and 1.58, 1.22-2.04) as 
compared to Group I (ﬁgure). NOD was associated with increased composite outcome of 
cardiovascular death, MI, PTCA or CABG (1.25, 1.07-1.46).
Conclusion: Use of beta blockers and trandolapril reduced risk while elevated BMI and 
presence of NOCAD or PTCA conferred higher risk for developing NOD. Incident diabetes 
portends poor prognosis in stable CAD. 
9:30 a.m.
1050-130 Differential Prevalence of Clinically Signiﬁcant 
Coronary Artery Disease Among Symptomatic Men and 
Women Referred for Coronary Artery Catheterization
Whittemore G. Tingley, Eric J. Topol, Szilard Voros, Alexandra J. Lansky, Robert S. 
Schwartz, William E. Kraus, Amy J. Sehnert, May Yau, Michael R. Elashoff , Steven 
Rosenberg, Philip Sager, CardioDx, Palo Alto, CA
Background - The evaluation of coronary artery disease (CAD) in symptomatic women 
is often considered more challenging than in men. Despite advances in non-invasive 
diagnostic testing, the prevalence of signiﬁcant CAD is little studied in women and men 
referred for coronary catheterization (CATH).
Methods - We addressed this issue in 875 pts enrolled at 31 US centers in the PREDICT 
trial, which is prospectively evaluating the ability of peripheral blood gene expression to 
identify CAD. All pts were referred for CATH based on local practice criteria and were 
symptomatic but not previously known to have CAD or myocardial infarction. CAD severity 
was evaluated by local site reads and by a blinded quantitative coronary angiography 
(QCA) core lab.
Results - The mean age was 58 (±12) yrs, 412 (47%) were women and 210 (24%) had 
diabetes. Stable or unstable symptoms were present in 78% and 22% of pts and 675 
(77%) had at least one non-invasive test (including 609 stress nuclear tests or echos). 
Based on local CATH reads, only 243 (28%) of pts had obstructive CAD (at least one 
lesion >70% diameter stenosis or a left main lesion >50%): 38% of men and 16% of 
women (P<0.0001), despite similar clinical variables. 490 (56%) pts had no or minimal 
disease (<25% lesion). QCA analysis yielded lower numbers with obstructive CAD (men 
vs women P<0.0001; ﬁgure).
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1050-135 Signiﬁcant Impact of Genetic Variants on Chromosomal 
Locus 1p13.3 on Serum LDL-Cholesterol and on 
Angiographically Characterized Coronary Artery 
Disease
Christoph H. Saely, Axel Muendlein, Simone Geller-Rhomberg, Gudrun Sonderegger, 
Philipp Rein, Stefan Beer, Alexander Vonbank, Heinz Drexel, Vorarlberg Institute for 
Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria, Private University in the 
Principality of Liechtenstein, Triesen, Liechtenstein
Background: Recently, genome-wide association studies identiﬁed a signiﬁcant impact 
of a novel locus on chromosome 1p13.3 on serum LDL-cholesterol, which is causally 
linked to coronary artery disease (CAD). Potential associations between variants on this 
locus and angiographically characterized coronary atherosclerosis are unknown.
Methods: We performed genotyping of variants rs599839, rs646776, and rs4970834 on 
chromosome 1p13.3 in a large cohort of 1610 consecutive Caucasian patients undergoing 
coronary angiography for the evaluation of CAD.
Results: The rare alleles of variants rs599839, rs646776, and rs4970834 were signiﬁcantly 
associated with decreased serum LDL-cholesterol (p= 0.003, p<0.001, and p= 0.005, respectively). 
Further, carriers of the rare alleles of variants rs599839 and rs646776 were at a signiﬁcantly lower 
risk of signiﬁcant coronary stenoses q50% than subjects who were homozygous for the frequent 
allele, with OR of 0.78 [0.63-0.96]; p = 0.019 and 0.74 [0.60-0.91]; p = 0.004, respectively. After 
multivariate adjustment including LDL cholesterol, the protective effect of the rare allele of variant 
rs646776 on CAD risk remained signiﬁcant (OR = 0.77 [0.61-0.97], p = 0.026).
Conclusion: We conclude that chromosomal locus 1p13.3 is signiﬁcantly associated 
with both serum LDL-cholesterol and angiographically characterized coronary 
atherosclerosis.
9:30 a.m.
1050-136 Cool It: Therapeutic Hypothermia for Cardiac Arrest in 
Patients With ST-Elevation Myocardial Infarction and 
Unique Beneﬁts With Combined Treatment
Leah A. Swanson, Kalie M. Edelstein, William M. Parham, Christopher E. Kapsner, 
Barbara T. Unger, Mary E. Kalb, James Hodges, M. Nicholas Burke, Anil K. Poulose, 
Timothy D. Henry, Michael R. Mooney, Minneapolis Heart Institute Foundation at Abbott 
Northwestern Hospital, Minneapolis, MN
Background: Out-of-hospital cardiac arrest (OOHCA) with ST elevation myocardial 
infarction (STEMI) leads to poor neurologic outcome. Therapeutic hypothermia (TH) has 
been shown to improve survival and neurologic outcome following OOHCA but has not 
been performed simultaneously with STEMI percutaneous coronary intervention (PCI).
Methods: Following the Level 1 transfer program for STEMI, the Cool It program 
established a regional TH system. OOHCA pts with STEMI are transferred to the cath 
lab for PCI. TH is implemented in the cath lab before PCI, and TH at 33ºC is continued 
for 24 hrs. Cerebral function after TH was measured by the ﬁve point Pittsburgh Cerebral 
Performance Category (CPC) scale. CPC 1 and 2 are favorable neurologic outcomes.
Results: From 2/06 to 5/08, 85 pts were treated with TH, 44 were Level 1 STEMI pts with 
59% of STEMI pts in cardiogenic shock. TH was initiated within 150 minutes in Level 1 
STEMI pts and 153 minutes in non-STEMI pts (p=0.88). For each hour TH was delayed, 
the relative risk of death increased by 20%. Compared to non-STEMI pts, STEMI pts 
had a higher survival rate (64% vs. 41%, p=0.052) and neurologic outcome (100% vs. 
82%, p=0.048).
Conclusions: OOHCA pts with STEMI displayed unique beneﬁts from TH with 
high survival rates and positive cognitive outcomes. Our results indicate the need for 
simultaneous execution of TH and STEMI protocols in OOHCA patients with acute MI. 
Given these positive outcomes, TH should be included as a part of acute MI programs 
that function as tertiary centers.
n=30 Baseline 1 mon 3 mon 5 mon
Angina Score
(100 highest stability)
S n=15 63±31 53±16 62±23 63±16
T n=15 57±18 69±25* 78±21* 87±16*
Physical Capacity
(100 highest function)
S n=15 57±26 56± 24 54±24 49±25
T n=15 62±24 69±22 68±24 75±18*
Stress SSS
S n=15 19±11 19±11 19±11 19±12
T n=15 16±9 14±8 15±8 14±8
P<0.01 S vs. T group, Kruskal-Wallis rank test & Wilcoxon rank sum test
9:30 a.m.
1050-133 Granulocyte-ColonyStimulatingFactor (G-CSF) 
Promotes Coronary Collateral Growth and Myocardial 
Microvascular Function in Patients With Coronary 
Artery Disease: A Randomized, Double-Blind, Placebo-
Controlled Study
Steffen Gloekler, Pascal Meier, Rainer Zbinden, Stefano F. de Marchi, Tobias Rutz, 
Andreas Indermuehle, Rolf Vogel, Stephan Windecker, Christian Seiler, University 
Hospital, Bern, Switzerland
Background:Coronary artery disease (CAD) is one of the leading causes of death 
in industrialized countries. About 1/5 to 1/3 of CAD patients are not suitable for the 
traditional revascularization therapies. Therefore, alternative strategies, like collateral 
growth promotion (arteriogenesis), are warranted. Since the amount of collateral ﬂow 
is directly related to survival, prognosis of CAD may be improved by arteriogenesis. 
Monocytes play a pivotal role in arteriogenesis. The purpose of the present study was to 
investigate the efﬁcacy and safety of G-CSF as a monocyte-stimulating factor with regard 
to collateral growth.
Methods:52 patients (age 63 +- 10 years) with CAD were prospectively included in the 
study, and they received G-CSF (5 micrograms/Kg per day, s.c.) or placebo during 14 
days. The study protocol comprised invasive measurement of functional collateral ﬂow 
and fractional ﬂow reserve (FFR) at baseline and follow-up. Collateral Flow Index (CFI) 
was determined during balloon occlusion by a pressure guide wire distal to the balloon-
occluded artery, and was calculated as: (Poccl-CVP)/(Pao-CVP); Poccl=mean coronary 
occlusive pressure; Pao=mean aortic pressure; CVP=central venous pressure. Of the 26 
G-CSF patients, 3 aborted the study prematurely because of side effects, and 1 due to a 
short episode of angina pectoris. Intention-to-treat-analysis.
Results:CFI changed from 0.116 +- 0.08 to 0.164 +-0.09 in the G-CSF group (p=0.0000012), 
and from 0.152 +-0.08 to 0.132 +-0.07 (p=0.02) in the placebo group (ﬁgure). FFR changed 
from 0.84 +- 0.11 to 0.86 +-0.10 in the verum group (p=0.03), and from 0.87 +-0.11 to 0.84 
+-0.12 (p=ns) in the placebo group. In the intracoronary and external ECG, G-CSF patients 
had less signs of myocardial ischemia during coronary occlusion in comparison to placebo 
patients after therapy (p= 0.0002 and 0.007). Angina pectoris during coronary occlusion 
was also reduced in G-CSF patients after therapy (p= 0.009).
Conclusions:This study shows for the ﬁrst time that G-CSF is both efﬁcient and safe for 
the promotion of coronary collateral growth in patients with CAD.
9:30 a.m.
1050-134 Postload Reduced Insulin Level Is Associated With High 
Mortality Rates in Patients With no Previous Diagnosis 
of Diabetes Mellitus
Shin Kadota, Mitsuo Matsuda, Masayasu Izuhara, Osamu Baba, Hirokazu Mitsuoka, 
Keisuke Shioji, Takashi Uegaito, Kishiwada City Hospital, Kishiwada, Japan
Background: Hyperinsulinemia and insulin resistance have been proposed for having a 
causal role in pathogenesis of atherosclerosis; however, the relation between post-load 
insulin levels and long-term survival is not clear. We sought to test the hypothesis that 
post-load insulin response is a predictor of outcome in patients with no previous diagnosis 
of diabetes mellitus (DM).
Methods: The data of 933 Japanese patients (621 males and 312 females) who were 
admitted to the hospital between 2002 and 2007 with suspected coronary artery disease 
and who underwent both coronary angiography and a 75g oral glucose tolerance test was 
analyzed. Various metabolic factors were measured including fasting, post-load plasma 
glucose and insulin levels. The determinant factors in association with major adverse 
cardiovascular events (MACE), including all-cause death, reinfarction, heart failure or 
angina requiring re-hospitalization, coronary artery bypass grafting, and percutaneous 
coronary intervention were examined by multivariate Cox regression analysis.
Results: The numbers of patients with normal, impaired and diabetic glucose tolerance 
were 326, 408 and 199, respectively. The differences of insulin levels in glucose 
tolerance status were signiﬁcant by one-way analysis of variance (fasting P=0.0004, 
1-hour P<0.0001, 2-hour P<0.0001). During the follow-up period (mean 1162 ± 688 
days), MACE occurred for 230 patients including 24 non-cardiac and 13 cardiac deaths. 
There were no signiﬁcant differences on MACE incidence or mortality between glucose 
tolerance statuses. Kaplan-Meier curves indicated that the lower response group of 
2-hour insulin levels (<75.3 μU/ml; median) was associated with higher mortality (Logrank 
P=0.006). Multivariate Cox regression analysis revealed that 2-hour insulin levels were an 
independent predictor of all-cause death (P=0.026), and 1-hour insulin levels were that of 
cardiac death (P=0.005), after adjustment for age, gender, number of stenosed vessels, 
ejection fraction, metabolic factors, and treatment.
Conclusions: Post-load reduced insulin response is seen as a predictor of long-term 
mortality for patients with no previous diagnosis of DM.
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ofﬁce in Hennepin County (population 1.2 million), Minnesota. We studied all SCD victims 
between the ages 25-60 years without an initially apparent cause of death and evaluated 
by the ME. We reviewed clinic records, conducted next-of-kin interviews and performed 
autopsy, laboratory testing and genetic analysis for mutations in genes associated with 
the long-QT syndrome. From August, 2001 to July, 2004, 114 cases were eligible. The 
next-of-kin consented to the study in 71.
Results: Mean age was 49.5+7 years, 86% were male and only 2 subjects had history 
of coronary heart disease (CHD). Coronary risk factors were highly prevalent for age 
(e.g. smoking 61%; hypertension 27%; hyperlipidemia 25%) but inadequately treated. 
On autopsy, 80% of the victims had high-grade coronary stenoses (>75% obstruction). 
Acute coronary lesions and previous silent myocardial infarction were found in 27% and 
34% of the victims, respectively. Further, 60% had recently ingested analgesics. Possible 
deleterious mutations of the ion channel genes were detected in 5 (7%) of the victims. Of 
these, 4 were in the sodium channel gene SCN5A.
Conclusions: Overwhelming majority of the younger SCD victims in the community have 
severe subclinical CHD, including undetected previous myocardial infarctions. Mutations 
in the long-QT syndrome genes were detected in a small minority. Analgesic use shortly 
before death suggests that the victims were feeling ill. Traditional coronary risk factors 
were prevalent and under-treated. These ﬁndings imply that improvements in the detection 
and treatment of subclinical CHD in the community are needed to prevent SCD.
9:30 a.m.
1050-140 The Signiﬁcance of ST Elevation in Right Precordial 
Leads in Acute Anterior Myocardial Infarction
Alon Barsheshet, Hanoch Hod, Dan Oiero, Athanasios Michailidis, Ilan Goldenberg, 
Michael Glikson, Michael Eldar, Shlomi Matetzky, Heart Institute, Sheba Medical Center, 
Tel Hashomer, Israel
Background: The clinical implications of ST-segment elevation in the right precordial leads 
in the circumstances of anterior acute myocardial infarction (AMI) are unknown.
We aimed to asses the clinical utility of ST-segment elevation in leads V3R and V4R in 
anterior AMI.
Methods: This study comprised 120 consecutive patients who were admitted within 12 
hours of symptoms onset of anterior ST elevation AMI. All had 18 leads electrocardiograms 
with right precordial leads. Patients were stratiﬁed into two groups based on whether they 
had ST elevation q 1 mV in V3R and V4R (group A) or not (group B). Early primary 
ventricular ﬁbrillation (VF) was deﬁned as VF occurring within 12 hours of symptoms 
onset and before coronary catheterization.
Results: Group A included 39 patients (age mean±SD 59±11, male gender 82%) and 
group B included 81 patients (age 58±14, male gender 84%). Group A patients were 
more likely to experience early primary VF and comprised more patients who suffered 
from heart failure (HF) compared with group B [For VF 8/39 (20%) vs. 2/81(2%), p=.0019, 
for HF 15/39 (38%) vs. 14/81(17%), p=.021]. Patients in group A compared with group B 
had a trend towards less spontaneous reperfusion (14% vs. 32%, p=.063) and had higher 
incidence of multivessel coronary artery disease [median (interquartile range) of 2 (1-3) 
vs. 1 (1-2), p=.097 respectively]. There was no signiﬁcant difference in the size of the 
infarct analyzed by peak CPK, sum of ST segment elevations or wall motion score index 
by echocardiography between the two groups.
Conclusions: In anterior myocardial infarction, ST-segment elevation in the right precordial 
leads is associated with increased risk for early primary VF and HF during hospitalization, 
independent of infarct size. Right precordial leads should be a routine part of the initial 
electrocardiogram in patients with acute myocardial infarction.
9:30 a.m.
1050-141 Association of Body Mass Index on Survival After In-
Hospital Cardiac Arrest.
Renuka Jain, Brahmajee K. Nallamouthu, Karl B. Kern, Paul S. Chan, University of 
Michigan, Ann Arbor, MI, Saint Luke’s Mid-America Heart Institute, Kansas City, MO
Background: Survival after in-hospital cardiac arrest may be inﬂuenced by patients’ 
Body Mass Index (BMI), which may affect the quality and effectiveness of resuscitation 
measures.
Methods: From 2006 to 2007, there were a total of 34,588 cases of cardiac arrest at 328 
hospitals within the NRPCR. Of these, 22,266 patients (64.4%) had available data on 
height and weight and formed the study cohort. We examined the association between 
BMI, categorized as underweight (<18.5 kg/m2), normal (18.5-24.9), overweight (25.0-
29.9), obese (30.0-34.9), and very obese (>35.0), and survival to discharge using 
multivariable logistic regression, after stratifying by cardiac arrest rhythm type and 
adjusting for differences in patient and hospital characteristics. 
Results: Of 4,499 patients with a pulseless arrest due to ventricular ﬁbrillation or 
tachycardia, 1,825 (40.6%) patients survived to discharge. Compared with overweight 
patients, patients at other BMI levels had lower rates of survival (p for trend=0.001) (Table 
1). In contrast, of 17,267 patients with arrests due to asystole or pulseless electrical 
activity, 2,773 (15.6%) survived. Cardiac arrest in patients who were underweight was 
associated with markedly lower rates of survival (Table 1).
Conclusions: BMI is associated with differential rates of survival after in-hospital 
cardiac arrest. Future studies are needed to evaluate the interaction of BMI with CPR, 
deﬁbrillation, and medication effectiveness. 
9:30 a.m.
1050-137 Incidence of Infection in Patients With Sudden Cardiac 
Death Treated With Therapeutic Hypothermia Versus 
Conventional Care
Brian E. Gulbis, Andrea C. Hall, James Constable, Punit S. Parasher, Christopher Y. 
Kim, Raghavendri Moturi, Tayyab Mohyuddin, Saurab Sanon, Santiago Segurola, Ramal 
Weragoda, H. V. Anderson, Stefano Sdringola, Richard W. Smalling, Ali E. Denktas, 
Memorial Hermann Heart and Vascular Institute - Texas Medical Center, Houston, TX, 
The University of Texas Health Science Center, Houston, TX
Background: Mortality for successfully resuscitated patients with sudden cardiac death 
(SCD) remains high. Our hospital utilizes therapeutic hypothermia in SCD patients in an 
attempt to improve survival and meaningful neurological recovery. A potential complication 
of therapeutic hypothermia is infection due to hyperglycemia and a decrease in white 
blood cell motility. We sought to establish whether the use of therapeutic hypothermia is 
associated with an increased incidence of infection.
Methods: Patients with out-of-hospital cardiac arrest admitted to the CCU between 
1/2004 and 12/2007 were reviewed, excluding transfers from outside facilities and 
patients with missing infection data. We evaluated the baseline characteristics, survival, 
and meaningful neurological recovery of patients with and without infection. The incidence 
of any infection, pneumonia, sepsis, and urinary tract infection (UTI) was compared in 
patients receiving therapeutic hypothermia versus conventional care.
Results: In 144 patients evaluated, the incidence of any infection was 70%, pneumonia was 
49%, sepsis was 50%, and UTI was 8%. Among infected patients, 69% had pneumonia, 
71% had sepsis, and 11% had UTI. Baseline characteristics were similar between patients 
with and without infection, except for witnessed cardiac arrest (95% versus 81%, p=0.02) 
and the mean minimum temperature (33°C versus 34.4°C, p<0.001), respectively. There 
was no difference in survival or meaningful neurological recovery between patients with 
and without any infection. There was a signiﬁcant decrease in survival in patients with 
pneumonia (33% versus 57%, p=0.004). There was a signiﬁcant increase in the incidence 
of any infection (70% versus 49%, p=0.02) and pneumonia (74% versus 54%, p=0.02) in 
patients treated with therapeutic hypothermia vs. conventional care.
Conclusions: In patients with SCD, use of therapeutic hypothermia was associated with 
an increase in the incidence of any infection and pneumonia. Pneumonia was associated 
with a decrease in survival. Further studies should be performed to determine whether 
patients treated with therapeutic hypothermia should receive empiric antibiotic therapy.
9:30 a.m.
1050-138 Exertional and Nonexertional Sudden Deaths: Re-
examining the Role of Hypertrophic Cardiomyopathy
Laudino M. Castillo-Rojas, David A. Appel, Jennifer A. McNear, Lena Avedissian, John 
E. Atwood, Lisa A. Pearse, Robert N. Potter, Allen P. Burke, Ladd Tremaine, Eric A. 
Shry, Philip J. Gentlesk, Stephen S. Reich, Robert E. Eckart, Department of Defense 
Cardiovascular Death Registry Group, Brooke Army Medical Center, San Antonio, TX, 
Armed Forces Institute of Pathology, Washington, DC
Background: Some types of genetic disease have a predilection towards a temporal 
association of sudden death with exertion. We sought to identify the activities associated 
with sudden death in a young cohort.
Methods: Records from the Ofﬁce of the Armed Forces Medical Examiner from 1998 to 
2008 were reviewed for sudden death in those less than age 40 years with known activity 
at the time of death.
Results: There were 381 sudden deaths identiﬁed (age 30.2±6.9 years, 96.1% male). 
Etiology of death with exertion was cardiac (124, 68.0%), non-cardiac (2, 1.0%), or 
idiopathic (61, 31.0%); non-exertional death was cardiac (134, 67.4%), non-cardiac 
(2, 1.1%), or idiopathic (58, 31.5%, p=0.99). Of exertional cardiac death, the most 
common cause of death was atherosclerosis (64, 51.6%), concentric LV hypertrophy 
without disarray (19, 15.3%), anomalous coronary artery (10, 8.1%), and hypertrophic 
cardiomyopathy (10, 8.1%). The activity associated with sudden death was most 
commonly physical ﬁtness training (45.1%), recreational sports (45.1%), or military 
training (3.8%). Death during running and basketball were commonly cardiac (71.4%), 
while death during swimming was commonly idiopathic (50.0%). In a population age 
18 to 40 years, idiopathic sudden death and atherosclerosis account for the majority of 
exertional sudden death (139, 75.6%) while hypertrophic CM (10, 5.4%) and concentric 
LV hypertrophy without disarray (19, 10.3%) are less common.
Conclusions: In a cohort of young adults with exertional death, idiopathic and 
atherosclerotic deaths are common causes, and examination of activity associated 
with death may provide clues as to etiology. Hypertrophic cardiomyopathy is much less 
common that previously reported in a population undergoing active surveillance and 
autopsy.
9:30 a.m.
1050-139 Etiology of Sudden Death Among Younger Adults in 
the Community: Results of Anatomic Metabolic and 
Genetic Evaluation
A. Selcuk Adabag, Gary Peterson, Fred S. Apple, Jack Titus, Richard King, Russell V. 
Luepker, University of Minnesota, Minneapolis, MN
Background: Identifying the community-dwelling persons at risk for sudden cardiac 
death (SCD) is challenging. Few studies have investigated the victim with contemporary 
laboratory techniques and few have focused on a community-based population. We 
hypothesized that a comprehensive examination of out-of-hospital SCD victims in the 
community will reveal clues about the risk factors for SCD.
Methods: It is mandatory to report all out-of-hospital SCD to the Medical Examiner’s (ME) 
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Other hospital characteristics, including geographical location, academic status, cardiac 
arrest volume, and presence of automatic external deﬁbrillator or medical emergency team 
programs were not associated with delayed deﬁbrillation. Similarly, there was wide variation 
in hospital rates of survival to discharge (5.3% to 63.6%). Although most hospital factors 
were not associated with survival, hospitals in the top-performing quartile for deﬁbrillation 
time had better overall rates of survival to discharge (OR of 1.41 [1.11, 1.77]; p <.001).
Conclusions: Rates of delayed deﬁbrillation vary widely among hospitals but are largely 
unexplained by available hospital factors. Given its association with improved survival, 
future research is needed to better understand best practices in deﬁbrillation speed 
among top-performing hospitals.
9:30 a.m.
1050-144 Association Between Waveform Characteristics of 
Ventricular Fibrillation and Survival in Out-of-Hospital 
Cardiac Arrest
Esther M. ter Braack, Wessel Keuper, Marc A. Brouwer, Freek WA Verheugt, Joep LRM 
Smeets, University of Twente, Enschede, The Netherlands, Radboud University Medical 
Centre Nijmegen, Nijmegen, The Netherlands
Background: Early deﬁbrillation in patients with ventricular ﬁbrillation (VF) in out-of-
hospital cardiac arrests (OHCA) is associated with a higher deﬁbrillation success rate 
and a better survival. Whether waveform characteristics of VF are associated with survival 
to discharge is the purpose of this study.
Methods: Patients with VF as initial rhythm and digital ECG recordings were selected 
from a prospective registry of OHCA between 2006 and 2008 in the Nijmegen area. 
Frequency and amplitude characteristics were calculated from the ﬁrst 4 seconds of 
digital VF signal. Complete follow-up was an additional entry criterium.
Results: In 155 patients a 4 seconds digital ECG recording was available and in 39 patients 
complete follow-up was present. From 39 analyzed patients, there were 8 patients who survived to 
discharge. Baseline characteristics between survivors and non-survivors did not differ: age (years) 
66.2 and 64.0 (p=NS); witnessed arrest (%) 100 and 81.3 (p=NS); call to arrival (minutes) 8 and 
7 (p=NS). Survivors showed signiﬁcantly higher frequency, amplitude and slope measures than 
non-survivors (see table, results displayed as median and 25-75 interquartile range).
Conclusions: In this study we found that the VF waveform of survivors had signiﬁcantly 
higher frequency and amplitude characteristics, which might reﬂect the total duration of 
ventricular ﬁbrillation. These measures can be used for future research to reﬁne shock 
protocols in treatment of ventricular ﬁbrillation.
Survival to 
discharge (n=8)
No survival to 
discharge (n=31)
p-value 
(Wilcoxon)
Median Frequency (Hz) 5.47 (4.62-7.17) 4.13 (3.16-4.86) 0.01
Dominant Frequency (Hz) 5.49 (4.39-7.02) 4.15 (2.69-5.37) 0.03
Mean Frequency (Hz) 5.81 (4.76-7.04) 4.58 (3.52-5.42) 0.02
Mean Peak-to-trough 
amplitude (mV) 0.38 (0.33-0.47) 0.25 (0.18-0.35) 0.03
Mean slope (mV/s) 10.03 (9.21-10.90) 6.37 (3.65-8.76) 0.001
Median slope (mV/s) 4.38 (3.90-4.86) 2.72 (1.60-3.85) 0.003
9:30 a.m.
1050-145 Outcomes of Therapeutic Hypothermia With Iced 
Saline and Endovascular Cooling in Shockable and 
Nonshockable Rhythms
Vinod S. Kudagi, Nitesh Sood, Jeffery Kluger, Joseph Taliercio, Justin Lundbye, Hartford 
Hospital, Hartford, CT
Background: Randomized studies of therapeutic hypothermia demonstrated improved 
outcomes in survivors of out-of-hospital cardiac arrest due to ventricular ﬁbrillation (VF). 
The reported trials used surface cooling, which is slow, labor intensive and incomplete 
and were restricted to patients with VF only. We investigated the efﬁcacy, safety, and 
outcomes of therapeutic hypothermia by infusing cold normal saline and endovascular 
cooling in patients (pts) with both VF and non-shockable rhythms.
Methods: We assessed consecutive 29 pts who were resuscitated from cardiac arrest 
and underwent endovascular therapeutic hypothermia at our institution. Of these, 22 pts 
received 2 liters of ice cold (4 °C) saline prior to endovascular cooling with Cool Gard 3000 
Thermoregulation system. The target temperature was 33 ± 1 °C. The primary endpoints 
were time to reach target temperature from initiation of hypothermia, feasibility of maintaining 
hypothermia and neurological recovery assessed by Pittsburgh cerebral performance 
category (PCPC) of 1 (good performance), 4 (vegetative state), and 5 (death).
Results: Out of 29 pts, 17 (58.6%) had VF and 12 (41.4%) had non- shockable rhythms 
with either pulseless electrical activity (PEA n=8) or asystole (n=4) at presentation. 
The mean age was 60 (±13) yrs with 86% males. The target temperature was reached 
in all patients (100%) with a mean time to target temperature of 220 (± 130) minutes. 
Temperature was effectively maintained at 33.6 ± 0.6 °C during 18 hrs of hypothermia.
Out of the 29 patients 15 had complete neurological recovery (CNR) (51.7%) (PCPC=1), 13 
patients died (PCPC=5) (44.8%) and 1 patient (3%) had persistent vegetative state (PCPC=4).
There were 10/17 pts with VF that had CNR (58.4%) compared to 5/12 (41.6%) with 
either PEA or asystole (p =0.3). There were no Alseus catheter or hypothermia related 
complications in any patient.
Conclusions: Therapeutic hypothermia using a protocol of cold normal saline infusion 
prior to endovascular cooling achieves target temperatures quickly in 100% of patients 
without complications. Complete neurological recovery occurs in a majority of patients 
irrespective of the rhythm at presentation.
9:30 a.m.
1050-142 Linear Increase in Left Ventricular Thrombus Over Time 
in Ventricular Fibrillation Conﬁrmed by Intra-cardiac 
Echocardiography
Martin C. Burke, Carmen Jaramillo, Thomas H. Freeman, Matthew Smelley, Dipak Shah, 
Ian Weisberg, John F. Beshai, Susan S. Kim, Albert C. Lin, Bradley P. Knight, University 
of Chicago, Chicago, IL
Mortality increases 10% every minute in cardiac arrest. To understand the poor outcome, 
we studied thrombus formation using direct imaging of the cardiac chambers with an 
intracardiac echocardiography (ICE) (Accuson, Mountain View, CA) probe during induced 
VF in pigs. Methods: Six adult pigs were anesthetized and ventilated. Vascular access 
was obtained by cut-down of the femoral and internal jugular veins. An ICE probe was 
placed in the right atrium and positioned to view the left ventricle (LV). A pacing wire was 
positioned into the right ventricle. VF was then induced with alternate-current energy. ICE 
images of the LV were stored at baseline (pre -VF), and at one minute increments in VF 
out to 20 minutes. Image analysis measured 2-dimensional area of LV thrombus over 
time in VF and was then compared to baseline chamber area. Results: Data from ﬁve pigs 
was analyzable. One pig suffered from asystole early in the experiment and was excluded 
from analysis. The entire study group maintained atrial electromechanical activity 
during VF. The mean baseline area of the left ventricles viewed by ICE was 8.7 ± 3.4 
centimeters2. The LV chambers were completely ﬁlled with thrombus within 16 minutes. 
A linear increase in thrombus burden is demonstrated in the ﬁgure. Conclusions: ICE 
images provide real-time evidence of progressive thrombus burden in the LV during VF. 
The contribution of the thrombus burden to the mortality and morbidity following cardiac 
arrest needs more evaluation. 
9:30 a.m.
1050-143 Hospital Variation in Time to Deﬁbrillation After In-
Hospital Cardiac Arrest
Paul S. Chan, Graham Nichol, Harlan M. Krumholz, John A. Spertus, Brahmajee K. 
Nallamothu, Saint Luke’s Mid America Heart Institute, Kansas City, MO, University of 
Washington - Harborview Center for Prehospital Emergency Care, Seattle, WA
Background: Delays to deﬁbrillation are associated with worse survival after in-hospital 
cardiac arrests. We determined the extent of variation in delayed deﬁbrillation among 
hospitals and factors that may explain this variation.
Methods: Adult inpatients with cardiac arrests amenable to deﬁbrillation (n=7,479) at 200 
hospitals from 2000 to 2008 were identiﬁed from the National Registry of Cardiopulmonary 
Resuscitation. Hospital rates of delayed deﬁbrillation, deﬁned as greater than 2 minutes, 
were assessed using hierarchical models, after adjusting for demographic, clinical, and 
cardiac arrest variables.
Results: Adjusted rates of delayed deﬁbrillation varied substantially among hospitals 
(range, 2.4% to 50.9%), with hospital differences accounting for a signiﬁcant amount of the 
total variation across institutions after adjusting for patient factors (median odds ratio [OR] 
of 1.49 for overall hospital-level effects). Among hospital factors evaluated, bed volume 
(reference: <200 beds; 200-500 beds: odds ratio [OR] of 0.62 [95% Conﬁdence Interval (CI) 
0.48 to 0.80]; >500 beds: OR of 0.74 [0.53 to 1.04]; p for trend <.001) and arrest location 
(reference: ICU; telemetry unit: OR of 1.92 [1.65 to 2.22]; nonmonitored unit: OR of 1.90 
[1.61 to 2.24]; p <.001) were associated with differences in rates of delayed deﬁbrillation. 
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LNAME-inhibitable O2- (Fig d).
Conclusions: Elevated preoperative levels of serum sCD40L, a measure of platelet 
activation, predicts the development of AF post-CABG. Patients with persistent AF at 6 
weeks have higher preoperative sCD40L, lower FMD and higher vascular O2- mainly due 
to uncoupled eNOS, at the time of surgery. 
9:30 a.m.
1050-149 Calciﬁcation at the Distal Anastomosis Is a Novel 
Predictor of Early Asymptomatic Vein Graft Failure in 
First-Time CABG Patients
Rhondalyn C. McLean, Susanna M. Nazarian, Tyler J. Gluckman, Edward P. Shapiro, 
Steven P. Schulman, John V. Conte, David R. Thiemann, Jeffrey J. Rade, Johns Hopkins 
School of Medicine, Baltimore, MD
Background: Saphenous vein grafts (SVGs) are the most frequently used conduits 
for coronary artery bypass graft (CABG) surgery. Despite advances in the surgical 
technique, up to 20% of SVGs continue to become occluded within the ﬁrst year after 
CABG surgery.
Objective: The goal of the present analysis was to evaluate the demographic, clinical and 
anatomic ﬁndings associated with early asymptomatic SVG failure in the modern era, as 
measured by multi-detector computed tomography (MDCT) coronary angiography.
Methods: Patency was assessed in 611 SVGs in 291 patients from the prospective, multi-
centered Reduction in Graft Occlusion Rates (RIGOR) study. The odds of SVG patency 
6 months post-operatively were analyzed using multilevel multivariate logistic regression 
with clustering on patient.
Results: At a mean of 6.5 months following CABG, MDCT revealed that 20.7% of SVGs 
were occluded. On univariate analysis, current tobacco use (OR 2.09, P = .03), female 
gender (OR 2.08, P = .04), and presence of calciﬁcation at the distal anastomosis (OR 
2.24, P = .03) were predictive of greater odds of SVG occlusion. Target vessel size 
>1.5mm (OR 2.78, P = .001) and skip grafts (OR 2.49, P = .001, when compared to 
independent grafts) were associated with higher odds of SVG patency. In multivariate 
modeling, calciﬁcation at the distal anastomosis (OR 2.09, P = .05), smaller target vessel 
size (OR 2.37, P = .003), and female gender (OR 2.46, P = .01) remained statistically 
signiﬁcant predictors of early SVG occlusion.
Conclusion: In this prospective clinical study, early SVG failure was associated with both 
demographic and anatomic factors. Optimal early SVG patency rates may be achieved 
through careful patient selection, as well as efforts to maximize target vessel size, utilize 
skip grafts, and choose anastomosis sites devoid of calciﬁcation. That the presence of 
calciﬁcation at the distal anastomosis is a predictor of early graft failure is an important 
new ﬁnding. Perhaps pre-operative evaluation of the coronary vessels by MDCT may be 
useful to guide the approach of cardiothoracic surgeons in the future.
9:30 a.m.
1050-150 Comparison of Drug-Eluting Stents and Coronary 
Artery Bypass Surgery for the Treatment of Left Main 
Coronary Artery Disease: Two-Year Follow-up Results 
From a Single Institution
Shengshou Hu, Yan Li, Zhe Zheng, Bo Xu, Wei Li, Runlin Gao, National Heart Center 
and Fuwai Hospital, Beijing, People’s Republic of China
Background: Several studies have compared the treatment effects of coronary stenting 
with drug-eluting stents and coronary-artery bypass grafting (CABG). However, limited 
data exist on the long-term outcomes of these two interventions for patients with 
unprotected left main coronary artery disease.
Methods: We evaluated 220 patients with unprotected left main coronary artery disease 
who received drug-eluting stents and 768 patients who underwent isolated CABG 
between April 2003 and February 2006. We compared adverse outcomes (death; 
myocardial infarction; and target-vessel revascularization) after adjustment for differences 
in baseline risk factors among the patients.
Results: Patients who underwent CABG were older and had more comorbidities than 
patients who received drug-eluting stents. Patients receiving drug-eluting stents had 
considerably higher 24-month rates of target-vessel revascularization (8.18% vs 1.70%). 
There was no signiﬁcant difference between the drug-eluting stents and CABG groups 
in the risk of death (hazard ratio [HR ]for the drug-eluting stents, 1.16; 95% conﬁdence 
interval [CI], 0.75 to 1.82). However, drug-eluting stents were associated with higher rates 
of myocardial infarction (adjusted HR 1.627, 95%CI 1.116 to 2.424). Among patients with 
left main plus multi-vessel disease, the comparison between drug-eluting stents (n=130) 
and CABG surgery (n=690) produced similar results.
Conclusions: In a cohort of patients with unprotected left main coronary artery disease, 
we found no signiﬁcant difference in rates of death between patients receiving drug-eluting 
stents and those undergoing CABG. However, CABG was associated with lower rates of 
myocardial infarction, and target-vessel revascularization than does drug-eluting stents.
9:30 a.m.
1050-146 Inﬂuence in Female Patients With Stable Multivessel 
Coronary Disease Submitted to Off-Pump and On-
Pump Coronary Surgery
Felipe Paulitsch, Neuza Lopes, Fernando Costa, Cibele Garzillo, Alexandre Pereira, 
Noedir Stolf, Luiz Cesar, Whady Hueb, Heart Institute University of Sao Paulo, Sao 
Paulo, Brazil
Background: Female patients experience greater events compared with males regarding 
coronary bypass surgery with the on-pump technique. We sought to determine whether 
the off-pump technique changes outcomes between genders.
Methods: This was a prospective study that included 279 patients with stable coronary 
artery disease, preserved left ventricular function, and the possibility of surgery by 
either the on-pump or off-pump method. Patients were randomized into 2 groups: on-
pump (n=137) or off-pump (n=142). There were 209 male patients (on-pump=110; off-
pump=99) and 70 female patients (on-pump=40; off-pump=30). Composite major events 
were: death, unstable coronary syndrome, stroke, and minor events were analyzed 
according to sex and pump use.
Results: Male patients had signiﬁcantly more Caucasian (81% vs. 64%, p=0.003), and 
females had more hypertension (84% vs 61%, p<0.01). There were more major combined 
events in female patients (27% vs 13%, p=001) with both techniques. However, we did not 
observe differences regarding mortality between male and female patients. Furthermore, 
no signiﬁcant differences were found among number of events and mortality stratiﬁed 
according to sex and cardiopulmonary bypass (CPB) use.
Conclusion: In the present study, the number of combined events was signiﬁcantly 
higher in women than in men. However, CPB did not signiﬁcantly inﬂuence outcomes 
between genders.
9:30 a.m.
1050-147 Should Use of Troponin Measurement for the Diagnosis 
of Myocardial Infarction After Coronary Artery Bypass 
Graft Surgery Be Reconsidered?
Asim A. Mohammed, Arvind Agnihotri, Roland RJ van Kimmenade, Abelardo Martinez-
Rumayor, Sandy Green, Rene Quiroz, James L. Januzzi, Jr., Massachusetts General 
Hospital, Boston, MA
Background:Consensus guidelines deﬁne post coronary artery bypass grafting (CABG) 
myocardial infarction (MI) using a troponin cut-point 5 times the upper reference limit 
(e.g. a troponin T [cTnT] >.15 ng/mL), together with symptoms and electrocardiographic 
(ECG) changes. However, post-CABG, symptoms are frequently not reliable, and ECG 
changes are not speciﬁc. Signiﬁcant reliance on biomarkers to diagnose post-CABG “MI” 
is inevitable; the ramiﬁcations of this are unknown.
Methods:Measurement of cTnT was performed at three time points during the ﬁrst 24 
hours following CABG surgery in 847 consecutive, unselected patients.
Results:The peak cTnT median (with inter-quartile range, IQR) was 1.08 ng/ml (IQR=0.60-
1.73 ng/ml). 97% of all patients studied, as well as 77% of patients who had off-pump 
CABG, were over the cTnT >0.15 ng/ml consensus-recommended cutoff for post-CABG 
MI detection. Despite prevalent release of cTnT, a linear association was found between 
cTnT and the incidence of complications, with cTnT remain independently predictive of 
mortality in adjusted analyses (HR=3.20; P <.001). In contrast to the consensus endorsed 
cut-point, a cTnT level of 1.60 ng/mL had excellent negative predictive value (NPV) for 
excluding likelihood of death (NPV=99%), death/heart failure (NPV=98%), death/need 
for prolonged vasopressor support (NPV=94%), or the composite of death/heart failure/
prolonged vasopressor support (NPV=93%).
Conclusions:Over-reliance on troponins following CABG will lead to a large number of 
inappropriate diagnoses of “MI”, particularly if using cut-points endorsed by consensus 
guidelines. As the goal of cTnT testing is to stratify risk following CABG, we believe a 
higher cTnT cut-point of 1.60 ng/mL will provide an improved NPV for excluding impending 
complications.
9:30 a.m.
1050-148 Preoperative Circulating sCD40L And Vascular Redox 
State in LIMA Grafts, Predict The Development Of Atrial 
Fibrillation Post-Coronary Artery Bypass Grafting
Charalambos A. Antoniades, Tim Van-Assche, Jonathan Diesch, Alexios S. 
Antonopoulos, Dimitris Tousoulis, Christodoulos Stefanadis, Barbara Casadei, David 
Taggart, Keith M. Channon, Paul Leeson, University of Oxford, Oxford, United Kingdom, 
University of Athens, Athens, Greece
Background: Atrial ﬁbrillation (AF) is accompanied by endothelial dysfunction, increased 
oxidative stress and platelet activation (increased circulating sCD40-ligand). Myocardial 
oxidative stress has been associated with increased risk of AF following coronary artery 
bypass grafting (CABG). We examined whether preoperative endothelial dysfunction and 
platelet activation predict the development of post-operative AF.
Methods: We studied 147 patients undergoing CABG. The day before CABG, endothelial 
function was assessed by ﬂow mediated dilation (FMD) in the brachial artery. Plasma 
sCD40L was measured by ELISA. Vascular O2- generation in LIMA grafts was measured 
by using lucigenin chemiluminescence, in the presence and absence of NOS inhibitor 
LNAME and NADPH. Patients were followed up prospectively for 6 weeks.
Results: The “in hospital” newly developed AF was 31.2%. The relative risk for post-
operative AF of patients in the highest vs lowest third of serum sCD40L was 3.83 [95%CI: 
1.12 -12.94], p=0.03 (Fig a). 3.4% of patients were still in AF at 6 weeks. These patients 
had higher pre-operative sCD40L (Fig b), lower FMD (Fig c), higher total O2- and higher 
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CABG only, or PCI only. We enrolled 493 patients, of whom 137 and 356 underwent SES 
and off-pump CABG, respectively, in our institute between 2003-2007. The incidence of 
the primary endpoint of major adverse cardiac and cerebrovascular events (MACCE) 
during follow-up (4.1+/-2.9 years) was similar between SES group and off-pump CABG 
group (24% vs. 16%, p=0.42). After adjusting for baseline variables, SES and off-pump 
CABG did not differ in terms of cardiac death (hazard ratio [HR] 0.88; 95% conﬁdence 
interval [CI] 0.19- 3.60; p=0.89), myocardial infarction and death (HR 0.44; 95%CI 0.10-
1.65; p=0.25) and MACCE (HR1.25; 95%CI 0.71-2.11; p=0.43). However, the risk for the 
incidence of revascularization was signiﬁcantly higher in the SES group than in the off-
pump CABG group (HR 2.47; 95%CI 1.65-3.28; P=0.01).Conclusion: Although SES was 
associated with a signiﬁcantly higher risk of revascularization than off-pump CABG, long 
term adverse cardiac and cerebrovascular events did not signiﬁcantly differ between the 
two procedures in diabetic patients with multivessel disease.
9:30 a.m.
1050-154 The Predictive Value of SPY Intraoperative Angiography 
on Longterm Graft Patency Post Revasculalization
Christine McCarty, Aaron Rastoka, Amy Helmuth, Lynn McLuckie, PinnacleHealth, 
Harrisburg, PA
Background: Intraoperative SPY angiography has been used to evaluate and revise 
coronary bypass grafts. The speciﬁcity and sensitivity of this operative study is high. 
However, longterm studies on graft patency have not been entertained. We examined the 
results of SPY patients to see if conﬁrmed intraoperative graft patency yielded improved 
longterm results.
Methods: From 2006 to 2007, 200 patients undergoing coronary revascularization were 
evaluated retrospectively. 100 patients were studied with SPY while the other 100 patients 
served as a control group. The studied endpoint for graft complications posoperatively 
included a positive stress test, ECHO or readmission with MI or with PCI, with follow-up 
time of one year.
Results: There were no differences between the two groups with regard to gender or 
signiﬁcant comorbidities such as HTN, DM, or cigarette smoking. Table 1 shows the type 
and distributions of the grafts placed in both groups. In the SPY group (98%) (98/100) 
were off pump while the nonSPY group had 33% (33/100) off pump. In the SPY group 
3.9% (11/286) of grafts were revised while no revisions occurred in the nonSPY group. 
There were 3 graft failures in the SPY group vs 11 in the nonSPY group. The Pearson Chi 
square value is 4.154, P-value of 0.042.
Conclusions: Statistical signiﬁcance was obtained deﬁning improved longterm graft 
patency with SPY angiography. This becomes important in an era of more minimally 
invasive revascularization, OPCAB, prior PCI and more arterial conduits
Type (Arterial-A or SVG-V) and Distribution of Grafts
SPY NONSPY
LAD-A 123 94
LAD-V 1 27
PCA-A 34 3
RCA-A 22 70
CX-A 80 17
CX-V 26 87
Total 286 298
9:30 a.m.
1050-155 Association Between new Onset Postcoronary Artery 
Bypass Graft Atrial Fibrillation and Body Habitus 
Measures and Gender
Giovanni Filardo, Cody Hamilton, Baron Hamman, Robert F. Hebeler, Jr., Paul Grayburn, 
Institute for Health Care Research and Improvement, Baylor Research Institute, Dallas, 
TX, Department of Cardiothoracic Surgery, Baylor University Medical Center, Dallas, TX
Background: Considering the increased prevalence of obesity and the growing number 
of patients undergoing cardiac surgery, addressing the uncertainty regarding the impact 
of body size/adiposity on risk for post-operative atrial ﬁbrillation (AFIB) is critical. Results 
regarding the relationship between body mass index (BMI) (Kg/m2) or body surface 
area (BSA) (m2) and AFIB following coronary artery bypass graft surgery (CABG) are 
inconsistent. Moreover, the effect of gender on this association is under-investigated.
Methods and Results: Post-operative AFIB was assessed in a cohort of 7,027 
consecutive patients without preoperative AFIB undergoing isolated CABG at Baylor 
University Medical Center, Dallas, TX between 1/1/1997-12/31/2006. Two propensity-
adjusted models controlling for risk factors identiﬁed by the Society of Thoracic Surgeons 
and other clinical/non-clinical details were used to determine how gender affected the 
relationship between post-CABG AFIB and BMI or BSA. After adjustment, BMI and 
BSA (both modeled using smoothing techniques to avoid categorization) were strongly 
associated (p<0.0001) with postoperative AFIB -higher BMI or BSA resulted in increased 
risk. Although evidence existed that gender was associated with AFIB (p<0.0001 and 
p=0.108 for BSA and BMI models, respectively), there was no indication that the effect of 
BMI or BSA on postoperative AFIB varied by gender.
Conclusions: Understanding BMI and BSA could assist decisions regarding referral and 
patient management pre-post CABG surgery. This study suggests that increased BMI and 
BSA are associated with higher risk of post-CABG AFIB and that risk for men is higher for 
the entire BSA spectrum and for extreme values of BMI.
9:30 a.m.
1050-151 Results of Radial Artery Grafting in Diabetic Patients
Robert F. Tranbaugh, Darryl M. Hoffman, Charles M. Geller, Loren J. Harris, Paul Stelzer, 
Bertram Cohen, Beth Israel Medical Center, New York, NY
Background: The choice of additional arterial conduit after the internal thoracic artery 
(ITA) in diabetic (DM) patients is controversial. Bilateral ITAs increase the risk of sternal 
infection while the radial artery (RA) may be prone to spasm causing decreased survival. 
We have thus compared our results of LITA and RA grafting in DM patients to non diabetic 
(non-DM) patients in order to clarify the role of the RA in DM patients. 
Methods: From Jan, 1995 to Jan, 2008, 1483 consecutive patients (selected for age <65 
yrs or no venous conduit) underwent isolated, primary CABG using the LITA and at least 
one RA. 34.5% of the patients were diabetic. These 511 DM patients had the same age 
(57 yrs, range 33-88 yrs) and EF (47%) as the 972 non-DM patients. The DM patients 
had signiﬁcantly (p<0.01) more women (26.8 vs. 12.4%), previous strokes (7.8 vs. 2.7%), 
PVD (11.2 vs. 5.3%), heart failure (6.3 vs. 1.5%), and renal failure (2.3 vs. 0.9%) than the 
972 non-DM patients.
Results: Operative and hospital mortality was 0% for the DM patients and 0.2% for the 
non-DM patients. DM patients had a trend towards higher rates of stroke (1.4 vs. 0.7%, 
p<0.30), sternal infections (1.6 vs. 0.9%, p<0.30) and respiratory failure (2.7 vs. 1.2%, 
p<0.06) than the non-DM patients. DM patients did have a signiﬁcantly higher rate of 
sepsis (2.0 vs. 0.5%, p<0.01). There was no difference in the rate of perioperative MI (1.0 
vs. 0.9%) and renal failure (1.0 vs. 0.6%). The 1, 5 and 10 year Kaplan Meier survivals 
were 99%, 92% and 89% for the DM patients and 99%, 96% and 90% for the non-DM 
patients (ns).
Conclusions: Myocardial revascularization using the LITA and RA results in excellent 
operative mortality and long term survival in DM patients despite a higher preoperative 
risk proﬁle. DM patients had a trend towards a higher rate of postoperative morbidity. The 
RA appears to be an excellent choice as an additional arterial conduit in DM patients.
9:30 a.m.
1050-152 Comparison of Bivalirudin and Unfractionated 
Heparin Plus Protamine in Patients With Coronary 
Artery Disease Undergoing Elective Percutaneous 
Coronary Intervention: Final Six-Month Result of the 
Antithrombotic Regimens aNd Outcome (ARNO) Trial
Guido Parodi, Angela Migliorini, Renato Valenti, Benedetta Bellandi, Umberto Signorini, 
Piergiovanni Buonamici, Nazario Carrabba, Guia Moschi, David Antoniucci, Department 
of Cardiology, Careggi Hospital, Florence, Italy
Background: Current antithrombotic regimens during percutaneous coronary 
interventions (PCI) include unfractionated heparin (UFH) or bivalirudin with or without GP 
IIb/IIIa inhibitors. Randomized studies have shown that bivalirudin plus provisional GP IIb/
IIIa inhibitors is superior to UFH plus routine GP IIb/IIIa inhibitors in terms of net clinical 
outcome (composite of death, myocardial infarction, target vessel revascularization, and 
major bleedings). It is not known if prompt reversal of UFH by protamine after PCI results 
in decreased bleeding complications and no increase in ischemic complications. 
Objective and Methods: To assess whether bivalirudin is superior to UFH plus protamine 
with respect to in-hospital REPLACE-2 major bleeding complications (primary end point) 
in elective PCI patients receiving a 600 mg clopidogrel loading dose q6 hours before 
PCI. GP IIb/IIIa inhibitor use was at the operator’s discretion. Secondary end points 
were: ischemic events rate (composite of death, myocardial infarction, target vessel 
revascularization) and net clinical outcome at 6 months. We randomly assigned 850 
patients to bivalirudin or to UFH (followed by 25 to 50 mg of protamine at the end of the 
procedure). Main exclusion criteria included: 1) PCI for chronic total coronary occlusion 
and 2) severe renal insufﬁciency. 
Results: The primary end point rate was 0.9% in patients randomized to bivalirudin and 
2.8% in patients randomized to UFH (p=0.043). At 1 month (follow-up rate 100%), ischemic 
events were lower and net clinical outcome better in the bivalirudin arm as comparred 
to UFH arm (2.8% vs 6.4% [p=0.014], and 3.3% vs 7.8% [p=0.004], respectively). At 
6-month follow-up (93% follow-up rate at October 6, 2008), major bleeding rate was still 
lower in the bivalirudin group (1% vs 4.8%; p=0.001). Complete 6-month follow-up results 
will be presented. 
Conclusion: In elective PCI patients bivalirudin as compared to UFH plus protamine 
is associated with less major bleeding complications. (Trial registration: clinicaltrials.gov 
Identiﬁer: NCT00448461)
9:30 a.m.
1050-153 Long-Term Outcomes of Sirolimus-Eluting Stent Versus 
Off-Pump Coronary Artery Bypass Grafting in Diabetic 
Patients With Multivessel Coronary Disease Involving 
Proximal LAD
Hiroshi Tamura, Katsumi Miyauchi, Takahiko Kojima, Ken Yokoyama, Takeshi Kurata, 
Taira Yamamoto, Atsushi Amano, Hiroyuki Daida, juntendo university, Tokyo, Japan
Numerous trials have compared coronary angioplasty with bypass surgery. However, 
there is no data regarding clinical comparison between off-pump coronary artery bypass 
grafting (CABG) surgery (using the internal mammary artery) and sirolimus-eluting stent 
(SES) in diabetic patients. This study was designed to compare the long-term clinical 
outcome of off-pump CABG with SES in diabetic patients with multivessel disease 
involving proximal left anterior descending or left main coronary artery in single center. Of 
all the patients who were screened for this observation, a team consisting of a surgeon 
and an interventionalist decided if the anatomy was suitable for both CABG and PCI, 
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Table
Transfemoral (n=512) Transradial (n=512) p-value
Catheterization success 511 (99.9%) 494 (96.5%) <0.0001
Cross over 1 (0.001%) 18 (3.5%) <0.0001
Angioplasty 192 (37.5%) 178 (34.8%) NS
Procedural success 191 (99.5%) 172 (96.6%) NS
Duration of procedure (min) 37.0 + 25.9 40.2 + 25.8 <0.05
Contrast dye (ml) 128.8 + 65.0 132.0 + 76.0 NS
Radiation exposure (Gycm2) 38.21 + 26.26 41.85 + 29.69 <0.05
Fluoroscopy time (min) 5.79 + 5.96 9.02 + 8.65 <0.01
Vascular complications 19 (3.7%) 3 (0.6%) 0.001
10:45 a.m.
0918-4 Comparison of Optimal Medical Therapy With or 
Without PCI on Cardiovascular Endpoints in Patients 
With Silent Myocardial Ischemia: Post Hoc Analysis 
From the COURAGE Trial
William E. Boden, Koon K. Teo, Pamela M. Hartigan, David J. Maron, G.B. John Mancini, 
Eric R. Bates, Bernard R. Chaitman, John Spertus, William J. Kostuk, Marcin R. Dada, 
Vipul Gupta, Steven P. Sedlis, Daniel S. Berman, Leslee J. Shaw, Robert A. O’Rourke, 
William S. Weintraub, Buffalo General Hospital, Buffalo, NY
Background: Both SWISSI-II (n=201 patients [pts] with recent MI) and ACIP (n=558 pts 
with stable CAD) showed that PCI signiﬁcantly reduced long-term mortality in pts with silent 
myocardial ischemia (SMI). Accordingly, we assessed the impact of adding PCI to OMT on 
clinical events among stable CAD pts in COURAGE without angina at baseline (BL) who had 
SMI (i.e., ECG ischemia and/or reversible stress myocardial perfusion imaging [MPI] defects).
Methods: A post hoc comparison was performed for the primary endpoint of death or 
MI, as well as for death (D), MI, and hospitalization for acute coronary syndrome (ACS); 
the composites of D/MI/stroke and D/MI/ACS; and subsequent revascularization (revasc) 
during a median 4.6 year follow-up.
Results: Compared to the 1,997 pts with angina at BL, there were no signiﬁcant 
differences in age, sex, cardiac risk factors, prior MI or revasc, extent of angiographic 
CAD, or ischemia by ECG or MPI in the 283 pts (12%) with SMI at BL. Other than diabetes 
(OMT=43%; PCI=24%), there were no BL differences in SMI pts by treatment assignment. 
Of note, SMI pts required less revasc (16%) than those with BL angina (27%), regardless 
of treatment assignment; P<0.001. Adjusted event rates reveal: 
Outcomes: SMI Pts PCI + OMTN=135
OMT
N=148 P value
D or MI 19 (14%) 27 (18%) 0.34
Death Alone 7 (5%) 16 (11%) 0.11
MI Alone 14 (10%) 12 (8%) 0.51
ACS Alone 10 (7%) 11 (7%) 0.99
D/MI/Stroke 20 (15%) 28 (19%) 0.36
D/MI/ACS 27 (20%) 35 (24%) 0.46
Subsequent Revasc 18 (13%) 28 (19%) 0.20
Conclusions: In COURAGE, the addition of PCI to OMT did not reduce long-term cardiac 
events in SMI pts with stable CAD. While SMI pts in SWISSI-II differ from both ACIP and 
COURAGE, the ~ 2-fold trend toward lower mortality with PCI suggests the need for a 
more deﬁnitive trial of PCI vs. OMT in SMI pts.
11:00 a.m.
0918-5 In Acute Coronary Syndrome Medical Therapy Is 
Superior to Early Coronary Revascularization for 
Patients With Low Risk Proﬁle
Raffaele Bugiardini, Markku Eskola, Heini Huhtala, Kari Niemelä, Pekka Karhunen, 
Rossella Miglio, Olivia Manfrini, Kjell Nikus, University of Bologna, Bologna, Italy, 
University of Tampere, Tampere, Finland
Background: The aim of the study was to evaluate the effect of early coronary 
revascularization on major acute cardiovascular events (MACEs) accordingly to patients 
risk proﬁle.
Methods: We enrolled 1188 consecutive patients with acute coronary syndrome who 
were admitted in a single academic hospital in Finland. Of these patients, 279 underwent 
in-hospital coronary revascularization and 909 were managed only with medical 
treatment. The outcome measure was the composite endpoint of death, stroke, myocardial 
infarction, and unstable angina requiring re-hospitalization. We used propensity analysis
to compensate for lack of random assignment to treatment groups and stratiﬁed patients 
into quintiles of risk accordingly to 10 clinical relevant variables
Results: At a median follow-up of 6 months, the rates of MACEs were similar in the 
two groups (34.5% versus 38.3%; p=0.25).. In the highest-risk group (1st quintile), those 
patients who received early revascularization did not have any major adverse event, 
whereas those who did not undergo early revascularization had a relevant number of 
MACEs (28.7%) and deaths (24.7%). Conversely, for the lowest-risk group (5th quintile), 
patients who underwent early coronary revascularization had a signiﬁcantly higher risk 
for MACEs (HR= 4.74, CI: 1.36-16.49, p=0.014) compared with patients managed only 
with medical treatment. No signiﬁcant differencewas observed across the remaining three 
categories of propensity scores.
Conclusions: The analysis of this registry suggests that in acute coronary syndrome, 
early-revascularization is more effective than medical therapy only in high-risk patients. 
Conversely, medical therapy is superior to early coronary revascularization in patients 
with low-risk proﬁle.
9:30 a.m.
1050-156 Causes and Importance of Troponin Elevation After 
Coronary Artery Bypass Graft Surgery: Prospective 
Analysis of 847 Patients
Asim A. Mohammed, Arvind Agnihotri, Roland RJ van Kimmenade, Abelardo Martinez-
Rumayor, Sandy Green, Rene Quiroz, James L. Januzzi, Jr., Massachusetts General 
Hospital, Boston, MA
Background:Troponin (cTnT) release after coronary artery bypass graft (CABG) is 
not understood, and the ramiﬁcations of cTnT elevation after such procedures remain 
controversial.
Methods:cTnT was measured at 3 time points during ﬁrst 24 hours after CABG in 847 
consecutive patients
Results:Median peak cTnT (interquartile range, IQR) was 1.08 ng/ml (IQR=0.60-1.73 
ng/ml). Multivariable linear regression analysis showed post-op cTnT was predicted 
by myocardial infarction < 1 week of surgery (T=5.45; P <.001), pre-op IABP (T=5.42; 
P<.001), intra/post-op IABP (T=3.61; P<.001), number of distal anastomoses (T=2.84; 
P=.005), bypass time (T=8.85; P<.001), number of intra-op deﬁbrillations (T=2.61; P=.009),
GFR (T=-5.93; P<.001), off-pump CABG (T=-3.01; P=.003) warm cardioplegia (T=-2.40; 
P=.02). Quintiles of cTnT were associated with complications (ﬁgure 1). In a multivariable 
model including the Society for Thoracic Surgery (STS) Risk Model, cTnT remained 
independently prognostic for death at 30 days (OR=3.20; P =.003), the composite of 
death/HF (OR=2.04; P=.008), death/need for multiple vasopressors (OR=2.70; P<.001),
and the triple composite of death/HF/pressors (OR=2.57; P <.001).
Conclusions:cTnT values following CABG are determined by complexity of presentation, as 
well as extent of grafting, procedure complexity, and cardioprotection strategies. cTnT values 
are additively prognostic to the STS risk score for adverse outcomes following CABG.
ACC.ORAL CONTRIBUTIONS
918
Hot Topics in Percutaneous Coronary 
Intervention
Tuesday, March 31, 2009, 10:30 a.m.-Noon
Orange County Convention Center, Room W307A
10:30 a.m.
0918-3 A Randomized Comparison of Transradial Versus 
Transfemoral Approach for Coronary Angiography and 
Angioplasty
Martin Brueck, Dirk Bandorski, Wilfried Kramer, Harald Tillmanns, Clinic of Wetzlar, 
Wetzlar, Germany
Background: Coronary angiography and angioplasty are usually performed via the 
transfemoral approach. Transradial access may offer some advantages in comparison 
with transfemoral access especially under conditions of aggressive anticoagulation and 
antiplatelet treatment. The aim of the study was therefore to evaluate the safety, feasibility 
and efﬁcacy by the transradial approach compared to the transfemoral access in a 
standard population of patients undergoing coronary angiography and angioplasty.
Methods: Between July 2006 and January 2008, 1024 patients were randomly assigned 
to transradial or transfemoral approach. Patients with an abnormal Allen test or history of 
coronary artery bypass surgery were excluded. Both groups were comparable concerning 
baseline clinical characteristics (age, sex, body mass index, cardiovascular risk factors, 
acute and recent myocardial infarction, LV ejection fraction, previous PCI). Procedures 
were performed by four experienced physicians.
Results: Table
Conclusions: The ﬁnding of the present study shows that transradial coronary angiography 
and angioplasty are safe, feasible and effective with similar results to those of the transfemoral 
approach. However, procedural duration, ﬂuoroscopy time and radiation exposure are 
higher using the transfemoral access. In contrast to the transfemoral approach, the rate of 
major vascular complications was negligible using the transradial access.
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Assessment of Risk in NSTE ACS 
Populations
Tuesday, March 31, 2009, 2:00 p.m.-3:30 p.m.
Orange County Convention Center, Room W307A
2:00 p.m.
0923-3 Different Risk Scores Predict Different Risk for the 
Same Patient With an Acute Coronary Syndrome: 
Implications for Contemporary Practice
Umesh U. Tamhane, Ralph H. Stern, Krishna Aragam, James B. Froehlich, Eva Kline-
Rogers, Kim A. Eagle, Hitinder S. Gurm, University of Michigan Medical Center, Ann 
Arbor, MI
Background: Current ACC/AHA guidelines advocate the Global Registry of Acute 
Coronary Events (GRACE) and Thrombolysis in Myocardial Infarction (TIMI) scores in 
risk stratiﬁcation of patients with ACS. We assessed the correlation between the predicted 
mortality by GRACE and TIMI score in an unselected ACS patient population.
Methods: We studied 2753 UA/NSTEMI and 698 STEMI patients admitted to University 
of Michigan between 1999-2005. We calculated appropriate GRACE and TIMI risk scores 
for each patient. Discriminatory performance of each score to predict in-hospital mortality 
was measured by the c-statistic. Within the UA/NSTEMI and STEMI subpopulations, 
scatter plots of TIMI versus GRACE risk scores were generated.
Results: The c statistics for in-hospital mortality for GRACE and TIMI score were 0.85 
versus 0.54 in UA/NSTEMI and 0.84 versus 0.83 in STEMI population. There were major 
clinically relevant differences in the predicted risk of death with the two scores (ﬁgure). 
In the UA/NSTEMI cohort, for a TIMI score of 5 (predicted mortality 5.6%), the predicted 
mortality with GRACE score ranged from a 0.2% to q 52%. In the STEMI cohort, for a 
TIMI score of 5 (predicted mortality 11.6%) the mortality risk with GRACE score ranged 
from 0.6% to 36%.
Conclusion: The two commonly used risk scores can provide markedly discrepant 
estimates of risk for the same patient even with similar discrimination in the overall 
population. These data call into question the value of routine use of these scores for risk 
prediction. 
2:15 p.m.
0923-4 Renal Dysfunction and Rapid Coronary Artery Disease 
Progression in Patients With Non-ST-Segment Elevation 
Acute Coronary Syndrome
Tatsuya Nakachi, Masami Kosuge, Kiyoshi Hibi, Toshiaki Ebina, Kengo Tsukahara, Jun 
Okuda, Noriaki iwahashi, Yoshio Tahara, Satoshi Umemura, Kazuo Kimura, Yokohama 
City University Medical Center, Yokohama, Japan
Background Renal dysfunction is a powerful predictor of adverse outcomes in non-
ST-segment elevation acute coronary syndrome (NSTE-ACS); however, its underlying 
mechanism has not been fully elucidated. Although renal dysfunction has been shown to 
be associated with the severity of coronary artery disease (CAD), the relation between 
renal dysfunction and CAD progression is unknown.
Methods We studied 231 patients with NSTE-ACS who underwent percutaneous 
coronary intervention for culprit lesion, followed by coronary angiography a mean of 8 
months later. Rapid progression of non-culprit lesion was deﬁned as an increase >15%
in stenosis severity at follow-up angiography. Estimated glomerular ﬁltration rate (eGFR), 
high-sensitivity C-reactive protein (hsCRP), cardiac-speciﬁc troponin T and lipid proﬁles 
were measured on initial admission. Patients were divided into the 2 groups according to 
the presence (n=73) or absence (n=158) of renal dysfunction deﬁned as eGFR <60 mL/
min/1.73 m2.
Results There were no differences in diabetes mellitus, hyperlipidemia, smoking, lipid 
proﬁles, positive-troponin T and medications between patients with and without renal 
dysfunction. Renal dysfunction was associated with older age (70 + 8 vs 64 + 10 years, 
p<0.0001) and higher rates of male (90% vs 77%, p=0.022) and hypertension (80% vs 
53%, p=0.0002), a higher level of hsCRP (0.195 vs 0.111 mg/dl, p=0.024). Patients with 
renal dysfunction were more likely to have multivessel disease (62% vs 45%, p=0.023 
11:15 a.m.
0918-6 Comparative Efﬁcacy of Primary Percutaneous Coronary 
Intervention, Facilitated Percutaneous Coronary 
Intervention and Fibrinolysis in Chinese Patients 
With ST-Elevation Myocardial Infarction: A Multicenter 
Randomized Clinical Trial
Yun Zhang, Shi Liang Jiang, Xiao Ping Ji, The Shandong Clinical Trail Group, The Key 
Laboratory of Cardiovascular Remodeling and Function Research, Jinan, People’s 
Republic of China
Background: Primary percutaneous coronary intervention (PPCI) is superior to facilitated 
percutaneous coronary intervention (FPCI) and ﬁbrinolysis in patients with ST-elevation 
myocardial infarction (STEMI) if the door-to-balloon time is less than 90 minutes. The 
purpose of this study was to ﬁnd out whether PPCI is superior to FPCI and ﬁbrinolysis in 
the Chinese patients with STEMI in the current clinical practice.
Methods: A multicenter clinical trial was conducted in 18 medical centers with PCI 
facilities in Shandong Province, China. A total of 513 patients with STEMI were enrolled 
and randomized to one of the three reperfusion strategies: (A) PPCI, (B) FPCI and (C) 
ﬁbrinolysis. Patients assigned to group A received immediate PCI at a mean door-to-
balloon time of 119.5mins. Patients assigned to group B were ﬁrst given an intravenous 
bolus of 8mg rt-PA followed by an infusion of 42mg rt-PA over a period of 60 mins and 
then PCI. Patients in group C received a dose of 100mg rt-PA using a standard protocol. 
The primary endpoint was 30-day cardiovascular death. The secondary endpoint was 
a composite of recurrent unstable angina pectoris (UAP), reinfarction, target vessel 
revascularization (TVR), congestive heart failure (CHF) and intracranial hemorrhage 
(ICH) at 30 days.
Results: There was no signiﬁcant difference in the incidence of cardiovascular death 
among the 3 groups at 30 days (3.4%, 3.0%, and 6.4% in group A, B and C, respectively, 
p=0.339). A signiﬁcant increase in the event rate of the secondary endpoint was found 
in group C (36.8%) compared with that in group A (10.3%) and group B (8.9%) (both
p<0.01). Subgroup analyses indicated that the difference in the secondary endpoint was 
mainly due to the reduction in the relative risk of recurrent UAP (3.4%, 4.8%, and 17.0% 
in group A, B and C, respectively, both P<0.01) and revascularization (2.3%, 3.0%,and 
25.7% in group A, B and C, respectively, both P<0.01). No signiﬁcant difference was found 
in primary and secondary endpoints between group A and group B.
Conclusions: Both PPCI and FPCI is superior to ﬁbrinolysis in the treatment of Chinese 
patients with STEMI. The efﬁcacy of FPCI is equal to that of PPCI if the door-to-balloon 
time is more than 90 mins.
11:30 a.m.
0918-7 Three-Year Comparison of Drug-Eluting Versus Bare 
Metal Stents
Robert J. Applegate, Matthew T. Sacrinty, Michael A. Kutcher, Renato M. Santos, Sanjay K. 
Gandhi, William C. Little, Wake Forest University School of Medicine, Winston-Salem, NC
Background. Long-term safety concerns after “off-label” drug-eluting stent (DES) use persist 
despite recent 2 year data showing comparable safety to bare metal stent (BMS) use.
Methods. We compared 3-year cumulative outcomes to landmark 2nd and 3rd year 
outcomes (non-fatal MI, all-cause mortality) in 1,147 consecutive patients who received 
BMS in the year prior to introduction of DES at Wake Forest University Baptist Medical 
Center and 1,246 consecutive patients that received DES after it became our routine 
choice with equivalent complete 3-year follow-up.
Results. Stents were used for “off-label” indications in 80% of patients. At 3 years, the 
hazard ratio for DES compared to BMS for cumulative target vessel revascularization 
was 0.65 (0.51-0.82), non-fatal MI or death was 0.85 (0.71-1.03), and all-cause mortality 
0.80 (0.64-1.01). The DES clinical beneﬁts occurred entirely within the ﬁrst year, with 
similar rates of these clinical endpoints in the second and third year. The cumulative HR of 
stent thrombosis DES compared to BMS was 1.07 (0.57-2.01), with similar rates of stent 
thrombosis in the third year, p=0.70 (see Figure).
Conclusions. The routine clinical use of drug-eluting stents for “off-label” indications 
was associated with lower clinical endpoints at 3 years than in a comparable group of 
patients treated with BMS, with similar cumulative rates of stent thrombosis. There was 
no evidence of late “catch-up” of adverse DES events.
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and rapid progression of non-culprit lesion (38% vs 20%, p=0.0035). Multivariate 
analysis revealed that renal dysfunction (OR 2.10, 95% CI 1.01 to 4.46, p<0.05) and 
hsCRP (OR 1.70, 95% CI 1.09 to 2.68, p=0.02) were independently associated with rapid 
progression.
Conclusions In patients with NSTE-ACS, renal dysfunction is associated with not only 
the severity of CAD but also rapid CAD progression. These ﬁndings may partly explain 
adverse outcomes in patients with renal dysfunction.
2:30 p.m.
0923-5 Cockcroft-Gault Is Better Than the Modiﬁcation of Diet 
in Renal Disease Study Formula to Predict Outcome 
Following a Myocardial Infarction - Data From Swedish 
Register of Information and Knowledge
Karolina Szummer, Stefan H. Jacobson, Pia Lundman, Johan Lindback, Ulf Stenestrand, 
Lars Wallentin, Tomas Jernberg, Karolinska University Hospital Huddinge, Karolinska 
Institutet, Stockholm, Sweden
Background: 
It is unknown which estimation of renal function best predicts outcome in patients with 
acute coronary syndrome.
Methods: All consecutive myocardial infarction (MI) patients (n=36347) admitted to a 
coronary care unit and entered in a nationwide register between 2003 and 2006 had 
glomerular ﬁltration rate (GFR) estimated by both the Cockcroft-Gault (CG) and the 
Modiﬁcation of Diet in Renal Disease formula (MDRD).
Results: The median (IQR) CG-GFR and MDRD-GFR was 68.3 ml/min (47.8-93.5) and 
71.6 ml/min (55.5-87.9), respectively. The estimations correlated well (r=0.83, p<0.001). 
At least moderate renal dysfunction (GFR<60) was identiﬁed more often with CG than 
with MDRD equation (39.9% versus 31.1%). Lower renal function indicated higher annual 
mortality by either estimation. However, within each quartile of MDRD-GFR, mortality 
increased with decreasing CG-GFR (Figure). A similar pattern was seen when patients 
were divided according to the classiﬁcation of the National Kidney Foundation. In a ROC-
analysis CG had a signiﬁcantly stronger association to outcome (AUC 0.78; 95% CI (0.77-
0.79) versus 0.73 95% CI (0.72-0.74)). After multivariable adjustment, CG still predicted 
one year mortality better than MDRD equation (1st quartile compared with 4th quartile: HR 
2.36 (2.01-2.78) with the CG; HR 1.58 (1.42-1.76) with the MDRD).
Conclusions: Cockcroft-Gault is better than the MDRD equation to predict mortality 
following a myocardial infarction.
2:45 p.m.
0923-6 Warfarin Is Independently Associated With Lower Risk 
of Six-Month Death or Myocardial Infarction in Patients 
With Atrial Fibrillation Following Acute Coronary 
Syndromes
Renato D. Lopes, Aijing Starr, Sana M. Al-Khatib, L. Kristin Newby, Rajendra H. Mehta, 
Frans Van de Werf, Kenneth W. Mahaffey, Paul W. Armstrong, Robert A. Harrington, 
Harvey D. White, Lars Wallentin, Christopher B. Granger, Duke Clinical Research 
Institute, Durham, NC
Background: Little is known about the use of and need for oral anticoagulant therapy in 
patients with atrial ﬁbrillation (AF) complicating an acute coronary syndrome (ACS). We 
examined warfarin use at discharge (according to CHADS2 score) and its association 
with 6-month death or myocardial infarction (MI) in ACS patients complicated by AF.
Methods: Of the 23,208 patients enrolled in the PURSUIT, PARAGON A, and SYNERGY 
trials, 4.0% (917 patients) had AF as an in-hospital complication and were discharged 
alive. Cox proportional hazards models were performed to assess 6-month outcomes 
after discharge.
Results: Overall, 13.5% of patients with ACS complicated by AF were discharged on warfarin. 
Patients receiving warfarin more often had diabetes, heart failure, or prior MI compared with 
those not receiving warfarin. Warfarin use among AF patients was similar across CHADS2 
score groupings (CHADS2 =0, 13%; CHADS2 =1, 14%; CHADS2 >=2, 13%). Among patients 
with in-hospital AF, warfarin use at discharge was independently associated with a lower risk 
of death or MI within 6 months of discharge (HR 0.35; 95% CI 0.14-0.91). Adjusted curves of 
6-month death or MI according to warfarin use at discharge are shown in the ﬁgure.
Conclusion: Warfarin use is associated with better 6-month outcomes among patients 
with AF complicating an ACS, but use is infrequent and is not related to CHADS2 score. 
This study highlights the need to better understand optimal antithrombotic therapy for AF 
occurring in the setting of an ACS. 
3:00 p.m.
0923-7 Anemia for Risk Assessment of Patients With Acute 
Coronary Syndromes
Francois Schiele, Nicolas Meneveau, Marie-France Seronde, Vincent Descotes-Genon, 
Joanna Dutheil, Romain Chopard, Fiona Ecarnot, Jean-Pierre Bassand, University 
Hospital Jean Minjoz, Besancon, France
Background: In patients admitted with acute coronary syndromes (ACS), those with 
anemia are at higher risk, but current risk score systems do not take into account the 
presence of anemia. We studied the impact of anemia on mortality and determined its 
incremental predictive value.
Methods: Demographic, clinical and biological characteristics at admission, as well as 
treatments and mortality were recorded in 1410 consecutive patients with ACS. The 
incremental value of adding the anemia information was determined by the changes in 
appropriateness of Cox models when anemia was added.
Results: Anemia was detected in 381 (27%) patients. They were older, had more 
co-morbidities, higher GRACE risk score, received fewer guidelines-recommended 
treatments and, as a result, had a four times higher mortality. When added to a prediction 
model based on the GRACE risk score, anemia remained an independent predictor 
of mortality. The addition of anemia improved both the discriminatory capacity and the 
calibration of the models. According to the GRACE risk score, the population was divided 
into 4 different risk groups: <1%, 1 to <5%, 5 to <10% and >=10%. The addition of anemia 
to the model allowed a reclassiﬁcation respectively 9%, 43%, 47% and 23% of patients 
into different risk categories.
Conclusions: Our data conﬁrm that anemia is an independent and important predictive 
factor of mortality, even after adjustment for co-morbidities, hemodynamic conditions and 
treatments used. Combined with the GRACE risk score, anemia allows improved risk 
classiﬁcation at admission for patients with ACS.
